Environmental control medical support team by Crump, William J. & Kilgore, Melvin V., Jr.
I THE UNIVERSITY OF ALABAMA IN HUNTSVILLE 
SCHOOL OF PRIMAFtY MEDICAL CARE I 
FINAL REPORT 
ENVIRONMENTAL CONTROL 
MEDICAL SUPPORT TEAM 
Submitted To: 
Space Station Development Project Office 
George C. Marshall S ace Flight Center 
National Aeronautics an B Space Administration 
Marshall Space Flight Center, AL 35812 
Prepared By: 
William J. Crurnp, M.D., Principle Investigator 
Director, Consortium for the Space Life Sciences 
School of Primary Medical Care 
and 
Melvin V. Kilgore, Jr. 
Technical Studies Coordinator, 
Consortium for the Space Life Sciences 
UAH Research Report Number 742 
October, 1988 
4 
a 
https://ntrs.nasa.gov/search.jsp?R=19890006134 2020-03-20T04:59:45+00:00Z
INTRODUCTION 
This re ort summarizes the activities conducted in support of the 
EnvironmentafControl and Life Support Team during December 7, 1987 through 
September 30, 1988. The majority of the ongoing support has focused on the 
ECLSS area. Through a series of initial meetings wth the ECLSS team and 
technical literature review, an initial list of critical topics was 
developed. These were prioritized by Dr. Randy Humphries’ group. Subtasks 
were then identified or additional related tasks received as action items 
from the ECLSS group meetings and the team worked to provide the required 
information. 
Although most of the efforts during this period were focused on 
providing MSFC personnel with information regarding specific uestions and 
ECLSS Medical Support Team and constructin data bases of technical 
information was also initiated and completed. Each of the specific tasks 
are discussed in the following Section. 
problems related to ECLSS issues, other efforts regarding i a entifying an 
SPECIFIC TASKS 
1.0 Determine areas of need where medical consideration and design 
Through a series of meetings with the ECLSS team and technical 
literature review, an initial list of critical topics was produced. These 
were prioritized by Dr. Randy Humphries’ group and structured as an 
outline. Sub-tasks were then identified, and the team worked to provide 
the required information. The working outline that was developed is 
resented in Appendix A. The original prioritized tasks are presented 
[elow: 
requirements interface. 
o Provide support to the mechanical design and integration of test 
systems as related to microbiological concerns. 
o Assist with design of Human Subjects Test Protocols 
o Interpretation and recommendations pertaining to air/water quality 
requirements 
o Assist in determining the design specifications required as related 
to the Technical Demoritrstion Program 
o Develop data base of all microorganisms recovered from previous 
subsystem testing 
o Estimates of health risk of individual microbes to test subjects 
o Assist with setting limits for safety of test subjects 
o Health monitoring of test subjects 
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o Assist in the preparation of test plans 
o Assist in the development of a QA/QC program to assure the validity, 
accuracy and precision of the analyses 
o Assist in developing test plans required for future "man in the 
loop" testing 
2.0 Assemble Support Team 
As the specific ECLSS questions were delineated, team members were 
recruited and the tasks were assigned. There was initial discussion with 
members of the Colleges of Science, Engineering, Nursing, Liberal Arts, and 
the School of Primary Medical Care as well as the Johnson Research Center 
within the University of Alabama in Huntsville. Contacts were also made in 
the Physiology De artments of the University of Alabama in Birmingham (UAE3) 
and Vanderbilt e niversity. In addition, further contacts have been made 
from the School of Biostatistics and Biomathematics at UAB, the Athletic 
Drug Testing Laboratory located at Vanderbilt University, the Space 
Research Center located at Texas A & M University and the Botany and 
Microbiology Department at Auburn University. Because the primary focus at 
this point is environmental microbial control, the personnel utilized 
during this period have been expert in this area. 
With the past experience of these efforts in hand, a primary Medical 
Support team can be defined which can offer the general expertise required 
by the MSFC Environmental Control/Life Support team for future efforts. A 
brief description of the key positions is provided below: 
Family Physician 
The majority of medical questions arising from life support design 
cross traditional speciality barriers and require a systems approach. The 
modern specialist in Family Medicine is broadly trained in abnormalities of 
all organ systems, unconstrained by patient age or gender. In addition, 
Family Practice training includes extensive exposure to medical care as a 
systems issue as well as the interactions of the ph sical and social 
physician will monitor the team's activities and provide the necessary 
general perspective to keep the group on target. 
environment in an individual's health, performance and il Y ness. The family 
Environmental Health Physician 
Many of the health concerns of ECLSS testing and operation are similar 
to ground based occupational and environmental health needs. The team 
member most qualified to address these issues must have trainin beyond the 
Occupational Medicine. This physician will become intensely involved in 
hardware design, integration, and operation, and will review each step for 
health and safety concerns. 
M.D. degree to include a Master's Degree or equivalent in Pubic 'T Health or 
Technical Studies Coordinator 
Successful completion of many of the necessary tasks will require 
sup lemental and adjunct activities of a variety of technical and 
lased research and verification, or support to problem understandin and 
proposed resolutions. The technical studies coordinator wilf be 
responsible for the coordination and supervision of technical personnel. 
In addition, he will be responsible for the timely completion of all 
required sub-tasks delegated to technical and specialized personnel. The 
technical studies coordinator must be versed in chemistry, microbiology, 
toxicology, ECLSS hardware and operation as well as have a basic 
understanding of medical issues. 
ro F essional personnel. This might include literature searches, laboratory 
Environmental Toxicologist 
A large portion of the Phase I11 test activities will involve the 
operation and performance evaluation of ECLSS hardware. A major concern of 
these test activities involve the safety and health maintenance of the test 
subjects involved. The environmental toxicologist will play a major role 
in the identification of health and safety concerns of the test subjects 
and in addition provide valuable information regarding the detection and 
identification of chemical and microbial contamination of the waste and 
product streams associated with the ECLSS. 
Chemist 
The methods of .detection and identification of chemical contaminants 
will be of upmost importance to both the performance evaluation of the 
ECLSS hardware and the verification of water quality. An individual versed 
in chemical and instrumental methodology will provide the necessary inputs 
required for the establishment of test plans, verification of laboratory 
performance and assurance of test subject safety. 
Microbiologist 
Many of the non-medical questions which arise are related to 
microbiology. For this reason, it is important to have knowledgeable 
representation in this field with direct experience in enumeration, 
detection and identification of environmental as well as medically 
significant microorganisms. In addition, microbiologists will play 
important roles in the establishment of test plans and microbial control 
options for the ECLSS test bed. 
Information Management 
The lar e volume of scientific and technical information requires 
In addition, integration of sub-component reports to complete task reports 
will require extensive technical merging and editing. The information 
specialist is responsible for these activities as well as other support 
functions such as interfacing with contract and support ersonnel, 
information searches. 
electronic co K lation to facilitate interpretation and information transfer. 
Preparing and delivering presentations, and coordinating and P acilitating 
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Specialized Professionals 
Because of the diversity of the potential problems which mi ht arise 
upon specialized individuals to answer and provide insi ht to particular 
questions. These individuals, although not be needed on a full time % asis, 
may be called u on at any time for the resolution of specific tasks. Below 
are some experts i B entified at this time. 
Toxicologist/Pharmacologist 
Filtration and Separation 
Instrumental Design 
Biostatistician 
during the course of the Phase I11 activities it will be essentia f to call 
The resumes of the current team members are included in Appendix B. 
3.0 Construct Data Base of Background Technical Information 
At the resent time, over 500 individual articles have been manually 
classified. &is information was computerized, and is continually updated 
as further information is produced by the regular literature searches. A 
current listing of these articles is presented in bibliography format with 
the abstracts (if available) in Appendix C. In addition, a bibliography 
produced by the National Library of Medicine that provides ready access to 
many of the lmportant subject headings is included in Appendix D. 
4.0 Provide Ongoing Technical Support to Development Project Office 
The majority of this ongoing sup ort has actually focused in the ECLSS 
items would e delegated to the UAH Medical Support Team. Oftentimes, 
feneral topic area these action items were specific topics within a 
initially defined as high priority. Presented in Appen ix E is the current 
information obtained and recommendations for the individual topic areas and 
action items. All pertinent supporting information is included in Appendix 
F. Copies of all presentation material used by the UAH team are provided 
in Appendix G. 
area, with re ular contacts with Dr. R umphries’ Team. Periodically, action % 
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FUTURE THRUSTS 
Below are areas identified from the original prioritized tasks and 
others which have developed which require further efforts. 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Assist with setting limits for safety of test subjects 
Assist in the development of test protocols necessary for 
institutional review 
Assist in the establishment and preparation of test plans 
Assist in the development of a QA/QC program to assure the validity, 
accuracy and precision of the analyses 
Identify and evaluate the removal of various drugs and/or 
phannacuticals by the urine reclamation system. 
Develop data base of all microorganisms recovered from previous 
subsystem testing 
Estimates of health risk of individual microbes to test subjects 
Assist in determining the design specifications required as related 
to the Technical Demonstration Program 
Assist in developing test plans required for future "man in the 
loop" testing 
BUDGET SUMMARY 
A summary of expenditures for the contract period is presented in 
Appendix H. 
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APPENDIX A 
Task Outline 
MASTER OUTLINE 
3/3/88 
I 
1 
1 
I 
I 
I 
D 
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Phasa I11 TO8t Aativitielr 
XOdia.1 A8pOot8 
1.0 Provide support to the mechanical design and integration of 
test systems as related to microbiological concerns. 
1.1 General Recommendations 
1.2 Material Recommendations 
1.3 System Integration 
1.4 Sampling Ports 
1.5 Sterilization/Decontamination 
1.6 Operational Requirements 
2 . 0  Assist with design of Human Subjects Test Protocols 
2.1 Test Subject Protocols 
2.2 Human Subject Guidelines 
2.21 Institutional Review Board 
2.22 System Certification 
2.23 Subject Injury 
2.24 Supporting Documents 
2.241 JSC HRPPC (Appendix A) 
2.242 HHS (Appendix B) 
2.243 UAH IRB (Appendix C) 
Assist in determining the design specifications required as 
related to the Technical Demonstration Program 
3.1 Documentation Review 
3.0 
3.2 
3.3 Recommendations 
Current water/air quality requirements review 
4 . 0  Interpretation of air/water quality requirements 
4.1 Identify current air/water quality requirements 
4.2 Develop and justify air/water quality requirements 
for recycled air and water 
4.3 
previous subsystem testing 
5.1 Biochemical Characterization of Unknowns 
Provide recommendations pertaining to above 
5.0 Develop data base of all microorganisms recovered from 
5.2 Identification of Presumptive Organisms 
5.3 FAME profiling of isolates 
5 . 4  Establish data base of isolates with respect to source 
5.5 Identify isolates which potentially represent health 
risks 
5.6 Characterize isolates based on susceptibly/resistance 
to antimicrobials 
6.0 Estimates of health risk of individual microbes to test 
subjects 
7 . 0  
8 . 0  
Assist with setting limits for safety of test subjects 
Health monitoring of test subjects 
8.1 
8.2 
Assist in the preparation of test plans 
9.1 Microbiological 
9.2 Chemical 
Delineation of parameters to monitor well subjects 
Guidelines for managing sick subjects 
9.0 
10.0 Assist in the development of a QA/QC program to assure the 
validity, accuracy and precision of the analyses 
Assist in developing test plans required for future "man in 
the loop" testing 
11.0 
1 
1 
I 
I 
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APPENDIX B 
Resumes of Key Personnel 
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WHMedid C l i n i c s  
F d y  Hdicine Program 
201 Govermr's Drive, S.W. 
Hmtsville, Alabama 35801 
230 Teakwod Drive 
€hntsville,Alabapa 3!%01 
(205) 882-3608 
BIKIHDUEAM)mA&: Jure 14, l953 
-D Geo%ia 
l#iRlmL sIIp;Ns: Hzrded, four children 
socIAL-Nu.1Bw: 26042-1 826 
Board of Fadly  Ractice, July 1982 
AhbamMedical I.(rsnse, 198O-present 
Tennessee Medical 1JrRwe, 1984-present 
Associate Professor of F d y  MecEcin)l, University of Alabana in 
Iimtsville, scbool of hrimaryMedLcal Care, September 1986- 
Presart 
Assistant Professor of F d y  Medicine, Ihhersity of Alabapa in 
RLnesvFlle, School of Primary MedLcal Care, March 1983-Septaher 
1986 
Adjurct Assistant Professar, UniversitJr of Alabama in Hmtsville, 
school O f  Prirpary & d i d  Care, -t of OB/GYN, JUE 1%- 
Nuve&er 1985 
Assistant Professor, Assistant Ret3idel.q Dixector a d  Assistant 
B l m a t h d  Mrector, mversity of ALabapa in BidngIm,  
DegBlctment Of F a p d l y m ,  Jdy 198%- 1983 
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mipal Investigator, " F d y  Practire Pezinatal- 
Project," F d y  Health Fbdatim of h e r i a ,  1983 
h ~ ~ e @ a l  of tbe Neid"xl," F d y  H e a l t h  Fourdation Of 
lwndpfd Investigator, "Social support and the M a t d  
America, 1982 
chief, HmWle  Hospital, Mvlsiar of F d y  Practice, October 
V i a & ,  Emtsville Eospital, MvLsim of F d y  Practice, 
1987-september 1988 
October 1 9 8 6 - S e p t e  1937 
present 
1987-pre3mt 
Research CrmaIttee, 1986-present 
Mmhec, University of Alabama in btsville canpaer Users 
Advborymmwee,  1984-1986 
Mder, University of Alabana in BLntsville Joint -er N e w  
Access rrmatttee, 1984-198s 
Hder ,  thiversity of Alabama in fhntsville school of primary 
Mdical Care AdvLaory Crmnittee on R a n > t h  and Tanae, 1984- 
pr-t 
Mmber, Wversity of Alabamt in Rmtsville S h o l  of Primixq 
M d h d  Care F d y  Ractice Res- PmmDtiOa Cannittee, 
1984-preSeat 
w, ucriversity of Alabama in Rmtsville Eumn Mjects in 
Research anmittee, Septembet 1 9 8 3 - m t  
C ~ ~ U X R I ,  Wversity of Alabapra in btsville school of R i w r y  
Medical Care Grants and I(lesearch wt+#r, 1983-presmt 
-, Alabana Journal of IkdiCd Sciences EditorLal Board, 1987- 
Board of Directors, Hope Place shelter far rbm2Stic Violence, 
w, Alabana Wta-AEdCan A c a d q  Of F d y  physicians 
Medical Director, F d y  Practice Qinics, uliversity of Alabana 
in Emtsville Sdml of Primary Medical Care, February 1987- 
F L p  co~rdimator, mversity of 
HdiCine progran, 1986-preSQt 
Mrector of Resear& DiviSirOn of FaaLly Medicine, Wversity of 
ALabapa in btsvi l le  scbool of primary M i d  Care, April 
1983-prt%3ent 
F d y  Medicine paailty k v d o p m t  F M p ,  Uversity of 
North Carolina at chapel Hill., 1982-1983 (-t with first 
-ty Ye=) 
esent 
in btsvf l le  Fzmily 
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RESUME 
NAME: Melvin Voorees Kilgore, Jr. 
POSITION: 
RANK: Research Associate 
Director, Analytical Research & Testing Laboratory 
EDUCATION: 
Universi of Alabama in Huntsville 1983 - 1986 
Master's r6e pee, Biological Sciences -1987 
Auburn University 
Graduate Courses: Chemistry 
Auburn University 
B.S. Microbiology 
1978-1980 
1974 - 1978 
1978 
Short Courses and Seminars: 
Resolution Gas Chromatography, Hewlett Packard, Binniagham, AL, 
Fe ruary, 1987 
Ins ecting Buildings for Asbestos, Georgia Tech, Atlanta, GA, July, 
198 $ . 
Managing Asbestos Projects, Georgia Tech, Atlanta, GA, January, 1988. 
PROFESSIONAL AFFILIATIONS 
American Association for the Advancement of Science 
American Society of Microbiology 
Association of Of6cial Analytical Chemists . 
American Chemtcal society 
PROFESSIONAL EXPERIENCE: 
University of Alabama in Huntsville 
The Kenneth E. Johnson Research Center 
June 1984 - Present 
Southern Research Institute 
Biotechnology Section 
Position: Biochemist 
June 1983 - May 1984 
Universi of Alabama in Huntsville Feb 1983 - May 1983 
h m t h  % Johnson Research Center 
Graduate Research Assistant 
PROFESSIONAL EXPERIENCE: (an t )  
Energy M a t e s ,  lac. 
Alternative Energy Division 
Technical Representative 
Auburn University 
Chemistry Department 
Graduate Research Assistant 
J u ~  1980 - Jan 1983 
Sep 1978 - May 1980 
Alabama Water Improvement Commission SCP 1975 - DCC 1977 
Monitoring and Surveillcnce Section 
Microbiological Technician 
PUBLICATIONS: 
"A Physiological Survey of the Effects of the Cis and Trans Isomers 
of Platinum (11) Diaminodichloride (PPD) Using the Prokaryotic 
System as a model," D.L. Elam, M.V. Kilgore, Jr., and P. Melius. 
resented at Southeastern Regional Meeting of the American Chemical 
&me@, Oct., 1978. 
"A Comparative Study on Induction of Mixed Function Oxidase 
Activity in the Rat, Mullet and Gulf Killifish," M.V. Kilgore, Jr., 
D.L Elam and P. Melius. Alabama Academy of Sciences, Mar., 1979. 
"Induction of Polyaromatic Hydrocarbon Oxidases in Marine Or anisms," 
P. Melius, M.V. Kil ore, Jr., D.L. Elam, Jr. and W.P. Sc % oor. XI 
International Congress o f Biochemistry, Jul., 1979. 
in Marine Organisms by HPLC," M. + . Kilgore Jr., 3. Melius, B. Tan, "Product Pattern and Kinetic Anal sis of Benzo(a) rene Metabolism 
D.L Elam and W.P. Schoor. Southeastern Regional Meeting of the 
"Biomass Conversion of Municipal Solid Wastes," D.R. Coleman, W.E. 
Meyers, M.V. Kilgore, Jr., C.L. Lishawa, and M.H. Eley. Miami 
International Symposium on the Bioshpere, Apr., 1984. 
"Ihe Production of Fuel Grade Ethanol from the Cellulose in Munici al 
Solid Waste," T.J. Laughlin, D.R. Coleman, M.V. Kil ore, Jr., C!L. 
Uhawa, and M.H. Eley. Sixth Symposium on Biotechnoogy Q for Fuels 
and Chemicals, May, 1984. 
"The Economics of Biomass Conversion of Munici a1 Solid Waste to 
Ethanol," C.L Lishawa, R.E. La-, D.R Coleman, W k Meyers, M.V. 
Kilgore, Jr., TJ. Laughlin, and M.H. Ele . Sixth Symposium on 
Biotechnology for Fuels and Chemicals, May, 1 B 84. 
"Mixed Function Oxidase Inductibility and Polyaromatic H drocarbon 
Metabolism in the Mullet, Sea Catfish and Gulf Kil r ifish," P. 
Melius, M.V. Kilgore, D.L. Elam, B. Tan and W.P. Schoor. 
Aromatic EIydrocarbons. Proceedings of the 4th &Ei% symposium, 1979. 
American Chemical Society, oct, 1979. 
PUBLICATIONS: (cant) 
"Metabolites of Benzo (a) rene in Arocolor 1254 Treated mullet," 
T o x i c o l o P v . p r A  of tbe 4th ASTM Symposium, 1979. 
"Indirect Atomic Absorption Method for Determinin 1,2-Diols via 
Digested Lead Periodate," B. Tan, P. Melius and M f t .  Kilgore, Jr. s- (1980) 52 (3) 602-604. 
"The Production of fuel Grade Ethanol from the Celldose in Municipal 
Solid Waste," T.J. Laughlin, D.R. Coleman, M.V. Kilgore, Jr., C.L. 
Lishawa and M. H. Eley. Proce edinnsQf r n 9 t h A n n u a l S o l a r d  
B. Tan, M.V. Kil ore, D.L. E PT am, P. Melius and W.P. Schoor. 
1984. 
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"Biomass Conversion of Municipal Solid Waste," D.R. Coleman, M.V. 
Kilgore, Jr., TJ .  Laughlin, C.L. Lishawa, W.E. Meyers and M.H. 
Eley. Proce €dings& &International- MLhCBiosDhera. 
1984. 
"Design of a Pilot for the Conversion of Municipal Solid 
waste to Ethanol," M.H. Eley, M.V. Kilgore, et.al., in proceedings of 
the Sixth mos ium M Blotechn~l~gy far Euels and Chemicals. 
Gatlinburg, , 01.6,p.W. 
"The Bioconversion of Municipal Solid Waste and Sewage Slud e to 
Ethanol," M.H. E l e w ,  Jr., et.al. in proceedin& e .  
w a s m m a  Chemicals. Minneapolis, m, vol. 1- 
"The Utilization of Municigal-Solid-Waste and 
Production of Ethanol, M.H. Ele&M. 
proceedings of the Einr &uqxxhm 
Minn&O&W voi 1, p. 54,1984. 
First * M  Advancesip 
pp ln I oce M u n i c i b a l W a s t e s f a r  
"Design of a Pilot Plant for the Conversion of Municipal Solid 
Waste to Ethanol," T.J. Laughlin, D.R. Coleman, W.E. Meyers, M.V. 
Biotechnolomr (inpress). 
T h e  Economics of Biomass Conversion of Municipal Solid Waste to 
Ethanol," C.L. Lishawa, R.E. Lacey, D.R. Coleman, W.E. Meyers, 
Kilgore, Jr., C.L. Lishawa, and M.H. Eley. BioenPineerlnn * a n d  
Jr., M.H. Eley, and TJ. Laughlin, Bioennineennn * a n d  
(in press). 
RESEARCH REPORTS: 
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Solid Has& (Phaae W. C.L. Lishawa, BiomaJs ‘ Q f  
M.V. K i 1 S T . J .  Lau bin, D.R. Coleman, W.E. Meyers, W.J. 
Suling, and M.H. E l e x  Progress Report, Commissioners of 
Jefferson County, Alabama, 1989. 
M.H. Eley, M. V. Kilgore, Jr., 
~ e r w o o d .  U A H e R e p o r t  No. 442, Catalytic Reactors, 
Inc., 1985. 
0 .  
’ Plant:AssemblvBPd sm@*m Grain EmnQ!Demonstratlon 
-Qf  
StudiesM 
W K i l g o r e ,  Jr., 
. .  QfCellplosicWastesfpEtbanal: 
? o . UAH Research Qf - Report No. 460, atalytic Reactors, Inc., 
1985. 
QfmPIansfQzlhcAdvanced l?K%w=M 
m r . ,  R. J. Zahorchak UAH R-?~c&?No. 476, 1986; 
Boeing Aerospace Company. 
Studies. M. . Kilgore, Jr., W.E. Dendy, et.al., UAH Resear= 
No. 545,1986, k i n g  Aerospace Company. 
c & . € n i A F  QfIkUrinePretreatmentMixer(UPM) 
K u d h w  s”fp”.’ Ki gore, Jr., et.al. UAH Research Report%?%!! tcrob pfkhcUrinePretreatmentMixer 
1986, Boeing Aerospace Company. 
Chemical Am&& nf Phase I Shower Studies. M.V. Kilgore, Jr., W.E. 
Dendy, et.al., UAH Research Report No. 549,1986. 
icrob pf Phase I Showel Studies. M. V. Kilgore, 
Jr., e t . a s  Research Report No. 550, 1986, Boeing Aerospace 
Chemical &i&& nf phase II SSba Studies. MV. Kilgore, Jr., W.E. 
Dendy, et.& UAH Research Report No. 551,1986. 
COmpanY. 
Qf Phase II &we[ Studies. M. V. Kilgore, 
Jr., et.al. AH Research Report No. 552, 1986, Boeing Aerospace 
’ nf $” L& Condensate. M. V. Kitgore, 
-AH Research eport No. 553, 1986, Boeing Aerospace 
aladcal- * Q f L a U d I &  
Water. M.V. Kilgore, Jr., 
W.E. Dene, et. UAH Research eport No. 554,1986. 
’ &&& nf ;Bpd W a t a  M. V. Kilgore, 
1986, Boeing Aerospace 
COmPaw. 
ampany.  
. . 
. . 
Research Report No. 5 
COmpamr. 
RESEARCH REPORT3 (ant)  
c h s m i @ ~ S u r m o r t p f  tbr €Iuni&-mv 
Studiea, M.V. Kilgore, Jr., W.E. Dendy, et.al., U H 
&!%%eport NO. 556,1986. 
1 
t 
andAnalvsisQfuHumiditvCondensateHeat 
M. V. Kilgore, Jr., et.al. UAH Research 
ing Aerospace Company. 
c l l s m i d . ~ a n d s u e p p r t  Qf hSDiralWoundRcverseWater 
Reclamation Svstem. M. . Kilgore, Jr., W.E. Dendy, et.al., UAH 
Research Report No. 558,1986. 
obi Qpg Analvsid,and SuppQEI Qf IbS Sghl Wound Reverse 
Osmosis Reclamation Svstern. M. V. Kilgore, Jr., et.al. UAH 
Research Report No. 559,1986, king Aerospace Company. 
ChemicalmandsuDDortfp*HollowFibcr=Osmosis M.V. Kilgore, Jr., W.E. WaterReclamatlon Svstem- 
andsuDDortsQthtrHollowFiberReverse Evaluation && M. V. Kilgore, Jr., 
' W a t e r  
Svstem M.V. Kilg- Dendy, 
. 
w Research Report No. 560,19 
et.al. UAH Research Report No. 561,1986, k i n g  Aerospace Company. 
. .  
et.al., UAH Research Report No. 562,1986. 
Procedurea-hIbSECLSSChemical 
M. V. ilgore, Jr. UAH Research Report No. 564, 1986, 
s l u i a I d v  
-pace ampmy. 
"A uatic bioassay Testing," M. V. Kilgore, Jr., Project Director. 
"Anal tical Laboratory Sup ort for the Area Industry," M. V. Kilgore, 
Jr., Project &rector. October 1984 - Lptember 1985 (S20,OOO.oO). 
"Establishment of Test Plans for the Advanced Development Programs," 
M. V. Kil ore, Jr., Pro'ect Director. Boeing Aerospace Corporation, 
"A uatic Bioassay Testing," M. V. Kilgore, Jr., Pro'ect Director. 
Amoco dl emical Corporation, November 1985 - September 1986 ($6,5d0.00>. 
Amoco & emicals Corporation, January 1985 - September 1985 ($5,100.00). 
September 1 1 85 - December i 985 ($8,172.00). 
CONTRAcls AND GRAN?S: (ant)  
"Independent Research and Develo ment Testing, Microbiological Sup rt 
k i n g  Aerospace corporation, December 1986 - October 1988 
"Establishment of Test Plans for the Advanced Development Programs," 
M. V. Kilgore, Jr., Pro ect Director. Boeing Aerospace Corporation, 
January 1986 - October 1986 i Sl4,902.0). 
"Advanced Development Pro ram Testin , Microbiological Support for 
Space Station Development," M. 6. Kilgore, o r., and R. J. Zahorchak, Co- 
Directors. Boeing Aerospace Corporation, January 1986 - October 1986 
($78,500.00). 
of a GC System for the Analysis of Reduced Sulfur Compounds," 
M. V. Kit ore, Jr., Project Director. Applied Technology Consultants, 
March 1986 - September 1986 (S7,OOO.OO). 
"Samplin and Trace Solvent Analysis of Ambient Air," M. V. Kilgore, 
Jr., Pro'ect hrector ,  Intergraph Corporation, March 1986 - April 1986 
for Space Station Development," M. 8 Kilgore, Jr., and R. J. Zahorc g. ak 
co-~ectom 
(S94,400.00). 
"Desi 
($1,9Oo.d). 
RESUME I 
? 
NAME: 
RESIDENCE: 
BUSINESS: 
DEGREES : 
1939 
1942 
1948 
1953 
EMPLOYMENT 
HISTORY 
1983- 
1977-78 
1966-70 
1964-66 
1964- 
WILLIAM F. ARENDALE 
1216 Stonehurat Or. S . E .  Phone: (205) 881-4631 
Huntsville, AL 35801 
The University of Alabama Phone: (205) 895-6473 
in Huntsville 
Chemistry Department 
Huntsville, AL 35899 
Central High School, Murfreesboro, Tennessee 
B.S., Science and Mathematics, Middle Tennessee State 
University 
M.S. Chemistry, University of Tennessee 
Thesis: The Identification of Organo-Selenium 
Compounds Obtained by the Oxidation of Stilbazoles 
with Selenium Dioxide. (With Dr. C. A. Buehler) 
Ph.D., Chemistry-Physics, University of Tennessee 
Dissertation: 
Deuterated Ketenes. (With Dr. W. H. Fletcher) 
Vibrational Spectra of Ketene ag Aerospacnc 
Technical consultant to United Space Boosters, Inc., 
Huntsville Alabama. Contracted efforts have included 
a study of the state-of-the-art related to sensors 
for Automated Weather Observing Systems, sensors for 
NDT/NDE systems, and materials and processes for . 
manufacturing optical components with emphasis on 
fiber optic systems and optrode designs. 
Technical Consultant to Hobgood, Calimafde et al, 
Patent Attorneys, New York, N.Y. Moore vs. U.S., 
patent infringement related to castable, elastomeric 
solid propellants. 
Technical consultant to Burns, Doane, Swecker and 
Hathis, Patent Attorneys, Washington, 0. C. Moore vs 
U.S. 
The University of Alabama in Huntsville. Director, 
Division of Natural Sciences and Mathematics. 
Responsible for developing programs in biology, 
chemistry, earth sciences, mathematics and physics. 
The University of Alabama in Huntsville. Assistant 
Director of Research Institute. 
The University of Alabama in Huntsville. Professor of 
64 
1951-64 
Chemistry. Interaction of electromagnetic energy with 
matter, scattering from laser illuminated targets, and 
hyper-Raman spectroscopy. 
as related to the ecological cycle and selenium 
deficiency diseases. Host recently, interest have 
been directed to real time monitoring systems. 
Philosophy of science, epistemology, and pedagogy of 
science. Teaching assfgnmnets have included general 
chemistry, analytical chemistry, instrumental analysis 
emphasizing the design of analog and digital 
instrumentation, physical chemistry, environmental 
chemistry, and chemometrics. 
Th chemistry of selenium 
Thiokol Chemical Corporation, Huntsville, Alabama. 
Chief Project Chemist, Head of Research Department, 
Director of Research and Assistant to General 
Manager and Technical Director. Themodynamics 
related to rocket propulsion, chemistry of 
polysulfide and butadiene copolymers, synthesis of 
high energy compounds, and rheology of suspensions. 
New formulations developed for ablative plastics, 
reinforced plastics, fiberglass composites. 
Applications and properties of metal whiskers, titanium 
and high strength ferrous alloys. 
of rocket otors and new plant facilities. 
Administrative assignments included responsibility 
for quality assurance program; safety program; 
personnel training programs; coordination of customer 
contacts; and preparation and monitoring of the Five- 
Year Plan and the Annual Operating Plan. 
Supervised design 
1950-51 University of Tennessee, Dissertation work for Ph.D. 
1948-50 Union Carbide Chemicals Corporation, Oak Ridge, Tenn- 
essee. Research Chemist. Studies of the organo- 
metallic and phosphate complexes of iron, uranium, 
and vanadium as a function of proton and electron 
activity. Results applied to leaching of low grade 
uranium containing soils and processing of solutions 
obtained. 
1948-49 University of Tennessee. Lecturer, Organic Chemis- 
try, Oak Ridge Program. 
1947-48 Chemical Warfare Senrice Research Fellow. 
1946-47 University of Tenessee. Instructor, Organic 
Chemistry. 
1944-46 Tennessee Eastman Corporation, Oak Ridge, Tennessee. 
Analytical Chemist. Laboratory Supervisor. Isotope 
Analysis Section. Principal Emphasis: Mass spectro- 
metry, radiation counters, and electrochemistry, 
65 
1942-44 E. I. Dupont, Alabama Ordnance Works. Analytical 
Chemist. Analyses of TNT, tetryl, smokeless powder, 
and the acid8 and organic intermediates used in the 
manufacture of  these materialr. 
PROFESSIONAL ACTIVITIES RELATED TO CURRENT RESEARCH INTERESTS: 
I. Chemometrics and the measurement process. 
included: 
containing pyridine and seleniunr in configurations that favor 
five membered rings for screening as antitumor agents, and 
oximes and tertiary amines from selenophene as reactivators 
and inhibitors for phosphrylated acetyl cholinesterase. 
Instrumentation developments including rapid scan 
spectrophotometry, use of fiber optics, and optrodes for data 
acquisition, and real time data processing. Process 
monitoring in real time. 
methodes for manufacturing optical components. 
Application8 have 
platinum and palladium complexes of compounds 
New materials and processing 
A. Professional Memberships. 
1. American Chemical Society 
2. American Physical Society 
3 .  Optical Society of America. Executive Committee 
Local Section 1969-70, 1972-74. Program Committee 1972. 
4. American Rocket Society. Fellow. American Institute 
of Aeronautics and Astronautics. Associate Fellow. 
Board of Directors, Alabama Section 1965-67. 
5. American Defense Prepardness Association. 
B. Publications and Presentations 
1. C. A. Buehler, J. 0. Harris, W. F. Arendale, 
"Reactions of and Stilbazolas with Selenium 
Dioxide", &. 22, 4953-6 (1950). 
2. W. F. Arendale and C. F. Coleman, Oak Ridge National 
Laboratory Report Y-664, October 1950, "Solubility of 
Uranous Toluene Sulfinate and related Compounds". 
3. W. H. Fletcher, W. F. Arendale, "Geometry of Ketenen. 
PhyS. a, 1898 (1953) 0 
4 .  W. F. Arendale, W. €I. Fletcher, "Infrared Spectra of 
CDZCO and CHDCOn, memo phvs. u, 1431-2 (1951). 
5. W. . Arendale, W. H. Fletcher, "Vibrational-Rotatio- 
nal Bands of Ketenen, Ehem. phvs. 24, 581 (1956). 
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6. 
7. 
8 .  
9. 
10 . 
11 
1 
12. 
1 
E 13 
I 
14 
I 
15 
16 . 
17 
W. F. Arendale, "Fuel-Binder Requirement for Compo- 
site Propellantsm, = - -. a, 725 (1956) . 
W. F. Arendale, W. €I. Fletcher, "Infrared Spectra of 
Ketene and Deuteroketenes", it a phvs. 26, 7937 
(1957) . 
W. F. Arendale, C. F. Coleman, mUraniu-Vanadium 
Recovery and Separation by Phosphate Precipitation", 
U. S. Patent 2,797,143 (1957) 
W. F. Arendale, T. A. Neely, "Solid Propellants", 
Encyclopedia of Chemical Technology, Interscience 
Encyclopedia of New York, 2nd Supplement Edition, 1960. 
W.F. Arendale and Virgil V. Vaughn, Evalu ation ai 
Selected sTechnicNes far Raman. m e r  0R a m  an8 
timulatea Raman mectro SCODV , UARI Research Report 
NO. 57, May 1968. 
. W. F. Arendale and H. Jeffreys, peflecti on nf 
Polarized-LiahtFromNearDiffuse 
urfaces, A thesis submitted by Harold B. Jeffreys in 
partial fullfillment of the requirements for the 
Master's degree, June 1986. 
W. F. Arendale and Harold B. Jeffreys, Studv 
m.tmmdEnercrvFromLaserIlluminatedTarQets, 
Final Report Contract DA-Ol-OZl-AnC-l2250(z), also 
issued as UARI Research Report No. 58, December 1968. 
(not in print). 
W. F. Arendale, "Chemistry of Propellants Based on 
Chemically Crosslinked Bindersm, Paropellants 
Manufacture, Hazard8, and Testing, Advances in 
Chamistry Series NO. 88, American Chemical Society 
Publication, 1969, pp 67-83. 
W. P. Arendale, "The Selenium Dilemma" presented as 
Seminar to the Chemistry Department at the University 
of Alabama i n  Birmingham, February 4, 1976. 
W. F. Arendale, "Solid Propellant Containing Ferro- 
cene Plasticizern, U. S. Patent 4,023,994, May 17, 
1977 . 
W. F. Arendale, "The Selenium Dilemmam, presented as 
UAH Chemistry Department Seminar, September 29, 1978. 
W. F. Arendale, "Thermometric Titrimetry as an Analy- 
tical Method", presented as a Seminar to Alabama ACM, 
Chemistry Department November 29, 1979. 
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I 
18 
19 . 
20. 
21. 
22 . 
23 . 
24 
25 
26. 
W. F. Arendale, wThermometric Titrimetry and Determi- 
nation of Thermodynamic Propertiesw, presented 
a6 a UAH Chemistry Department Seminar, November 30, 
1979 
W. F. Arendale, nPreparation of Selenophene 
Derivatives For Invivo Testing, A Pilot Studyw, 
proposal to U.S. Army Medical Research and 
Development Command, Sept. 1982. 
W. F. Arendale, Larry A. Parker* and Robert T.Quier 
Jr.*, %andling and Disposal of Chemical Wastew, Work- 
shop UAH Campus, December 8-10, 1982. (+  J .  T. Baker 
Chemical Company) . 
W. F. Arendale, "Linpack Fortran I V  Subroutines Now 
Available", Computer Words X I 1  Nov 1982, p5. 
W. F. Arendale and Phillip Franklin, "The Disso- 
ciation Constant(s) for 2,2'-Pyridyl Thiophenen, 
presented Alabama Academy of Science Meeting, Tusca- 
loosa, Alabama, March 3-5, 1983. Abstract published 
The Journal of the Alabama Academy of Science, N, 
133 (1983) 
W. F. Arendale, V h e  Transition From Analog to 
Digital Data Acquisition", presented to the South- 
eastern Analytical Chemist Association April 14-16, 
1983 
W. F. Arendale, "A Preliminary Evaluation Of The 
Guided Wave, Optical Waveguide Spectrophotometerw, 
presented to the Southeastern Analytical Chemist 
Association, April 26-28, 1984. 
W. F. Arendale, "The W Spectrum of Benzene Using a 
Rapid Scan Spectrophotometerw, presented to the 
Southeastern Analytical Association, April 18-20, 
1985 
W. F. Arendale, "Use of Target Factor Analysis to 
Calculate Acid Dissociation Constantsw, presented to 
Chemistry Section, Alabama Academy of Science, March 
26, 1987. Abstract published The Journal of the 
Alabama Academy of Science, 1987, 58, 95. 
68 
11. Epistemology, philosophy of ~cience, pedagogy of science 
A. Professional membership6 
1. 
2. 
3. 
4 .  
5 .  
60 
7. 
8. 
9. 
10 . 
Alabama Academy 02 Science. 
72, Chairman, Local Arrangements Committee Annual 
Meeting 1966-67 and 1972-73. Finance Committee 1969- 
73. President 1978-79. Delegate to National Asso- 
ciation 02 Academies 1979-. 
Committee on Requirements for Certification of High 
School Teachers, 1980-, Committee for Long Range 
Planning 1982- . 
American Association of Advancement of Science. 
Fellow. COHdttee x 1979-1986, Committee Y, 1986- . 
Fellow, Treasurer 1969- 
Delegate to AMs 
Committee X, 1979-1986, COIUUittee Y81986- . Special 
American Chemical Society. Member, Chemical 
Education and Physical Chemistry Sections. 
1954, Chairman-Elect 1955 and Chairman 1956 North 
Alabama Secion. 
Secretary 
National Science Teachers Association. 
Society of College Science Teachers. Committee on 
Science and Technology 1982- . 
Alabama Science Teachers Association. Member of 
Committee on Science and Technology 1982-. 
Alabama Education Association. 
The Gorgas Scholarship Foundation, Inc., Trustee 
Rotary Club, Huntsville, Alabama. Member Scholarship 
Committee 1972-76. Member International Relations 
Committee 1977-78. 
19730. 
Chemistry Department Committee for Self-study on 
State Department of Education Requirements for 
Teacher Certification. 
B. Publications and Presentations 
1. W. F. Arendale, "Should Chszists Be Trained as Astro- 
nauts (Are Trained)w, prepared for Chemical Educat- 
ion Conference, Holyoke, Massachusetts, August 1972. 
Invited as panelist for one session of conference. 
Reported Chem, Ep. a# 17 (1973) 
2. W. F. Arendale, "The Purpose and 
Introductory Chemistry Coursesw, 
Conference on Chemical Education, 
69 
Content of 
The Third Biennal 
July 30, 1974. 
3 .  
4.  
5 .  
6. 
7. 
8. 
9. 
10 . 
11. 
12 . 
13 . 
W. P. Arendale, Weaaured as We MeasureN, presented 
as Keynote Address, Luncheon, First Annual UAH metric 
Conference, January 27, 1977. 
W. P. Arendale, NThermodynamics a La Piaget, Weinhold 
and Gibbsu, presented 174th ACS National Meeting, 
Chicage, Illinois, August 31, 1977. 
W. F. Arendale, NA Chemist's Search for the.Missing 
VolumeN, presented to Alabama Academy of Science 
Meeting, April 1978. 
W. F. Arendale, Whould Chemists be Trained as 
Astronauts (Are Trained) - A Second LookN, presented 
Fifth Biennial Conference on Chemical Education, F o r t  
Collins, Colorade, July 26, 1978. 
W. F. Arendale, Critique of papers presented in 
Session titled, %enera1 Papers An, Fifth Biennial 
Conference on Chemical Education, Fort Collins, 
Colorade, July, 1978, published L Chem. Eg. M, 10 
(1979) . 
W. F. Arendale, "The Alabama Secondary Principals 
Association Position on Teaching of ScienceN, 
presented to Huntsville-Madison County Science 
Teachers December meeting, December, 1978. 
W. F. Arendale, "The Scientific Method? An 
Introduction to EpistemologyN, talk to Huntsville 
Mensa, March 16, 1979. Talk arranged by the UAH 
Speaker's Bureau. 
W. F. Arendale, NSafety and the Lawu, amd wCourse 
Summaryn, concluding talks in Course on Laboratory 
Safety arranged by Alabama Department of Education 
and Huntsville-Madison County Science Teachers 
Association. Banquet speaker, May 7, 1979. 
W. F. Arendale, w a t i v a  Fnalvsh Labomtory 
Fall Term 1979. 2nd edition, Winter Term 
1980. 
W. F. Arendale, Vhe Free Enterprise SystemN. Talk 
to Sparban High School students. 
Huntsville-Madison County Chamber of Commerce, March 
Sponsored by 
3 ,  1980. 
W. F. Arendale, Proposal to Department of Education, 
Wsing a Personal Computer For Computer Assisted 
Lecturing (CAI,)". Dec. 15, 1982. 
70 
I 
Y 
1 
14. W. F. Arendale, "Replace That Overhead Projector With 
Your Computerw, presentation to Science Education 
Section, Alabama Academy of  Science, April 29, 1985. 
Abstract published Journal of the Alabama Academy 
Science u, 135, 19580 
C. Reviews of Text for Journal of Chemical Education. 
1 
J 
I 
n 
I 
II 
W. F. Arendale, Book Review of C. DOdson, Wstxy 
W. F. Arendale, Book Review of Charles G. Wade, 
Contemporary Chemistry, J. Chem. Ed. 558 A105, 
(1978) 0 
W. F. Arendale, Book Review of Mary Maier, utro- 
duction u! Chemic a1 Science, submitted Journal of 
Chemical Education. Editor decided that book did not 
deserve review. 
W. F. Arendale, Book Review of Clyde R. Dillard and 
ana Pronerti es, published L Chem. Ep. x, A223 
W. P. Arendale, Book Review of Audrey L. Companion. 
memica1 Bonding, published L Chem. a. x, A220 
Daniel E. Goldberg, Chemistrv, Reactions. Structure Q L  
(1979) 0 
(1980) 0 
W. F. Arendale, Book Review of Robert L. Wolke, 
Chemistry Explained, J.  Chem. Ed. 58, A65 (1981). 
W. F. Arendale, Book Review of Ralph S. Becker and 
Wayne E. Wentworth, Genera C h e m w ,  2nd addition, 
A201, (1982) 0 
W. P. Arendale, Review of Software S. J .  Moss, 
"Free Radical Polymerization Using the Rotating 
Sector Methodow 
Chemical Education. Publication pending. June 1983. 
W. F. Arendale, Review of George 0. Abell and Barry 
Singer, Science f;ha paranormaL for Journal of 
College Science Teaching, 1983. 
W. F. Arendale, Review of Barbara Gastel, DeRenthg 
S c i e m  &Q f;ha public, for Journal of College Science 
Teaching, 1984. 
Project Seraphim and Journal of 
W. F. Arendale, Review of F. W. Pifield and d. 
Kealey, Uvtical-8 submitted to Journal of 
Chemical Education, August 1985. 
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RESUME 
NAME: TmothylLeeHu81 
RANK: ResearchAdystIII 
POSITION Lead Microbiologist 
EDUCATION 
B.S. in Microbiology, University of Alabama, 1980 
M.S. in Microbiology, University of Alabama, 1982 
Professional Societies and Honors: 
Alpha Lambda Delta (Freshman Honorary) 
Arts and Sciences Honors Program (inactive) 
D e a a ’ s k t  1976,1979 
President of Pasteur society 1979-1980 
Collegiate Civitan 
. 
SKILLS: 
Bacterial Culture Curator 
Regulation of Antibody Responses (adjuvant studies) 
T and B Cell Collaboration 
Tissue Culture (includin cell line and h bridoma) 
Gel Electrophoresis 
Chromosomal and Plasmid DNA Isolation and Characterization 
Column CHromatograp h y (including ge 1 and affinity) 
Environmental Bacteria 
Wet Chemistry Techniques 
PROFESSIONAL EXPERIENCE 
The University of Alabama in Huntsville 
Kenneth E Johnson Research Center 
Position: Lead Microbiologist 
Oklahoma Medical Research Foundation 
Oklahoma City, OK 
Position: Research h i s t a n t  
Aug 1986 - Present 
Sep 1985 -June 1986 
The University of Texas 
MdcalBranch 
Department of Mcrobiolop 
Position: Research Asmaate 
April 1982 - Aug 1985 
PROFESSIONAL EXPERIENCE: (ant) 
"'he University of Alabama 
Department of Miaobioloky 
Position: Graduate Teachmg Assistant 
Sep 1980 - March 1982 
PUBLICATIONS: 
Articles: 
Stinson, R.S., R.D. Lemmon, D.W. Bag et, T.L. Huff, J.A. Malone, G.L. 
Borde teb  pertus& vaccine by detergent treatment. Journal of Biol. 
Sloan, A.L. Winters. 1986. Removal o f lipopolysaccharide from acellular 
Stand. 14:261-271. 
Weigent, D.A., E.H. Beachy, T.L. Huff, J.W. Peterson, G.J. Stanton and S. 
Baron. 1983. Induction of human gamma interferon by structurally defined 
pol ptide fragments of Group A Streptococcal M Protein. Infect. Immun. 
43:l % -126. 
Abstracts: 
Huff, T.L., D.A. Weigent, J.W. Peterson, G.J. Stanton and S. Baron. 1985. 
Induction of IFN gamma by Streptococcal M protein and host resistance to a 
bacterial challen e. Presented at the Texas branch meeting of the American 
Wei ent, D.A., T.L. Huff, J.W. Peterson, S. Baron and G. John Stanton. 
198f  Bacterial induced interferon (IFN) protects mice against 
pneumococcal infections. Presnted at FASEB Spring Meeting. 
Weigent, D.A., E.H. Beachy, J.W. Peterson, T.L. Huff, et.al. 1983. 
Induction of human gamma interferon by peptic extracts of streptococcal M 
Annual Meeting of the Amencan Society for Microbiology, New 
Huff, T.L., D.A. Wei ent, J.W. Peterson, et.al. 1983. Isolation and 
characterization of an ib N inducer in Presnted 
at the Texas branch meeting of the A m e r i c a n - a r  
Clark, LA, T.L. Huff, A.L. Winters and R.S. Stinson. Leukocyte 
and macrophaqe responses to Bordetella nertussiss whole cell and 
experimental vaame 15A-1B. 
Huff, T.L. Huff., J.A Clark, A.L. Winters and R.S. Stinson. 1982. 
Comparison of the rotective and immunolopical properties of B o r d e t e b  
Dertusais whole cel P and experimental vaccines. Federation Proc. Vol. 
419283. 
Society for Micro 6 iology. 
&%LA 
1982. 
Huff, T.L., J.A. Clark, A.L. Winters and R.S. Stinson. 1982. Comparitive 
stud of whole cell and experimental B o r d w  vaccines in mice. 
FA&B sp  ring Meeting 
I 
I 
I 
1 
I 
I 
Clark, J.A. T.L. Huff, et.al. 1982. Role of eritoneal and alveolar 
macrophages in immunity to Bordetella Dertussis. FASEB B pring Meeting. 
Robert J. Zahorchak, Elizabeth E. Richard, and ? mothy L HU& 
Jr., Robert J. Zahorchak, E r izabeth E. Richard, Timothy L. Huff, Shawn E. 
Research- 
Multifil tration Unit Microbiological Anal sis. Melvin V. Kilgore, Jr., 
Shower Water Phase 11 Stud . Microbiological Analysis. Melvin V. Kilgore, 
Prince and Natalie R Otey. 
S iral Wound Reverse Ososis Unit Microbiolo ical Analysis. Melvin V. 
I& ore, Jr., Robert J. Zahorchak, Elizabeth E! Richard and Timothy L. 
H& 
Hollow Fiber Reverse Osmosis Unit Microbiolo ical Anal sis. Melvin V. 
Kilgore Jr., Robert J. Zahorchak, Elizabeth E. kichard, '&mothy L. Huff, 
Shawn E. Prince and Natalie R. Otey. 
Urine Pre-Treatment Mixer Microbiological Anal sis. Melvin V. Kilgore Jr., 
Robert J Zahorchak, Elizabeth E. Richard and Timothy L Huf€. 
Humidity Condensate Heat Exchanger Microbiolo ical Analysis. Melvin V. 
Kilgore Jr., Robert J. Zahorchak, Elizabeth E. Richard an d Timothy L Huff. 
Stinson, R.S., T.L H u g  J. Robinson, G. Sloan, R. Lemon and A Winters. 
Immunomodulation of Borde t e& whole cell vaccine and acellular 
fractions. (Submitted to Infect. 
Huff, T.L., D,.A. Wei ent, J.W. Peterson, S. Baron and G. John Stanton. 
M protein and its role in Induction of gamma 
response to bacterid challenge. f!!%%%% ect. Immun.). 
Huff, T.L., D.A. Weigent, J.W. Peterson, G.J. Stanton, E.H. Beachy and S. 
Baron. Isolation and characterization of a M protein-like inducer from 
& b y  F 
r>neumoniae. (Submitted to Infect. Immur~). 
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RESUME 
NAME: 'Theresa Ann Curry 
RANK: Research Analyst II 
POSITION Microbiologist 
EDUCATION Ma 1983: B.S. in Microbiology-University of 
Ala r( amainHuntsville. 
HONORS AND 
ACIWITES Al ha Lambda, Freshman Honor Socie Athletic f !Lociation Sc olarship- 1980; Alumni 
Scholarshi -1981; Dean's list-five quarters; 
Tri-Beta ational Biolo ical Honor Societ f President-1982-83; Who's do Among Students 
American Universities and Colleges; Voted 
"Outstanding Senior". 
Fr 
PROFESSIONAL 
AFFILIATIONS: 
American Society for Microbiology 
American Society for Quality Control 
PROFESSIONAL EXPERIENCE: 
The University of Alabama in Huntsville 
Kenneth E. Johnson Research Center 
Position: Microbiologist 
Sep 1987 - Present 
Augusta Reading Foundation 
School for Dyslexic & Hyperkinetic Children 
Position: Biology Teacher 
Sep 1986 - Aug 1987 
KendU Company 
Microbiology Division 
Position: Laboratory Supenrisor 
Aug 1983 - Aug 1986 
Supervisor. Main responsibilities include supervision o y  LaboratorJ seven (7 Employed 3 years with the Kendall Company as Microbiolo 
technicians which perform bioburden and resistance studies, sterility 
testing, LAL pyrogen testing and support testing for the company. Other 
responsibilities include environmental monitoring, certifying equi ment 
indicators. 
{including production sterilizers) and product, and validating bio P ogical 
PROFESSIONAL EXPERIENCE: (cont) 
The University of Alabama in Huntsville 
Department of Biol 'cal Sciences 
Position: Laboratory "es! echnician 
1981 - 1983 
Responsibilities included: Preparation of media, buffers, microbiological 
reagents and stains, maintenance of stock cultures and departmental ammal 
room. Familiar with Public Health rules for treatment of laboratory 
animals. Other responsibilities included supervision of other lab- 
assistants in microbiology prep room and assisting in laboratory 
instIUCtiOtL 
Industrial Sterilization and Microbiological Quality Control-1983 
Limulus Amebocyte Lysate Workshop on Testing and Regulation-1984 
Statistical Process Control Methods Workshop1985 
Quality Control In The Microbiology Laboratory-1985. 
PUBLICATIONS: 
"The interaction between Candida blastospores and murine alveolar 
and peritoneal macrophages." Presented at American Society for 
Microbiology, New Orleans, LA, Marc4 1983. 
APPENDIX C 
Current Medical Support Team 
Bibliography 
Scientific Papers And Posters; List Of Abstracts. Aerospace 
Medical Association Annual Scientific Meeting,l985. 
ABSTRACT: None - 8 Naturwissenschaften. 73:OOOl-0455. 1986. 
1 
ABSTRACT: None 
Methods For Measuring The Acute Toxicity Of Effluents To Aquatic 
Organisms, 3rd Edition. Environmental Monitoring and Support 
Laboratory, Office of Research and Development, U.S. 
Environmental Protection Agency, Cincinnati.,l985. 
ABSTRACT: This manual describes methods for measuring the acute 
toxicity of effluents to freshwater and marine macroinvertebrates 
and fish. The methods include a preliminary ranqe-finding test, 
a screening test, and multi-concentration (definitive) static and 
flow-through toxicity tests. Also included are guidelines on 
laboratory safety, quality assurance, facilities and equipment, 
effluent sampling and holding, dilution water, test species 
selection and handling, data interpretation and utilization, 
report preparation, organism culturing, and dilutor and mobile 
bioassay laboratory design. 
I 
I 
a 
1 
Streptomyces DD-Carboxypeptidase-Transpeptidases. Exopeptidases, 8 Chapter 51, :0611-0636. . 
ABSTRACT: None 
Skylab Mission Report Third Visit. NASA/JSC 08963, Houston, Texas, 
1974. 
ABSTRACT: In addition to microbial monitoring o f  the crewmembers I 
as detailed in JSC-16888, attention must be given t o  the reusable 
spacecraft and its associated hardware. This monitoring will 
provide a basis for implementation of appropriate prophylaxis, 
treatment, or replacement procedures f o r  insuring the maximum 
safety of crewmenbers. The increased crew size may result i n  a n  
increased microbial l o a d  within the Shuttle orbiter and thereby 
provide a potential for microbial contaminatin and buildup. 
Microbiological sampling and monitoring of selected sites and 
components within the confines of the spacecraft will be u s e d  fcr 
evaluation actual or potential microbial contamination. T h e  
comparison of pre- and postflight data will as a monitor of the 
effectiveness of cleanup procedures in preparation for a 
subsequent mission. 
1 
I 
u 
Microbial Sample Collection Handbook. NASA/JSC-18633, 1983. 
ABSTRACT: None 
8 Space Lab 3 Microbial Contamination Control Plan In S u p p o r t  O f  DSO 0437. NASA JSC2 0381,. 
ABSTRACT: This document will encompass s p e c i f i c  g u i d e l i n e s  a n d  I 
ORIGINAL PAGE PS 
OF POOR QUALITY 
3Irj l IC :RAPHY LIS. - I 
procedures f o r  the monitoring of crewmembers, animals, 
spacecraft, Spacelab, animals housing, Hangar L,and the Research 
Animal Holding Facility (RAHF), and animal food and water for the 
Spacelab 3 (SL-3) mission. The microbial sampling schedule 1s 
given in Table 1. 
Test Results Operational Ninety-Day Manned Test Of A Regenerative 
Life Support System. Advance Biotechnology And Power 
Department, McDonnell Douglas Astronautics Compant For Langley 
Research Center, NASA. NASA CR-111881, MDC G2282,. 
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ABSTRACT: None 
KDI Quick Test. Keystone Diagonostics, INC., 9062 Route 108, 
Columbia, Maryland 21045, 301-992-7592,. 
ABSTRACT: The KDI QUIK TEST Drug Screens are the first practical 
approach to drug testing in the workplace. Rapid, economical, 
accurate and simple-to-use, the screening procedures will detect 
drugs of abuse in urine samples. 
I 
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Cancer Risk of Pestivides in Agricultural Workers. JAMA, 260/7 
:0959-0966. 1988. 
ABSTRACT: This report discusses some of the inherent limltalons 
of  cancer studies in animals and humans and presents a 
qualitative carcinogen risk assessment of a numger of pesticides 
based on the judgment of national and international authorities 
who have reviewed the availabel experimental and epidemiologic 
evidence. A large number of  pesticidal compounds have shown 
evidence of genotoxicity or carcinogenicity in animal and in 
vitro screening tests, but no pesticiedes-except arsenic and 
vinyl chloride( once used as an aerosol propellant)- definitely 
have been proved to be carcinogenic in man. Resolution 94 
(1-861, which was referred to the Board of Trustees, calls f o r  
the American Medical Association, through its scientific journals ! and publications, to alert physicians to the potential hazards of  
agricultural pesticides, to provide physicians with advice on 
such hazards for  their patients, and to urge that these 8 substances be appropriately labeled. This report addresses the 
potential carcinogenicity of pesticides by review of the 
available literature. a Pentoxifylline and Leukocyte Function. Pentoxifylline and Leukocyte 
1 
I 
Function, :0001-0252. 1987. 
ABSTRACT: None 
Essays in Microbiology. Essays Micro., :0002-0031. 1978. E ABSTRACT: None 
Troubled Waters. Hippocrates, 1988. 
ABSTRACT: When you discover that the very water you drink is 
deadly, you don't just sit back and take it. Four communities I 
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tell their stories. 
I A t  14s  of the Light Scattering Characteristics of Microparticles. 
Science Spectrum, Inc., Santa Barbara, California 93105,1975. 
ABSTRACT: This Atlas is a collection of differential scattering 
patterns, i.e. the relative intensity of scattered light as a 
function of the angle of scattering. It has been prepared for 
use with the Differential 1 and Differential 11 light scattering 
photometers manufactured by Science Spectrum, Inc., Santa 
Barbara, California. Most of the data are presented to 
correspond to the use of plane-polarized green laser light of 
- I 
I 
t wavelength 514.5nm. 
Bottled Water Study. Environmental Protection Agency PB-227 736, 
1972. 
ABSTRACT: Although piped water is available to at least 75 
percent of the nation's population, the production and sale of  
bottled water has become an established and growing industry. In 
some parts of the country, particularly in those areas where the 
only available natural vater is heavily mineralized, bottled 
water has always been an important source of drinking water. 
Since the recently aroused interest in our environment, the use 
of bottled water has rapidly increased. Fears regarding the 
pollution of city vater supplies, whether or not founded on fact, 
have caused people to distrust the quality of the product issuing 
from the faucet. In addition, a dissatisfaction by the public 
with the taste and odor of their drinking waters has influenced 
the increase in the use of bottled waters. Rising affluence has 
also had a part, since people could now afford to purchase a 
deluxe product, supposedly much superior to the every day waters 
that the city water system provided. When, in 1970, a study of 
Community Water Supplies vas published by the Water Supply 
Division, Environmental Protection Agency (then the Bueau of 
Water Hygiene, United States Public Health Service), the bottled 
water industry received an unexpected (and unintentional 1 boost. 
The study revealed shortcomings and potential hazards in many 
communtiy water supplies, and the immediate reaction of the 
public was distrust of piped water and an increase in sales of 
bottled water. The Water Supply Division recognized the 
importance of this increase in the use o f  bottled waters by the 
public and was interested in determining the quality and health 
surveillance being provided by the manufacturers. To determine 
existing conditons a small pilot survey was undertaken. 
I 
d 
Bottled Water. Published by the Office of the Federal Register 
National Archives and Records Administration (21 Parts 100 to 
169) ,1986. 
ABSTRACT: Bottled water sold in interstate commerce is under the I 
jurisdiction of the Food and Drug Administration, DHEW. FDA has 
established quality standards for bottled water which are 
essentiallly equivalent to the EPA standards in effect for tap 
water. However, there is no monitoring program for bottled water 
as there is for tap water, s o  compliance with FDA's standards 
1 
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cannot be determined for a particular brand of bottled water 
without actually having an analysis performed. Most states also 
have regulations pertaining to bottled water, but few states have 
programs for monitoring the quality of bottled water available 
within their jurisdictions. Bott2ed water may be distilled and 
reconstituted to a particular formula, may be carbon filtered, 
ozonated, or may receive various onter kinds of treatment. These 
processes are intended to produce a bottled water which is 
pleasing to the taste and is consistent in aesthetic 
characteristics. While some of the types of treatment can be 
expected to remove contaminants, no information is available on 
the contaminants, no information is available on the contaminant 
content of any of the many brands of bottled water. Since 
bottled water is most frequently sold on the basis of its 
aesthetic characteristics, the consumer's choice is usually based 
on his personal taste preference. No comparison of bottled 
waters on the basis of  purity or freedom from contaminants has 
been made. If a consumer is interested in the quality of a 
particular brand (or lot) of bottled water, he should contact the 
Bureau of Foods, Food and Drug Administration, DHW, Washington, 
D.C. 2 0 2 0 4 ;  or the State agency responsible for regulation of 
bottled water. The latter may be the health department, the 
departmlent of the environment, or the agriculture department 
depending on the individual state. If these agencies do not have 
the desired information, the consumer may wish to have a sample 
analyzed by a private water testing laboratory. It would be 
advisable to specify which contaminants the analyst is to look 
for in such cases, since the cost of the analysis is dependent on 
the number and nature of contaminants investigated. 
~ 
Monoclonal-Based Tests for Respiratory Syncytial Virus, Adenovirus 
and Influenza Virus A & B. Analytab Products, Division of 
Sherwood Medical, 2 0 0  Express Street, Plainview, NY 118903,. 
ABSTRACT: Accurate and reliable-Four times faster than indirect 
method, Rapid, one-step direct immunofluorescent technique 
Pumphrey Avenue, Auburn Al. 36830,. 
ABSTRACT: EPA estimates that there are approximately 2,000,000 
underground storage tanks (UTS) in the U.S. Most of these tanks 
contain petroleum products, petrochemicals or other chemicals. 
It is estimated that approximately 16,000 of these tanks contain 
hazardous waste. Various trade organizations and regulatory 
agencies have estimated that from two to 2 5  percent of these USTs 
are leaking. Products leaking from USTs can cause a variety of 
problems with enormous financial liabilities for the UST owner. 
Some products may leak from the UST and contaminate the 
surrounding soil and groundwater. Other products may travel 
through the soil as a vapor, accumulate in basements of nearby 
structures and reach explosive or toxic concentrations. In many 
cases, migration of both liquid and vapor phases will occur, 
endangering human health and the environment. Abandoning a 
nonleaking UST can cost the owner $10,000-20,000 depending on 
tank contents and final disposition of the tank, Remediation of 
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damage caused by leaking USTs can easily exceed $25,000 
considering long term monitioring under an approved restoration 
and closure program. There are certain cases involoving 
extensive soil and groundwater contamination in which remediation 
costs have exceeded $ 3  million. Lawsuits in excess of $ 2  billon 
have been filed for damages due to leaking USTs at a single 
service station. Clearly the UST problem impacts anyone involved 
with property on which UST is sited. Parties to a lawsuit 
resulting from a leaking UST (LUST) can easily include the 
property owner, the tenant (if the property is leased), real 
estate firms, mortgage bankers and lenders. amd the tank 
installer. 
Genetics and Biochemistry of Pseudomonas. Genetics and Biochemistry 
of Pseudomonas, :0001-0341. 1975. 
ABSTRACT: Over the years microbial biochemists have been 
challenged by the diversity of the metabolic reactions catalysed 
by members of the genus Pseudomonas and consequently their 
investigation of members of this genus has played a vital part in 
building up our knowledge of bacterial intermediary metabolism, 
particularly with respect to possible degradative routes. 
Latterly, interest in the pseudomonads has become much wider. 
Not only has the relative eclipse of Gram-positive bacteria as 
human pathogens revealed the presence of the so-called 
opportunistic pathogens (of which Pseudomonas aeruginosa is a 
particularly vicious example), but also pseudomonads have assumed 
a steadily increasing importance in industrial microbiology. 
Much of our knowledge of modern molecular biology has come from 
studies on Escherichia coli, but this organism is far from 
universally representative. It is to try to define what is known 
of another group of bacterial species of potential practical 
importance that these contributions have been collected and 
published in this form. 
Abe M., Higashi S. B-Glucosidase And B-Galactosidase From The 
Periplasmic Space Of Rhizobium trifolii Cells. J. Gen. Appl. 
Micro. , 28~0551-0562. 1982. 
ABSTRACT: High amounts of B-glucosidase (MW 74,000) and 
B-galactosidase (MW 1 2 2 , 0 0 0 )  were isolated from the periplasmic 
space of Rhiaobium trifolii 4s (infectious strain), compared with 
the cell homogenated. The characterization of B-glucosidase and 
B-galactosidase was determined. Both enzymes were inhibited by 
the addition of Cu2+, Fez+, Zn2t, Hg2t and p-chloromercuribenzoic 
acid. The B-glucosidase exhibited a strong hydrolytic activity 
on cellobiose, sophorose and laminaribiose to glucose, and the 
B-galactosidase degraded lactose and 
O-B-D-galactosyl-1,3-D-arabinoside to their respective 
components. Both enzymes hydrolyzed polysaccharide only 
sl ight ly . 
Altman P.L., Talbot J.M. Nutrition and Metabolism in Spaceflight. J. 
Nutr., 117:0421-0427. 1987. 
ABSTRACT: The U.S. Space Station being planned f o r  the 1990s wlll 
. LLIOGKAPHI LISTING 
accommodate six or more crew members on 90-d flights in low earth 
orbit. Adequate nutrition will be essential for maintaining crew 
health, effectiveness and morale. Although much is known from 
prior space experience about in-flight metabolism, nutrition and 
associated food technology, imporBant gaps in knowledge exist 
that need additional research, development and analysis to meet 
Space Station requirements. This paper is a synopsis of a report 
prepared be the Life Sciences Research Office (LSRO), FASEB, from 
a study of the nutritional and metabolic aspects of spaceflight. 
It reviews available data on the metabolic responses t o  
spaceflgiht including extravehicular activity, physiological 
reponses to microgravity that influence metabolism and energy 
needs, in-flight nutritional experience, space menus, food 
packaging,in-flight food service methodology, water supply and 
disposal of food wastes. The LSRO ad hoc Working Group 
identified critical gaps in knowledge and suggested corresponding 
research approaches for acquiring essential new data. The 38 
research suggestions detailed in the report address in-flight 
metabolic needs, nutrient requirements, for systems and 
nutritional countermeasures. 
ames J.B., Howard G., Blanden P.D., Krygier V. Bacterial and 
Endotoxin Retention by Charge-modified Filters. Semiconductor 
International, :80-82. 1988. 
ABSTRACT: A past study showed that bacteria can peretrate 0 . 2  um 
rated sterilizing grade filters during long-term water service. 
However, it was demonstrated that 0.1 um rated filters can retain 
100% of these bacteria. Thus, the question of grow-through or 
penetration during periods of long-term water service can be 
resolved if a 0.1 rated (or finer) filter is used and properly 
maintained. Growthrough will not then occur. Concern over the 
breakdown of Gram negative bacteria collected on the filter 
surface, to give cell fragments which then may peretrate the 
filter, has been studied. These bacterial cell wall fragments, 
which contain endotoxins, have a negative charge in water and can 
be removed by a positively charged matrix. 
Anderson D.J., Reschke M.F., Homick J . E . ,  Werness S.A.S. Dynamic 
Posture Analysis Of Spacelab-1 Crew Members. Exp. Brain Res., 
64:0380-0391. 1986. 
ABSTRACT: Dynamica posture testing was conducted on the science 
c ~ e w  of the Spacelab-1 mission on a single axis linear motion 
platform. Tests took place in pre- and post-flight sessions 
lasting approximately 2 0  min each. The pre-flight tests were 
widely spaced over the several months prior to the mission while 
the post-flight tests were conducted over the first, second, 
fourth, and sixth days after landing. Two of the crew members 
were also tested on the day of landing. Consistent with previous 
postural testing conducted on flight crews, these crew members 
were able to complete simple postural tasks to an acceptable 
level even in the first few hours after landing. Our test were 
designed to induce dynamic postural responses using a variety of 
stimuli and from these responses, evaluate subtle changes in the 
postural control system which had occurred over the duration of 
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the flight. Periodic sampling post-flight allowed us to observe 
the time course of readaption to terrestrial life. Our 
observations of hip and shoulder position, when subjected to 
careful analysis, indicated modificaton of the postural response 
from pre- to past-flight and that-demonstratable adjustments in 
the dynamic control of their postural systems were taking place 
in the first few days after flight. For transient stimuli where 
the platform on which they were asked to stand quickly moved a 
few centimeters fore ar aft then stopped, ballistic or open loop 
'programs' would closely characterize the response. During these 
responses the desired target position was not always achieved and 
of equal importance not always properly corrected some 15 seconds 
after the platform ceased to move. The persistent observation 
was that the subjects had a much stronger dependence on visual 
stabilization post-flight than pre-flight. This vas best 
illustrated by a slow or only partial recovery to an upward 
posture after a transient base-of-support movement with eyes 
open. Postural responses to peristent wideband pseudorandom 
base-of-support translation stimuli were modeled as time 
invarient linear systems arrived at by Kalman adaptive filter 
techniques. Derived model parameters such as damping factor and 
fundamental frequency of the closed loop system showed 
significant modification between pre- and post-flight. This 
phenomenon is best characterized by movement of the poles toward 
increasing stability. While pre-flight data tended to show 
shoulders and hips moving in phase with each other, post-flight 
data showed a more disjoint behavior. One can speculate that 
this change illustrates a shattered postural organizaton or an 
acquired strategy not designed to stabilize terestrial posture 
but as a carry over from optimum inflight postural control. 
Given our observations one can never be certain if these changes 
represent modifications in the physiology of posture of 
purposeful changes in strategy. As in other examples of motion 
behavior, the time domain analysis as represented by the step 
changes in position is not always reconcilable with the system 
modeling of pseudorandum responses and subsequent frequency 
domain analysis as represented by the pseudorandum noise stimuli. 
We present the observed data with arguments and some 
contradictions as to the nature of the adaptive changes which 
occur in the postural control system. 
Armstrong D.W., Martin S.M. Bacterial Fermentation Of Cellulose: 
Effect Of Physical and Chemical Parameters. Biotech. Bioeng., 
2 5 : 2 5 6 7 - 2 5 7 5 .  1983. 
ABSTRACT: Acetivibrio cellulolyticus converts cellulose directly 
to ethanol, acetate, H2, and C02. The effects of various 
physical and chemical parameters, and their interdependence, 
including pH, temperature, redox, and ethanol toxicity on this 
fermentation, were studied. Controlling pH at 6 . 8  favored a 
predominance of ethanol over acetate. Supplementation of the 
medium with additional reductant, concomitant with a lower redox 
potential, increased ethanol formation. Results from 
ethanol-challenged cultures indicated that cell lysis occurs with 
growing but not with nongrowing cells. A stable strain was 
adapted for growth in ethanol concentrations almost sevenfold 
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greater than the parent organism. 
Microbe. Microbiological Headlines,:0011. 1984. 
Associated Press .  Drug Produced On Space Flight Is Contaminated By 
ABSTQACT: None 
Baisch F., Beck L. Body Impedance Measurement During SpaceLab Mission 
D1 . The Physiologist, 30/1:S0047-S0048. 1987. 
ABSTRACT: Quantificatlon of body fluid redistribution and loss 
during space flight and observation of the effects on the heart 
were the aims of this experiment. The impedance of two body 
segments (Z-torso and Z-body) to a 100 k H z  1mA constant current, 
the first derivative of the torso segment and the ECG were 
recorded with a 24-hs personal recorder. Data were obtained from 
two astronauts during launch and reentry and inflight from 
another two. The recumbent period prior to launch is decisive 
for fluid redistribution in the compartments covered by this 
method. The amount of fluid shifted is comparable to that 
produced by daily positional changes. A fluid loss of about 2.51 
can be infered through the values of Z-body and anthropometric 
factors. Cardiac output, as assessed by dZ/dt, was increased 
more than 30% of control even of the 2nd inflight day; on the 4th 
day its values were however lower than pre-flight. It was not 
possible to demonstrate deconditioning effects on the heart of 
the payload specialists during this multidsciplinary Spacelab 
Mission. Heart rate and its variability strongly suggest 
increased cardiac parasympathetic activity. 
I 
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Balazs M.K. A Summary Of New Methods For Measuring Contaminants In 
Ultrapure Water. Microcontamination, January:0035-0040, 1 0062-0063. 1987. 
c ABSTRACT: It has been will documented that the presence of trace quantities of materials in ultrapure water can have a devastating effect on the yield percentage of semiconductor manufacturing 
operations, In the past ten years, this problem has been a major 
focal point for bouth manufacturers of water-purifying equipment 
and the analytical laboratories that test the water. The results 
of their combined efforts have led to a severe tightening of 
pure-water specifications. In spite of the tremendous 
improvements that have been made in the quality of pure water, 
however, it has become apparent that water specifications need to 
be tightened even more because of  the reduced linewidths and film 
thicknesses of  today's ICs. In order to tighten the 
specifications, it must be possible to measure smaller quantities 
of material in pure water-something it is not always possible to 
do using current methods of analysis. 
Microcontamination, 1988. 
ABSTRACT: During the next five years, we'll see much more 
widespread use of ozone in the semiconductor industry. More than 
95% of all contamination problems that affect 
I 
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semiconductor-device yields are caused by organic compounds. 
Specification for purified water will continue t o  tighten as 
further improvements occur in our ability to detect lower and 
lover levels of contaminants. 
Barabas S .  Monitoring Natural Waters for Drinking-Water Quality. Wld. 
- 
Hlth. Sta'sist., 391986. 
ABSTRACT: Reaching the mid-way point in the International 
Drinking Water Supply and Sanitation Decade is a fitting occasion 
to review the progress to date in achieving the Decade's goals. 
There is still time to benefit from both successful case 
histories and failures by learning how to overcome certain 
difficulties, modify approaches or redesign strategies. This 
article will review an international programme which monitors 
water quality, from the perspectives of the safety of 
drinking-water supplies and the protection of water resources on 
which such supplies depend. The significance of this activity 
will be only too apparent if one bears in mind that contaminated 
natural waters are the predominant cause of the most widespread 
diseases on earth today. The availiable statistics are alarming. 
It is reported (1) that over one-half of the world's population, 
or more than 2 billion men, women and children, at one time or 
another, suffer from infectious diseases due to exposure to 
folluted wpters. Approximately 250 million new cases of 
waterborne or water-related diseases are reported each year, from 
which about 10 million die. The article will first outline the 
nature of waterborne diseases and the consideration of fresh 
water as a finite resource. The objectives, orgaization and 
operation of the Global Environmental Monitoring System for Water 
(GEMS/Water) will then be presented, Finally, the water quality 
dqta that have been gathered over the years by the GEMS/Water 
programme will be critically reviewed. 
Barbaree J.M., Gorman G.W. ,  Martin W.T., Fields B.T., Morrill W.E. 
Protocol For Sampling Environmental Sites For Legionellae. App. 
Env. Micro. , 53/7:1454-1458. 1987. 
ABSTRACT: A protocol for sampling environmental sites was 
developed and used to identify possible sources of Legionella 
species in support of epidemiologic investigations at two 
hospitals. In hospital A, legionellae were isolated from 4 3  of 
106 ( 4 0 % )  different sites. Three separate Legionella pneumophila 
serotypes and a previously unrecognized species were present in 
different combinations in the positive samples. Two of five 
cooling towers contained the same L. pneumophila serogroup 1 
monoclonal type i 1 , 2 , 4 , 5 )  as was isolated from patients. The 
same monoclonal type was also isolated from make-up water for the 
two cooling towers, a hot water tank, water separators in four 
main air compressor systems for respiratory therapy, and cold and 
hot water faucets. In hospital B, 13 of 37 ( 3 8 % )  sample sites 
contained legionellae, all of which were L. pneumophila serogroup 
1. The monoclonal type matching isolates from patients (1,2,4,5) 
was found at the highest concentration in a hot water tank, but 
It was a l s o  present at four other sample sites. Since 
legionellae not related to disease may be found in many of t h e  
, E l 3 L  OGRAPHY L. 
sites sampled, an epidemiologic association with the probable 
source should be established before intervention methods, such as 
dlsinfectlon, are undertaken. 
Barnes S., Spenney J.G. Improved Enzymatlc Assays for Blle Acids 
Using Resazurin and NADH Oxidoreductase From Clostrldlum 
Kluyveri. Clin. Chimica., 102/2-3:0241-0245. 1980. 
ABSTRACT: The recent application of resazurin as a fluorigenic 
electron acceptor in the enzymatic analysis of bile acids has 
proveded a simple and specific method for serum bile acid 
quantitation in clinical analysis [1,21. The absence of blank 
sample fluorescence, which complicated previous enzymatic 
methods, has eliminated the need for preliminary solvent or resin 
extraction of serum [3,41 and has facilitated the application of 
automated methods [51. Our studies, reported here, indicate that 
(a) the sensitivity can be enhanced by conducting the indicator 
step at pH 6 . 5 ,  and (b) the assay can be quantitated by measuring 
changes of either absorbance or fluorescence. 
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Batjer J.D., Williamson L.J., Polissar L., Hamlin W.B. Effects Of 
Bacterial Contamination Of Reagent Water On Selected Laboratory 
Tests. Am. J. Clin. Path., 71:0319-0325. 1979. 
ABSTRACT: The effects of three widely spaced levels of bacterial 
contamination of reagent water on several chemistry, 
radioimmunoassay, and coagulation procedures vere studied. These 
included determinations of lactate dehydrogenase, creatin 
kinase, aspartate transaminase, alkaline phosphatase, blood urea 
nitrogen, total protein, thyroid-stimulating hormone, digoxin, 
thrombin time, activated partial thromboplastim time, and 
prothrombin time. Statistical analyses included calculations of 
means and coefficients of variation, and analysis of variance, as 
well as correlaton coefficients for test results versus logarithm 
of bacterial contamination. Statistically and clinically 
significant differences occurred together only for an elevated 
level of creatine kinase. 
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Batra K.K., Omand J., Baselt R . C .  Serum Quinidine Concentrations as 
Measured by Direct Fluorometry, Double-Extraction Fluorometry, 
and Enzyme Immunoassay. Clin. Chem., 27/5:0780-0781. 1981. 
ABSTRACT: We conclude from our results that the direct 
fluorometric procedure for serum quinidine no longer has a place 
in the management of quinidine therapy. The discrepancies that 
may arise with this method between the measured serum 
concentration and the actual clinical condition are simply 
unacceptable in view of the current availability of more specific 
I 
methods. 
Baugh P. 3 .  Photodegradation and Photooxidation of Cellulose. 
Department of Chemistry and Applied Chemistry, University of 
Salford, UK,. 
ABSTRACT: Progress in the study of the photodegradation and 
photooxidation of cellulose and to some extent cellulose 1 
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derivatives in the last decade is reviewed with those aspects in 
vhich there have been significant recent advances receiving most 
attention. Direct and sensitized photooxidation of cellulose are 
discussed and model system work is treated in a parallel fashion. 
In relation to both, particular a+tention is paid to the recent 
flourish in activity in the study of the nature of free radicals 
generated in photoirradiated celluloses. This decade has seen a 
decline in activity of certain aspects of the photosensitized 
degradation of cellulose, particularly that concerning dye 
seneitizers, although the controversy over the involvement of 
singlet oxygen in relation to the validity of the acativated 
oxygen theory in phototendering has continued during this period. 
Photoinitiated grafting is given some scope from the standpoint 
of the nature of the free radicals acative in initiating the 
polymerization of added monomer,generated in cellulose by direct 
photolysis and via metal ion photosensitization. Work on the 
photostabilization and destabilization of cellulose derivatives 
I 
1 
- 
is also summarized. 
I Baumgarten R.J. European Vestibular Experiments on The Spacelab-1 
Mission: 1. Overview. Exp. Brain Res., 6 4 : 0 2 3 9 - 0 2 4 6 ,  1986. 
ABSTRACT: During the flight of Spacelab-1 a series of vestibular 
experiments was performed on the crew by a group of European 
investigators. Control experiments were carried out on the same 
subjects pre- and postflight. The tests included caloric 
stimulation of the ears, threshold measurements of response to 
linear acceleration, motion sickness provocative stimuli, 
vestibulo-ocular reflexes during linear and angular stimulation, 
estimation of the subjective vertical (luminous line 
measurements) and static ocular counterrotation at various tilt 
angles. The caloric experiment proved the existence of a 
nonthermoconvect ive mechanism of caloric nystagmus in space. 
Most of the other test results point to a greater dependence on 
visual and somatosensory than on otolith cues in the 
threshold to perception of linear acceleration in flight and the 
temporary reduction o f  ocular counterrotation at lateral tilts 
.postflight, suggest a decreased gain of the otolith system as a 
possible effect of space vestibular adaptation. 
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1 microgravity environment. Some results, in particular the raised 
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Bentle L.A., Dutta S . ,  Metcoff J .  The Sequential Enzymatic I Determination of DNA and RNA. Anal. Biochem., 116: 3005-0016. 
1981. 
ABSTRACT: Enzymatically small quantities of native DNA and RNA in 
crude tissue homogenates can readily be specifically determined 
using ethidium bromide as a fluorescent indicator. The ethidium 
bromide-polynucleotide complexes of DNA and RNA serve as 
effective substrates for deoxyribonuclease and ribonuclease, 
respectively. Optimal divalent metal cation requirements were 
determined for a commone reaction medium that is compatible for 
both the DNase and RNase reactions. To a single reaction 
mixture, that contains a biological sample, sequential addition 
of DNase and RNase produces a specific and rapid decrease in 
fluorescence that is proportlonal to the respective amounts of  
I 
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.DNA and RNA present. Levels of DNA and RNA found in six 
different tissues of the rat were determined enzymatically by 
this method and compared to that obtained by alternate 
techniques. Enzymatically determined values were highly 
reproducible and correlate well wTth those values obtained by 
more time-consuming, conventional methods. Most enzymatically 
determined RNA levels in tissues, however, were significantly 
greater than those levels obtained spectrophotometrically. 
Advantages of the enzymatic procedure for analysis of tissue 
polynucleotide content are: (1) rapid determination of both DNA 
and RNA within a single sample aliquot allowing maximum use of 
available sample; ( 2 )  extensive fractionation and extraction of 
the tissue are not required; ( 3 )  it is especially useful when 
quantities of tissue are limited; and ( 4 )  sensitivity to 0.05 and 
0.25 ug of DNA and RNA, respectively. Reaction conditions 
developed for the assay also provide for a highly sensitive means I to continuously monitor DNA hydrolysis; DNase activity is 
directly proportional to the amount of enzyme added. 
I Bergstrom I., Heinanen A., Salonen K. Comparison Of Acridine Orange, 
Acriflavine, And Bisbenzimide Stains For Enumeration Of Bacteria 
I 
I 
In Clear And Humic Waters. App. Env. MIcIo., 51/3:0664-0667. 
1986. I 
ABSTRACT: In highly humic vater, acridine orange precipitated 
with dissolved humic matter, resulting in such bright background I fluorescnce that no bacteria could be seen. With bisbenzimide 
staining, a similar precipitate was nonfluorescent but obscured 
many cells. An acriflavine staining method proved useful and I reproducible both in clear and in humic waters. Fading of 
fluorescence was not a problem, and stained samples could be 
stored after preparation. The fluorescence of cells stained with I acriflavine was weaker than that with acridine orange, making counting extremely snall cells slightly more difficult with the 
former stain. 
I Berry C.A. Medical Legacy of Skylab As of May 9, 1974: The Manned 
Skylab Missions. Aviat. Space Environ. Med., 47/4:0418-0424. 
1976. 
ABSTRACT: The purpose of these summary remarks is to put into 
proper focus the magnificent achievement created by the S k y l a b  
Medical Team in concert with their engineering colleagues and 
most importantly, the astronauts who had to serve as both 
investigators and subjects. Indeed, by their ingenuity and 
capability of handling the numerous problems encountered due t o  
engineering deficiencies, they have shcvn man to be indispensable 
in long-duration space flight. 
Identification of Phytopathogenic Pseudomonas Spp. J. appl. Bact. 
ABSTRACT: To study the value of phage sensitivity tests f o r  the 
identification of phytopathogenic pseudomonanda, 284 isolates 
from various sources were examined for their sensitivity to 9 
Billing, E. The Value of Phage Sensitivity Tests for the I 
, 26/2:0193-0210. 1963. 
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phages. Phages came from infected plants ( 4 1 ,  meat ( 2 1 ,  manure 
(21 and from a culture of Ps. mors-prunorum, P27 (1). The main 
part of the study was concerned with isolates of Ps. syringae 
from lilac ( 6 1 ,  stone fruits ( 2 2 1 ,  pear ( 4 6 1 ,  Ps. mors-prunorum 
(171, Ps. phaseolicola (16) and Ps. lachrymans (111, but single 
isolates of other phytopathogenic Pseudomonas spp. ( 3 0 1  were also 
examined. Strains of Ps. aeruginosa ( 5 )  and pseudomonads from 
soil, water and chicken meat (151) were included for comparison. 
Three of the phages 2, 12B and 33 from plant sources showed a 
high degree of specificity €OK Ps. phaseolicola, Ps. syringae 
(pear isolates) and Ps. syringae (lilac isolates), respectively, 
but in no case was this absolute. Most isolates of the 4 species 
studied in detail showed characteristic but not specific patterns 
with phages 12S, 15 and 21. Many of the phytopathogens were 
sensitive to phage 12S, but pseudomonads from soil, water and 
chicken meat were not lyzed by this phage. Of this latter group 
4 4 %  were lyzed by one or more of the phages from meat or manure 
(14, 15, 20 and 21). Ps. aeruginosa was not lyzed by any of the 
phages. The ninth phage, P27, lyzed a proportion of Ps. syringae 
isolates from pear but none of the other pseudomonads tested. 
Tests for oxidase, sucrose oxidation, gelatinase and lecithinase 
activity were found useful in conjunction with lesion tests for 
screening purposes. Many of the phytopathogens, especially those 
having affinities with Ps. syringae, were oxidase negative. From 
these results and those of other workers it is concluded that 
phage sensitivity tests can play a useful part in the 
identification of phytopathogenic pseudomonads, if used in 
conjunction with other tests. The importance of the host in 
connection with phage sensitivity patterrns is emphasized; also 
the fact that isolates from a wide geographical area and 
saprophytes from the vicinity of the host plant need to be 
examined if an adequate assessment of the value of phage is to be 
obtained. 
Billing, E. Further Studies on the Phage Sensitivity and the 
Determination of Phytopathogenic Pseudomonas spp. J. appl. Back., 
33 :0478-0491. 1970. 
ABSTRACT: An interim determinative scheme f o r  phytopathogenic 
Pseudomonas s p p .  by a variety of cultural and biochemical tests 
was suggested by Lelliott, Billing & Hayward (1966) following the 
study of 156 green fluorescent phytopathogenic pseudomonads. The 
phage sensitivity of these and 80 additional cultures C O  20 
phages from a variety of sources are described. Information on 
the morphology of these phages is now available (Bradley, 1963a). 
A few nutritional tests which seem to be of diagnostic value at 
the species level are also included and a relationship between 
the presence of a heat stable antigen (Lovrekovich et al., 1963) 
and phage sensitivity patterns is discussed. 
I 
I 
Blumer M. Polycyclic Aromatic Compounds In Nature. :0035-0045. . 
I ABSTRACT: These multiple-ring hydrocaron molecules have been found in soils and sediments around the world. They are 
unusually stable, and their origins presented an intriguing 
puzzle. I 
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Bolan M.P., Nieswand G.H., Singley M.E. How Research Helps The 
Operation Of a Compost Plant. Compost Science/Land Utilization, 
1979 Conference Proceedings-Part II,20/5:0017-0021. 1979. 
ABSTRACT: The research components at the Camden Compostlng 
Project reflect each operation - dewatering, mixing, aeration, 
screening, curing, use - as sludge is processed into compost. 
Therapeutic Expectations. Aviat. Space Environ. Med., 56 
:0066-0068. 1985. 
- 
Borison H.L. A Misconception of Motion Sickness Leads to False 
ABSTRACT: The emetic chemoreceptor trigger zone (CTZ), located in 
the area postrema of the medulla oblongata, is generally believed 
to be indispensable for the vomiting in motion sickness and by 
extrapolation, also in space sickness. Accordingly, it has been 
postulated that a "motion vomiting substance" is secreted into 
the cerebrospinal fluid in the emetic process. Furthermore, 
certain therapeutic measures against motion sickness are aimed at 
preventing the presumed chemical stimulation of the CTZ. This 
concept originated from laboratory experiments in which ablation 
of the area postrema protected some dogs and monkeys against 
motion-induced vomiting. More recent experiments, however, 
showed that verified lesions of the area postrema were not 
effective in preventing motion sickness in cats. It appears that 
an indispensable unidentified element close to but separate 
experiments. The overall evidence leads to the conclusion that 
the area postrema is not essential for motion-induced vomiting. 
Therefore, no functional basis exists for the postulation of a 
motion vomiting substance, and it is irrational for the treatment 
of motion sickness to seek pharmacologic blocking agents that act 
at the CTZ. 
Brennan D.H., Girvin J.K. The Flight Acceptability Of Soft Contact 
Lenses: An Environmental Trial. Aviat. Space Environ. Med., 56 
: 0 0 4 3 - 0 0 4 8 .  1985. 
ABSTRACT: Seventeen officer aircrew, wearing s o f t  contact l e n s e s ,  
were subjected to adverse conditions likely t o  be encountered in 
military aviation. The stresses included hypoxia, rapid 
decompression, pressure breathing, vibration, climatic extremes, 
G forces, and the prolonged wearing of an aircrew respirator. 
Their visual performance wearing contact lenses under stress did 
not differ significantly from the control values; either when 
wearing corrective flying spectacles or contact lenses when not 
under stress. It is considered that from the environmental 
standpoint soft contact lenses are suitable for aircrew. As 
contact lenses may not be tolerated by all, and may cause 
undesirable side-effects in some, their use should be restricted 
to the aircrew to whom they offer the maximum advantages. The 
group most likely to benefit are young, well motivated myopes 
flying fast jets. 
Brorstrom E., Grennfelt P., Lindskog A. The Effect Of Nitrogen 
Dioxide And Ozone On The Decomposition Of Particle-Associated 
Polycyclic Aromatic Hydrocarbons During Sampling From The 
Atmosphere. Atm. Environ., 17/3:0601-0605. 1983. 
ABSTRACT: The effects of NO2 and 03 exposure on the degradation 
of polycyclic aromatic hydrocarbow (PAH) during high-vloume 
sampling of airborne particulate matter were studied. Addition 
of 1 ppm NO2 during ambient air sampling caused degradation of 
pyrene, benz(a)anthracene and benzo(a)pyrene, most probably due 
to nitration. Acid particles seem to enhance the reaction. The 
results indicate that NO2 concentrations within the range 
normally formed in urban air may cause degradatin of some 
reactive PAH. Addition of 200 ppb ) 3  caused degradation in one 
of the three experiments only. 
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Brorstrom E., Grennfelt P., Lindskog A. The Effect of Nitrogen 
Dioxide and Ozone on the Decomposition of Particle-Associated 
Polycylilc Aromatic Hydrocarbons During Sampling from the 
Atmosphere. Atm. Environ., 17/3:0601-0605. 1983. 
ABSTRACT: The effects of NO2 and 03 exposure on the degradation 
of polycyclic aromatic hydrocarbons (PAH) during high-volume 
sampling of airborne particulate matter were studied. Addition 
of 1 ppm NO2 during ambient air sampling caused degradation of 
pyrene, benz(a1anthracene and benozo(a)pyrene, most probably due 
to nitration. Acid particles seem to enhance the reaction. The 
results indicate that NO2 concentrations within the range 
normally formed in urban air may cause degradation of some 
reactive PAH. Addition of 200 ppb 03 caused degradation in one 
of the three esperiments only. 
I 
I 
I 
I 
I 
Brundage J.F., Scott R.M., Lednar W.M., Smith D.W., Miller R.N. 
Building-Associated Risk OF Febrile Acute Respiratory Diseases In I Army Trainees. JAMA, 259/14:2108-2112. 1988. 
I 
I 
ABSTRACT: Airborne transmission of infectious agents and 
associations of indoor air pollutants with respiratory illnesses 
are well documented. We hypothesized that energy conservation 
measures that tighten buildings a l s o  increase risks of 
respiratory infection among building occupants. At f o u r  Army 
training centers during a 47 month period, incidence rates of 
febrile acute respiratory disease were compared between basic 
trainees in modern (energy-efficient design and construction) and 
old barracks. Rates of febrile acute respiratory disease were 
significantly higher among trainees in modern barracks (adjusted 
relative risk estimate, 1.51; 95% confidence interval, 1.46 to 
1.561, and relative risks were consistent at the four centers. 
These results support the llypothcsis that tight buildings with 
closed ventilation systems significantly increase risks of 
respiratory-tranmitted infecton among congregated, 
I 
I immunologically susceptible occupants. 
I 
Buchanan P. The Closing Gap Between Occupational Medicine and Flight 
Medicine In The Space Station Era. Biomedical Office, NASA, J. 
F. Kennedy Space Center, Texas, U.S.A.,:0237-0244. . 
I ABSTRACT: None 
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Bucker H., Horneck G., Reitz G., Graul E.H., Berger H., Hoffken H., 
Ruther W . ,  Helnrlch W . ,  Beaujean R. Embryogenesis and 
Organogenesis of Carauslus Morosus Under Spacefllqht Conditions. 
Naturwlssenschaften, 73:0433-0434.  1986. 
ABSTRACT: None 
Bungo M.W., Charles J.B., Johnson P.C. Cardiovascular Deconditioning 
During Space Flight And The Use of Saline As A Countermeasure To 
Orthostatic Intolerance. Avlat. Space Envlron. Med., 56  
:0985-0990. 1985. 
ABSTRACT: Alterations in the physiology of the cardiovascular 
system have been noted during all exposures to the microgravity 
experienced in space flight. Of most importance to the 
operational function of Space Shuttle crewmembers in orthostatic 
intolerance. Although complex changes occur as a result of 
adaptation to weightlessness, the redistribution and loss of body 
fluid apparently plays a substantial role. Utilizing 
ground-based bed rest data as an analog to the absence of 
gravitational force excountered in orbital flight, a saline 
loading countermeasure was developed. In this study, 17 
' crewmembers consumed various amounts of salt and fluid prior to 
the reentry phase of Space Shuttle flights; 9 other astronauts 
served as control subjects. The countermeasure reduced the heart 
rate response to orthostatic stress 29% and reversed the fall in 
mean blood pressure. A Cardiovascular Index of Deconditioning 
(defined as CID=delta HR- delta SBPtdelta DBP) equalled 21 in 
those who utilized the countermeasure, a significant improvement 
toward baseline (p<O.003) when compared to the control group CID= 
4 9 .  The encouraging results of these investigations have led to 
the adoption of the countermeasure as an operational procedure by 
Shuttle crewmembers. 
Bungo M.W., Goldwater D.J., Popp R . L . ,  Sandler H. Echocardiographic 
Evaluation Of Space Shuttle Crewmembers. J. Appl. Physioi., 
62/1:0278-0283. 1987. 
I ABSTRACT: Echocardiographic measurements were obtained before and after space flight from 17 members of four shuttle crews. 
Measurements obtained 1 h after landing ( L t O )  compared with 
preflight values (n=7) demonstrated an increase in heart rate 
(HR) (16 beats/min, 30.5'%, P < 0.05), mean arterial pressure 
(lZ%, P < 0.051, and systemic vascular resistance (34% P < 0.05). 
End-diasolic volume index (EDVI) f e l l  17 ml/m2 (-23%, P < 0.005) 
and stroke volume index (SVI) fell 15 ml/m2 (-28%, P < 0.05). 
Repeat measurements taken 1-2 wk later (n=17) demonstrated that 
HR had returned to normal ( 4  beats/min, P < 0.05); however, EVDVI 
remained significantly below preflight levels (-ll%, P < 0.005). 
End-systolic volume index (ESVI ) was also still significantly 
lower ( - 2 3 % ,  P < 0.01). This delayed recovery occurred despite 
ability of the subjects to fully ambulate and exercise during the 
postflight period. These results indicate that spaceflight 
induces significant changes in heart volume affecting left 
ventricular function. The exact rasons for these specific 
I 
I 
I 
I 
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chanqes remain unknown and vi11 require additional measurements 
before, during, and after flight. The prolonged recovery period 
for the present subject group probably relates to their high 
level of aerobic conditioning. 
Buoni C.M., Hill C.E., Arthur H.F., Johnson L.R., Balog P.P., Rench 
J.D., Coutant R.W., Rodman C.W. Space Station Contamination In 
Pressurized Environments: Issues And Options. Battelle Columbus 
Laboratories Report, NASA KSC Contract NAS10-11033,1985. 
ABSTRACT: None 
I 
Canaveris G., Nau G.J. Intraventricular Conduction Disturbances In 
Flying Personnel: Development and Prognosis Of Bifascicular 
Blocks. Aviat. Space Environ. Xed., 58:0683-0689. 1987. 
ABSTRACT: The evolutive characteristics as well as the 
qualification criteria applied in 21 cases of bifascicular blocks 
detected in a presumably healthy population consisting of 6,915 
male individuals engaged in cilvilian flying activities 
(prevalence: 0.3%) were studied. The cases were divided in four 
groups according to the type and severity of the conduction 
disturbance. The sequence of conduction disturbances, ages and 
electrical axis rotation velocity are assessed. Bifascicular 
blocks may be complete 01 incomplete. The proqression towards 
advanced conduction disturbances may affect the involved 
fascicles independently. Cases with incomplete bifascicular 
block have better prognosis, followed by those with primary 
conduction system disease. The mean time between the development 
of first and second conduction disturbance was 3.5 years. On an 
individual basis, once those etiologies which by themselves imply 
a future risk are ruled out, and provided they do not show 
evolutive features in frequent repeat evaluations, they may be 
waivered for flying activities with a proposed maximum age of 60 
years. 
1 
Carlsson A.S., Nilsson B., Walder M.H., Osterberg K. Ultraviolet 
Radiation and Air Contamination During Total Hip Replacement. J. 
Hospital Infection, 7:0176-0184. 1986. 
ABSTRACT: Ultraviolet radiation of the operationg room was 
assessed bacteriologically in an open randoaized study of 30 E total hip procedures. Volumetric air-sampling demonstrated that 
the number of colony forming units (cfu m-3) were significantly 
reduced (P<O.OOl) by uv light, bouth close to the wound and in 
the periphery of the operationg room. No adverse effects of P uv-irradiation were observed either in the patients or the staff. 
In operationg rooms fitted with a 'zonal ventilation' system and 
with an air change rate of about 70 h-1, the addition of uv 
irradiation during surgery may achieve 'ultra clean' air. 
However, in conventionally ventilated operating rooms 
uv-irradiation alone is probably not sufficient to do s o .  
I Chahal D . S .  Solid-state Fermentation With Trichoderma reesei For 
I 
Cellulase Productio . App. Env. Micro., 49/1:0205-0210. 1985. 
.dGRAPHY LA. .LNG 
I 
ABSTRACT: Cellulase yields of 250 to 430 IU/G of cellulose were 
recorded in a new approach to solid-state fermentation of wheat 
straw with Trichoderma reesel QMY-1. This 1s an increase of CA. 
72% compared with the yields (160 to 250 IU/G of cellulose) in 
liquid-state fermentation reported in the llterature. High 
cellulase activity 16-17 1U/ML) per unit volume of enzyme broth 
and high yields of cellulases vere attributed to the grovth of 
T. reesei on a hemicellulose fraction during its first phase and 
then on a cellulose fraction of vheat srrav during its later 
phase for cellulase production, as well as to the close contact 
of hyphae with the substrate in solid-state fermentation, the 
cellulase system obtained by the solid-state fermentation of 
wheat straw contained cellulases (17.2 IU/ML), B-glucosidase 
(21.2 IU/ML), and xylanases ( 5 4 0  IU/ML). This cellulase system 
was capable of hydrolyzing 78 to 90% of delignified wheat straw 
(10% concentration) in 96 H, without the addition of 
complementary enzymes, B-glucosidase, and xylanases. 
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Chambers A. Long Residence, An Uncharted Field. Astro. Aero, 1 : 0061-0063. 1983. 
ABSTRACT: None 
Chance B. Techniques For The Assay Of The Respiratory Enzymes. I 
Techniques for Metabolic Studies, :0273-0290. . 
I ABSTRACT: None 
Chen M., Hickey P.J. Elimination Of Overgrovth In Delayed-Incubation 
Membrane Filter Test For Total Coliforms By m-ST Holding Medium. 
App. Env. Micro., 52/4:0778-0781. 1986. 
ABSTRACT: Two holding media were compared for their effects of 
total coliform recovery by the delayed-incubation membrane filter 
procedure. LES-MF holding medium contains tryptone, m-Endo 
broth, dipotassium hydrogen phosphate, sodium benzoate, 
sulfanilamide, para-aminobenzoic acid, and cycloheximide (pH 
7.0). m-ST holding medium contains ethanol, sodium 
monophosphate, dipotassium hydrogen phosphate, sulfanilamide, and 
Tris (pH 8.6). In test with natural water and wastewater samples 
from various sources recovery with LES-MF and m-ST were similar 
after a 1-day holding period. With LES-MF, however, after a 2 or 
3 day holding period, coliform bacteria frequently were partially 
or totally overgrown by noncoliforms, causing significant 
reductions in coliform counts. No significant overgrowth was 
observed with m-ST. We propose that m-ST be used for all holding 
periods longer than 1 day. 
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Christensen J.M., Talbot J.M. A Review of The Phychological Aspects # of Space Flight. Aviat. Space Environ. Med., 57:0203-0212. 1986. 
ABSTRACT: Instances of overt, serious functional impairment of 
space crews caused by adverse psychologic responses have not been 
scientifically documented. However, transient disorientation, 
spatial illusions, and visual disturbances as well as anomalous 
myopias, sleep disturbance, and instances of substandard 
BIBLIOGRA~ - A . s r n  j 
performance have been described. Moreover, anecdotal information 
describes significant psychologic aberrations in space flight. 
Adequate scientific data are lacking for optimal psychological 
and psychophysiological methods for crev selection, training, and 
performance evaluation, for identAfying key psychosocial factors 
for crew compatibity, cohesiveness, and productivity, and for 
determining the effects of space flight on perceptual, 
intellectual, and motor skills. The ad hoc Working Group, 
converted to review psychological aspects of space flight, 
favored establishment of a comprehensive research and development 
program to address the deficiencies identified in the study. 
Clement G., Gurfinkel V.S., Lestienne F., Lipshits M.I., Popov K.E. 
Changes of Posture During Transient Perturbations In 
Microqravity. Aviat. Space Environ. Med., 56:0666-0671. 1985. 
ABSTRACT: The control of goal-directed arm movement and of body 
stability before, during, and 3 d after a 7-d spaceflight has 
been investigated. The findings show that the anticipatory and 
compensatory activities of the postural muscles were highly 
reproducible during the first days of the space mission. The 
sequence of these activities, studied in two situations- in which 
the platform either was fixed of could rotate about near the 
rotation exis of the ankle- was similar to a ground-based 
situation. The trajectory of various body segments demonstrated 
that a 7-d exposure to microgravity did not result in major 
changes in posture. Furthermore, vislon seemed t o  play an 
important role in the control of standing posture at the 
beginning of the flight. Postural perturbatins, elicited by 
unexpected displacements of the foot support, involved leg muscle 
reflexes whose amplitudes were greatly reduced compared to those 
@ 
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on earth. 
I Cohen B.L., Gromicko N. Adequacy Of Time Averaging With Diffusion 
Barrier Charcoal Adsorption Collectors For 222RN Measurements In 
Homes . Health Physics, 54/2:0195-0202. 1988. 
ABSTRACT: Radon-222 Levels in homes are known to undergo 
short-term fluctuations over times ranging f rom less than an hour 
to a few days, as well as long-term seasonal variations. Since 
we are usually interested in time-averaged 222RN Levels, it is 
important to know how well a measurement device determines this 
average. Clearly the average over a full year as can be done 
with a Beta track detector, and that is therefore unquestionable 
the most meaningful measurement. However, regardless of the 
desires of scientists, the great majority of measurements are 
made for 1 MO Qr less during which seasonal variations are of 
negligible importance. For these, it is important to know how 
well they average over short-term fluctuations. In this paper, 
we consider that question, in particular, we determine the 
average deviation of a single measurement from the 1-MO Average. 
Collins M.D., Jones D. Distribution of Isoprenpid Quinone Structural 
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P Types in Bacteria and Their Taxonomic Implications. Micro. 
Reviews, 45/2:0316-0354. 1981. 
BIBLIOL ...-,,.. LISTING 1 
ABSTRACT: Chemotaxonomic methods, such as cell wall analyses and 
deoxyribonucleic acid base ratio and homology determinations, now 
figure prominently in microbial systematics. TO date, the use of 
lipids as chemical characters has generally recelved less 
attention by bacterial taxonomist%. However, studies involving 
fatty acid and polar lipid analyses have yielded encouraging 
results. A class of terpenoid lipids w i t h  a similar inherent 
potential in chemotaxonomy aze the isoprenoid or respirator 
quinones. Isoprenoid quinones are constituents of bacteria 
plasma membranes and play important roles in electron transport, 
oxidative phosphorylation, and, possibly, active transport. The 
results of the early studies indicated that the inherent 
structural variation exhibited by isoprenoid quinones might be of 
value in microbial systematics. The majority of subsequent 
studies on the isoprenoid quinones of bacteria have been 
preformed by biochemists, whose primary interest is in the 
function of these compounds in bacterial cells and not in their 
value as taxnomic markers. Over the last decade, however there 
have been a number of comparative studies designed to assess the 
value of these compounds in microbial taxonomy. Thus, there is 
now a comparable body of material on isoprenoid quinone 
structural types and their distribution in a large number of 
bacterial genera. However a great deal of this information is 
fragmentary and scattered through the literature in papers not 
necessarily concerned with taxonomy. Therefore seemed opportune 
to review the literature in this field and vhere possible,to 
attempt to evaluate the data in the context of taxonomic 
groupings based on other criteria. 
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Collins M.D., Jones D. Distribution of Isoprenoid Quinone Structural 
Types in Bacteria and Their Taxonomic Implications. Micro 
Reviews, 45 /2 :316-354 .  1981. 
‘i ABSTRACT: Chemotaxonomic methods, such as cell wall analyses and 
deoxyribonucleic acid base ratio and homology determinations, now 
figure prominently in microbial systematics. To date, the use of 
lipids as chemical caracters has generally received less 
attention by bacterial taxonomists. However, studies involving 
fatty acid and polar lipid analyses have yielded encouraging 
results. A class of terpenoid lipids with a similar inherent 
potertial in chemotaxonomy are the isopernoid or respiratory 
quinones. 
Collmer A . ,  Wilson D.B. Coding And Expression Of A Thermomonospora YX 
Endocellulase Gene In E. coli. Biotechnology, 1983. 
ABSTRACT: A set of E. coli transformants (2,500) containing 
plasmid pBR322 with Thermomonospara YX DNA inserts larger than 3 
kb was prepared. The transformants were screened directly for 
exhibiting cellulase activity were found. One colony contains a 
plasmid (pD365) that contains a 7.6 kb insert, including the 
entire gene coding for the major endoglucanase activity of 
Thermomonospora YX. The other colony (D315) had two plasmids in 
it: pD316 contains a 8.5 kb insert which includes at least 80% of 
the major endoglucanase gene; pD315 contains a 6.6 kb insert and 
8 
8 
fi 
,B the ability to hydrolyze carboxymethyl cellulose. Two colonies 
4 
does not express cellulase activity. 
prepared for each plasmid and the endoglucanase gene was 
localized to a 2.3 kb Sal1 fragment in pD316 and to a 3.7 kb 
EcoRI fragment in pD365. These fragments were subcloned into 
plasmids containing active promotgrs regulated by the lactose 
repressor. The new strains each made 50  times more cellulase 
than the original strains. E. coli transformants containing 
plasmids pD316, pD365 and their dervatles secrete about 30% of 
their endoglucanase activity into the medium, 30% into the 
periplasmic space, while 40% remains in the cytoplasm. 
Thermomonospora YX DNA restriction digests were fractionated by 
agarose gel electrophoresis and the fragments which hybridized to 
pD315 and pD316 were detected by nitrocellulose blotting 
techniques. The results indicated that each plasmid contains a 
single contiguous segment of Thermomonospora YX DNA and that the 
pD315 and pD316 inserts are linked in the Thermomonospora YX 
genome. 
Restriction maps were 
Colombo G.V., Greenley D.R., Putnam D.F., Sauer R.L. Advanced 
Microbial Check Valve Development. The American Society of 
Mechanical Engineers, #81-ENAs-45,. 
ABSTRACT: The Microbial Check Valve (MCV) is a flight qualified 
assembly that provides bacteriologically safe drinking water for 
the Space Shuttle. The l-lb unit is basically a canister packed 
with an iodinated ion-exchange resin. The device is used to 
destroy organisms in a water stream as the water passes through 
it. It is equally effective for fluid flow in either direction 
and its primary method of disinfecton is killing rather than 
filtering. The MCV was developed to disinfect the fuel cell 
water and to prevent back contamination of stored potable water 
on the Space Shuttle. This paper reports its potential for space 
applications beyond the basic shuttle mission. Data are 
presented that indicat the MCV is suitable for use in advanced 
systems that NASA has under development for the reclamation of 
humidity condensate, wash water and human urine, 
Compton, D. A .  C., Hill, S. L., Wright, N. A., Druy, M. A., Piche, 
J., Stevenson, W. A . ,  Vidrine, D. W. . In-Situ FT-IR Analysis of 
a Composite Curing Reaction Using a Mid-Infrared Transmitting 
Optical Fiber. In-Situ FT-IR Analysis of a Composite Curing 
Reaction Using a Mid-Infrared Transmitting Optical Fiber, 
:0002-0022. . 
ABSTRACT: The use of a mid-infrared transmitting fiber to carry 
the infrared beam of an FT-IR spectrometer outside of the optical 
bench is reported. In addition it is demonstrated that it is 
possible to analyze samples using the fiber as an Internal 
Reflection Element. The fiber is covered with a protective 
coating which can be removed for a short region, to allow contact 
with the sample over a controlled length. Two examples of the 
use of an optical fiber for remote sampling are discussed. The 
first shows that a spectrum of a liquid sample (2-butanone) may 
be easily measured, and the second shows how a fiber may be used 
to monitor the progress of a curing reactions in thermoset 
composite materials. The spectrum of a resin was recorded before 
the cure by embedding the optical fiber in the graphite 
fiber/polyimide matrix resin prepreg, and then the progress of 
the cure monitored during the curing process. Thls type of 
remote sampling shows treemendous potential for opening totally 
new areas of usage for FT-IR spectrometry, including the studies 
of hazardous materials, enclosed reactions, and processes that do 
not allov samples to be taken inside the spectrometer. 
Connors M. Dentistry Moves Into Space. TIC, XLVI/4:0001-0003. 1987. 
ABSTRACT: None 
Cooper H.R., Chorpenning F.W., Rosen S. Preparation And Chemical 
Composition Of The Cell Walls O f .  Streptococcus mutans. Inf. And 
Imm., 11/4:0823-0828. 1975. 
ABSTRACT: Purified cell walls from Streptococcus mutans strain 
BHT were prepared without the use of proteolytic enzymes in order 
to retain all cell wall constituents for chemical analysis. Of 
four methods employed, the Ribi cell fractionator produced 
disrupted cell suspensions which could be most thoroughly 
purified on sucrose gradients. Results of chemical analyses on 
purified cell walls prepared in this manner represented 99.2% 
recovery. They indicated the presence of 6.8% protein, 8.9% 
glycerol teichoic acid, 33.6% non-peptidoglycan polysaccharide, 
and 49.9% peptidoglycan. 
Cornet P., Millet J., Beguin P., Aubert J.P. Characterization Of Two 
(Cellulose Degradation) Genes Of Clostridium thermocellum Coding 
For Endoglucanases. Biotechnology, 1983. 
ABSTRACT: Two structural genes, celA and celB, coding 
respectively for the endoglucanases A and B of Clostridium 
thermocellum, were subcloned from cosmids of a gene bank into 
plasmid pBR322. Both genes are carried in a DNA sequence of 
about 2.7 kb. They share no homology and are not contiguous on 
the C. thermocellum chromosome. They are expressed in E. coli 
independenatly of their orientation in the coloning vector. 
Cosman B.C., Brandt-Rauf P.W. . Infectious Disease In Antarctica And 
Its Relation To Aerospace Medicine: A Review. Aviat. Space 
Environ. Med., 58:0174-0179. 1987. 
ABSTRACT: In many aspects, an Antarctic Station provides 
parallels to the environments encountered in space exploration, 
particularly with reference to infectious disease. In both 
instances, small groups of peDple 1i-;e in isolation for long 
periods of time in a functionally sterile atmosphere. Therefore, 
studies of infectious disease in Antarctica should provide 
important insights into the experiences to be expected in 
spaceflight. This paper presents a summary of the information on 
the infectious and immunologic aspects of isolation derived over 
the years from research in Antarctica. 
Council on Scientific Affairs. Cancer Risk of Pesticides in 
Agricultural Workers. JAMA, 260/7:0959-0966. 1988. 
ABSTRACT: This report discusses one of the inherent limitations 
of cancer studies in animals and humans and presents a 
Qualitative carcinogen risk assessment of a number of pesticides 
based on the judgement of national and international authorities 
who have reviewed the available experimental and epidemiologic 
evidence. A large number of pesticidal compounds have shouwn 
evidence of genotoxicity or carcinogenicity in animal and in 
vitro screening tests, but no pestidices except arsenic and vinyl 
chloride (once used as an aerosol propellant)- definitely have 
been proved to be carcinogenic in man. Resolution 94 (1-861, 
which was refferred to the Board of Trustees, calls for the 
American Medical Association, through its scientific journals and 
publications, to alert physicians to the potential hazards of 
agricultural pesticides, to provide physicians with advice on 
such hazards for their patients, and to urge that these 
substances be appropriately labeled. This report addresses the 
potential carcinogenicity of pestidices by review of the 
available literature. 
Crosse, J. E., Garrett, C. M. E. . Studies on the 
Bacteriophagy of Pseudomonas Mors-Piunorum, Ps. Syringae and 
Related Organisms. J. Appl. Bact., 26/2:0159-0177. 1963. 
ABSTRACT: A group of 23 phages, mainly isolated with Pseudomonas 
mors-prunorum and Ps. syringae as the propagating strains, was 
tested against more than 2 0 0  pseudomonads including named plant 
pathogens and a variety of saprophytes. The majority of the 
phages had a wide host range, and did not distinguish between 
plant pathogens and saprophytes, thus confirming the close 
relationship between these two groups. The most reactive 
bactezia were 60 English isolates of Ps. mors-prunorum, 48  from 
cherry and 12 from plum, and 28 isolates of Ps. syringae from 
pear. Patterns of reaction within these 3 groups were relatively 
homogeneous and each group was distinct and differed from all 
other isolates tested. Ps. syringae isolates froni other hosts 
were less uniform and occasionally shared reaction patterns with 
other species, e . g .  Ps. cannabind and Fs. glycinea. Similar 
relationships were observed with pllages at both high titre an2 at 
routine test dilution including the difference in phage 
sensitivity between the c!ierry and p l u m  strains of Ps. 
mors-prunorum. On the basis of 7 biochemical tests the plum and 
cherry strains were indistinguishable but they differed from all 
Ps. syringae isolates tested by giving white growth in 5 %  S U C L C I S C  
brotll and in failing to liquefy gelatin. Furthermore, unlike 
most Fs. syringae isolates they were a l s o  unable to hydrolyze 
desculiri and were tyrosinase positive. There was no clear 
evidence in this investigation of correlation between phage 
sensitivity and biochemical activity. Eleven isolates from 
various European countries, designated Ps. mors-prunorum, 
differed widely both in phage sensitivity and biochemical 
activity and some o f  them may be more appropriately called Ps. 
syringae. Others may be intermediate forms between these 
species. The relationship between Ps. mors-prunorum and Ps. 
syringae and the nomenclature of these organisms are discussed 
and a concept of  ecotypes suggested as a substitute f o r  species. 
BII ,IClLi?A. HY L I S T I h .  
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Crowley J . S .  Simulator Sickness: A Problem For Army Aviation. Aviat. 
Space Envlron. Med., 58:0355-0357. 1987. 
ABSTRACT: "Simulator sickness" descr lbev  a symptom complex 
frequently reported by pilots durilng or after flight simulator 
training. There were 112 helicopter pilots at a U.S. Azmy AH-1 
Cobra Flight Weapons Simulator (FWS) who completed a 
symptom-orientaed objective questionnaire. Of these, 40% 
reported symptoms of dysequilibrium; pilots developing simulator 
sickness had significantly more total and AH-1 fliqth time. 
Adaptation of the syndrome occurred with increasing F W S  
experience. The history and aeromedical significance of 
simulator sickness are briefly reviewed, and a case report 
presented. A mandatory grounding policy in use locally is 
described. Potential treatment strategies are briefly discussed. 
1. 
I 
Dally E.L., Stokes H.W., Eveleigh D.E. A Genetic Comparison Of 
Strains Of Zymomonas mobilis By Analysis Of Plasmid DNA. 
Biotech. Let., 4/2:0091-0096. 1982. 
ABSTRACT: Strains of Zymomonas mobilis were examined for their 
ability to act as recipients of plamid DNA and for the 
relatedness of native plasmids which these strains harbor. We 
conclude that the high-ethanol producing strains CP3 and CP4 are 8, identical. 
Daniel1 W.E., Couser W.G., Rosenstock L. Occupational Solvent 
Exposure And Glomerulonephritis. A case Report and Review of the 1 Literature. JAMA, 259/15:2280-2283. 1988. 
ABSTRACT: We describe a patient who presented with renal failure 
after a one-year period o f  unprotected heavy occupational 
exposure to organic solvents. Renal biopsy results and 
serological findings were diagnostic of anti-glomerular basement 
membrane antibody-mediated glomerulonephritis. An analytic 
review of tlie literature revealed substantial evidence linking 
solvent exgosure to the development of glomerulonephritis (GKS), 
with seven of nine case-corltrol studies demonstrating a 
statistically significanat association. Odds ratios were 
reported by 01 could 5 c  calculated for s i x  of theze studies, and 
the five positive studies detected a 2.8 to 2.9 fold increased 
risk for GN among solvent-exposed individuals. The findings in 
Levera1 of these studies of dose-response relatioships, the 
reports of variations i n  d i s e a s e  severity i r i  r e l d t i o n  to e x p o s u r e  
intensity, a n d  tile absence of alternative explanations for the 
dssociation provide additional supportivc evidence for a s o l v e n t  
effect. I n  the majority of cases of anti-glomerular basement 
membrane antibody-mediated GN and other types o f  GN, there is no 
remarkable preceding exposure to organic solvents. However, we 
ccnclude that in the case presented herein and in cases o f  GN 
with similar exposure histories, solvent exposure may play a 
significant contributing role in the development of GN. 
drugs in man: a review. J. Royal SOC. Med., 79:96-99. 1986. 
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Davies I.B., Grind I.M., Pottage A . ,  Turner P. Development of new 
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ABSTRACT: The period of development of a new drug averages 10-15 
years from initial invention of the chemical structure to 
approval for general use. In the US, the current cost can 
approach 100 million dollars, while elsewhere it can be 
approximately 15-20 millon pounds sterling. Two main stages are 
involved in drug development: the preclinical stage comprises 
chemistry (synthesis, purification, patenting), pharmacology, 
pharmacokinetics and toxicology in animals and pharmaceutical 
development of dosage forms; the clinical stage includes four 
phases which embrace all studies done in man. The major aim of 
drug development is a safe and effective product. I f  a drug 
causes many minor side effects, or  one serious one, development 
will probably be stopped unless the drug is of unique clinical 
benefit. However, for some drugs unusual serious adverse drug 
reactions (ADR) have been identified for the first time after 
marketing, benoxaprofen (Opren), indomethacin slow release, and 
zimeldine. In these cases the incidence of the ADR was s o  low, 
about 1:10,000-1:100,000 patients treated, that it was impossible 
to identify even in the large-scale clinical trials done before 
marketing; it follows that this type of rare ADR cannot be 
avoided even with extensive testing before ,marketing, and this 
must be accepted if development of new drugs is to continue. 
This paper rewiews the development programme of new drug (new 
chemical entity, NCE) taking approximately 5 - 7  years form initial 
administration to man to the point of approval for marketing by 
the various European and North Ametical requlatory authorities. . 
Valdez G.F., De Giorgi G.S., De Ruiz Holgado A.P., Oliver G. 
Effect Of The Rehydration Medium On The Recovery Of Freeze-Dried 
Lactic Acid Bacteria. App. Env. Micro, 50/3:1339-1341. 1985. 
ABSTRACT: Sixteen cultures of lactic acid bacteria were 
freeze-dried in 10% nonfat skim milk plus 0.75 M adonitol and 
rehydrated by using different rehydration media. Marked 
variations in their capacity to repair cellular damage after 
freeze-drying were observed among the species and strains under 
condiseration. 
Vicente A., Borrego J.J., Arrabal F., Rornero P. Comparative Study 
Of Selective Media For Enumeration Of Pseudomonas aeruginosa From 
Watez By Membrane Filtration. App. Env. Micro., 51/4:0832-0840. 
1986. 
ABSTRACT: In the present study, mPA-D and mPA-E agar, 
modifications of mPA-C agar that reduce background fecal 
strptococci that interfere with the differentaition and 
enumeration of the Pseudomonas aeruginosa colonies grown in other 
mPA media, are proposed for use in analyzing natural water 
samples. In addition, the efficiencies of several culture media 
for the recovery of P. aeruginosa in water after membrane 
filtration and multiple-tube techniques are compared. The degree 
of selectivity, precision, efficiency, and sensitivity achieved 
with the proposed media exeeded that achieved by current methods. 
Furthermore, they yielded equal rates of accuracy and 
specificity. Incubation at 36 C resulted in an improved recovery 
.. 
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of stressed P. aeruglnosa. In concluslon, we propose the use of 
mPA-D and mPA-E agar, both incubated at 36 C for 2 4 - 4 8  h, for 
analyzing rlver water and seawater, respectlvely. 
I 
1 
Delllnqer J . A . ,  Taylor H.L., Porqes S f W .  . Atropine Sulfate Effects fi 
4 
On Aviator Performance and On Respiratory-Heart Perlod 
Interactions. Aviat. Space Environ. Med., 58:0333-0338. 1987. 
ABSTRACT: In this study, 20 human volunteers received a placebo 
and atropine doses of 0 . 5 ,  1.0, 2.0 ,  and 4.0, mg 75  kg-1 in a 
Latin Square double blind deslgn, and effects were monitored for 
3 h postinjection. The 2.0 mg and the 4 . 0  mg doses resulted in 
Significant flight simulator performance decrements beginning at 
1 h postinjection with only minimal recovery by 3 h 
postinjection. Electrocardiogram data were used to estimate the 
amplitude of respiratory sinus arrhythmia (RSA) which vas more 
sensitive than mean heart period o r  mean heart period variance to 
the effects of atropine. These parasympathetic effects were 
relatively rapid in onset and peaked vithin the first 40-min 
period for the 2.0 and 4.0 mg doses. The onset of performance 
effects were delayed 1 h 4 0  min for the 2.0 mg and 1 h 00 min for 
the 4 . 0  mg treatments. 
@ 
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P Dement W.C., Seidel W.F., Cohen S.A., Bliwise N.G., Carskadon M.A. 
Sleep And Wakefulness In Aircrew Before And After Transoceanic 
Flights. Aviat. Space Environ. Med, 5 7  (12, Suppl.):B0014-B0028. ' 1986. 
ABSTRACT: Aircrew were studied before and after flying one of two 
routes: San Francisco (SFO) to London (LHR) or  SFO to Tokyo 
(NRT). After an adaptation night, sleep and daytime sleepiness 
were objectively measured in SFO and during the first layover 
(L/O) of the target trip. Baseline sleep was slightly shorter 
than normally reported for similar age subjects and, for several 
reasons, is not an ideal basis for subsequent comparison. 
Nevertheless, L/O s l e e p  periods tended to provide either less 
total sleep or less efficient sleep. Crewmember's estimates of 
their s l e e p  duration correlated well with objectve measures, but 
estimates of daytime sleepiness correlated poorly with 
objectively measured sleepiness. During baseline there was a 
significant midday sleep tendency as measured by the Multiple 
Sleep Latency Test. This tendency occurred at almost the same 
time (GMT) on the second L/O day in LHR. Since sleepiness has a 
persistent rhythm which is maximal twice per day, it is suggested 
that L/O sleep periods be taken at these times of maximal 
sleepiness and that peak workload should coincide with the 
subsequent periods of maximal alertness. Although the overall 
quality of sleep diminished only slightly on this L/O, it is 
possible that if this relatively small loss accumulated over 
successive L/Os, the effects on daytime sleepiness could be 
measurable. 
DeRoos R.L., Wheeler D.J. Medical uses of high-purity vater. R Hospitals, 46/13:0100-0104. 1972. 
ABSTRACT: Providing the different kinds of water used in health II 
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care institutions 1s a formldable challenge. Water 1s used in 
the cleaning of equipment, in medical support equipment such as 
artlf iclal kidney machines and respiratiors, in the preparation 
of infant formulas and injectable soultions, and so on. As 
steam, vater is used in heating equipment, in autoclaves, in 
steam cookers, and in steam sanitizers. The water needed may be 
ordinary municipal tap water, or it may be high-purity water. 
This article discusses the uses of high-purity water, some 
considerations for determining the type of water required, and 
different methods for providing these special types of water. 
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Detroy R.W., Rhodes R.A. Biological Conversion Of Agricultural 
Lignocellulosics To Ethanol And Digestible Feedstuffs. 
Workshop 2:  Conversion Of Lignocellulosic Materials To Simple 
Carbohydrates ,1980. 
ABSTRACT: Chemical and biological methods for delignification 
coupled to enzymatic bydrolysis of freed cellulose are being 
studied at the Northern Regional Reserach Center, Peoria, I l l .  
The immmediate objective is enhanced production of alcohol from 
biomass. The oyster mushroom, Pleurotus ostreatus, NRRL 2366, 
vas grown on native vheat strav (WS) ammended with ammonium 
sulfate, urea, or oatmeal. The fungus degraded the 
lignocellulosec WS, as evidenced by 10 to 45% and 15 to 55% 
decreased in lignin and cellulose, respectively, after 36 days. 
The initial lignin and cellulose utilization vas also greater 
with oatmeal amendment. Soluble reducing sugars in WS remained 
constant during the first 15 days of incubation; however, free 
reducing sugars increased twofold to threefold the remainder of 
the fermentation period regardless of nitrogen amendment. The in 
vitro digestibility of WS as measured by release of reducing 
sugar after cellulase treatment increased twofold to threefold 
after a 90 day fermentation period. Fermented WS thus would have 
improved digestibility in animal diets and the mycelium should 
contribute increased nutritional value. 
Dinterfass L. Background And Development of the Space Project on 
"Aggregation Of Red C e l l s t t  Austral. Physical Enq. Sci. In Med., 
6/4:0156-0165. 1983. 
ABSTRACT: None 
Dixon G.A., Adams J.D., Harvey W.T. Decompression Sickness And 
Intravenous Bubble Formation Using A 7.8 PSIA Simulated 
Pressure-Suit Environment. Aviat. Space Environ. Med., 57 
:0223-0228. 1986. 
N 
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ABSTRACT: The purpose of this study was to determine the minimum 
space-suit pressure required to prevent decompression sickness 
(DCS) during operational conditions in a 50% oxygen/50% nitrogen 
environment. In this study, 30 male volunteer subjects were 
exposed in groups of three, to three consecutive daily 
extravehicular activity (EVA) simulations at 7.8 psia (5,031 m 
altitude equivalent) for a continuous period of 6 h. During each 
altitude exposure, the subjects participated in similar exercise 
workloads expected to be experienced by astronauts during a 
typical EVA scenario. Precordial Doppler monitoring revealed 
that 73.3% of the subjects had intravenous bubbling during at 
least 1 d of the 3h of exposure, with 26 .7% remalnlng bubble-free 
during the entire study. No correlation was found between either 
body fat or age and incidence of bubble formation. One case of 
DCS occurred during the study indicating that 7 . 8  psia 1s not 
sufficient pressure to preclude DCS in a 50% exyqen/50% nitrogen 
environment. The necessary pressure awaits further study. 
Dolbeare F. Dynamic Assay Of Enzyme Activities In Single Cells By 
Flow Cytometry. J. Histochem. And Cytochem., 27/12:1644-1646. 
1979. 
ABSTRACT: Three enzymes in single cells were assayed dynamically 
by flow cytometry using four fluorogenic substrates. Acid 
phosphatase was determined with 
7-bromo-3-hydroxy-2-naphtho-o-anisidine (naphthol AS-BI) 
phosphate and 4 methylumbelliferone (MU) phosphate, neutral 
esterase with fluorescein diacetate, and lactic dehydrogenase 
with NAD-sodium lactate. Fluorescence measurements obtained with 
the flow cytometer were converted into relative specific enzyme 
ac'tivities for single cells with molar fluorescence coefficients 
determined with a spectrofluorometer. Specific activities 
obtained from spectrofluorometric data were compared with 
activities for 4-methylumbelliferone phosphate hydrolysis and for 
lactic dehydrogenase than did similar assays by standard 
spectrofluorometry. Product diffusion may be the greatest cause 
for this discrepancy. 
Du Moulin G.E., Coleman E.C., Whyte J . H .  Bacterical Colonization and 
Endotoxin Content of a New Renal Dialysis Water System Composed 
of Acrylonitrile Butadiene Styrene. App. and Env. Micro, 53/6 
~1322-1326. 1987. 
ABSTRACT: We measured encotoxin and bacterial levels in tap 
water, in vater purified by reverse osmosis, and in dialysate 
samples over a 4-mounth period in a new 10-bed renal dialysis 
unit. Water treated by reverse osmosis is conducted to 10 
stations through 111 m of piping composed of acrylonitrile 
butadiene styrene (ABS). All determinations were made prior to 
the opening of the unit and after the system was purged for 35 h 
with all bedside station taps open. Formaldehyde disinfection of 
the piping system was attempted with a recommended protocol after 
11 weeks by feeding 2.5 liters of 37% formaldehyde (0.8596, 
vol/vol) into the delivery system. Prior to water purging, 2 4  ng 
of endotoxin per ml vas detected. This level decreased to 2.0 ng 
of endotoxin after the purging. Levels of endotoxin Lemained 
below 1.0 ng of endotoxin per ml throughout the duration of the 
study. In contrast, the level of viable microorganisms recovered 
from the trated vater vas approximately 3.5 times 10,0000 CFU/100 
ml. Even after disinfection of the system, there was no 
significant decrease in culturable bacteria from the water even 
though endotoxin levels were lover. Species isolated from the 
renal dialysis system were predominately pseudomonads, whereas 
species isolated from the tap water were Bacillus and 
Flavobacterium species. ABS provides a surface suitable for 
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long-term colonization and grovth of bacteria. Currently 
recommended decontamination protocols are ineffective in removing 
potentially pathogenic bacteria from ABS pipes and thus 
constitute an increased risk to patients undergoing dialysis. 
Marchessault R.H. . High-Resolution 13C CP/MAS 
NMR Spectra Of Solid Cellulose Oligomers And The Structure Of 
Cellulose 11. J. Am. Chem. SOC., 105:2469-2472. 1982. 
ABSTRACT: Hlgh-resolution solid-state 13C NMR spectra of 
cellulose I1 samples and of the complete series of solid 
cellulose oligomers up to cellohexaose have been obtained by 
using cross-polarization/magic-angle spinning (CP/MAS) 
techniques. Comparison of the spectra of the solid oligomers 
whth those of cellulose I1 preparations indicates that the 
charatersitic features of cellulose I1 structure appear in the 
cellotetraose spectrum and are fully developed in those of 
cellopentaose and of the higher oligomers. Thus a single-crystal 
X-ray structure determination on one of the higher oligomers 
should reveal the deta-ils of the cellulose I1 structure that the 
13 C NMR data suggest is made up of two independent chins. A 
comparison of the chemical shifts for samples of cellulose I, I1 
and IV shows characteristic displacements of C-4 and C-6 carbons 
for each polymorph. 
Drinking Water. Biosensosors, :287-300. 1986. 
ABSTRACT: A large proportion of drinking water is abstracted fox 
treatment from lowland rivers-about 30% in the UK-and this water 
is at particular risk from sudden and poisonous industrial or 
agricultural pollution. To cover the range of potential 
pollutants it may be possible to use biosensors as broadband 
monitors for toxins. The underlying assumption is that some 
bilolgical processes, when challenged with a toxin, will be 
affected in a way analogous to that of man, and that therefore 
on-line scrutiny of such processes will p r o v i d e  early warning o f  
substances liable to be detrimental to human health. Suitable 
processes for study might involve multi-cellular organisms, whole 
cells or enzymes. To date, most practical work has concentrated 
on fish, but enzymes and single cells hold out the promise of  
quicker response and, possible, easier maintenance. 
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Dudley R.L., Fyfe C.A., Stephenson P.J., Deslandes Y. ,  Hamer G.K., 
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Eveleigh D.E., Montenecourt B.S. Increasing Yields Of Extracellular 
Enzymes. Advances In Applied Microbiology, 25:0057-0073. . 
ABSTRACT: None 
Fan L.T., Lee Y. Kinetic Studies Of Enzymatic Hydrolysis Of Insoluble 
Cellulose: Derivation Of A Mechanistic Kinetic Model. Biotech. 
Bioeng., XXV:2707-2733. 1983. 
ABSTRACT: A c3mprehensive mechanistic kinetic model for enzymatic 
hydrolysis of insoluble cellulose has been synthesized by 
combining models for several key aspects which have been derived 
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independent of each other. The model takes into account the 
major contributing factors: the nature of the enzyme system, the 
structure of cellulose, and the mode of interaction between the 
enzyme and cellulose molecules. It consists of set of 
simultaneously occurring ordinary-differentlal equations with ten 
kinetic constants. All of the kinetic constants have been 
determined independently by carrying out critically designed 
experiments, and they appear in the comprehensive model without 
any arbitrary manipulations. The governing equations of the 
model have been numerically simulated by means of the computer 
subroutine CSMP 111. The model predicts the progress of 
hydrolysis of cellulose over a wide range of experimental 
conditions and hydrolysis times reasonably well. The model can 
even be applied to predict the progress of hydrolysis for 
intensively pretreated cellulose with a minor adjustment. The 
applicability of the model f o r  the actual process development is 
also discussed. 
Fan L.T., Lee Y.H., Beardmore D.H. Major Chemical and Physical 
Features of Cellulosic Materials as Substrates for Enzymatic 
Hydrolysis. Department of Chemical Engineering, Kansas State 
University, Manhattan KS 6 6 5 0 6 , .  
ABSTRACT: This review emphasizes the structure and morphology of 
cellulose, which are pertinent to understanding the enzymatic 
hydrolysis of cellulose. Physical and chemical constraints on 
the susceptibility of cellulose to hydrolysis will be examined. 
In addition, the relationship between the capillary structure of 
cellulose fiber and enzmatic hydrolysis will be discussed. 
Fang H.S., Tsai M.L., Lea I.T. Further Studies On The Application Of 
The Compartmentalization/Airlock Concept To Aircraft And 
Spacecraft. Aviat. Space Environ. Med., 56:1209-1212. 1985. 
ABSTRACT: The effect of the application of the 
compartmentalization/ airlock on accidental decompression was 
studied in conscious rats, mice, and guinea pigs. It vas 
observed that in unprotected rats and mice, 7 8  of 102 middle ears 
( 7 6 . 5 % )  exhibited hemorrhages with their eardrums intact; and in 
unprotected guinea pigs, 37 of 5 0  eardrums ( 7 4 % )  revealed rupture 
associated with hemorrhages of all middle ears (100%). Seven 
cases of malleus fractures (14%) were also found in unprotected 
guinea pigs. On the other hand, none of the protected animals 
showed signs of middle ear barotrauma. The protective efffects 
of the tolerance of middle ears In the present study showed the 
same tendency as that on the tolerance of lungs in our previous 
study. These findings indicate that the applicaton of the 
compartmentalization / airlock would be of great value in 
protection against accidental rapid decompression of pressurized 
aircraft and space craft. 
Favero M.S., Drake C.H. Factors Influencing The Occurrence Of High 
Numbers Of Iodine Resistant Bacteria In Iodinated Swimming Pools. 
App. Micro., 1 4 / 4 : 0 6 2 7 - 0 6 3 5 .  1966. 
ABSTRACT: It has been shown that, although iodinated 
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swimming-pool waters are usually free from coliform bacteria and 
enterococci, the total counts frequently become relatively high. 
Pseudomonas alcaligenes and Alcaligenes faecalis have been shown 
to account for most of these high counts. 
therefore, to compare the microbial flora of four alternately 
cholrinated and iodinated swimming pools. By means of the 
membrane filter method and suitable selective media, examinations 
were made for total viable counts, coliform bacteria, 
enterococci, staphylococci, Streptococcus salivarius, and P. 
aeruginosa. Colonies also were picked from membrane filters 
incubated on standard plate count agar and identified. The 
results shoved that, although viable counts were significantly 
higher during the iodinated periods, the specific types of 
bacteria determined were either fever than or the same as in 
chlorinated periods. During chlorination, the predominant 
microbial flora consisted of staphylococci and members of the 
genus Bacillus. During iodination, however, the P. 
alcaligenes-A. faecalis group accounted for 92 to 99% of the 
microbial flora. The accumulation of high numbers of these 
bacteria vas shown to be due to thier iodine resistance and their 
ability to grow rapidly in pool water in the absence of free 
iodine. 
It vas of interest, 
Fennington G., Neubauer D., Stutzenberger F. Adenosine 3',5'-Cyclic 
Monophosphate Levels In Thermonomonspora curvata During 
Cellulase Biosysnthesis. Biotech. Bioeng., 25:2271-2276. 1983. 
ABSTRACT: None 
Ferchak J.D., Pye E.J. Effect Of Glucose And Other Sugars On The 
B-1,4-Glucosidase Activity Of Thermomonospora fusca. Biotech. 
Bioeng., 25:2855-2864. 1983. 
ABSTRACT: The cell-associated b-glucosidase activity of 
Thermomonospora fusca, strain YX, shoved both PNPGase and 
cellobiase activities. The cellobiase activity vas found by HPLC 
assay to have very low product inhibition, vhereas the PNFGase 
activity vas more significantly inhibited. O f  the various sugars 
and sugar analogs tested f o r  inhlbitlon of the P N P G a s e  actlvlty, 
gluconolactone had the greatest effect. The low product 
inhibition of the cellobiase activity vas further demonstrated by 
the production of glucose syrups to 20% concentration from both 
cellobiose and swollen c e l l u l o s e  (Avicel). This characteristic 
is of practical importance in the development of a commercial 
process f o r  the production of glucose syrups from cellulose. 
Growth experiments gave further evidence for the probability of 
separate enzymes for the PNPGase and cellobiase activities 
I 
I 
Ferraris R., Carosso R . ,  Fiorentini M.T., De La Pierre M., Marcelino 
M., Eandi M., Gamalero S . R .  Enzymatic Determination Of Faecal 
Bile Acids. Bollenttino-Societa Italiana Di Biologia Sperimtale, 
56/1:0015-0021. 1980. 
ABSTRACT: None 
Fishman N. Patlent Smart. Mlles Inc. Diagnostics Division, E 
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Elkyhart, In. 46515,. 
ABSTRACT: Months of data are stored in the patlent's Glucometer M 
Blood Gulcose Meter, then reported through my office computer or 
the Glucofacts Data Printer. See-fng all that lnformatlon at once 
lets me make faster, better decisions about treatment regimens. 
Methods For Equating Performance Between Alternative Motion 
1/ 
Flach J.M., Riccio G.E., McMillian G.R., Warren R. Phychophysical 
1 
I Simulators. Ergonomics, 29/11:1423-1438. 1986. 
ABSTRACT: Psychophysical matching techniques were employed to 
equate the subjective experience of motion is two roll-axis 
motion simulation devices: the RATS, a whole-body motion 
environment, and the dynamic seat sub-system of the ASCOGS, 
presenting motion cues through a moving seat pan. Two 
psychophysical techniques, cross-modality matching and magnitude 
estimation, yielded similar results. These results indicated 
that motion sensitivity increased with roll angular frequency 
for both simulators. However, the rate of increase at high 
frequencies was greater for the RATS than for the dynamic seat. 
These results were used to design a fliter for the dynamic seat 
which enhanced high-frequency signal components. Tests in a 
roll-exis tracking task showed that performance in the dynamic 
seat using this filter was both quantitatively (in terms of 
r.m.s. error) and qualitatively (in terms of frequency 
characteristics) similar to performance in the whole-body motion 
environment. 
Frein E.M., Montenecourt B.S., Eveleigh E.D. Cellulase Production By 
Trichoderma reesei Immobilized On K-Carrageenan. Biotech. Let., 
4/5:0287-0292. 1982. 
ABSTRACT: Cellulase production by Trichoderma reesei mutant 
RUT-C30, immobilized on 4 %  k-carrageenan beads, was monitored in 
continuous culture for 13 days. Cellulase production averaged 
2 6 . 0  Filter Paper Units (FPU)/L/hr; carbon and nitrogen 
requirements per FPU produced were reduced to 1/4-1/2 those of 
conventional continuous c u l t u r e .  
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Friederici A.D., Levelt W.J.M. Cognitive Processes of Spatial 
Coordinate Assignment. Naturwlssenschaften, 73:0455-0458. 1986. 
b ABSTRACT: None 
Gaid K., Cavelier C., Martin G. Mechanisms Of Biological Purification 
On Activated Carbon. Water 3esear=h, 16:0007-0017. 1982. 
ABSTRACT: Activated carbon was used for the treatment of waste 
water, and a study made of the fixing-properties of the adsorbent 
and the part played by micro-organisms. 
remains to be demonstrated because it has not yet been proved 
that bacteria are fixed on carbon. 
mechanism of activated carbon was c?.rried out in three stages. 
The first vas a survey of the adsorption on this material of 
various products present in waste water [amino-acids, enzymes, 
The process of "fixing" 
Study of the biological 
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total organic matter (CODII. In the course of these tests, the 
part played by the micro-porosity of activated carbon in regard 
to such molecules was observed. In the second stage, by using 
various techniques (electron microscope, scanning and 
transmission, X-ray fluorescence,,Castaing micro-gauge), we 
determined the part played by fixation-spots inltially present on 
carbon (surface functio,is, heavy metals) during bacterial 
development. In the third stage, we correlated the eliminated 
organic pollution with the bacterial mass present on the 
adsorbing material. The conlusions drawn were that the 
micro-porosity of carbon does not play a fundamental part in the 
adsorption of organic matter in sewage, but it does come into 
play in the adsorption of certain molecules taken separately 
(amino-acids, enzymes), and that the presence of fixation-spots 
(metals, surface functions) can have same influence during 
bacterial development. Experiments are in progress to determine 
the part played by the specific surface in regard to the 
adsorbable molecules and its correolation with the bacterial mass 
and also, to observe the part played the adsorbing material and 
the bacteria in regard to the non-adsorbable molecules (ethanol, 
0 
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f methanol). 
Gallegos J.A., Gallegos J.A. Estimation and Control Techniques for 
Continuous Culture Fermentation Processes. Biotech. Bioeng., 26 
: 0 4 4 2 - 0 2 5 1 .  1983. 
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ABSTRACT: The use of digital computers in fermentation processes 
has increased in recent years. There have been several works 
dealing with data acquisition, parameter and state estimation, 
optimization, and control of such processes. There is 
considerable activity both in industry and research institutions 
in the use of digital computers for optimal control of 
fermentation systems. However, there still remains some unsolved 
problems. This article presents some results obtained when 
modern control techniques are applied to these processes. The 
article is organized as follows. A discussion about the main 
problems of computer control of fermentation processes is first 
presented. The objectives of computer-aided fermentations are 
mentioned. Then, a simple process model of a continuous culture 
fermentation process is described. This process model will be 
used throughout the work to test some control laws designed for a 
certain class of nonlinear multivariable systems. The synthesis 
of these control laws is detailed later. One of the main 
problems in the implementation of a control law is accessibility 
to the state vector. This problem is discussed and some methods 
to overcome the problem, in a fermentation process, are a l s o  
presented. In particular, the design and realization of 
observers for the substrate concentration are described. The 
designed observers are included in a feedback control structure 
for nonlinear systems and the obtained simulation results are 
presented. 
Garcia R., Sauer R.L., Plerson D.L. Development Program f o r  a Zero-G I Whole Body Shower. 1985. 
ABSTRACT: In 1985, the Man-Systems Divlslon a t  t h e  Johnson Space I 
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Center initated a program for the development of a whole body 
shower suitable for operation in a microgravity environment. 
Supportlng thls development effort has been a systematic research 
program focused on four critical apects of the design (i.e., 
human factors engineering, blomedTca1, mechanical, and 
electrical) and on the interfaces between the whole body shower 
system and the other systems to be aboard the Space Station ( e .  
g . ,  the water reclamation and air revitalization systems). A 
series of tests has been conducted to help define the design 
requirements for the whole boby shower. Crew interface research 
has identified major design parameters related to enclosure 
configurations, consumable quantities, operation timelines, 
displays and controls, and shower and cleanup protocols. 
Mechanical research has provided data on relative humidity, air 
and water temperatures and flow rates, liquid and gas separation, 
and system efficiency. Electrical research has characterized and 
quantified the power requirements for an optimized system. 
Biomedical research not only has provided data relevant to the 
indentification and control of microorganisms introduced into the 
system by human usage but also has led to a new area of research; 
that is, a study of the effects of biofilm within the shower 
system. defining the interfaces between the whole body shower 
system and the other Space Station systems and determining the 
impact of the whole body shower system on the performance of 
those systems are of paramount importance in this development 
program. In order to define these interfaces, a closed-loop test 
was conducted with the water reclamation system to evaluate the 
effects of the shower waste water on the design of the water 
reclamation system. 
Garcia R., Verostko C.E., Pierson D.L. Zero-G Whole Body Shower 
Development Program Phase I1 Test Plan. NASA Human Research 
Master Protocol Information,. 
ABSTRACT: A Whole body shower (WBS) can be disigned and 
fabricated to include the human engineering concepts necessary to 
satisfy the hygienic, physiological, and social n e e d s  of 
crewmembers engaged in long duration space missions while being 
compatible with the Space Station mechanical Systems ( e . g . ,  the 
water reclamation system). Moreover, the microbial buildup in 
the shower system can be maintained at a safe level by selecting 
components that do not harbor microorganisns and by establishing 
appropriate cleaning procedures. 
and Chronic Effects of Microgravity. The Physiologist, 30/1 
Gazenko O.G., Grigoriev A.I., Kozlovskaya I.B. Mechanisms Of Acute 
4 (Suppl) :SOOOl-S0005. 1987. 
ABSTRACT: None 
Gazenko O.G., Ilyin E.A. Physiological Investigations of Primates 
Onboard Biosatellites Cosmos-1514 And Cosmos-1667. The 
Physiologist, 30/1 (Suppl):S0031-S0035. 1987. 
ABSTRACT: It is known that the early period oL adaptation to 
weightlessness occupies the first 5-7 days of space flight. 
I' 
I 
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During t h i s  time period many physiological changes that 
constitute the so-called space adaptation syndrome develop. A 
comprehensive study of this syndrome vas the primary goal of 
physiological investigations of four monkeys flown onboard 
Cosmos-1514 and Cosmos-1667 i n  1983 and 1985. The flight 
duration vas 5 and 7 days, respecxively. 
Gazenko O.G., Shulzhenko E.B., Egorov A.D. Cardiovascular Changes In 
Prolonged Space Flights. ACTA Physiol. Pol., 37/2:0053-0068. 
1986. 
ABSTRACT: In prolonged space flights, the cardiovascular function 
vas examined at rest and during provocative tests. As compared 
to the preflight data the following changes were seen: higher 
heart rate at rest and during LBNP test, decrease of stroke 
volume at rest and during LBNP test and a less marked increase 
(or decrease) during exercise test, symptoms of a greater heart 
load which transformed to the syndrome of myocardial hypodynamics 
(preload) during LBNP test or to the syndrome of myocardial 
hyperdynamics (afterload) during exercise test (with other than 
preflight ratios of systolic and diastolic time intervals). The 
above cardiovascular changes did not , as a rule, aggravate with 
flight time and can be viewed as adaptive reactions to 
microgravity. 
by fliud redistribution in the cranial direction, diminished 
participation of the muscle system in circulation, and 
involvement of unloading reflexes from the cardiopulmonary 
eeceptor zones. 
The above cardiovascular changes were primarily produced 
Geekie D.A. Aeronautics Act Changes Medical Practice. CMAJ, 133 
:0310-0313. 1985. 
ABSTRACT: None 
Ghose T.K., Ghosh P. Cellulase Production And Cellulose Hydrolysis. 
Process Biochem., 14/11:0020-0024. 1979. 
ABSTRACT: More recent problems associated with cellulase 
production, pretreatment of cellulosic substance and t h e i r  
accessibility to enzymatic hydrolysis are discussed. Important 
aspects of mathematical models based on the kinetics of 
cellulose-cellulase system are briefly reviewed. 
Ghosh S . ,  Henry M . P . ,  Sajjad A .  Novel Two-Phase Anaerobic 
Gasification With Solid-Bed Acid Digestion in Tandem With 
Fixed-Film Methane Fermentation. Icstitute of Gas Technology, 
USA,. 
ABSTRACT: The development and performance of a novel solid-bed 
two-phase anaerobic digestion system are described. The system 
consists of a bed of organic feed operated in tandem with an 
acid-phase slurry digester and a methane-phase upflow anaerobic 
filter. The bed and the acid-phase digesters liquefy and convert 
the organics to volatile fatty acids (VFA) without gas 
productlon, while a high methane-content p r o d u c t  gas is collected 
I 
I 
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from the methane-phase filter. With municipal refuse feeds, VFA 
and ethanol were the major products from acid-phase digestion, A 
high methane content (up to 8 8  mol % )  gas was the major product 
from the methane phase filter. - I 1 Giampietro P . F . ,  Desnick R.J. Supplement ALA Dehydratase: A 
Sensitive Coupled-Enzyme Assay. Division of Medical Genetics, 
Mount Sinai School of Medicine, New York, New York,:0144-0145. . 
ABSTRACT: A coupled-enzyme assay for the specific and sensitive 
fluorometric determination of S-aminolevulinic acid (ALA) 
dehydratase has been developed. This assay is at least 10 times 
more sensitive than the existing colorimetric methods for 
porphobilinogen (PBG) quantitation using 
p-dimethylaminobenzaldehyde. The coupled-enzyme assay for ALA 
dehydratase is similar to the second stage of the A L A  synthase 
fluorometric assay detailed by Bishop et al. 1 
Goldstein I.S. Hydrolysis Of Wood. Dept. of Wood and Paper Science, I N. Carolina State University,:0413-0416. . 
ABSTRACT: Although wood hydrolysis has been practiced on a 
commercial scale during wartime conditions and is still practiced 
in the USSR, renewed interest and development work has been 
generated by the energy crisis, with ethanol from glucose 
fermentation assuming the role of a leading potential liquid fuel 
extender for gasoline. Recent developments in both enzymatic and 
acidic hydrolysis of wood are reviewed. 
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Gordon A.S. Influence Of Alginate On Attachment Of Vibrio spp. To 
Stainless Steel Surfaces In Seawater. App. Env. Micro., 53/5 
~1175-1177. 1987. 
ABSTRACT: The influences of alginate on the attachment of Vibrio 
alginolyticus and Vibrio pelagius biovar I1 to stainless steel 
was investigated. When the bacteria were in stationary phase, 
alginate decreased the number of attached bacteria in the case of 
each Vibrio sp. In contrast, when V. pelagius biovar I1 was 
grown on alginate and harvested in log phase, attachment was 
increased. This effect may be due to nutrient availability at 
the surface o r  to receptors on the bacterial surface which 
interact with alginate adsorbed to the metal. 
Gould M.J. Alkaline Peroxide Delignification Of Agricultural Residues 
To Enhance Enzymatic Saccharification. Biotech. Bioeng., 26 
:0046-0052. 1984. 
ABSTRACT: Approximately one-half of the lignin and most of the 
hemicellulose present in agricultural residues such as wheat 
straw and corn stover ate solubilized vhen the residue is treated 
at 2 5  C in an alkaline solution of hydrogen peroxide. The 
delignification reaction is most efficient when the ratio of 
hydrogen peroxide to substrate is at least 0 . 2 5  (v/v) and the pH 
is 11.5. The supernatant fraction from a given pretreatment, 
after addition of makeup peroxide and readjustment of the pH, can 
be recycled to treat at least six additional batches of 
. .  
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substrate, resulting in a substantial concentration of 
hemicellulose and soluble lignin degradation products. 
Hydrolysis of the insoluble fraction with Trichoderma reesei 
cellulase after alkaline peroxide-treatment yields glucose with 
almost 100% efficiency, based upon the cellulose content of the 
residue before treatment is a simple and sfficient method for 
enhancing the enzymatic digestibility of lignocellulosic crop 
residues to levels approaching the theoretical maximum. 
Graeber R.C., Lauber J . K . ,  Connell L . J . ,  Gander P.H. International 
Aircrew Sleep And Wakefulness After Multiple Time Zone Flights: 
A Cooperative Study. Aviat. Space Environ. Med., 57 (12 Suppl.) 
:B0003-B0009. 1986. 
ABSTRACT: An international research team has carried out an 
electroencephalographic study of sleep and wakefulness in flight 
crevs operating long-haul routes across seven o r  eight time 
zones. Folloving baseline recordings, volunteer crews (n=56) 
from four airlings spent their first outbound layover at a sleep 
laboratory. This paper provides an overview of the project's 
history, its research design, and the standardization of 
procedures. The overall results are remarkably consistent among 
the four participating laboratories and strongly support the 
feasibility of cooperative international sleep reseearch in the 
operational arena. 
Grams R.R., Massey J . K . ,  Jin Z.M., Hickey S. Medical Diagnostic 
Support For Spacecraft. J. Med. Systems, 10/2:0185-0194. 1986. 
ABSTRACT: None 
Graybiel A., Lackner J.R. Treatment of Severe Motion Sickness With 
Antimotion Sickness Drug Injections. Aviat. Space Environ. Med., 
58:0773-0776. 1987. 
ABSTRACT: This report concerns the use of intramuscular 
injections of scopolamine, promethazine, and dramamine to treat 
severely motion sick individuals participation in parabolic 
flight experiments. The findings indicate that a majority of 
individuals received benefit from 50  mg injections of 
promethazine or 0 . 5  ml injections of scopolamine. By contrast, 
50-mg injections of dramamine and 25-mg injections of 
promethazine were nonbeneficial. The use of antimution drug 
injections for treating space motion sickness is discussed. 
Griffin H., Dintzis F.R., Krull L., Baker F.L. A Miczofibril 
Generating Factor From The Enzyme Complex Of Trichoderma reesei. 
Biotech. Bioeng., 26:0296-0300. 1 9 8 4 .  
ABSTRACT: Ample literature and symposia now exist which examine 
questions of enzymatic degradation of cellulose. The intent of 
this vork is to describe the isolation of a factor from a 
commercial Trichoderma reesei preparation and to demonstrate that 
this factor interacts with filter paper cellulose to generate 
microfibrils without causing release of water-soluble 
carbohydrates, and synergisticaly interacts with chromatographed 
. .  . i  1 BIBLIOGRAPHY LISTING ' 
cellulase protein peaks such that the amount of substrate 
solubilized by a specific amount of protein fraction is 
increased. Visual evidence of mlcroflbrll generatlon is 
demonstrated by scanning electron-micrographs (SEMI. 
Grlndeland R., Hymer W.C., Farrlngton M., Fast T., Hayes C., Motter 
K., Patil L a ,  Vasques M. Changes In Pituitary Growth Hormone 
Cells Prepared From Rats Flown on Spacelab 3 .  Am. J. Physiol., 
252  (Regulatory Integrative Comp. Physiol. 21) :R0209-R0215. 1987. 1 
ABSTRACT: Anterior pltultarles from "small" ( 2 5 0  g) and "large" 
( 4 0 0  g )  rats flown on the 7 day Spacelab 3 mission were pooled 
and trypsinized into two single-cell suspensions. Compared with 
ground-based controls, flight cells appeared to contain more 
intracellular growth hormone (GH) but release less GH over a 6 
day culture period. After implantation into hypophysectomized 
rats, both sets of flight cells released only 50% of the GH 
compared with the control cells. Glands from large flight rats 
conained 4 4 %  somatotrophs compared with 37% f o r  controls; small 
animals showed no difference. There were no striking differences 
in somatotroph ultrastructure between cells in the four groups. 
Western blot analysis indicated that there were no major 
differences in immunoactive GH variants. High-performance liquid 
chromatography fractionation of culture media indicated that 
small flight cells released much less of a high-molecular weight 
variant rich in GH bioactivity. The results suggest that GH 
cells from rats exposed to ,microgravity may experience secretory 
dysfucntion. The possibility that thi.s occurs directly at the 
pituitary cell level is discussed. 
1 
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Guy W.W. Partially Closed System Will Save Big Money. Astro. Aero., 
:0050-0053. 1983. 
ABSTRACT: None 
I Haggin J: New Generation of Membranes Developed for Industrial 
Separations. Chem. Eng., 1988. 
ABSTRACT: For many years, membranes were confined to specialty 
applications, usually as delicate, often expensive, and 
frequently low-volume separation devices. With a few exceptions, 
industrial membranes were feeble imitations of the biological 
masterpieces found in living organisms. However, in the 
mid-1970s this picture changed abruptly. New membrane materials 
began to appear, the technique of making composite membranes was 
develped, and the integration of membrane separatoxs into 
chemical processing technology accelerated. Today, membranes 
have found wide acceptance in the traditional chemical and 
petroeum refining industries, as well as a new role in the 
rapidly developing specialty chemicals industries, where highly 
selective catalysis is essential and where catalyst use must be 
intimately combined with pre-or postreaction preparation and 
separation. This article focuses on efforts to develap and 
expand applications for scme of the more conventional operations 
emploging membranes in high-volume industrial sperations. A 
future article will look at some of the more exotic developments 
fi 
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making use of membranes. 
Haggln J. Membranes Play Growlng Role in Small-scale Industrial 
- Processing. Chem. Eng., 1988. 
ABSTRACT: With industrial demands growing for better separation 
and/or purification in chemical, pertoleum, 
pharmaceutical,biotechnology, and other areas, mambrane 
technology has been attraction9 more and more attention, This 
article examines many of the smaller scale operations that are 
now using membrane technology or are seen as potential 
application areas. An earlier CGEN article focused on efforts to 
develop and expand applications for some of the more conventional 
operations employing membranes in. high-volume industrial 
separations. 
Halliwell G. Cellulosic Materials and Their Pre-Treatment. Proc. 
Bioconversion Symp., :0081-0095. 1977. 
ABSTRACT: Although vast amounts of cellulosic materisls are 
synthesised annually the absence of mountaious regions for the 
polymer testify to the efficancy of cellulolytic microbes in its 
removal to cell protein and related products. Unfortunately, man 
has s o  far been unable to emulate in the laboratory this 
remarkable ability of certain baceria and fungi and has turned to 
pretreatment of cellulosic matter. Such procedures cover four 
main areas,chemical, physical, enzmic and a combination of these. 
Native cellulose, the form most resistant to biological 
degradation is readly swollen at low temperature in as little as 
two hours in certain acids and becomes 10-20 times more 
susceptible to hydrolysis, even by enzyme preparations from 
microorganisms not normally considered celluloytic. 
Susceptibility to enzyme hydrolysis can be increased even further 
by extending acid treatment to dissolve cellulose thence to be 
folloved by its reprecipitation in a very finely divided form 
(regenerated cellulose). Enzyme preparations from either 
Myrothecium verrucaria or Trichoderma spp readily achieve 
complete dissolution of regererated cellulose within 2 4  h ~ .  
Unfortunately chemical treatment like the use of alkalis provides 
swollen material of relatively low density. An alternative 
procedure that might prove useful here since it provides large 
surface areas and is applicable not only to purer forms of 
cellulose but also to naturally occurring cellulosic naterial 
such as grass, straw, hay and sawdust utilises the ability of 
dilute peroxide and iron salts to disintergrate the substrate to 
very short fibers. Physical treatments including ball-milling 
offer considerable promises since they can increase 
susceptibility and yield procucts of high bulk density. Finally, 
the use of cellulase preparations themselves to provide increased 
contact surface by comminution natural fibers should be 
considered. 
which crystalline cellulose passed before solubilisation is 
extensive and can be expecited considerably by 
agitation.3on-cellulolytic enzyme preparations from such microbes 
as M. verricaroa can also accomplish this stage. It is a 
property freely available in crude enzyme extracts of such 
This reaction constitutes and early stage through 
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microbes as well as in filtrates from the cellulolytic varieties. 
As such it would appear to offer some advantages and interestion 
posslbllltles In vlew of  the wider range of microbes available 
and recent proposals for improvlny the economy of enzymic 
sacchariflcatiom by recovering cellulase with fresh inputs of 
substrate. 
c 
Hansson G., Molin J. End Product Inhibition In Methane Fermentations: 
Effect Of Carbon Dioxide On Fermentative And Acetogenic 
Bacteria. Euro. J. App. Micro. Biotech., 13:0242-0247. 1981. 
ABSTRACT: None 
Hara A., Fukuyama K., Epstein W.L. Angiotensin-Converting Enzyme 
Measured in Mouse Tissue by Inhibition of Histidyl-Ieucine 
Peptidase. Biochem. Med., 26/2:0199-0210. 1981. 
ABSTRACT: Angiotensin-converting enzyme (ACE) is a dipeptidyl 
carboxypeptidase which hydrolyzes angiotensin I to produce the 
vasopressor angiotensin I1 and degrades the vasodeepressor 
bradykinin (1,2). The enzyme is a vascular endothelial cell 
ectoenzyme ( 3 , 4 )  and is widely distributed in various mammalian 
tissues (4-71,  but it is also present in parenchymal cells of 
kidney, where it plays a role in regulation of aldosterone 
formation and renal function ( 2 , 4 , 8 ) .  Recently, ACE was detected 
in epithelioid and giant cells in vivo (9), and in monocytes and 
macrophages in vitro ( 1 0 , l l ) .  The assay of ACE in tissues 
usually is done spectrophotometrically as 
ethyl-acetate-extractable hippuric acid released from the 
synthetic substrate, hippuryl-L-histidyl-L-leucine (hip-His-Leu) 
(12). However, insensitivity of the method limits ACE 
measurement in some tissues (6). Roth and his co-workers (13,141 
first designed a more sensitive fluorometric method using 
o-phthaldialdehyde-coupled L-histidyl-L-leucine (His-Leu1 
produced from N-benzyloxycarbonyl-L-phenylalanyl-His-Leu (15). 
The substrate was subsequently changed to hip-His-Leu by Yang and 
Neff for assay of ACE in rat brain (16). Although the assay 
method was further modified by Friedland and Silverstein (171, it 
still had a drawback. Since most animal tissues contain His-Leu 
peptidase (181, the apparent value obtained by fluorometric ACE 
assay required an adjustment for His-Leu peptidase activity. 
Silverstein and co-workers used a mathematical correction for 
measuring ACE in tissues and macrophages in man (10,11,19,20) and 
animals (21). We measured levels of both ACE and His-Leu 
peptidase in murine tissues by fluorometric assay and sought an 
inhibitor of His-Leu peptidase activity. Among various alcohols 
tested, n-butanol was found to selectively inhibit His-Leu 
peptidase, but not ACE. ACE levels were then established i n  12 
tissues and in subcellular fractions of lung, kidney, and liver 
by inhibiting His-Leu peptidase with n-butanol. 
Harris M.I. Classification And Diagnostic Criteria For Diabetes And 
Other Categories Of Glucose Intolerance. Chapter 11, Attachment 
5.8,. 
ABSTRACT: Diabetes mellitus comprises a heterogeneous group of 
~~ 
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disorders characterized by high blood glucose levels. Four major 
types of diabetes have been defined by the National Diabetes Data 
Group: insulin-dependent diabetes (IDDM), noninsulin-dependent 
diabetes (NIDDM), gestational diabetes (GDM), and diabetes 
secondary to other conditions. In addition, impaired glucose 
tolerance (IGT) is a class that encompasses persons whose glucose 
tolerance is intermediate between normal and diabetic. Diabetes 
can be diagnosed by the presence of classical slgns and symptoms 
of diabetes and unequivocally elevated blood glucose levels; by a 
fasting plasma glucose greater than o r  equal to 140 mg/dl; o r  by 
an abnormal oral glucose tolerance test, with a venous plasma 
glucose value greater than or equal to 200 mg/dl at 2 hours after 
7 5  grams oral glucose being a hallmark criterion for diabetes. 
Harrison M.H. Athletes, Astronauts, And Orthostatic Tolerance. Sports 
1 
I 
Medicine, 3 : 0 4 2 8 - 0 4 3 5 .  1986. 
ABSTRACT: Specific alterations in autonomic functions induced by 
endurance training may lead to a reduced abiltiy to withstand 
orthostatic stress. This possibility has caused some authorities 
to suggest that, because of potentially greater pooling of blood 
in the lower extremities during gravitational loading, 
endurance-trained athletes may make poor astronauts. Although 
results from spaceflight studies have provided little evidence to 
support this suggenstion, data from water-immersion studies 
indicate that endurance-trained athletes do become more 
orthostatically intolerant following a few hours of simulated 
weightlessness. Unfortunately, other evidence supporting the 
hypothesis that endurance training reduces orthostatic tolerance 
has not received adequate publication in the open scientific 
literature. 
One the other hand, a number of studies which have been 
openly reported clearly refute this hypothesis. Nevertheless, 
the established physiological differences between endurance 
athletes and non-athletes are themselves sufficient to suggest 
that the hypothesis could be tenable. Consequently, it has  t o  be 
concluded that the presently available information is both 
qualitatively and quantitatively inadequate to permit any 
def intle statement regarding a possible relationship between 
aerobic power and orthostatic tolerance. 
I 
I ' 
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8 Hart L.G. Wearing Contact Lenses In Space Shuttle Operations. Aviat. 
Space Environ. Med., 56:1224-1225. 1985. 
ABSTRACT: More and more mission specialists are being trained to 
operate in the Space Shuttle and to eventually maintain a 
permanent station in space, Since up to 48% of the general 
population wears a visual correction of some sort, it is logical 
to assume that this percentage will also be found in the 
astronaut population. This paper proposes that the soft contact 
lens can be worn successfully in the space environment. The 
contact lens of choice is the continuous-wear soft contact-which 
is proving to be quite successful for the general public. These 
lenses must be fitted at least 6 months before space flight in 
order to make sure thay can be worn successfully. 
1 
1 
I 
Harte. Fluorometric System . U . S .  Patent 4,056,724,November 1, 8 1977. 
ABSTRACT: A fluorometric system ta determine the kind and amount 
of substances derived from a biological fluid (e.g., serum or 
urine) or tissue in which the substances to be detected (e.g., 
antigen, antibody, hormone or enzyme) are coated onto a substrate 
suface in fluorescent form. Multiple coating areas of different 
samples may be employed. The fluorometric system includes a 
source of filtered light to excite fluorescence, optical systems 
for conducting the excitation light to such coating, and optical 
systems f o r  receiving emitted fluorescence and for detecting the 
same. The system efficiency and optical characteristics 
disclosed avoid photobleaching; limit fading; and are especially 
adapted to provide accurate surface reading fluorometry. 
@ 
I 
8 
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Harte R.A. Fluorometric System, Method and Test Article. United 
States Patent, 1976. 
ABSTRACT: A fluormetric system to determine the kind and amount 
of substances derived from a biological fluid (e.g., serum or 
urine) or tissue in which the substances to be detedted (e.g., 
antigen, antibody, hormone or enzyme) are coated onto a substrate 
surface in fluorescent form. Multiple coating areas of different 
source of filtered light to excite fluorsecence, optical systems 
for conduction the exciation 1ight.to such costing, and optical 
systems f o r  receiving emitted fluorescence and for detecting the 
same. The system efficiency and optical charateristics disclosed 
avoid photo bleaching; limit fading; and are especially adapted 
to provide accurate surface reading fluorometry. 
Henney M.R., Knopp K.D. Shuttle Air Monitoring. NIS/LSL Test Plan 
I 
8 samples may be employed. The fluorometric system includes a 
a 
E 
Number 79-875;. 
I ABSTRACT: None 
Henriksen J.A. Good Practice For Installing Pharmaceutical Water 
Systems. Process Engineering, 1983. 
ABSTRACT: The supply of pure water through a piping network can 
best be assured by following a number of validation procedures 
during installation. 
8 
I 
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Herson D.S., McGonigle B., Payer M.A., Baker K.H. Attachment AS A 
Factor In The Protection Of EnLcLobacter cloacae From 
Chlorination. App. Env. Micro., 53/5:1178-1180. 1987. 
ABSTRACT: Enterobacter cloacae attached t o  drinking water 
distribution particles was subjected to chlorination. Attachment 
resulted in the protection of these organisms from disinfection. 
This effect was found to be dependent upon both the level of 
chlorine in the system and attachaent time. The results obtained 
in this study indicate that attached organisms may play an 
important role in coliform outbreaks. 
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Hills B.A. Compatible Atmospheres For A Space Suit, Space Station, 
And Shuttle Based On Physiological Principles. Aviat. Space 
Environ. Med., 56:1052-1058. 1985 .  
ABSTRACT: Fundamental physioloqicsl principles have been invoked 
to design compatible environments f o r  a space suit, space 
station, and the space craft used to transport the astronauts 
from Earth. These principles include the long-term memory of 
tissues for a bubble-provoking decompression, the intermittent 
nature of blood flow in the tight connective tissues responsible 
for the bends whose incidence in aviators have been shown to be 
related to bubble volume by the Weibull distribution. In the 
overall design an astronaut breathing a mixture of 30% oxygen in 
nitrogen for 4-5 h in a space craft at 11.9 psia can transfer to 
a space station filled with the same mix at 8 . 7  psia and, after a 
further 4-5  h, go EVA at any time vithout any oxygen prebreathing 
at any stage. The probable incidence of decompression sickness 
has been estimated as less that 0 . 5 %  using the present suit 
operating at 4.3 psia but the risk could be reduced to zero if 
the suit pressure were increased to 6.5 psia. 
Hunter K.W. Technological Advances in Bedside Monitoring: Biosensors. 
Arch. Pathol. Lab Med., 111:633-636. 1987. 
ABSTRACT: The need to monitor certain key biochemical parameters 
in hospitallized patients is driving the development of 
biosensors, a new class of medical device for real-time, on-line 
quantitative analysis. A biosensor is a microelectronic device 
that utillizes a biological molecule (eg, antibody, enqyme, or 
receptor) as the sensing or signal-transducing element. 
Biosensors can be configured into simple, rapid, and 
cost-effective laboratory devices that will allow the clinical 
pathologist to become even more responsive to the primary care 
physician. In those instances where measurements on discrete 
samples do not provide the required information, continuous 
monitoring with implantable biosensors could provide realtime 
data on levels of critical endogenous or exogenous substances. 
By hybridizing recent advances in transdermal substance 
collection with the analytical capabilities of bioseilsors, 
devices f o r  continous noninvasive monitoring at the bedside can 
be envisioned. The clinical pathologist can and should play a 
key role in the clinical evaluation and implementation cf such 
technological addvances. 
Igarashi M., Kobayashi K. Space Motion Sickness and Space 
Vestibulology. Department of Otorhinolaryngology and 
Communicative Sciences, Baylor College of Medicine, Houston, 
Texas, U.S.A,,:0228-0236. . 
ABSTRACT: Given the relatively short period of the space flight 
missions and more inexperienced personnel expected to be aloft, 
if the time in space should be optimized, the critical processes 
which occur in the body equilibrium system during the period of 
initial exposure to space environment must be thoroughly 
investigated. It is most important that improved management of 
space motlon sickness (including the predlctlon, prevention and 
. .  . .  . I ’  . r. 6 
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countermeasures) is properly developed. The improvement will 
fully depend on advances in our research on the etiology and 
pathology of  this debilitating condition. 
Inman F.N. Filtration And Separation In Antibiotic Manufacture. 
Presented at a meeting of the Filtration Society on January 2 4 ,  
1984 in London,1984. 
ABSTRACT: The manufacture of a typical semi-synthetic antibiotic 
is described in detail. The preparation of the initial culture, 
the fermentation stage, the extraction and preparation of bulk 
sterile product and the final filling of vials with sterile 
powder or solution for injection together use many forms of 
filtration and separation. In this respect, antibiotic 
manufacture is similar to other large-scale fine chemical 
manufacturing processes, but there is the additional and 
essential requirement for contamination control as extraneous 
micro-organisms can adversely affect antibiotic production in 
many ways, and some stages have to be operated aseptically for 
Ieasons that are self-evident. The high demands made upon the 
equipment are discussed and practical applications described. 
Isaac-Renton J.L., Fung C.P.J., Lochan A. Evaluation Of 
Tangetial-Flow Multiple-Filter Technique For Detection Of Giardia 
lamblia Cysts In Water. App. Env. Micro., 52/2:0400-0402. 1986. 
ABSTRACT: A system of tangential-flow filtration vas evaluated 
for use in the detection of Giardia cysts in drinking vater. 
This method was more sensitive in recovering cysts than a 
frequently used wound-orlon system of throughfiltration 
Janik D.S., Sauer R . I . ,  Pierson D.L., Thorstenson Y . R .  Quality 
Requirements For Reclaimed/Recycled Water. Technical Memorandum 
58279,1987. 
ABSTRACT: Water used during current and previous space missions 
has been either carried or made aloft. Future human space 
endeavors will require some form of water reclamation and 
recycling. There is little experience i n  the U.S. space prograin 
with this technology. Water reclamation and recycling constitute 
engineering challenges of the broadest nature that will require 
an intensive research and development effort if this technology 
is to mature in time for practical use of the proposed U.S. Space 
Station. In order fox this to happen, reclaimed/recycled water 
specifications will need to be devised to guide engineering 
development. Present NASA Potable Water Specifications are n o t  
applicable to reclaimed OK recycled water. Adequate 
specifications for ensuring the quality of the reclained of 
recycled potable water do not exist either within or outside of 
NASA. NASA experience with potable water systems is reviewed, 
limitations of present water specifications are examined, world 
experience with potable vater reclamation/recycling systems and 
system analogs is reviewed, and an approach to developing 
peritinent biomedical water specifications for spacecraft is 
presented. Space Station water specifications should be designed 
to ensure the health of all likely spacecraft inhabitants 
BIBLIOGkAPH .' LISA'ING 1 
lncludlng man, animals, and plants, both separately and 
collectfvely. 
Jauchem J.R., Waligora J.M., Taylor G.R., Horrigan D.J., Johnson P.C. 
Hematological Changes Following Rgpetitive Decompressions During 
Simulated Extravehicular Activity. Int. Arch. Occup. Environ 
Health, 58:0277-0285 .  1986. 
ABSTRACT: A study was performed to evaluate decompression 
procedures suggested for use prior t o  Space Shuttle 
extravehiclular activity. 
in 12 male human subjects before and after exposure in an 
altitude chamber to a 3-day staged decompression schedule, with 
simulated extravehicular activity. 
significant increases occurred in white blood cell count and 
activated partial thromboplastin time, and platelet aggregate 
ratio was significantly decreased. Pre-exposure samples from 
subjects who were susceptible to formation of venous gas emboli 
(VGE) exhibited a significantly lower degree of ADP-induced 
platelet aggregation and a significantly higher amount of 
lymphocyte blastogenic transformation in response to the mitogen 
phytohemagglutinin than samples from VGE-resistant subjects. The 
results indicate that, following this decompression profile, 
small but significant changes occur in several hematological 
parameters, and that levels of certain parameters may be related 
to susceptibility to VCGE formation during decompression. 
Jennings R.T. Women And The Hazardous Environment: When The Pregnant 
Patient Requires Hyperbaric Oxygen Therapy. Aviat. Space Environ. 
8 
Hematological parameters were measured 
1 
Following the exposure, 
I 
I 
1 Med., 58:0370-0374. 1987. 
ABSTRACT: Women are now being exposed in increasing numbers to 
environmental hazards. Normal operations in that environment 
plus accidents of training prodecures may result inconditions 
such as decompression sickness, air embolus, hyperoxia, or carbon 
monoxide poisoning occurring in a woman who also happens to be 
pregnant. This article examines the animal data and human 
experience in these conditions in both early and late gestation. 
The risk of these conditions to the mother and fetus is assessed 
compared to the problems associated with hyperbaric oxygen 
therapy (HBO) in pregnancy. Suggestions are made regarding the 
appropriate use of HE0 therapy in pregnancy. Further medical 
investigation is requested. 
1 
a 
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Johnson D.G. Aeronautics Act And ?he Doctor-Patient Relationship. 
CMAJ, 135:1254-1256. 1986. 
ABSTRACT: None 
I Johnson K., Duez C., Frere J.M., Ghuysen J.M. . B-Lactamases ( 
Actinomycetes species), Chapter 53f. Antibiotic Inactivation and 
Modification, :0687-0698. . 
ABSTRACT: None 
I Johnson P. Saliva: A way To Obtain Specimens In An Operational 
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Setting . Space Medical Branch Report, American Medical 
Association,. 
ABSTRACT: None - 
Kanas N. Psychosocial Factors Affecting Simulated and Actual Space 
Missions. Aviat. Space Environ. Med., 56:0806-0811. 1985. 
ABSTRACT: As space missions become longer and broader in scope, 
and as crews become more heterogeneous, psychological and 
interpersonal factors will take on increasing importance. In 
order to isolate instructive psychosocial issues and trends, a 
review was made of over 60 American and Russian simulation and 
spaceflight studies and reports. Although the missions 
accomplished most of their goals, psychological and social 
stresses were evident in the crew members. Psychosocial problems 
tended to relate to mission length. There was evidence that the 
use of appropriate psychological testing and interpersonal 
sensitivity training could improve crew selection and ameliorate 
problems in the simulation studies. It is time to apply this 
knowledge to actual spaceflight conditions. 
Kanas N. Psychological and Interpersonal Issues in Space. Am. J. 
Psychiatry, 144/6:0703-0709. 1987. 
ABSTRACT: As future manned space missions become longer, and as 
crews become more heterogeneous, psychological and interpersonal 
factors will take on increasing importance in assuring mission 
success. On the basis of a review of more than 60 American and 
Soviet space simulation studies on Earth, along with reports from 
U.S. and Soviet space missions, the author identifies nine 
psychological and seven interpersonal issues, which are discussed 
along with pertinent research findings and examples from manned 
spaceflights. He concludes that more psycholqical and 
interpersonal research should be done under actual spaceflight 
conditions and offers suggestions. 
Kass J . R . ,  Bruzek W., P r o b s t  T., Thumler R., Vieville T., Vogel H. 
European Vestibular Experiments on the Spacelab-1 Mission: 2 .  
Experimental Equipment and Methods. Exp. Brain Res., 6 4  
: 0 2 4 7 - 0 2 5 4 .  1986. 
ABSTRACT: A series of vestibular experiments were performed in 
conjucntion with the first Spacelab mission, consisting of sets 
of  pxe-, in- and postflight tests. A multipurpose experimental 
apparatus w e d  for the diverse flight and ground test is 
presented. Additional apparatus together with the multi-purpose 
package were used in the baseline data collection facility at the 
landing site at NASA Dryden Flight Research Facility for the 
ground tests. The tests involved optokinetic, caloric and 
mechanical (whloe-body of head -alone) stimulation. The latter 
included linear acceleration in the subjects's xyz axes, static 
roll and yaw about an earth-vertical axis. Physiological 
parameters such as electro-oculogram (EOG), blood-volume-pulse 
(BVP), respiration, as well as the stimulus variables such as 
acceleration and caloric temperature were transmitted to the 
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ground and recorded there. The flight and ground testing 
schedules are outlined. 
venture are discussed, and some suggestions are made for future 
improvement. - 
Problems arising from this complex 1 
1 Kaysner C.A., Abeyta C., Wekell M.M., Depaola A., Stott R.F., Leitch 
J.M. Virulent Strains Of Vibrio vulnificus Isolated From 
Estuaries Of The United States West Coast. Appl. Env. Micro., 
53/6:1349-1351. 1987. 
ABSTRACT: Vibrio vulnificus was isolated from United States West 
Coast estuaries at a low frquency (5.9%) from 529 samples of 
water, shellfish, and sediment. Four strains tested with 
iron-treated mice had 50% lethal dose values ranging from 7.6 to 
360 CFU, compared with a 50% lethal dose of 4.9 CFU for a 
clinical isolate that caused the death of a septicemic patient. 
The presence of this pathogen may be a hazard to users of marine 
beaches and consumers of raw shellfish on the West Coast, 
especially to persons most susceptible to V .  vulnificus 
septicemia. Species-specific antiflagellar serum and a gene 
probe for cytotoxin-hemolysin production were useful for 
8 
e 
8 screening these environmental isolates. 
I 
Kaysner C.A., Abeyta C., Wekell M.M., Depaola A . ,  Stott R.F., Leitch 
J.M. Incidence Of Vibrio cholerae From Estuaries Of The United 
States West Coast. App. Env. Micro., 53/6:1344-1348. 1987. 
ABSTRACT: The incidence of Vibrio cholerae in shellfish, 
sediment, and waters of California, Oregon, and Washington was 
determined during the summer of 1984. Samples from 24 distinct 
, estuaries were analyzed qualitatively. V. cholerae non-01 was 
found in 23 estuaries and in 44.6% of the 529 samples examined. 
V.  cholerae 01 Inaba was isolated from water samples from water 
samples in Morro Bay, Calif. Vibrio mimicus was found in 2.3% of 
the samples. Cholera entertoxin was not found in cell-free 
filtrates of the 100 isolates tested in the Y-1 mouse adrenal 
cell assay, but heat-labile cytotoxic activity vas  observed with 
1 
5 
3% of the isolates. 
Kellogg, J.A., Manzella J.P., Shaffer S.N., Schwartz B.B. Clinical 
Relevance of Culture Versus Screens far the Detection of 1 Microbial Pathogens in Urine Specimens. Am. J. Med., 83:739-745. 
1987. 
ABSTRACT: The use of scxeens to detect "signigicant :evels" of 
pathogenic microorganisms in urine specimens offers the 
advantages of both rapidly reporting results and controlling 
costs. Many of these screens, however, are insensitive at 
microbial counts below (1015 colony-forming units (CFU)/ml of 
urine. It is increasingly apparent that patients with almost any 
type of uninary tract infection (except f o r  most patients who are 
asymotomatic o r  who have pyelonephritis) may have urine 
concentrations of pathogens as low as (1012 to (1013 CFU/ml. 
This review documents factors that can contribute to diminished 
concentrations of microorganisms in urine, lists patient 
population in. whose urine microoqanisms in concentrations well  
I 
1 
.. . 
below (1015 CFU/ml have been asscoiated with infection, and makes 
recommendations for selection of laboratory tests, including 
rapid screens, f o r  the diagnosis and management of urinary tract 
infections. 
Kenealy W.R., Zeikus J.G. Characterization And Function Of 
Phosphoenolpyruvate Carboxylase In Methanobacterium 
thermoautotrophicum. FEMS Micro. Let, 14:0007-0010. 1982. 
ABSTRACT: None 
1 
I 
I Kerby R., Zeikus G.J. . Growth Of Clostridium thermoacetlcum On 
I 
H2/C02 Or CO As Energy Sources. Cur. Micro., 8:0027-0030. 1983. 
ABSTRACT: The type stain Fontaine of Clostridium thermoaceticum 
proliferated on H2/C02 as energy source and was culturally 
adapted to grow on 100% CO in the headspace. The doubling times 
at 55 C on CO of H2/C02 were 16 and 18 h, respectivly. Under 
these conditions, the substrate-product transformation 
stoichiometries observed were: 4H2 t 2.1 CO2 = 0.9 acetate and 4 
CO = 2C02 t 1.1 acetate. It is concluded that C. thermoaceticum 
has a single carbon growth physiology. I 
Kirsch E.J., Sykes R.M. Progress In Industrial Microbiology. 
;0155-0237. 1971. 
ABSTRACT: None 
1 Kirsch K., Haenel F., Rocker L. Venous Pressure in Mlcrogravity. 
1 
1 
1 
1 
Naturwissenshcaften, 73:0447-0449. 1986. 
ABSTRACT: In microgravity (micro-g) when the hydrostatic 
component of the intravascular pressure is eliminated, a 
redistribution of body fluids occurs leading to a fluid shift 
tovards the cephalic parts of the body. Therefore, elevated 
venous pressures should be expected in the vein of the upper part 
of the body as compared to the values on ground. However, O U L  
measurements during the Spacelab 1 Mission failed to show this. 
It was thought that 2 2  h after entry into the micro-g 
environment, when we had the first chance to measure, adaptive 
mechanisms had already counteracted this pressure increase. 
Therfore, the attempt was made to measure venous pressure as 
early as possible during the D1 Mission. 
Kiyohara H., Sugiyana M., Mondello F . J . ,  Gibson D.T., Yano K. Plasmid 
Involvement In The Degradation Of Polycyclic Aromatic 
Hydrocarbons By A Beijerinckia Species. Biochem. Biophys. Res. 
Comm., 111/3:0939-0945. 1983. 
1 
I ABSTRACT: None 
Klibansky M.M., Otero M.A., Gonzalez L.F. A New Function For Overall 
Optimization Of Yeast Production. Biotech. Bioeng., 25  
ABSTRACT: The influence of several operating variables onthe 
:2493-2502. 1983. 
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p r o d u c t i v i t y  a n d  n u t r i t i o n a l  q u a l i t y  of C a n d i d a  u t i l i s  ar-d!cI 
c a r b o u - l i m i t e d  g rowth  c o n d i t i o n s  was s t u d i e d .  Four  r c s p o n s c s  
were a n a l y z e d :  biomass y i e l d  (Y), i n  v i t r o  d r y  m a t t c r  
d i g e s t i b i l i t y  ( a ) ,  n u c l e i c  a c i d  c o n t e n t ,  a n d  p r o t e i n  c o n t e n t  (F). 
T h r e e  u p e r d t i n g  v a r i a b l e s  were s t i i d i e d :  d i l u t i o n  r a t e ,  
t e m p e r a t u r e ,  a n d  c a r b o n - n i t r o g e n  r a t i o  i n  t h e  g r o w t h  medium. 
C o r r e l a t i o n  d e s c r i b i n g  t h e  i n f l u e n c e  o f  o p e r a t i n g  v a r i a b l e s  or1 
the  s t u d i e d  r e s p o n s e  p a r a m e t e r s  were d e v e l o p e d .  F r o m t h e s e  
c o r r e l a t i o n s  r e s p o n s e  s u r f a c e s  were d r a w n .  A new f u n c t i o i l ,  
a lpha-PdY,  is p r o p o s e d  as a more c o m p r e h e n s i v e  c r i t e r i o n  f o r  
s e l e c t i n g  t h e  o p t i m a l  c o n d i t i o n s  u n d e r  t h e  c o n s t r a i n t  o f  
s a t i s f y i n g  m u l t i p l e  o b j e c t i v e s .  I t  is d e m o n s t r a t e d  t o  be 
s u p e r i o r  t o  t h e  y i e l d  c o e f f i c i e n t  a l o n e  i n  t h i s  r e s p e c t ,  s i n c e  i t  
a c c o u n t s  f o r  f a c t o r s  t h a t  are i m p o r t a n t  t o  t h e  n u t r i t i o r l a l  
a s p e c t s  o f  t h e  p r o c e s s .  
I 
I 
X r i L i f e l  € I . ,  S c h o b e r t h  2.14. O c c u r r e n c e  Of F o l y a n i n e s  In The S t r i c t l y  
Al-raeKobiC, A c e t o g e i i i c  B a c t e r i u m  A c e t o b a c t e r i u m  wuudii. Fcml; 
M i c r o .  L e t . ,  11/1:0059-0061. 1981. 
ABSTRACT: None 
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K O  C . Y . ,  Joh f i son  J.L., Barriet t  L . B . ,  XcNbir H . M . ,  V e r c e L l o t t i  J.R. A 
S c r , s i t i v e  E s t i i i i a t i o n  Of T h e  FLLCLi;ta<c Cf S L i l i b l i l t ;  F I J S  C k ' L r ' . '  L U r  A I I L  
C~lKOKldtogr3j31iy. A I : J . ~ .  Blochem, 80:0183-0192. 1977. 
In B,-axyxiborj .dsl ,=ic AciZ By HigF. - 7 % -  r t & f O X i i \ a r i i e  Liqaid 
ABSTRACT: A r a g i d  h i g h  p e r f o r m a n c e  l i q u i d  c l l r o m a t u g r a p h i c  :E:?LC) 
ir.c:t!,td is del;criFJcd which  o f f e r s  a f a s t  q u a n i t i t a t i v e  p rocedure  
f o r  d e t e r m i n i n g  t h e  p e r c c r l t ~ g e  of  q u i n i n e  ( G )  p l u s  c y t u s i n e  (C) 
i r l  DKA k E c p r a t i o i 1 s  after d C i 5  f k ~ d K O l y S i s  i : i  :So& f o r m i c  a c i d .  As 
l i t t l e  d~ 1 0  ug of DXA is; a m e n a b l e  tu t h i s  CiiidlySis. A:thuucjh 
t h y m i n e  is s o m e t i m e s  p o o r l y  r e s o l v e d  from i m p u r i t i e s  a t  the 
s o l v e n t  f r o n t ,  The p c r c e n t a g e  of G t C  was f o u i d  t o  be a c c t i r a t e l ~  
d e t e r m i n e d  u s i n g  a d e n i n e  ( A )  s i m p l y  f rom t h e  r a t i o r :  cjf 
c o n c e n t r a t i o n  from C / ( A t C )  o r  ( G t C ) / ( 2 A t G t C ) .  The HFLC nethc:rJ. 
g a v e  v a l u e s  f o r  t h e  p e r c e n t a g e  of  G t C  i l l  CLUSIZ  agreen;cr i t  w i t ! ;  
t h e r i n a l  m e l t i n g  point and buoyant density v a l u e s  dcternii:.c;l f;r 
L I i c  DF:A u f  te1-i G . i i ; i c t C L i a l  L P e c i t . 5  iii.12 two f t i i i c j : .  
Koclli € i . A . ,  B a n d l e r  R . ,  G i b s o n  S . R .  F l u o r e s c e n c e  M i c r o s c o p y  Pioce2:urc ;  
FUL Q ~ d r i L i t d t i u ~ i  O f Yeast ,  11-A B e v e r a g e s .  App. Env. M i c r o . ,  8 5?/3:0599-0601. 1986. 
ABSTRACT; Existing metho2s  f o r  q u a n t i t a t i n g  y e a s t s  i n  Level-ages 
i n c l t i d e  t i m e -  ioI-iJiini:-iJ p l a t e  co;lr.t; t h a t  Z e t r c t  u i i l i  li*ii;As LC**> - -  
drid ~ A c i T i a C y t o I i l e t L L  c o u r i t s  Liiat axe reliable onLy at v e r i  1Aigh 
c o n c e n t x G t i o r i a  ( ~ . g . ,  IC6 t u  20 si 1 C C  cc l l r ;  ijLi I L L )  . ? I ~ . L  i i c b  
X I C L I ~ L J C  dcscr ILcJ  hcLr  ~ ~ I V U ~ V C S  t h e  use  of I l u o r e s c e i l L e  
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l 
mic~c j r ;eopy  w i t h  t h e  f l u o r e s c e n t  s t a i n  a n i l i n e  b l u e  t o  
d i f f c r e n t i a t c  yei is ts  (dtid u t h e r  furicjc) f rom background,  f o r  cdsy 
c o n t i n g  a n 2  a l s o  may be u s c d  i n  c o n j u n c t i o n  w i t h  meuibranc 
f i l t r a t i o n  t u  c o n c e n t r a t e  y e a s t s  f r o m  l i q u i d s  b e f o r e  c e l l  
e n u m e r a t i o n .  R e c o v e r i e s  a v e r a g e d  31.5% f u r  L e v e r a g e s  s p i k e d  w i t h  
l e v e l s  of 5 0 0  t o  G 0 0 , O O O  u r y a r r l i s m s  p e r  m l .  The c o r r e l a t i v r i  
c o e f f i c i e r l t  of  c o u n t  t o  s p i k e  l e v e l s  was 0 . 3 9 6 % .  I 
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1 Kohl R.L. Failure of Metoclopramide To C o n t r o l  Emesis Of Nausea Due 
TO stressful Angular Or Llnear Acceleration. Aviat. Space 
Envlron. Med., 58:0125-0131. 1981. 
ABSTRACT: Orally administered metoclopramide (REGLAN) at doses of 
10 or 20 mg, 7 5  min prior to either stressful linear acceleration 
(parabolic flight) of cross-coupled accelerative semicircular 
canal stimulation in a rotating chair was evaluated for its 
ability to prevent emesis o r  nausea 11, respectively. Although 
metoclopramide is an effective antiemetic agent that enhances 
gastric emptying and prevents cancer chemotherapy-induced emesis, 
we were unable to demonstrate any significant (p<O.O5) effects of 
this drug on motion sickness. 
Effects of Five New Sympathomimetic Drugs Suggest a New Principle 
For the Prevention Of Space Motion Sickness. Aviat. Space 
I 
1 
I Kohl R.L., Calkins D.S., Mandell A.J. Arousal and Stability: The 
1 Environ. Med., 57:0137-0143. 1986. 
I 
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ABSTRACT: Sympathomimetic agents are frequent components in 
antimotion-sickness drug combinations because of their usefulness 
in counteracting the sedation caused by stressful motion or 
resulting from the administration of other antimotion-sickness 
drugs. The noradrenergic neurochemistry of the brain's 
arousal-attentional systems prompted us to evaluate the efficacy 
of five nev sympathomimetic drugs and to further define the role 
of arousal in susceptibility to motion. Subjects were orally 
administered methamphetamine (20 mg), phenmetrazine (25 mg), 
phentermine (37.51, methylphenidate (20 mg), or pemoline ( 7 5  mg) 
2 h prior to taking a Staircase Profile Test. All of the drugs 
increased resistance to stressful Coriolis stimulation by 
80-120%. Methylphenidate and pemoline shoved fewer side effects. 
These findings, interpreted in conjunction with the documented 
ineffecacy of most anticholinergic and antihistaminergic drugs 
tested to date, suggest that sympatheomimetic drugs of a 
generalized state of arousal can inhibit the development of 
motion s i c k n e s s .  
Kropp K.D. Shuttle Crew And Environmental Bacteriology, NSI/LSL Test 
Plan K80-881. NASA JSC, NSI/LSL Test Plan #80-881,1980. 
ABSTRACT: This study will be initiated in order to assay 
preflight and postflight samples from the Shuttle crewmembers for 
medically important aerobic bacteria and to determine the 
microbial load of the inner surfaces of the Orbiter before and 
after flight. 
Kumar N.J., Krishnamoorthi K.P., Swaminathan T. Studies On 
Nitrification Of Aniline With Acclimated Activated 
Biotech. Bioeng., 26:0197-0202. 1983. 
ABSTRACT: Aniline, a toxic organic pollutant, occurs in a number 
of industrial effluents. Apart from carbonaceous oxygen demand, 
aniline imposes a nitrogenous oxygen demand, due to its nitrogen 
content, in excess of that required for cell growth. Incomplete 
I 
8 
Sludge. 
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biodegradation will result In ammonia production; this also 
exerts toxicity. Hence, nitrification of aniline should be 
ensured in the biological treatment before discharge into 
receiving streams. Aniline, however, is reported to inhibit the 
nitrificatin process. Aniline degradation vas studied in 
laboratory continuous activated sludge vith an acclimated culture 
developed in synthetic feed to determine the extent of complete 
biological degradation. Aniline-N (even at 400  mg/L aniline 
concentration) could be converted to nitrate-N with ammonium-N 
and nitrite-N formed as intermediates at a detention time of 2 4  
h. The nitrification, however, was suppressed by aniline. The 
degradation of aniline to ammonia releases the suppression and 
the nitrification proceeds rapidly. 
Kutch J.M. Letters To The Editor. Pride And Professionalism, . 
ABSTRACT: None 
Lackner J . R . ,  Graybiel A. Sudden Emesis Following Parabolic Flight 
Maneuvers: Implications For Spacemotion Sickness. Aviat. Space 
Environ. Med., 5 7 : 0 3 4 3 - 0 3 4 7 .  1986. 
ABSTRACT: Episodes of emesis unaccompanied by the usual prodromal 
signs of motion sickness have been reported by astronauts in the 
space shuttle program. Such reports have raised the issue 
whether space motion sickness has different characteristics from 
terrestrial motion sickness. We present evidence here from 
parabolic flight experiments that sudden vomiting can occur in 
response to a provocative vestibular stimulus even vhen no 
premonitory exposure conditions, the absence of prominent signs 
of symptoms of motion sickness does not necessarily mean an 
absence of sensitization. 
Lack .ner J.R., Graybiel A. Head Movements In Non-Terrestrial Force 
Environments Elicit Motion Sickness: Implications For The 
Etiology of Space Motion Sickness. Aviat. Space Environ. Med., 
5 7 : 0 4 4 3 - 0 4 4 8 .  1986. 
ABSTRACT: Space motion sickness has become an operational concern 
in manned space flight. Considerable evidence exists that head 
movements in f r e e  fall, especially pitch movements, are 
provocative until adaptation occurs. The question arises whether 
space motion sickness is an unique nosological entity of is due 
to body movements in a non terrestrail force environment, a f o r c e  
environment for which the body's dynamic sensory-motor adaptions 
to 1 G are no longer appropriate. To evaluate this issue, we had 
subjects make controlled head movements durlrrq exposure to high 
gravitoinertial force levels, 1 . 8 - 2 . 0  G, in parabolic flight 
maneuvers. Head movements in pitch vith eyes open were most 
evocative of motion sickness, yaw movements with eyes covered 
were least provocative. This pattern is identical to that which 
occurs vhen the same types of head mevements are made in the free 
fall phase of parabolic maneuvers. It appears that space motion 
sickness is the consequence of prolonged exposure to a 
non-terrestrial force background rather than of exposure to free 
fall per s e .  
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Lackner J.R., Grayblel A. The Effective Intensity of Coriolis, Cross 
Coupling Stlmulatlon Is Gravitolnertlal Force Dependent: 
Impllcatlons For Space Motion Sickness. Avlat. Space Environ. 
Med., 57:0229-0235 .  1986. 
ABSTRACT: Coriolis, cross-coupled angular acceleration 
stimulation readily induces motion sickness under terrestrial 
conditions. Nevertheless, the Skylab astronauts, when tested 
with such Stimulation in-flight, sure insusceptible event though 
each had been susceptible preflight. It is unclear whether this 
decreased susceptibility was the consequence of in-flight 
adaptation of in part the result of immediate changes in 
sensory-motor and vestibulo-motor function that occuz during 
exposure to microgravity conditions. To evaluate this issue, we 
have tested individuals both in the high and low force phases of 
parabolic flight maneuvers using constant levels 1) subjects are 
less susceptible when tested in 0 G than t2 Gz 2) the perceived 
intensity and provocativeness of Coriolis stimulation decreases 
in 0 G and increases in t2 Gz relative to t1 Gx baseline values; 
and 3) changes in the apparent intensity of Coriolis stimulation 
OCCUK virtually immediately when background gravitoinertial force 
level is varied. These findings explain in large part why the 
Skylab astronauts were refractory to motion sickness during 
Coriolis stimulation in-flight. The general implication for 
space motion sickness are discussed. 
Landstrom U., Lofstedt P. Noise, Vibration And Changes In Wakefulness 
During Helicopter Flight. Aviat. Space Environ. Med., 5 8  
:0109-0118. 1987. 
ABSTRACT: The investigation was carried out in cooperation with 
the helicopter school AF 1 in Boden. Measurements were made in 
two different types of helicopter, Hkp 3 and Hkp 6 .  Three 
different parameters were recorded during the flights: noise, 
vibration, and wakefulness. Noise and vibration exposures were 
mainly correlated to the main rotor energy and frequency. both 
types of exposure were dominated by lower frequencies, below 10 
Hz. Analyses of wakefulness during long-distance flights, about 
4 h, and short-distance flights, less than 2 h, were based on EEG 
and EKG recordings. As expected the level of wakefulness was 
influcrlced by the s t r e s s  upon the pilots. Take-offs aiid 
landings, as well as unexpected events during the flight, were 
correlated to an increased level of wakefulness. In some cases 
flying was correlated to a gradual increase of weariness. The 
correlation between wedriness,. types of flying, and the external 
environmental factors of noise and vibration, is also discussed. 
I Lange R.D., Andrews R.B., Gibson L.A., Congdon C.C., Wright P., Dunn 
C.D.R., Jones J.B. Hematological Measurements In Rats Flown On 
Spacelab Shuttle, SL-3. Am. J. Physiol., 252 (Regulatory 
Intergrative Comp. Physiol. 21):R0216-R0221. 1987. 
ABSTRACT: Previous studies have shown that a decrease in red cell 
mass occurs in astronauts, and some studies indicate a 
leukocytosis occurs. A life science module housing young and 
I 
I 
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mature rats vas flown on shuttle mission Spacelab 3 (SL-3), and 
the results of hematology studies of flight and control rats are 
presented. Statistically signif icant increases in the 
hematocrit, red blood cell counts, and hemoglobin determinations, 
together with a mild neutrophilia and lymphopenia were found in 
flight animals. No significant changes were found in bone marrow 
and spleen cell differentials of erythropoietin determinations. 
Clonal assays demonstrated an increased erythroid colony 
formation of flight animal bone marrow cells at erythropoietin 
doses of 0.02 and 1.0 U/ml but not 0.20 U/ml. These results 
agree with some but vary from other previously published studies. 
Erythropoietin assays and clonal studies were performed for the 
first time. 
1 
I 
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Lantz J.B., Winkler H.E., Schubert F.A., Jensen F.C. Development Of I An Advanced Combined Iodine Dispenser/Detector. The American 
1 
I 
1 
1 
Society of Mechanical Engineers Publication,l977. 
ABSTRACT: Injection of Iodine (12) into water is widely used to 
control microbial growth. An advanced, entirely automated Device 
for I2 injection has been developed for spacecraft application. 
Transfer of I2 into the water from a concentrated form is 
controlled electrochemically via feedback from an intergrated 
photometric I2 Level Detector. All components are contained 
vithin a package weighing only 1.23 kg dry, occupying only 1213 
cm3 of space, and having the capcity to iodinate 10,900 kg of 
water to 5 ppm. These features exceed design specifications. 
The device performed satisfactorily during extended testing at 
variable water flow rates and temperatures. Designed to meet 
specification of the Shuttle Orbiter, the device will find 
application in the regenerative vater systems of advanced 
spacecraft. 
Laughlin T.J., Coleman D.R., Kilgore M.V., Lishawa C.L., Eley M.H. 
The Production Of Fuel-Grade Ethanol From The Cellulose In 
I 
I Municipal Solid Waste. 
I 
ABSTRACT: Two systems that effectively convert the cellulose i n  
municipal s o l i d  waste (MSW) to fuel-grade ethanol have been 
evaluated. These systems yield about 4 0  gallons per ton of MSW. 
Our economic analyses indicate that these systems would be cost 
effective at a 500-1500 MSW ton/day scale. 
Leach C.S., Schneider H.J. Spacelab Life Sciences 1 And 2 Scientific 
Research Objectives. The Physiologicst, 30/1 (Suppl.) 1 :S0006-S0009. 1987. 
ABSTRACT: The pressurized Spacelab module was designed and built 
to allow investigators to conduct research in space in an I environment approximating that of a ground-based laboratory. It 
is configured to allow multiple investJgations employing both 
human and non-human subjects. This flexibility is exemplified by 
the SLS-1, SLS-2, and SLS-3 experiment complement. Twenty-one 
experiments will be performed on these missions; the areas to be 
investigated are renal-endocrine function, I cardiovascular-cardlopulmonary function, hematolagy, immunology, 
BI ILIOGAAPH~ LISTING 
metabolic activity of muscle, calcium metabolism, the vestibular 
system, and general biology, A plan for integration of 
measurements will allow each lnvestlgatlon to use data from other 
experiments. The experiments make up a scietlflcally balanced 
payload that addresses fundamentai biomedical problems associated 
with space flight and provides the first opportunity to study the 
acute effects of weightlessness in a comprehensive, interrelated 
I 
I 
fashion. 
I Leahy T.J., Gabler F.R. Sterile Gas Filtration. 1983. 
ABSTRACT: None 
Lechene C. Analysis of Attomole Quantities of Chemical Elements, 
Metabolites, and Enzymes in Cellular and Subcellular Volumes. 
Proc. Int. Workshop on Developmental Renal Physiology, 
:0041-0052. 1980. 
ABSTRACT: This chapter reviews the different uses of a physical 
method, electron probe microanalysis, for the analysis of 
chemical elements in very small volumes of biological material. 
A technique is outlined for scaling down a chemical and physical 
method, fluorescence spectrometry, for this analysis of organic 
compounds in fluid volumes in the picoliter range. The examples 
given illustrate the different possibilities of applications as 
they have been used in renal, reproductive, or developmental 
physiology and as they could apply to renal developmental 
biology. 
I Lechevallier M.W., Schiemann D.A., Mcfeters G.A. Factors Contributing 
1 
I 
To The Reduced Invasiveness Of Chlorine-Injured Yersinia 
enterocolitica. App. Env. Micro., 53/6:1358-1364. 1987. 
ABSTRACT: The invasion of epithelial cells in vitro and in vivo 
by chlorine-injured Yersinia enterocolitica vas assessed by I direct microscopic observations. These experiments showed that 
injury by chlorin inhibited invasiveness of virulent Y .  
enterocolitica. Two requirements appeared to be necessary for 
invasiveness: (i) the organism must be viable and metabolically I active, and (ii) the organism must have certain surface 
components to initiate engulfment. Inhibition of RNA synthesis 
by rifampin and protein synthesis by chloramphenicol, 
tetracycline, and spectinomycin inhibited the invasiveness but 
not the attachment of Y. enterocolitica to epithelial cells. 
Membrane preparations from untreated and antimicrobial-agents 
treated Y. enterocolitica blocked the invasiveness. Chlorifie d i d  
not change the hydrophobicity of surface charge of unjured Y. 
enterocolitica. The results indicate that invasion0 was more 
than simple association of the bacterium vith the epithelial cell 
and involved a specific trigger to stimulate engulfment. 
Lee J.M., Woodward J. Properties And Application Of Immobilized 
I 
u 
I 
B-D-Glucosidase Coentrappen With Zymomonas mobilis In Calcium 
Alginate. Biotech. Bioeng., 25:2441-2451. 1983. 
ABSTRACT: The enzyme b-d-glucosidase has been immobilized on I 
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concanavalin A-Sepharose to give a maximum loading of 2050 
units/q dry weight of support material. The immobilized 
b-d-glucosidase was also entrapped withln calcium alginate gel 
spheres with apparently only 35% retention of activity vhen 
assayed with lOmM cellobiose. However, it vas discovered that, 
unlike the immobilized enzyme, the entrapped immobilized enzyme 
vas not subject to substrate inhibition up to lOOmM cellobiose, 
suggesting that a concentration gradient of cellobiose existed 
between the bulk solution and the interior of the gel sphere. 
Thus, the activity of the entrapped immobilized enzyme was almost 
twice as high as that of the immobilized emzyme when assayed with 
lOOmM cellobiose. Concanavalin A-Sepharose- immobilized 
b-d-glucosidase and the bacterium Zymomonas mobilis coimmobilized 
in calcium alginate gel spheres converted cellobiose to ethanol 
in both batch and continuous-flow fermentation systems. 
Insoluble Cellulose: (11). Analysis Of Extended Hydrolysis 
Times. Biotech. Bioeng., XXV:O939-0966.  1 9 8 3 .  
ABSTRACT: The kinetics of enzymatic hydrolysis of pure insoluble 
cellulose by means of unpurified culture filtrate of Trichoderma 
reesei was studied, emphasizing the kinetic characteristics 
associated with the extended hydrolysis times. The changes in 
the hydrolysis rate and extent of s o l u b l e  protein adsorption 
during the progress of reaction, either apparent of intrinsic, 
were investigated. The hydrolysis rate declined drastically 
during the initial hours of hydrolysis. The factors causing the 
reduction in the hydrolysis was examined; these include the 
transformation of cellulose into a less digestible form and 
product inhibition. The structural transformation can be 
partially explained by changes in the crystallinity index and 
surface area. The product inhibition was caused by the 
deactivation of the adsorbed soluble protein by the products, 
which essentially represents the so-called tfun-competitive" 
inhibition. The kinetics of B-glucosidase were also studied. 
The result has shown that the action of B-glucosidase in 
competitively inhibited by glucose. It has been found t h a t  the 
integrated form of the initial rate expression cannot be used in 
predicting the progress of reaction because the digestibiltiy o f  
cellulose changes drastically as the hydrolysis proceeds, and 
that the rate expression for enzymatic hydrolysis of cellulose 
cannot be simplified or approximated by resoration to the 
pseudo-steady-state assumption. A mechanistic kinetic model of 
cellulose hydrolysis should include the following major 
influencing factoi-s: 1) lnude of action of enzyme, 2 )  structure of 
cellulose, and 3 )  mode of interaction between the enzyme and 
cellulose molecules. 
1 Leigh R.J., Daroff R.B. Space Motion Sickness: Etiological Hypotheses 
I 
I 
1 
I 
I 
I 
I 
I 
I 
Lee Y.H., Fan L.T. Kinetic Studies Of Enzymatic Hydrolysis Of 
I 
and a Proposal For Diagnostic Clinical Examination. Aviat. Space 
Environ. Med., 5 6 : 0 4 6 9 - 0 4 7 3 .  1 9 8 5 .  
ABSTRACT: The general notion that space motion sickness (SMS) is 
due to a I1conflict" between vestibular, visual, and other sensory 
inputs has gained popular acceptance. We have reviewed three 
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specific hypotheses for SMS and identified characteristic 
disorders of  ocular motility that each hypothesis would predict. 
Accurate recording of horizontal and verlcal eye movements during 
free head movements in space craft presents technical 
difficulties. We suggest that careful clinical examination may 
be useful, provided the examinaton is directed towards detection 
those specific abnormalities predicted by each hypothesis. 
Linko M. An Evaluation of Enzymatic Hydrolysis of Cellulosic 
Materials. Technical Research Center of Finland, Biotechnical 
Laboratory, Box 192, SF-00121 Helsinki 12, Finland,. 
ABSTRACT: The diminishing one-way resorces must be replaced by 
renewable, plentiful organic materials such as cellulose. 
Enzymatic hydrolysis of cellulose has been intensively studied in 
recent years, since acid hydrolysis of cellulose has not proved 
to be economically fesible. In spite of the abundance of 
cellulose, it is not very easy to find suitable cellulosic 
materials that could be collected from a limited area and would 
be cheap enough, taking into account collecting, transport, 
handling, and storage costs. the correct choice of material 
depends on local conditions. For example, sugarcane bagasse would 
be useful in certain areas. An enzyme preparation capable of 
completely breaking down cellulose is needed for the hydrolysis. 
Trichoderma viride is the most efficient producer of 
extracellular cellulases known at present. Since several types 
of cellulases are needed, it is possible that two or more 
organisms will be used in the future. Pretreatment of cellulosic 
materials prior to hydrolysis is inevitable, but all the known 
methods, such as alkali treatment or  ball-milling, are rather 
costly. The product of complete hydrolysis is glucose, which can 
be used as such for various purposes or as raw material for other 
products. The economic feasibility of processes based on 
enzymatic hydrolysis of cellulosic materials is uncertain s o  far, 
but the potential of these processes encouages further 
developmental work. 
Human Physiology. The Physiologist, 3011 (Suppl.):SO01O-s0012. 
1987. 
Linnarsson D. The E s a  Anthrorack Project: Integrated Research In 
ABSTRACT: The evolution of terrestial l i f e  has taken place under 
the constant influence of gravity, but in all fields of life 
sciences there is a lack of knowledge about the importance and 
nature of the influence of gravity on life processes. This is 
true also for the area of human physiology. A new exciting tool 
for expeiimentation became available with the onset of the manned 
exploration of space. 
microgravity could be observed as experimental subjects. Areas 
where new insights could be gained were in the control of balance 
and locomotion, in cardiovascular dynamics, in fluid balance and 
in bone mineralization. 
The men and women who were exposed to 
Lockwood, R., Furusawa, E., Furusawa, S. Toxicity of Pretazettine in 
Rats and Cats. Prox. West. Pharmacol. SOC., 2 4 : 0 2 5 9 - 0 2 6 0 .  1981. 
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ABSTRACT: Pretazettine is an alkaloid from Narcissus tazetta 
having therapeutic activity in mice against Rauscher erythrocytic 
leukemia (1) and spontaneous AKR lymphocytlc leukemia ( 2 ) .  This 
activity may be due partly to revarse transcriptase inhibition 
('antiviral effect') and partly to protein biosynthesis 
Anhibition ('cytostatic effect') ( 3 ) .  We now report an 
investigation of toxicity and associated pharmacological effects 
of PTZ in rats and cats. 
I 
Lornzi G., Fuchs-Blslin P., Cogoll A. Effects of Hypergravity On 
"Whole-Blood'' Cultures of Human Lymphocytes. Aviat. Space 
Environ. Med., 57:1131-1135. 1986. 
I 
ABSTRACT: The purpose of this paper is to present a detailed 
description of the effects of hypergravity on the mitogenic 
response of human lymphocytes to concanavalin A .  The effect of 
cultures of lymphocytes isolated from periphral blood are 
compared with those on whole-blood cultures obtained by diluting 
fresh blood with culture medium 1:lO. Whole-blood cultures of 
lymphocytes from crew members will be investigated inflight on 
the Spacelab missions D1 in 1985 and S L S l  in 1987. In 
hypergravity there is an increase in lymphocyte activation of up 
to 500%. A similar increase can be induced by pre-incubating the 
cultures in hypergravity prior to exposure to concanavalin A at 
1G. The effect is less evident in cultures of isolated 
lymphocytes. The influence of autologous plasma and erythrocytes 
has also been investigated. Plasma and hypergravity have a 
synergistic and positive effect of lymphocyte activation, i.e. 
cultures of separated lymphocytes show the highest activations 
when incubated at G and supplemented with autologous plasma. 
Conversely, erythrocytes depress lymphocyte activation. 
M. A Family Physician's Guide to Toxnet. Center for Disease 
Control, Agency for Toxic Substances and Disease Registry, 
Chambless, 2 8  South, F 3 8 ,  1600 Clifton Road, NE, Atlanta, GA 
3 0 3 3 3 , .  
ABSTRACT: Toxnet is a computerized system of toxicologically 
oriented data banks operated by the National Library of Medicine 
(NLM). This minicomputer-lased system permits efficient access 
to valuable data on potentially toxic OK otherwise hazardous 
chemicals. 
Lutzen M.W., Nielsen M.H., Oxenboell K . M . ,  Schulein M., 
Stentebjerg-Olesen B. Cellulases And Their Application In The 
Conversion Of Lignocellulose To Fermentable Sugars. Phil. Trans. 
R. SOC. Lond., B300:0283-0291. 1983. 
ABSTRACT: Several processes have been developed for the enzymic 
conversion of lignocellulose to fermentable sugars. Most of 
these processes have employed the cellulolytic enzyme system from 
Trichoderma reesei. The action of a commercial cellulase 
preparation, Celluclast, from T. reesei on microcrystalline 
cellulose is compared with that of cellulolytic enzymes from 
other microorganisms. It is concluded that the Trichoderma 
system is not unique. More effective enzyme complexes can be 
I 
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produced from other microorganisms. In particular, systems from 
different Aspergillus species are shown to be more effective. 
The enzymic conversion of llngocellulose t o  fermentable sugar has 
not yet been scaled up, undoubtedly f o r  technical and economic 
reasons. 
furthermore the enzymic hydrolysis involves several consecutive 
reactions, each of which may be rate limiting. Enzyme costs have 
a great impact on process economy. The conversion of cellulose 
into fermentable sugar requires approximately 100 times more 
enzyme protein than the corresponding hydrolysis of gelatinized 
starch, Therefore, wlth today's enzyme technology, the use of 
cellulose as a raw material is not competitive with processes 
based on starch. 
The cellulose substrate-is very inaccessible, and 
Marco R., Vernos I., Gonzalez J., Calleja M. Embryogenesis and Aging 
of Drosophila Melanogaster Flown In The Space Shuttle. 
Naturwissenschaften, 73:0431-0432. 1986. 
ABSTRACT; None 
Marmur J. A Procedure For  The Isolation Of Deoxyribonucleic Acid From 
Micro-organisms. J. Mol. Biol., 3:0208-0218. 1961. 
ABSTRACT: A method has been described for the isolation of DNA 
from micro-organisms which yields stable, biolgically active, 
highly polymerized preparations relatively free from protein and 
RNA. Alternative methods of cell disruption and DNA isolation 
have been described and compared. DNA capable of transfroming 
homologous stains has been used to test various steps in the 
procedure and preparations have been obtained possessing high 
specific activities. Representative samples have been 
characterized for their thermal stability and sedimentation 
be haviour . 
Marmur J., Doty F. Thermal Renaturation Of Deoxyribonucleic Acids. J. 
Mol. Biol., 3:0585-0594. 1961. 
ABSTRACT: The conditions that produce the optimal re-formation 
of the native DNA conformation from denatured.DNA have been 
examined. The restoration of the native conformation, called 
thermal renaturation, has been found t o  depend markedly on the 
source of the DNA; msnimalian DNA conring f ro in  cells with very 
large DNA content renatures only slightly, bacterial DNA with 
g r e a t l y  reduced DNA content per cell undergoes extensive 
renaturation, and the very smallest bacteria together with 
bacteriophage, having the lowest DNA contents, show neaxly 
complete renaturation. With a given DNA, the optimal 
renaturation was found to occur at about 25 degrees below the 
denaturation temperature, Tm. The extent of renaturation was 
optimal above 0.4 m-NAt and increased with molecualr weight. The 
identity of the renatured DNA and the native material can be 
shown in two ways: the similarity of the absorbance-temperature 
curves and the similarity of the rate of thermal inactiviation of 
biological markers at temperatures somewhat above Tm. This 
reproduceability of the helix-coil transition and the course of  
thermal inactivation demonstrates that the same secondary 
. -  
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structure has reformed and that non-specific hydrogen bonding is 
not involved. 
I 
P 
8 J. M O ~ .  ~ial., 5:0109-0118. 1962. 
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Marmur J., Doty P. Determination of  the Base Composition of 
Deoxyribonucleic Acid from its Thermal Denaturation Temperature. 
ABSTRACT: The previously discovered linear relation between the 
base composition of DNA, expressed in terms of percentage of 
guanine plus cytosine bases, and the denaturation temperature, 
Tm, has been further investigated. By means of measurements on 
41 samples of knouwn base composition the previously observed 
relation has been confirmed. It can be summarized thus: for a 
solvent containq 0.2m-Na+, Tm=69.3+0.41(G-C where Tm is in 
degrees Centigrade and G-C refers to the mole percentage of 
guanine plus cytosine. The deviations of experimental points 
from this relation are no more than that expected from the 
uncertainties of base analysis and the variations of a half 
degree in the reproducibility of determining the Tm. 
Consequently it appears that the measurement of the Tm is a 
satisfactory means of determining base composition in DNA. The 
Tm values are most simply measured by following the absorbance at 
260 mu as a function of temperature of the DNA solution and 
noting the midpoint of the hyperchromic rise. Only 10-50 ug of 
DNA are required. A number of other DNA samples of unknown base 
composition have been examined in this manner and their base 
@ 
s 
E compositlons recorded. 
Martin E.A. An Investigation Regarding The Use of a Dynamic Seat-Pan 
Display For Training And As a Device For Communicating Roll-Axis 
Motion Information. Aviat. Space Environ. Med., 57:1189-1193. 
1986. 
ABSTRACT: This paper describes a research program conducted to 
determine the feasibility of providing useful angular 
onset-motion information via a broad-area tactual seat-pan 
display. The experiment was designed to evaluate the utility of 
the d i s p l a y  as a training device as w e l l  as its efficacy for 
imparting motion information. The results indicate that, with 
proper attention given the drive law, the tactual display can 
elicit both prformance and control behavior indistinguishable 
from that observed in a whole-body motion environment. 
Unfortunately, the training transfer results were n o t  as 
encouraqinq. These results indicated that the seat-pan display 
as used in this study was not adequate f o r  training naive 
subjects to properly i n t e r p r e t  and use the motion inEormation 
available in a whole-body motion environment. 
Martyak J.E. Reverse Osmosis/Deionized Water Bacterial Control At The 
Central Production Facility. Microcontamination, January 
:0034-0037, 0055. 1988. 
ABSTRACT: None 
Matsumoto T., Suzuki O., Katsumata Y., Oya M., Nimura Y., Akita M., 
Hattorl T. A Fluorometric Assay f o r  Total Diamines in Human Urine 
BIBLIOGRAPHY LISTING E 
Using Human Placental Diamine Oxidase. Clin. Chimica., 112/2 
:0141-0148. 1981. 
ABSTRACT: The detailed procedure for a new fluorometric assay for 
total diamines in human urine is described. The dlamlnes were 
purified from tne urine by cation-exchange chromatography and 
incubated with human placental diamine oxidase. Hydrogen 
peroxide formed in the diamine oxidase reaction was measured 
fluorometrically by converting homovanillic acid to a highly 
fluorescent compound in the presence of peroxidase. Because of 
its simplicity and high sensitivity, our present method seems 
useful for routine clinical investigation. The data obtained 
from normal subjects and patients suffering from various forms of 
cancer are also presented. 
Matsuyama T., Sogawa M., Yano I. Direct Colony Thin-Layer 
Chromatography And Rapid Characterization Of Serratia marcescens 
Mutants Defective In Production Of Wetting Aqents. App. Env. 
Micro., 53/5:1186-1188. 1987. 
ABSTRACT: A bacterial mass (ca. 1 mg) was placed directly on a 
thin-layer chromatography plate and developed shortly in 
chloroform-methanol (2:l vol/vol). After being dried, the 
bacterial mass was developed in chlorofrom-methanol-5 M ammonia 
(80:25:4 vol/vol). The obtained chromatogram indicated the 
characteristic lipid compositions of the bacteria. So, it became 
possible to examine bacterial colonies at once for the 
identification of mutants defective in the production of specific 
lipids. 
McDonald L.C., McFeeters R.F., Daeschel M.A., Fleming H.P. A 
Differential Medium For The Enumeration Of Homofermentative And 
Heterofermentative Lactic Acid Bacteria. App. Env. Micro., 53/6 
:1382-1384. 1987. 
ABSTRACT: A medium was developed f o r  the differential enumeration 
of homofermentative and heterofermentative lactic acid bacteria. 
Essential components of the medium included fructose (14mM1, 
KH2P04 (18mM), bromcresol green (as a pH indicator), and other 
nutrients to support growth. In agar medium, homofermentative 
colonies were blue to green, while heterofermentative colonies 
remained white. A total of 21 Lactobacillus, Pedlococcus, 
Leuconostoc, and Streptococcus species were correctly classified 
with the medium. 
McFeters G.A., Kippir, J.S., Lechevallier M.W. Injured Coliforms In 
Drinking Water . App. Env. Micro., 51/1:0001-0005. 1986. 
ABSTRACT: Coliforms were enumerated by using m-Endo agar LES and 
m-T7 agar in 102 routime samples of drinking water from three New 
England community water systems to investigate the occurrence and 
significance of injured colforms. Samples included water 
collected immediately after conventional treatment, during the 
backwash cycle, at various points in the distribution system, and 
1 week after the break and subsequent repair of a distribution 
main. Injured coliforms in these samples average > 9 5 % .  m-T7 
. .  
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agar yielded 8-38 fold more coliforms than did m-ENdo agar LES. 
The geometric mean of coliforms recovered by m-Endo agar LES was 
(1 conflrmed coliform per 100 ml, although m-T7 agar yielded 5.7 
to 67.5 confirmed coliforms per lQ0 ml. In addition, the 
majority of these samples giving positive results on m-T7 agar 
produced no detectatle counts on m-Endo agar LES. These 
findings indicated that coliforms were injured and largely 
undetected by use of accepted analytical media in the system 
examined. 
McHale A., Coughlan M.P. Properties Of The B-Glucosidases Of 
f 
t 
Talaromyces emersonii. J. Gen. Micro, 128:2327-2331. 2/5/1982. 
ABSTRACT: The thermophilic fungus Talaromyces emersonii wher, 
grown on cellulose-containing medium produces three extracellular 
forms of B-glucosidase, I(Mr 135000)# I1 (Mr, lOOOOO), I11 
(Mr,45700), and one intracellular form, B-glucosidase IV (Mr, 
57600). With the exception of B-glucosidase I1 vhich has yet to 
be isolated in quantities for characterization each has been 
shown to be a glycoprotein and to exist as a single polypeptide. 
Each of the purfied enzyme preparations catalysed cellobiose 
hydrolysis but only B-glucosidase IV, at the concentrations of 
substrates used, also catalysed glucosyl transfer to cellobiose. 
4' 
McIaerney M.J., Bryant M.P. Syntrophic Associations Of H2-Utilizing 
Methanogenic Bacteria And HZ-Producing Alcohol And Fatty 
Acid-Degrading Bacteria In Anaerobic Degradation Of Organic 
Matter. Anaerobes Anaerobic Infect. Symp. Int. Congr. 
Microbiol.,l978. 
b 
ABSTRACT: None 
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Mednieks M.I., Hand A.R. Salivary Gland Ultrastructure and Cyclic 
AMP-Dependent Reactions In Spacelab 3 Rats. AM. J. Physiol., 2 5 2  
(Regulatory Integrative Comp. Physiol. 21):R0233-R0239. 1987. 
ABSTRACT: Environmental stimuli influencing catecholamine levels 
induce changes in cyclic AMP-dependent reactions and cell 
morphology in the rat parotid. Responses of salivary glands to 
spaceflight were determined by measurement of cyclic AMP-mediated 
reactions in fresh-frozen salivary glands and by microscopic 
evaluation of ultrastructure in fexed parotid glands. Decreased 
cell-free protein phosphorylation accurred in parotid glands in 
three of five flight anumals. Protein kinase activity ratios 
were decreased in the soluble and increased in the particulate 
fractions of Apcelab 3 (SL-3) rat sublingual glands, compared 
wiLh ground controls. Biochemical analyses show that effects of 
space flight on salivary glands are similar to those induced 
experimentally by physiological manipulation of alteration of 
catecholamine levels. Morphological evaluation of three SL-3 rat 
parotid glands showed increased numbers of lysosomes, autophagic 
vacuoles containing degenerating secretory product, and 
accumulation of lipid droplets. Since these animals lost weight, 
cofisistent with disruption of food and water consumption, 
morphological changes may in part be due to decreased masticatory 
stlmulatlon, as occurs with reduced food lntake of a llquid dlet. 
The observed changes may reflect physiological responses of the 
gastrointestinal and autonomic systems to effects of spaceflight. 
Merrlll A.H., Wang E., Jones D.P., Hazgrove J.L. Hepatic Function In 
Rats After Spacefllght: Effects on Lipids, Glycogen, And Enzymes. 
Am. J. Physiol., 2 5 2  (Regulatory Integrative Comp. Physiol. 21) 
:R0222-R0226. 1987. 
ABSTRACT: The inclusion of rats aboard Spacelab 3 ( S L - 3 )  allowed 
analyses of liver lipids, glycogen, hepatic enzymes of 
cholesterol, glycerolipid and sphlngollpid biosynthesis, and 
other enzyme activities. Glycogen content was markedly elevated 
in livers from the flight animals compared with controls. 
Cholesterol was 24% (P < 0.04) lower in livers from the 
experimental groups, whereas blood cholesterol was 19% higher (P 
< 0.05). The activity of 3-hydroxy-3-methylglutaryl-CoA 
reductase, the rate-limiting exzyme of steroid biosynthesis, was 
80% lower (P < 0.01). Total phospholipids and sphingolipid 
levels did not differ significantly. The specific activity of 
fatty acyl-CoA synthetase, which is responsible for activation of 
fatty acids, was 37% (P < 0.02) there was no difference per gram 
of liver. The initial exzymes of sphingolipid and glycerolipid 
biosynthesis were assayed; serine palmitoyltransferase was 40% 
lower (P < 0.01), and glycerol 3-phosphate acyltransferase did 
not differ. Hepatic cytochrome P-450 content decreased by 50% 
after spaceflight. Enzymes that did not differ significiantly 
between the two groups include cytochrome b5, glutathione 
S-transferase, tyrosine aminotransferase, aspartate 
aminotransferase, and cystathionase. These findings suggets that 
space flight alters hepatic metabolism of several classes of 
conpounds. 
Michels D.B., West J.B. Distribution Of Pulmonary Ventilation And 
Perfusion During Short Periods Of Weightlessness. J. Appl. 
Physiol., 45/6:0987-0998. 1978. 
ABSTRACT: Information of the distributions of pulmonary 
ventilation and perfusion was obtained from four subjects on 
board a Learjet during 112 weightless periods lasting up to 27 s 
each. Zero gravity (G) was obtained during all or part of each 
test by varying the aircraft flight profile. Single-breath N2 
washouts were performed with the test inspiration containing an 
initial bolus of argon at residual volume (RV). When the test 
inspiration was at 0 G with the washout at 0 G or greater, the 
terminal rises and the cardiogenic oscillations i n  both N2 and 
argon were small and often absent. If instead the test 
inspiration was at 1 G with the washout at 0 G, the terminal 
rises were again small or absent but the cardiogenic oscillations 
remained. The terminal rese and the cardiogenic ascillations for 
N2 but not argon, were also nearly eliminated by performing just 
the preliminary exhalation to RV at 0 G with the test inspiration 
and washout following at 1 G. Alveolar plateaus for N2 sloped 
upward at 0 G apparently due to nontopographical inequalities of 
ventilation. In further tests during air breathing, recordings 
were made of expired partial pressure of oxygen (PO21 and carbon 
dioxide (PC02) following a brief hyperventilation and a 15 s 
1 
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breath hold. These recordings revealed marked cardiogenic 
ascillations in PO2 and PC02 at 1 G that were enhanced at 2 G but 
almost eliminated at 0 G. The results suggest that virutally all 
the topoyraphical inequality of ventilation, blood flow, and lung 
volume seen under 1 G conditions are abolished during short 
periods of 0 G. 
Mld-South Testing. Bioassay Testing Procedures For NASA. Quarterly 
Report,DSN001, DSNOO31986. 
ABSTRACT: None 
Miller G.L., Blum R., Glennon L.E., Burton A.L. Measurement Of 
Carboxymethylcellulase Activity. Anal. Biochem., 2:0127-0132. 
1360. 
ABSTRACT: None 
Mishra C., Rao M., Seeta R., Srinivasan M.C., Deshpande V. Hydrolysis 
Of Lignocelluloses By Penicillium funiculosum Cellulase. Biotech. 
Bioeng., 26:0370-0373. 1984. 
ABSTRACT: This cornmumication reports the studies on 
saccharification of lignocelluloses by P. funiculosum cellulase 
and certain studies on the kinetic aspects. 
Mittelman M.W. Biological Fouling of Purified-Water Systems: Part 1, 
Bacterial Growth and Replication. Microcontamination, October 
:0051-0055, 0070. 1985. 
ABSTRACT: The efficiency of many industrial operations is often 
closely tied to the quality of purified water used. The tie is 
particularly strong in the microelectronics industry, where 
ultrapure water is essential to a number of manufacturing 
processes. Clearly, it is important that contaminants that may 
affect water quality-and, ultimately, product quality and systems 
operations-be identified and isolated from the water system. 
11, Detection and Enumeration. Microcontamination, November 
~0044-0058. 1985. 
Mittelman M.W. Blological Fouling of Purified-Water Systems: Part 
ABSTRACT: The unique ability of microorganisms to adapt to their 
environment allows them to survive under extremely 
nutrient-limited conditions. This unusual physiology contributes 
to a number of difficulties associated vith the analysis of these 
contaminants. This column will describe various microbiological 
testing methods designed for application to high-purity waters. 
Mittelman M.W. Biological Fouling of Purified-Water Systems: Part 
111, Treatment. Microcontamination, January:0030-0070. 1986. 
ABSTRACT: This column will provide insight into the factors 
involved in the selection of biofouling treatments. Biological 
fouling presents a number of special treatment problems. 
Pur,ified-water systems contain both planktonic and adherent 
BIBLIOGRAPHY LISTING 
bacterial populations; since the latter make up the bulk of the 
total bacteria present, the treatment used must be capable of 
killing the bacterla in blofllms as well as those in the 
overlying water, In addition, the attached bllofllms must be 
removed from surfaces and flushed from the system in order to 
prevent organic or ionic contamillation. Other essential factors 
in treatment selection are product, process, and system-component 
compatibility. Finally, since most treatments for biological 
fouling employ chemicals, safety and environmental considerations 
.1 
' are of great importance. 
Mittelman M.W., Geesey G.G., Hlte R.R. Epifluorescence Microscopy. 
Microcontamination, 1983. 
ABSTRACT: None 
Mohler S.R. Case From The Aerospace Medicine Resident's Teaching 
File, W4. Aviat. Space Environ. Med., : 0 2 7 1 - 0 2 7 4 .  1985. 
ABSTRACT: An airline captain with a presenting sign of some 
premature ventricular contractions. The clinical presentation, 
evaluation, and diagnosis of the pilot are discussed. The 
aeromedical disposition and prognosis of this patient are 
provided. 
Mohler S.R. Age and Space Flight. Aviat. Space Environ. Med., 56 ' : 0 7 1 4 - 0 7 1 7 .  1 9 8 5 .  
F 
ABSTRACT: Criteria for space flight crew and passenger selection 
should be based on the following three considerations: (1) 
freedom from impairing disease, ( 2 )  ability to perform mission 
requirements and ( 3 )  motivation to undertake the mission. 
Chronologic age of itself is not a valid criterion. Forecast 
life expectancy and vitality relative to mission duration are 
valid criteria and can be applied on an individual basis using 
modern assessment techniques. The good health and vitality 
characterizing the upper ages of today's population widens the 
opportunity to utilize increasingly broad fields of experience 
and skills In future space flights, further enhancing the odds 
f o r  total mission accomplishment. 
t 
Moloney A., Coughlan M.P. Sorption Of Talaromyces emersonii Cellulase 
On Cellulosic Substrates. Biotech. Bioeng., XXV:0271-0280 .  
1983. 
ABSTRACT: The sorption characterstics of the cellulase system o f  
Talaromyces emersonii on various cellulosic substrates were 
examined. Analysis of reaction mixture supernatants by 
electrophoresis and enzyme assay showed that all components of 
the cellulase system were rapidly adsorbed by cellulose and then 
gradually returned to the liquid phase as the hydrolysis of the 
substrate progressed. The extent of adsorption in the rapid 
phase vas influenced by pH, temperature, the nature of the 
3 
I substrate, and its concentration. 
8 Moloney A.P., Considine P.J., Coughlan M.P. Cellulose Hydrolysis By 
~ ~ 
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BIBLIOGRAPHY LISTING 8 
. .  
The Cellulases Produced By Talaromyces emersonii When Grown On 
Different lnducing Substrates. Biotech. Bioeng., XXV:1169-1173. 
1983. - 
ABSTRACT: Pulp obtained from the processing of subar beet at a 
local factory is mixed with molasses and sold as cattle food. 
However, the value of the pulp would be increased considerably if 
its constituent cellulose and hemicellulose fractions could be 
converted to fermentable sugars. To this end we are 
investigating the enzymic hydrolysis of beet pulp using the 
cellulase system produced by the termophilic fungus, Talaromyces 
emersonii. In this Communication, we report on the initial 
results of such studies. 
1 
Moloney A.P., Hackett T . J . ,  Considine P . J . ,  Coughlan M.P. Isolation 
Of Mutants Of Talaromyces emersonii CBS 814.70 With Enhanced 
Cellulase Activity. Enzyme Micro. Technol., 5 1983. 
ABSTRACT: By a combination of genetic mutation and’modification 
of growth medium the cellulase activity of culture filtrates of 
Talaromyces emersonii CBS 814.70 has been increased four-fold to 
approximately 2 U ml-1 and a productivity of 20-25 Ul-lh-1. At 
50 degrees C this system was completely stable for at least 24 
hours. At 60 degrees C in static reaction mixtures 19% of the 
original activity was lost compared with 21% vhen mixtures were 
shaken. At 70 degrees C the loss of activity after 4 hours was 
64% without shaking and 70% when shaken. The cellulase system 
from Trichoderma reesei vas deciedly less than that of 
Talaromyces emersonii under each of the above conditions. The 
ability of each enzyme system, separately and together, to digest 
beet pulp vas investigated. 
fl ’ 
Montenecourt B.S., Eveleigh D.E. Preparation Of Mutants Of 
Trichoderma reesei With Enhanced Cellulase Production. App. 
Environ. Micro., 34/6:0777-0782. 1977. 
ABSTRACT: The development of an agar plate screening technique 
has allowed the isolation of a range of mutants of Trichoderma 
reesei capable of synthesizing cellulase under Conditions of high 
catabolite repression, The properties of one of these mutants 
(NG-14) is described to illustrate the use of this technique. 
NG-14 produced five times the filter paper-degrading activity per 
ml of culture medium and tvice the specific activity per mq of 
excreted protein in submerged culture vhen compared with the best 
existing mutant, QM9414. NG-14 also showed enhanced 
endo-B-glucanase and B-glucosidase production, Although these 
mutants were isolated as cellulase producers in the presence of 
5% glycerol on agar plates, in similar liquid medium, NG-14 
exhibits only partial derepression of the cellulase comples. 
Since the proportions of filter paper activity, endO-B-glUCanaSe, 
and cellobiase were not the same in mutants NG-14 and QM9414, and 
the yields of each enzyme under conditions repressive for 
cellulase synthesis were different, differential control of each 
enzyme of the cellulase complex is implied. These intial results 
suggest that the selective technique for isolating 
hyper-cellulase-producing mutants of Tricholerma will be of 
1 
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considerable use in the development of commercially useful 
celluloytic strains. 
Montenecourt B.S., Evelelgh D.E.  Production And Characterization Of 
High Yielding Cellulase Mutants Of Trichoderma reesei. 
Department of Biochemistry And Microbiology Cook College, 
Rutgers The Stat University of New Jetsey, New BrUnSWiCk, New 
ABSTRACT: Biological conversion of cellulosic materials to 
glucose by the use of microbial cellulase enzymes is an 
attractive alternative to chemical hydrolysis since enzmes 
generally are non-polluting, reusable, energy sparing and catayze 
high conversion efficiencies without undesirable side products. 
Enzymatic conversions to date have not been economical due to the 
high production costs and low yield of the enzymes produced by 
the available microbial strains. In an effort to overcome these 
economic bottlenecks, improved strains of trichoderma reesei have 
been isolated by mutation and selection which are capable of 
overcoming some of the rigid controls on enzyme synthesis and 
activity. The selection techniques and the characteristics of 
several high yielding mutants are discussed. These mutants 
hyperproduce all of the enzymes in the cellulase complex. One 
mutant C-30 is resistant to catabolite repression and appears to 
have a partially end-product resistant B-glucosidase. 
Jersey 08903,. 
Montenecourt B.S., Eveleigh D.E. Semiquantitative Plate Assay for 
Determination of Cellulase Production by Trichoderma viride. App. 
Env. Micro, 33/1:0178-0183. 1977. 
ABSTRACT: A plate clearing assay vas devised to screen f o r  
high-producing cellulase mutants of Trichoderma viride. The 
method employs (i) the use of either rose bengal or oxgall to 
limit colony size and (ii) Phosfon D 
(tributyl-2,4-dichlorobenzylphosphonium chloride) to enhance, 
cellulase detection, in combination with acid-swollen cellulose 
on agar plates. The method vas used to isolate constitutive 
cellulase mutants of T. viride and should prove useful for 
isolation9 high-producing mutants from a range of organisms. 
This technique has been also used to determine the concentration 
at which glucose and glycerol inhibit cellulase synthesis by 
catabolite repression in the wild-type strains. 
Morris N.J.H. Air, Gas And Liquid Filtration In The Pharmaceutical 
Industry. 1984. 
ABSTRACT: The production of proteins, vaccines, antibodies, 
hormones vitamins and enzymes involves high technology proceses 
which require aseptic and sterile supplies of gases or liquids 
throughout the manufacturing cycle. Recent advances in methods 
of filtration for compressed air, gases and liquids are leading 
to longer service life with higher retention efficiencies. This 
paper highlights the need for filtration in pharmaceuticals and 
describes test programmes designed to establish the value of 
hollow fibres as a superior filter medium. 
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Moser R., Woolley F.R. A Prevention Armamentarium For Aeromedical 
Practitioners. Aviat. Space Environ. Med., 58:0590-0599 .  1 9 8 7 .  
ABSTRACT: Recent advance in preventaive medicine offer 
practitioners exceptional opportunities to help patients and 
their families have longer, healthier, and moPe enjoyable lives. 
Those involved in aerospace medicine are uniquely qualified by 
their training and experience to apply this enhanced prevention 
armamentarium. The discussion considers a number of activities 
and techniques which can provide important patient benefits at 
acceptable costs. 
Mowery R.A. Automated LC Allovs Engineers to Monitor Ongoing 
Processes. Indust. Research and Devel., June:0102-0105. 1983. 
ABSTRACT: Process liquid chromatography analyzes streams of 
reactants and products, permitting quick process changes when 
needed. 
8 MSFC. Major Concerns For Microbial Contamination Of The ECLS . . 
ABSTRACT: None 
Muraca P., Stout J.E., Yu V.L. Comparative Assessment Of Chlorine, 
Heat, Ozone, And UV Light For Killing Legionella phneumophila 
Within A Model Plumbing System. App. Env. Mlcxo., 5 3 / 2  9 : 0 4 4 7 - 0 4 5 3 .  1987. 
ABSTRACT: Nosocomial Legionnaires disease can be acquired by 
exposure to the organism from the hospital water distribution 
system. As a result, many hospitals have instituted eradication 
procedures, including hyperchlorination and thermal eradication. 
We compared the efficacy of ozonation, UV light, 
hyperchlorination, and heat eradication using a model plumbing 
system constructed on coppez piping, brass spigots, Plexiglas 
reservoir, electric hot water tank, and a pump. Legionella 
pneumophila vas added to the system at 10 7 cfu/ml. Each method 
vas tested under three conditions; (i) nonturbid water at 2 5  C, 
(11) turbid water at 25 C, and (iii) maintenance. Both UV light 
and heat ( 6 0  C) produced a 5 log kill in less than 1 h. In 
contrast, both chlorine and ozone required 5 h of exposure to 
produce a 5 log decrease. Neither turbidity nor the higher 
temperature of 43 C impaired the efficacy of any of the 
disinfectant methods. Surprisingly, higher temperature enhanced 
the disinfecting efficacy of chlorine. However, higher 
temperature accelerated the decomposition of the chlorine 
residual such that an additional 120% volume of chlorine was 
required. All four methods proved efficacious in eradicating L. 
pheumophiL-. from a model plumbing system. 
Musial C.E., Arrowood M.J., Sterling C.R., Gerba C.P. Detection Of 
Cryptosporidium In Water By Using Polypropylene Cartridge 
Filters. App. Env. Micro., 53 /4 :0687-0692 .  1 9 8 7 .  
ABSTRACT: Members of the genus Cryptosporidium are protozoan 
parasites that cause gastroenteritis in humans and animals and 8 
~ ~~ 
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appear to be spread largely by the fecal-oral route. A method 
was developed for the concentration and detection of 
Cryptosporidium oocysts in water to assess their occurance in the 
environment and potential for waterborne disease transmission. 
This method was developed by using spun polypropylene cartridge 
filters. Optimal conditions for concentration, filter elution, 
filter porosity, and detection were determined. Fluoresceinated 
monoclonal antibodies were used f o r  oocyst detection. 
Experiments also were conducted to study the effect of flow rate, 
lov oocyst numbers, and the additon of detergents of recovery and 
retention of oocysts. The method that was developed was 
sensitive enough to detect oocysts at levels of less than 1 per 
liter. Using this method, we isolated Cryptosporidium oocysts 
from secondarily treated sewage. 
Nair G.B., Misra S., Bhadra R.K., Pal S.C. Evaluation Of The 
Multitest Medium For Rapid Presumptive Identification Of Vibrio 
cholerae From Environmental Sources. App. Env. Micro., 53/5 
~1203-1205. 1987. 
ABSTRACT: The multitest V. cholerae medium'(VC medium) for rapid 
presumptive identification of V. cholerae was evaluated. On the 
basis of reactions in the VC medium, 379 strains recovered during 
a yearlong ecological study in Calcutta were presumptively 
identified as V. cholerae. Further phenotypic characterization 
of these strains revealed that the reactions of 371 (97.9%) 
isolates vere consistent with that of V. cholerae. 
False-positive reactions were exhibited by eight (2.1%) strains, 
three of vhich vere identified as V. fluvialis biotype 1. By 
slightly varying the basic formulation of the VC medium, we could 
elimiate some false-positive reactions. On the basis of the 
present evaluation, ve recommend the routine use of the VC 
medium. 
NASA. Information Summaries: Space Station. 1986. 
FBSTRACT: None 
Nasser A.M., Metcalf T.G. An A-Elisa To Detect Hepatitis A Virus In 
Estuarine Samples. App. Env. Micro., 53/5:1192-1195. 1987. 
ABSTRACT: An amplified enzyme-linked immunosorbent assay 
(A-ELISA) for detecting and quantifying hepatitis A virus in 
estuarine vater samples is described. The test was five times 
more sensitive than a standard ELISA and at least two times more 
sensitive than radioimmunoassay. Test sensitivity vas unaffected 
by the procedures used to concentrate the virus in estuarine 
samples or by the presence of humic and tannic acids in test 
samples. Nonspecific reactions vere not encountered with an 
number of enteroviruses or with a rotavirus. 
and specificity combined with speed, low Cost, and freedom from 
radiolabels made the A-ELISA useful for detecting hepatitis. A 
virus in environmental samples. The virus was detected in 3 of 
20 estuarine vater samples examined by A-ELISA. 
A high sensitivity 
Natelson B.H., Goldvater D.J., De Roshia C., Levin B.E. Visceral 
B I BL I OGRAPHY L I S I  I NG 
Predictors Of Cardiovascular Deconditioning In Late Middle-aged 
Men. Aviat. Space Environ. Xed., 56:0199-0203. 1985. 
ABSTRACT: A major task for space biologist is to try to delineate 
methods which can be used to predict the degree of cardiovascular 
deconditioning that given individuals might develop while in 
space. Toward that end, we have studied a number of different 
visceral and behavioral variables in a group of late middle-aged 
men (55-65 years) on day 1 and day 5 of a bedrest regimen. 
During each 8-h study period, data were collected every 15 min. 
Mean arterial blood pressure and plasma cortisol and 
norepinephrine concentrations were significantly higher on the 
day 5 than on the day 1 of bedrest; heart rate, core temperature, 
plasma epinephrine and subjective arousal were unchanged. 
Pairvise correlations between each of these variables and the 
time to blackout on a t 3 - G ~  test of acceleration tolerance 
administered on day 9 of bedrest (mean decrease in latencies from 
prebedrest was 52%) revealed a significant correlation for the 
mean arterial blood pressure variable. Thus, these data indicate 
that men in this age span with relatively low resting blood 
pressures are at greater risk for developing clinical signs 
relating to their cardiovascular deconditioning than other men 
with higher basal blood pressures. 
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Neely W.C. Factors Affecting The Pretreatment Of Biomass With Gaseous 
Ozone. Biotech. Bioeng., 26:0059-0065. 1984. 
ABSTRACT: Treatment of a wide variety of lignocellulosic biomass 
with gaseous ozone results in greatly enhanced susceptibility to 
cellulase enzyme hydrolysis and to digestion by rumen 
microorganisms so that it can be used as ruminant animal feed or 
for the production of glucose via enzymatic hydrolysis. By use 
of appropriate reaction conditions a useful degree of such 
pretreatment may be obtained in 1-2 h contact time with an ozone 
consumption of ca.4-6% of the dry weight of the biomass. 
Nemiroff M.P. Effects of Hyperbaric Oxygne of Growth and Metastases 
of the Lewis Lung Tumor in Mice. J.HYPERBARIC MED., 3/2 
:0089-0095. 1988. 
ABSTRACT: Effects of hyperbaric oxygen (HBO) on tumor growth  and 
lung metastases were investigated using the Lewis lung squamous 
carcinoma in a mouse model. Ninety Swiss vhite mice vere 
injected vith 1 mm3 of the tumor in a standardized fashion and 
randomly assigned to a control or HBO group. Mice receiving HBO 
were treated at 2.5 ATA for 90 min twice a day for 7 d. Tumor 
volumes, tumor veights, and lung metastaes vere analyaed at 
specified times by a "blinded" researcher. Results indicated 
that there were no significat differences between HBO and control 
groups on any of the parameters measured. Results of the current 
study indicate that HBO does not enhance tumor growth or lung 
metastases. 
Neubert J . 4  Briegleb W., Schatz A. Embryonic Development of The 
Vertebrate Gravity Receptors. Naturwissenschaften, 73:0428-0430. 
1986. 
ABSTRACT: None 
Nicholson A.N. Sleep And Wakefulness sf the Airline Pilot. Avlat. 
Space Environ. Med., 58:0395-0401. 1987. 
ABSTRACT: There are tvo overriding concerns in the design of 
schedules for aircrew who have to cope with irregularity of their 
sleep due either.to vork at unusual times of the day oz to time 
zone changes. The first is that aircrew must be able to achieve 
an acceptable sleep pattern, and this is likely to involve short 
periods of sleep and naps. These, inturn, depend on limits to 
duty hours. The second is that the arrangement of work must bear 
in mind that prolonged duty and duty at certain times of the day 
may both involve relatively lov levels of performance, and 
modelling can identify the adverse interactions of these 
influences. It is also important that the quality of the sleep 
of the individual pilot is taken into consideratin when there are 
undue difficulties in coping with irregularity of vork. 
Nocturnal Sleep And Daytime Alertness of Aircrev After 
Transmeridian Flights. Aviat. Space Environ. Med., 57 (12, 
@ 
d 
Nicholson A.N., Pascoe P.A., Spencer M.B., Stone B.M., Green R.L. 
Suppl.):B0043-B0052. 1986. 
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ABSTRACT: The nocturnal sleep and daytime alertness of aircrew 
vere studied by electroencephalography and the multiple sleep 
latency test. After a transmeridian flight from London to San 
Francisco, sleep onset was faster and, although there was 
increased wakefulness during the second half of the night. sleep 
duration and efficiency over the vhole night vere not changed. 
The progressive decrease in sleep latencies observed normally in 
the multiple sleep latency test during the morning continued 
throughout the day after arrival. Of the 13 subjects, 12 took a 
nap of around 1-h duration in the afternoon preceding the return 
flight. These naps vould have been encouraged by the drowsiness 
at this time and facilitated by the departure of the aircraft 
being scheduled during the early evening. An early evening 
departure had the further advantage that the circadian increase 
in vigilance expected during the early part of the day vould 
occur during the latter part of the return flight. 
#, 
Nicolaides N. Skin Lipids; Their Biochemical Uniqueness. Science, 
186:0019-0026. 1974. 
3 
ABSTRACT: None 
Nieto J.J., Ventosa A.,  Ruiz-Berraquero F. Susceptibility Of 
Halobacteria To Heavy Metals. App. Env. Micro, 53/5:1199-1202. 3 1987. 
ABSTRACT: Sixty-eight halobacteria, including both culture 
collection strains and fresh isolates from videly differing 
geographical areas, were tested for susceptibility to arsenate, 
cadmium, chromium, cobalt, copper, lead, mercury, nickel, silver, 
and zinc ions by an agar dilution technique. The culture 
1 
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collection strains shoved different susceptibilities, clustering 
into five groups. Halobacterium mediterranei and Halobacterium 
volcanii vere the most metal tolerant, whereas Haloarcula 
californiae and Haloarcula sinaiiqnsis had the highest 
susceptibilities of the culture collection strains. Different 
patterns of metal susceptibility vere found for all the 
halobacteria tested, and there was a uniform susceptibilty to 
mercury and silver. All strains tested were multiply metal 
tolerant. 
Nojima S. The Development Of Continuous Alcohol Fermentation By 
Immobilized Living Cells. Chem. Econ. Eng. Rev., 15/4:0017-0022. 
1983. 
ABSTRACT: Technology for a continuous alcohol fermentation 
process was developed by means of immobilized living cells using 
yeast cells and specially designed artificial resins. Yeast 
which has the ability to make alcohol was screened from 
Saccharomyces genus and mixed vith prepolymers of 
photo-crosslinkable resin, then illuminated with an active ray 
(for example, chemical lamp) to change the prepolymers into three 
dimensional cross-linked polymers in which yeast was entrapped. 
Specially shaped immobilized yeast was packed in an fermentor and 
a diluted molasses solution fed to the fementor. The 
fermentation temperature vas kept at about 30-31 C and the pH at 
4-5. A s  a result of a bench scale test (10 liters of ethanol a 
day) and pitot plant test (250 liters of ethanol a day), the 
constant activity of the yeast and high alcohol yield on sugar 
during long-term operation vas confirmed and it vas also 
established that the alcohol productivity vas several times that 
of conventional suspended state batch system fermentation. 
Nystrom J . M . ,  Andren R . K .  Pilot Plant Conversion Of Cellulose To 
Glucose. Process Biochem., 11/10:0028-0034, 1976. 
ABSTRACT: The concept of transforming municipal, agricultural, 
and industrial cellulosic wastes into usable resources has long 
exicited the scientific community. Our new found avareness of 
our depleting resources has been repsonsible for the support, 
both scientific and political, given to the development of many 
cellulose utilising technologies. In a process conceived at the 
US Army Natick Research and Development Command, cellulose is 
hydrolysed to glucose via the action of a complex of enzymes 
knovn as 'cellulase'. A small pilot facility has been built and 
operated to develop an economic process technology for both the 
production of enzymes and the hydrolysis of various cellulosic 
materials. A highly instrumented concept vith designed 
processing flexibility has greatly accelerated the development 
efforts. Improved processing techniques have led to both 
enhanced production of cellulase via submerged fermentation of 
Trichoderma virlde and more optimum use of these biological 
catalysts in enzyme reactors. 
O'Sullivan J.B. Gestational Diabetes: Factors Influencing The Rates 
Of Subsequent Diabetes. Attachment J.9,:0425-0435. . 
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ABSTRACT: The design of our initial study of gestational diabetes 
provided both an intervention trial and a longitudinal study. 
The results of the intervention trial, which concerned the 
effects of insulin treatment on the outcome of pregnancy, were 
summarized in the First Colloquium on Carbohydrate Metabolism in 
Pregnancy and the Newborn in 1973 (O'Sullivan, 1975). On the 
occasion of the Second Colloquium, my comments vi11 be confined 
to data from the longitudinal study providing current information 
on the rates of subsequent diabetes from that initial 'study and 
to some of the factors that determine these rates. 
O'Sullivan J.B. Lone Term Follow Up Of Gestational Diabetics. 
Unknown, Attachment J.lO,:O503-0517. . 
ABSTRACT: None 
Obenhuber D.C., Folsome C.E. Carbon Recycling In Materially Closed 
Ecological Life Support Systems. Biosystems, 211988. 
ABSTRACT: Materially closed microbial ecosystems represent model 
life suppoft systems for the future human habitation of space. 
These ecosystems vhen subjected to a constant energy flux seem to 
be reliable and self-sufficient systems for recycling of 
biologically produced carbon compounds. 
Odum H.T. Limits of Remote Ecosystems Containing Man. Am. Biol. 
Teacher, 25:429-443. 1963. 
ABSTRACT: Considering a controversy among those attemptiong to 
provide support for man in Space, three kinds of systems are 
contrasted: A .  the conventional engineering approach with pipes, 
electrical circuits, fuel, and maintenance parts sent from earth; 
B. the physiological approach vith a fev biological species in 
culture to complement man in a simple ecosystem, vhich also 
requires heavy subsidies in energy materials, cont~ols, and parts 
from earth; C. the ecological approach vith a complex 
multispecies climax ecosystem self sufficient vith all its 
maintenance and control functions in the form of many highly 
minaturized and specialized biogeochemical circuits. Some 
fallacies in previous estimates of the amount of solar energy 
required to support man in space are described: A .  the incorrect 
use of theoretical reversible high effciencies for computing 
potentials in defiance of the great body of empirical data on the 
noderately low efficiency of successful self maintaining 
ecosystems; B. the omission of the energetic costs of the 
accompanying species necessary for stable chemical cycles and 
system maintenance; C. the neglect of the high trophic position 
of man and the necessity of heat losses during food chain 
transfers to him. The extimated minimum solar area for a closed 
and stable climax ecosystem supporting man vithout outside 
subsidies is estimated as 2 acres. To develop such a system 
including man for space encapsulation, the multiple seeding 
method is recommended. 
Oetgen W.J., Jones S . L . ,  Pettyjohn F.S. Intracardiac 
I Electrophysiologic Studies In The Medical Evaluation of Aviators. 
BXdLIOGRAPHY LISTING c 
Aviat. Space Environ. Med., 56:0443-0450. 1985. 
ABSTRACT: Ten aviators vith cardiac symptoms or 
electrocardiographic abnormalities undervent electrocardiographic 
testing. Four patients vere studTed because of symptoms 
including palpitaitons, near-syncope, and sudden cardiac death. 
Six patients vere studied because of electrocardiographic 
abnormalities including AV block, right bundle branch block, 
sinus bradycardia, ventricular tachycardia, and questionable 
Wolf f-Parkinson-White syndrome. Three patients vith bradycardia 
and/or AV block vere found to have increased vagal tone. A 
fourth patient had near-syncope and intra-Hisian block. Of four 
patients evaluated for palpitations and/or tachycardias; one had 
nonsustained ventricualr tachycardia; one had easily inducible 
ventricualr tachycardia and fibrillation; one had a normal study, 
and one had coronary artery disease vith an unanticipated 
prolonged HV interval. The diagnosis of congenital right bundle 
branch block and Wolff-Parkinson-White syndrome vere confirmed in 
the final two patents. Performance of electrophysiologic testing 
provided objective data to allow appropriate therapeutic and 
administra.tive decisions in these aviators. 
1 
1 
Ohmine K., Ooshima H., Harano Y. Kinetic Study On Enzymatic 
Hydrolysis Of Cellulose By Cellulase From Trichoderma viride. 
Biotech. Bioeng., XxV:2041-2053. 1983. 
ABSTRACT: Pure cellulose (Avicel) vas hydrolyzed batchvise at 50 
C and pH 4.8 by cellulase from Trichoderma viride (Meicelase 
CEP). Then the effects of the crystallinity of cellulose as well 
as the thermal deactivaton and product (cellobiose and glucose) 
inhibition to cellulase on the hydrolysis rate were 
quantitatively investigated. While these factors had evidently 
retarded the enzymatic hydrolysis of cellulose to a significant 
extent, the hydrolysis rates observed could not be explained. 
For practical purposes, an empirical, simple rate expression was 
developed which included only one parameter: an overall rate 
retardation constant. This empirical rate expression held for 
the hydrolysis of at least two kinds of cellulosic materials: 
Avicel and tissue paper. 
I 
8 
Ohmine K., Ooshima H., Harano Y. Kinetic Study On Enzymatic 
Hydrolysis Of Cellulose By Cellulase From Trichoderma viride. 
Biotech. Bioeng., 25:2041-2053. 1983. 
ABSTRACT: None 
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c Oman C.M., Lichtenberg B.K., Money K.E., mcCoy R.K. M.I.T./Canadian 
Vestibular Experiments On The Spacelab-1 Mission: 4. Space 
Motion Sickness: Symptoms, Stimuli, and Predictability. Exp. 4 Brain Res., 64:0316-0334. 1986. 
ABSTRACT: Space sickness symptoms were observed by 4 specially 
trained observers on Spacelab-1. Three reported persistent 
symptoms, and vomited repeatedly durinq the first and/or second 
day of flight. Head movements on all axes vere provocative, 
particularly in pitch and roll. Head acceleration data recorded 
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from 2 symptomatic crevmen shoved that after several hours of 
physical activity in orbit, symptoms appeared, and thereafter 
both crewmen were compelled to limit head movements. Firm body 
contact with motionless surfaces helped alleviate symptoms. When 
crewmembers floated into unfamiliar body orientations in the 
cabin, inherent ambiguities in static visual orientation cues 
sometimes produced spatial reorientation episodes vhich vere also 
provocative. Symptoms largley resembled those of other forms of 
prolonged motion sickness, superimposed upon other sypmtoms 
attributable to fluid shift. All 4 eventually used anti-motion 
sickness drugs. When they did, vomiting frequency was reduced. 
By the 4th day, symptoms subsided,and head accelerations again 
increased in magnitude and variability. Sickness intensity in 
orbit was not predicted by statistically concordant results of 6 
acute preflight susceptiblity tests. Hovever, results from a 
longer duration preflight prism goggles test shoved an apparent 
correlation1 All subjects were asymptomatic making head 
movements in parabolic flight 4 days after the mission, but not 
1 year later. Overall, results support the view that space 
sickness is a motion sickness. 
1 
Ooshima H., Sakata M., Harano Y. Adsorption Of Cellulase From I. Trichoderma viride On Cellulose. Biotech. Bioeng. 
8 25:3103-3114. 1983. 
ABSTRACT: The adsorption of cellulase from trichoderma viride 
(Meicelase CEPI on the surface of pure cellulose vas studied. 
The adsorption vas found to obey apparently the Langmuir 
isotherm. From the data concerning the effects of temperature 
and the crystallinity of cellulose on the Langmuir adsorption 
parameters, the characteristics of the adsorption of the 
individual cellulase components, namely CMCase (endoglucanase) 
and Avicelase (exoglucanase), vere discussed. While 
B-glucosidase also absorbed on the surface of cellulose at 5 
degrees (2, it did not at 50 degrees C. 
Oven A.J. The Diode-Array Advantage in UV/Visible Spectroscopy. The 
Diode-Array Advantage in UV/Visible Spectroscopy, Hewlett-Packard 
CO.,:~-60. 1988. 
ABSTRACT: The development of diode-array spectrophotometers was a 
major advancement in UV/Visible spectorphotometer technology. In 
1979, Hevlett-Packard introduced the HP 8450A, the vorld's first 
commercially available diode-array spectrophotometer. It 
possessed a revolutionary new optical system and introduced the 
concept of total intergration of spectrophotometer, 
microprocessor control and data processing. Compared to 
conventional, serial scanning spectrophotometers, a diode-array 
instrument acquires the spectral data simultaneously vithout 
mechanically moving parts. The most obvious benefit to the user 
is speed. However, the design differences result in a series of 
other advantages, vhich will be discussed in this booklet. As a 
result, diode-array spectrophotometers can not only replace 
conventional instruments in most applications, but their benefits 
clearly make them superior in most cases. Initially, because of 
the high price, the advantages of diode-array spectroscopy could 
8 .  
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only be appreciated by a relatively small number of specialized 
laboratories. Now, the HP 8452A diode-array spectrophotometer is 
available at a price that is comparable to that of conventional 
instruments. This has been achieved through a combined effort in 
optimizing the design, developing now technologies and nev 
manufacturing concepts. 
Ozkaynak H., Ryan P.B., Wallace L.A., Nelson W.C., Behar J.V. Sources 
And Emission Rates Of Organic Chemical Vapors In Homes And 
Buildings. 1987. 
- ABSTRACT: In recent years several efforts have been made to 
investigate the sources of volatile organic chemicals (VOCs) in 
offices and residential buildings. However, the largest data 
base by far has been compiled by NASA (McDonnell Douglas, 
contractor), vho have tested the VOC Emmissions for over 5,000 
Materials used in the space program. Many of these (paints, 
epoxies, pens, cosmetics, etc.) are available commercially and 
are used in homes and offices across the United Stated. By 
utilizing this unique data base, stored on a personal computer, 
we calculated emission rates of ten common VOCa using the test 
results from a large number of materials and household products 
found in most U . S .  buildings. Ongoing analysis efforts using 
this important data set are also presented. 
Pace N. Weightlessness: A Matter Of Gravity. N. Eng. J. Med, 297/1 
:0032-0037. 1977. 
ABSTRACT: None 
Park Y . 8  Davis M.E., Wallis D.A. Analysis of a Continuous, Aerobic, 
Fixed-Film Bioreactor. I. Steady-State Behavior. Biotech. Bioeng. 
8 26:0457-0467. 1984. 
ABSTRACT: The analysis of a continuous aerobic, fixed-film 
bioreactor is performed by simulating the behavior of penicillin 
production in a three-phase fluidized bed. Rigorous mathematical 
models are developed for a fluidized-bed fermentor in which 
bioparticles are fluidized by the liquid medium and air. The 
steady-state performance of the fluidized-bed reactor is 
appraised in terms of penicillin productivity and outlet 
concentration by considering the tvo extremes in contacting 
patterns, complete back-mix and plug flow, in the absence of a 
groving biofilm. The results show that the complete back-mix 
contacting pattern is preferred over that of plug flov due to the 
nature of the penicillin kinetic relationships. It is also shown 
that for the dual-nutrient (glucose and oxygen) penicillin 
reaction system the optimum biofilm thickness does not equal the 
peretration depth of a limiting nutrient, but hepends upon the 
total reactor configuration, 
Park Y., Davis M.E., Wallis D.A. Analysis of a Continuous, Aerobic, 
Fixed-Film Bioreactor. 11. Dynamic Behavior. Biotech. Bioeng., 
26:0468-0476. 1984. 
ABSTRACT: The dynamic analysis of a contionous,aerobic, 
~ ~- ~ _ _ -  ._ 
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fixed-film bioreactor has been performed. Rigorous mathematical 
models have been developed for a fluidized-bed fermentor with 
biofilm growth. The transient performance of the reactor is 
appraised in terms of outlet peniCillin concentration for 
constant, as well as variable carbon substrate feed rates. The 
effect of the reactor oxygen transfer capacity is elucidated for 
those cases employing substrate feeding strategies. The results 
shov that penicillin production in a continuous, fixed-film 
bioreactor reaches a maximum vith processing time, but 
subsequently decreases as cell mass accumulates and substrate 
deficiencies occur. The maximum production level can be 
maintained for increased operating times if the substrate supply 
is continuously increased. The duration of this prolonged 
production is a direct function of the rate of increase and the 
operating time at vhich the increase is initiated. The oxygen 
transfer capacity of the reactor vas found to be important to the 
effectiveness of a feeding strategy. 
Parker D.E., Reschke M.K., Arrott A.P., Homick J . L . ,  Lichtenberg B.K. 
Otolith Tilt-Translation Reinterpretation Following Prolonged 
Weightlessness: Implications For Preflight Training. Aviat. Space 
Environ. Med., 56:0601-0606. 1985. 
ABSTRACT: Observations vith three astronauts yielded two major 
findings. First, perceived self-motion during sinusoidal roll 
differed immediately postflight from preflight. Betveen 70 and 
150 min after landing, roll vas perceived primarily as linear 
translation. Secondly, more horizontal eye movement vas elicited 
by roll stimulation immediately postflight relative to both 
preflight observations. These results support as "otolith 
tilt-translation reinterpretation" hypothesis, vhich has clear 
implications for understanding astronaut reports of space motion 
sickness during the early period of orbital flight. A proposal 
for tfprophylatic adaptation training" vhich may provide preflight 
adaptation to veightlessness, derives from this research. 
Patterson-Buckendahl P., Arnaud S.B., Mechanic G.L., Martim R.B., 
Grindeland R.E., Cann C.E. Fragility and Composition of Growing 
Rat Bone After One Week In Spaceflight. Am. J. Physiol., 252 
(Regulatory Integrative Comp. Physiol. 21):R0240-R0246. 1987. 
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ABSTRACT: To gain some in8sight into the early effects of 
spaceflight on skeletal metabolism, ve quantified the major 
chemical constituents and a noncollagenous protein, osteocalcin, 
in the third-lumbar verebrae and humeri from 8-vk old rats that 
vere part of the 7-day NASA Spacelab 3 flight experiments. The 
ratio of calcium to hydroxyproline in the humeral diaphysis 
increased from 8.5 in preflight to 9.8 in ground simulation 
control and only to 8.9 in flight bones. There vas no 
demonstrable change in the fraction of nonmineralized collagen. 
Osteocalcin content was reduced in the humerus and vertabra. 
Reduced accumulation of mineral and osteocalcin with no 
associated decrease in collagen in flight animals suggests that 
both mineralization and collagen metabolism are impaired in 
graving animals during spaceflight vithin a fev days after 
launch. Strength tests of the humeri of flight rats shoved 
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substantial deficits that appeared to be related, not only to the 
reduced bone mass, but also to the composition and quality of new 
bone formed. 
Perin M.M. Space Nursing. Nurs. Clln.-N. Am., 20/3:0497-0503. 1985. 
ABSTRACT: The challenge is to have man living and working in a 
permanently based space station. Nursing, is on the threshold of 
expanding the health.care role to man's adaptation in outer 
space. Elements of man's physiollgic and psycholigic responses 
are involved in determining the most productive use of man and 
machines in the space environment. Curricular considerations for 
a career in space nursing can produce effective contributions 
toward health care maintenance of the space station personnel. 
The challenge for nursing is to become a collaboration team 
participant in the exploration of living and vorking in space. 
E 
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Perry T.W., Reid D . H .  Spacelab Mission 4-The First Dedicated Life 
Sciences Mission. Aviat. Space Environ. Med., 54/12:1123-1128. 
ABSTRACT: Spacelab is a large,versatile laboratory carried in the 
bay of the Shuttle Orbiter. The first Spacelab mission dedicated 
entirely to life sciences is Spacelab-4. It is scheduled for 
launch in late 1985 and vi11 remain aloft f o r  7 days. All of the 
investigations are currently classified as "tentatively 
selected,PP with "final selection" and confirmation planned for 
late 1983. The 24 tentatively selected investigation have been 
combined into a comprehensive, integrated exploration of the 
effects of acute veightlessness on living systems. An emphasis 
is placed on studying physiological changes previously observed 
in manned space flight. This payload has complementary designs 
in both human and animal investigations in order to validate 
animal models of human physiology in weightlessness. The 
experimental subjects include humans, squirrel monkeys, 
laboratory rats, two species of plants, and frog eggs. The 
primary scientific objectives include study of the acute cephalic 
fluid shift, cardiovascular adaptation to veiqhtlessness 
(including postflight reductions in orthostatic tolerance and 
exercise capacity), and changes in vestibular function (including 
space motion sickness), associated with weightlessness. 
I 
Secondary scientific objectives include the study of red cell 
mass reduction, negative nitrogen balance, altered calcium 
metabolism, suppressed in vitro lymphocyte reactivity, 
gravitropism and phototropism in plants, and fertilization and 
I 
I early development in frog eggs. The rationale behind this payload, the selection process, and details of the individual 
investigations are presented in this paper. 
1 pettitt D . J . ,  Bennett P . H . ,  Knowler w.c.8 Baird R., Aleck K.A. 
Gestational Diabetes Mellitus And Impaired Glucose Tolerance 
During Pregnancy: Long-Term Effects On Obesity And Glucose 
Tolerance In The Offspring. Diabetes, 34 (Suppl. 2):119-122. 
1985. 
ABSTRACT: The effects of disturbances ln carbohydrate metabollsm 
' 1983. 
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during gestation were studied in the offspring of 1049 Pima 
Indian vomen who had no previous diagnosis of diabetes. Rates of 
fetal and maternal complications of pregnancy among women with 
diabetes first diagnosed during the pregnancy were similar to 
those among women in whom diabeteS was recognized before 
gestation. Offspring, aged 5-19 yr, of vomen with abnormal 
glucose tolerance during pregnancy had a higher mean percent 
desirable veight and a higher mean postchallenge plasma glucose 
concentration than did offspring of vomen vith normal glucose 
tolerance. Percent desirable veight and glucose concentration, 
hovever, vere both lower than found in offspring of women with 
diabetes diagnosed before the pregnancy. Thus, metabolic events 
during pregnancy, as indicated by the detection of abnormal 
glucose tolerance during gestatin, appear to have long-term 
effects on obesity and glucose tolerance in the offspring. 
Microbial Agents of Disease, :0365-0374. . 
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Pickett M.J. Gram Negative Rods, Genus Psuedomonas. Specific 
I ABSTRACT: None 
8 Specifications For Space Station. Johnson Space Center,1985. Pierson D.L., Cintron M.N. Microbiological Requirements And 
ABSTRACT: None 
Pipes W.O., Minnigh H.A., Moyer B., Troy M.A. Comparison Of Clark's 
Presence-Absence Test And The Membrane Filter Method For 
'Coliform Detection In Potable Water Samples. App. Env. Micro., 8 52/3 :  0439-0443. 1986. 
1 
ABSTRACT: A total of 2,601 water samples from s i x  different water 
systems vere tested for coliform bacteria by Clark's 
presence-absence (P-A) test and by the membrane filter (MF) 
method. There vas no significant difference in the fraction of 
samples positive for coliform bacteria for any of the systems 
tested. It vas concluded that the tvo tests are equivalent for 
monitoring purposes. Hovever, 152 samples vere positive for 
coliform bacteria by the MF method but negative by the P - A  test, 
and 132 samples vere positive by the P-A test but negative by the 
MF method. Many of these differences for individual samples can 
be explained by random dispersion of bacteria in subsamples when 
the colifrom density is low. Hovever, 15 samples had MF counts 
greater than 3 and gave negative P-A results. The only apparent 
explanation for most of these results is that coliform bacteria 
vere present in the P-A test bottles but did not produce acid and 
gas. Tvo other studies have reported more samples positive by 
Clark's P-A test than by the MF method. 
1 
Popendorf W. Report On Agents. Am. J. Indust. Med., 10:0251-0259. I 1986. 
ABSTRACT: Recommendations vere formulated on sampling strategies 
and characteristics of different sampling methods. 
Microbiological products, such as endotoxins and proteases vere 
suggested to be included apart from traditional dust 
@ 
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measurements. It was recommended that priority should be given 
to establishing dose-response relationships and that the 
importance of anaerobic organisms be evaluated. A summary of 
components within organic dust suspected of contributing to 
respiratory disease was presented. 
Regulation In Space Flights of Varying Duration . The 
PhysiOlOgiSt, 30/1 (SUppl):Soo4~-soo44. 1987. 
ABSTRACT: In the course of adaptation to space flight effects and 
subsequent readaptation to Earth gravity regulatory systems, 
adevelop significant changes. This gives an impetus to the study 
of changes in hormonal regulation as a function of flight time. 
In this context the key problem, which is the subject of the 
present report, is the blood content of hormones and responses to 
them of target organs. 
I 
Popova I.A., Afonin B.V., Davydova N.A., Crigoriev A.I. Hormonal 
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Putnam D.F., Thomas E.C., Colombo G.V. Water Management Results for . the 90-Day Space Station Simulator Test. MDAC Paper WD 1582, 
1971. 
ABSTRACT: Water management subsystem data are presented for a 
four-man 90-day test conducted in the Space Station Simulator 
with closed water and oxygen loops and no resupply. All 
expendables including food, urine pretreatment chemicals, filter 
beds, and machinery spare parts were stored onboard and no 
pass-ins were made during the test. Elements of the subsystem 
were: (1) isotope-heated VD-VF unit; ( 2 )  wick evaporator and 
humidity control unit; (3) detoxification-multifiltration unit; 
(4) potable water storage and distribution system; ( 5 )  backup 
potable water supply; and (6) wash water recovery unit. The 
performance data include mass and energy balances, water 
chemistry, and microbiological profiles. Pretest qualification 
procedures are covered as well as operating protocol used during 
a 
4 
f 
1 the manned test. 
8 Tech. I n d . ,  :0130-0135,0439. 1979. Pycraft C.H. T h e  Pulping Of Straw By Enzymatic Degradation. Paper 
ABSTRACT: In recent years, attention has been focused not only on 
re-cyclilng of waste paper but also on other indigenous sources 
of fibre. Studies have shown that cereal straw is the most 
promising such source and, supposing a system of collection can 
be contructed, the author considers an oblique approach to the 
still unsatisfactorily-solved question of how best to degrade the 
unwanted part of straw to retain suitable fiber. He proposed the 
use of enzymes-collectively cellulases-and explains how they act 
and considers the practicability of the idea. 
@ 
Pyle B.H., McFeters G.A. Effect Of Growth Medium On Sensitivity Of 
Pseudomonads To Iodine And Their Recovery After Desinfection. 8 1987. 
ABSTRACT: This study was initiated to examine the sensitivity of 
Pseudomonas spp. to iodine and their ability to recover after 
- 
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disinfection. It has been shown that the degree of bacterial 
resistance to disinfection may be related in part to the 
conditions under which the organisms had been growing before 
disinfection. In this investigatlon we have examined the 
sensitivity of two Pseudomonas spp. to iodine after growth in 
rich nutrient media (brain heart infusion and mineral salts 
supplemented with glutamate and glucose) and low nutrient 
conditions (phosphate buffered water and reverse osmosis water). 
The ability of these species to recover after iodination was also 
examined because this may be a significant factor in the 
detection of pseudomonads after disinfection. 
6 Raddin J.H. A Perspective On Human Performance As The Limiting Factor 
In Aircraft Performance. Aviat. Space Environ. Med., 58 
I 
1 
:0393-0394. 1987. 
ABSTRACT: The popular notion appears to be growing that the human 
is the limiting factor in aircraft performance. Proponents cite 
recent instances of pilot loss of consciousness during maneuvers. 
The aerospace medicine perspective differs, seeing the aircraft 
not as a vehicle in which to make hard turns, but as a 
mission-directed weapon system for which the pilot is the 
enabling factor. Various llhuman limition factors1' are described 
among requirements staffs, developers, researchers, trainers, and 
operators. A plea is made to pursue available avenues to improve 
manned weapon system performance and to see even our most 
sophisticated weapons as human instruments. 
Cellulase From Pestalotiopsis versicolor. Biotech. Bioeng. , 25 
ABSTRACT: Production of cellulase from Pestalotiopsis versicolor 
was studied in a shake flask culture. The cellulase system was 
found to be rich in B-glucosidase. Kinetic parameters such as pH 
and temperature have been optimized for the varioius enzyme 
components. 
Ray R.J., Retzlaff S . E . ,  Radke-Mitchell L., Newbold D.D., Price D.F. 
A Membrane-Based Subsystem for Very High Recoveries of Spacecraft 
Waste Waters. NASA Technical Memorandum 860984,:0645-0659. No 
I 
I 
Rao M.A., Mithal B.M., Thakur R . N . ,  Sastry K.M. Productions Of 
:2395-2398. 1983. 
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Date. 
ABSTRACT: This paper describes the continued development of a I 
membrane-based subsystem designed to recover up to 99.5 % of the 
water from various spacecraft waste waters. Specifically 
discussed are 1) the design and fabrication of an 
energy-efficient reverse osmosis (RO) breadboard subsystem; 2 )  
data showing the performance of this subsystem when operated on a 
synthetic wash-water solution--including the results of a 92 day 
test; and 3) the results of pasteurization studies, including the 
design and operation of an in-line pasteurizer. Also included in 
this paper is a discussion of the design and performance of a 
second RO stage. This second stage results in higher-purity 
product water at a minimal energy requirement and provides a 
substantial redundancy factor to this subsystem. 
4 
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Raymond C.A. Unearthly Medicine Demands Special Devices. JAMA, 0 
259/17:2514-2515. 1988. 
ABSTRACT: The tools NASA is develaping for the Health Maintenance 
Facility have some of the flavor of science fiction, because they 
vi11 need to be adapted to the conditions of microgravity. The 
core diagnostic component of the facility will include capability 
to do a complete blood count, urinalysis, clinical chemistry and @ electrolyte measurements, basic microbilolgy, and diagnostic 
imaging. 
4 Razin A., Razin S. Methylated Bases In Mycoplasmal DNA. Nucleic Acids 
Research, 8/6:1383-1390. 1980. 
3 ABSTRACT: The D N A ~  of four Mycoplasma and one Acholeplasma species were found to contain methylated bases. All of the five 
species contained 6-methyladenine (m6Ade), the methylated base 
characteristic of prokaryotic DNA. The extent of methylation of I adenine residues in the mycoplasmal DNA ranged from 0.2% in 
mycoplasma capricolum to about 2% in Mycoplasma arginini and 
Acholeplasma laidlovii DNAs. About 5.8% of the cytosine residues 
in M. hyorhinis DNA were methylated also. Analysis of cell 
culture DNA for the presence of m6Ade as a means for detection of 
contamination by mycoplasmas, and the phylogenetic implications 
of the finding of methylated bases in mycoplasmal DNAs are 
discussed. 
8 
Reanney D. Extrachromosomal Elements As Possible Agents Of Adaptation @ And Development. Bact. Revievs, :0552-0590. 1976. 
ABSTRACT: None 
Reysa R.P., Price D.F., Olcott T., Gaddis J . L .  Hyperfiltration Wash 
Water Recovery Subsystem - Design And Test Results. SAE 1 Technical Paper Series N0.831112,1983. 
ABSTRACT: The hyperfiltration Wash Water Recovery Subsystem is 
considered the most promising water recovery process for the 
large quantities of wash water needed for a Space Station. A 
preprototype Hyperfiltration Subsystem has been developed by 
Lockheed Missiles and Space Corporation (LMSC) to satisfy 
projected vash vater recovery requirements of 10.9 Kgms/hr (24 
lbs/hr) utilizing a hyper filtration module consisting of 
cintered metal tubes having a polymeric filtration layer. Two 
hyperf iltration module designs, manufactured by Abcor, Inc. and 
Carre, Inc., are currently being evaluated at NASA JSC. This 
paper presents a description of the preprototype subsystem design 
and important design features, configuration, module test results 
comparisons and recommemdations for future development and 
testing. 
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I Rickloff J.R. An Evaluation Of Sporicidal Activity Of Ozone. App. 
Env. Micro., 53/4:0683-0686. 1987. 
ABSTRACT: This study was undertaken to determine the feasibility I 
~ ~~ ~~ ~ ~ 
BIBLIOGRAPHY LISTING 
. . .  
of sterilizing surfaces vith ozone-saturated vater by the methods 
of the Association of Official Analytical Chemists (AOAC). w 
Initially, it was determined that there was no apparent 
difference in ozone resistance beiween spores of Bacillus 
subtilis and Clostridium sporogenes when they are suspended in 
water. Both species were inactivated by a 10-min exposure at 
ambient temperature. Resistance vas incrgased vhen the spores 
vere dried on AOAC carriers. Viable organisms vere recovered 
after an exposure of 40 min at ambient temperature. An increase 
in the reactor water temperature to 60 C did not improve the 
effectiveness of the ozone in sterilizing AOAC carriers. Dried 
spores of C. sporogenes were more resistant than E. subtilis 
spores because of a greater accumulation of organic matter on the 
carriers. No significant sporicidal activity was demonstrated 
after 40 min for spores of either species vhen they vere 
inoculated on silk suture loops. The data suggest that organic 
loading and poor ozone penetrability are key factors in effecting 
the ability of ozone to sterilize surfaces rapidly. 
Environmental Legionellae To Selective Isolation Procedures. App. 
Env. Micro., 53/12:2704-2707. 1987. 
ABSTRACT: A survey of water samples to determine the efficacy of 
standard procedures for the isolation of environmental 
legionellae was conducted. Marked variations in intraspecies 
resistance to selective agents and treatments vere Observed, and 
in experiments with one of the isolates, the response vas 
modified by culture conditions. Five selective prodedures 
incorporating acid (pH 2.2) and heat (50 c# 30 min) treatments, 
vith and vithout plating on buffered charcoal-yeast extract agar 
supplemented with vacomycin (5 ug/ml), polymyxin B (60 U/ml), and 
cycloheximide (80 ug/ml), caused 5 to 99% decreased in viable 
counts of pure clutures in water suspensions. The differences in 
the responses of the cultures to the five treatments vere 
statistically significant. Cells in retained samples of 
naturally contaminated water from which the original cultures had 
been isolated were significantly less sensitive than aitifically 
grown isolates. The sensitivities of the laboratory-grown cells 
to the treatments vere affected by the length of incubation of 
buffered charcoal-yeast extract agar. Whereas acid resistance 
increased after 24 h of incubation, resistance to the antiboitic 
I 
1. 
Roberts K.P., August C.M., Nelson J.D. Relative Sensitivities Of 
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Robins J. Measuring Esposures and Assessing Health Effects. 
Environmental Tobacco Smoke, Committee on Passive Smoking Board 
on Environmental Studies and Toxicology National Research 
Council,:294-337. 1986. 
ABSTRACT: This appendix gives an approach to risk assessment that 
considers both the epidemiologic data and some measures of 
exposure to the constituents of ETS. 
Roser D.J., Bavor H.J., McKersie S . A .  Application Of Most-Probable 
Number Statistics To Direct Enumeration Of Microorganisms. App. 
Env. Micro., 53/6:1327-1332. 1987. I 
. .  
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ABSTRACT: A novel method for rapid determination of total 
microbial cell numbers was investigated. The method involves the 
application of most-probable-numb2r estimation statistics to 
direct microscopic counting of microbial cells by using a 
particle sizins graticule. Its accuracy and reliability were 
tested vith computer simulations of bacterial cell distributions 
encountered in ecological studies. Good estimates of cell 
numbers were obtained when the cell density varied from 3-6000 
cells per field, i.e., over 3 orders of magnitude. Low levels of 
contagion did not markedly influence cell estimates, althouhg 
high levels, corresponding to discrete scattered microcolonies, 
did. Hovever, these could be recognized visually. Estimates of 
cell numbers in Breed smears confirmed its speed and good 
correlation0 with the standard quadrat counting technique under 
real experimental conditions. 
I 
E 
Ross H.E., Schwartz E., Emmerson P. Mass Discrimination In 
Weightlessness Improves With Arm Movements of Higher 
Acceleration. NatUrWiSSenSChaften, 73:0453-0454. 1986. 
ABSTRACT: None 
Ross M . D .  Anatomic Evidence For Peripheral Neural Processing In 
Mammalian Graviceptors. Aviat. Space Environ. Med., 56 I :0338-0343. 1985. 
ABSTRACT: Ultrastructural study of.utricular and saccular maculas 
demonstrates that their innervation patterns are complex. There 
is a clustering of type 1 and type 2 hair cells based upon a 
sharing of afferents, a system of efferent-type beaded fibers 
that is of intramacular (mostly calyceal) origin, and a 
plexus-like arrangement of afferents and efferents at many sites 
in the neuroepithelium. Results suggest that information 
concerning linear acceleration is processed peripherally, 
beginning at,the hair cell level, before being sent to the 
central nervous system. The findings may supply a structural 
b a s i s  for peripheral adaptation to a constant stimulus, and for 
lateral inhibition to improve signal relative to noise. 
RUSSO, D. M. Behavioral Technology and its Application to Fire 
I 
D 
a 
Toxicology Research. Southwest Foundation for Research and 
Education, San Antonio, Texas 78284, N79-12037,:0160-0179. . c 
ABSTRACT: The application of behavioral technology to the 
toxicity testing of pyrolysis/combustion (P/C) products is 
discusseed and two categories of behavioral tests commonly 
employed in fire toxicology programs are reviewed. Data are 
presented from a comparison of carbon monoxide (CO) induced 
incapacitation in rats performing in a rotating wheel or under a 
Sidmon free-operant schedule of shock avoidance. Rats performing 
in the rotating wheel were behaviorally incapacitated at CO 
concentrations and carboxyhemoglobin levels significantly lower 
than those which incapacitated operant avoidance animals. It is 
concluded that different measures of behavioral incapacitation 
may vary since incapacitation is a function of the particular 
a 
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toxic mechanism at work and the behavioral requirements of the 
specific task employed in the test procedure. 
RUSSO, D. M., Kaplan H. L. Effects of-Carbon Monoxide on TWO 
Behavioral Measures in the Rat. Proc. West. Pharmacol. SOC., 21 
:0419-0425. 1978. 
ABSTRACT: During the past decade numerous behavioral end points 
have been used in toxicological evaluations of thermal 
decomposition products. However, little research has been 
conducted which allows a comparison of these different end 
points. Such comparisons should provide useful information about 
the susceptibility of different behaviors to toxic 
incapacitation, supply further knowledge about specific 
mechanisms of incapacitation, and ultimately provide a guideline 
by vhich appropriate behavioral end points may be chosen. The 
following two experiments were part of a preliminary assessment 
of the applicability of two different behavioral methodologies to 
the toxicological evaluation of pyrolysis and combustion 
products. The purpose of the experiments was to compare the 
course of changes in two behaviors in animals exposed to 
increasing concentrations of carbon monoxide (CO). Specifically, 
the experiments were designed to compare CO induced 
incapacitation of simple motor behavior in a rotating wheel with 
CO induced changes in a more complex operant avoidance behavior. 
RUSSO, D. M., Sgro, P., SChneider, H. J. Effects of Polyurethane and 
Polyimide Thermal Decomposition Products on Shock Escape and 
Avoidance Behavior. Neurobehavioral Tox. Teratology, 3 
:0265-0270. 1981. 
ABSTRACT: Thirty-six male Sprague-Dawley rats were exposed for 15 
minutes to the decomposition products of either a polyurethane or 
polyimide foam vhile performing an unsignalled shock 
escape-avoidance task. These products were generated by placing 
lg samples of the foams on a conductive plate heated to either 
435, 605, or 775 degrees Celcius. The decomposition products and 
behavioral toxicity of the 2 foams varied differentially with 
test temperature. A t  the 2 lower temperatures, the decomposition 
products of polyurethane proved to be more behaviorally 
disruptive than those of polyimide, while at 775 degrees Celcius 
the reverse was true. These results indicate that operant 
behavior technology brings a sensitivity to material testing 
which may prove quite useful for future assessments of potential 
behavioral toxicity. 
Ryu D.Y., Kim C., Mandels M. Competitive adsorption of cellulase 
Components And Its Significance In A Synergistic Mechanism. 
Biotech. Bioeng., XXVI:O488-0496. 1984. 
ABSTRACT: Some studies on the adsorption of cellulase on 
cellulose revealed part of the mechanisms involved in the 
enzymatic hydrolysis of cellulose and provided some clues to the 
synergistic mechanism of cellulase complex. 
cellulase was significantly affected by the reaction conditions 
and physical chemical characteristics of cellulose. 
The adsorption of 
1 
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Endoglucanase consisted of adsorbable and nonadsorbable 
components. Cellobiohydrolase had the strongest adsorption 
affinity. Each cellulase component 1s postulated to have 
distinctly different adsprption sltes on cellulose, corresponding 
to the activesites in the hydrolysis reaction, Competitive 
adsorption kinetics betreen cellulase componets were also 
observed during the adsorption process. The degree of 
competitive adsorption was most remarkable when the composition 
of cellulase components was nearly the same as that in the crude 
cellulase complex. This seems to show the optimal relative 
composition of cellulase components. The synergism between 
cellobiohydrolase and endoglucananse could be elucidated more 
clearly by this competitive adsorption model of the reaction 
mechanism. 
Saeman J.F. Key Factors In The Hydrolysis Of Cellulose . Biomass As 
A Nonfossil Fuel Source, Chapter 9,:0186-0197. 1981. 
ABSTRACT: None 
Safarik J., Rogers D.M., Ridgway H.F. Effects Of Biocidal Agents Of 
Bacterial Adhesion To Reverse Osmosis Membranes. 
ABSTRACT: The flux and mineral rejection of reverse osmosis (ROI 
membranes are advesely affected by microbial surface fouling. 
Because fouling translates into increased operation costs, the 
Orange County Water District is conducting studies on the 
mechgnism of biofouling in RO systems. Our experiments have 
focused on the use of chemical biocides to reduce biofilm 
formation. The effects of biocidal agents were quantified by 
measuring attachment of radiolabeled fouling microorganisms ( 
Mycobacteria BT2-4) to RO membrane surfaces in response to 
biocide treatment. A variety of biocides including quaternary 
ammonium compounds and chlorine vere tested. The effects of 
compounds on adhesion depended on their chemical structures and 
concentrations, as well as on the bacterial type and polymer 
structure of the RO membrane. Results will be used to formulate 
more effective membrane c l e a n e r s  of inhibitors of biofilm 
development. 
Sagan L. On The Origin Of Mitosing Cells. J. Theoret. Biol., 14 
:0225-0274. 1967. 
ABSTRACT: A theory of the origin of eukaryotic cells ("higher" 
cells which divide by classical mitosis) is presented. By 
hypothesis, three fundamental organelles: the mitochondria, the 
photosynthetic plastids and the (9t2) basal bodies of flagella 
were themselves once free-living (prokaryotic) cells. The 
evolution of photosynthesis under the anaerobic conditions of the 
early atmosphere to form anaerobic bacteria, photosynthetic 
bacteria and eventually blue-green algae (and protoplastids) is 
described. The subsequent evolution of aerobic metabolism in 
prokaryotes to form aerobic bacteria (protoflagella and 
photomitochondria) presumably occurred during the transition to 
the oxidizing atmosphere. Classical mitosis evolved in 
protozoan-type cells millions of years after the evolution of 
. .  . .  I BIBLIOGRAPHY LISTING 
photosysnthesis. A plausible scheme for the origin of classical 
mitosis in primitive amoeboflagellets is presented. During the 
course of the evolution of mitosis, photosynthetic plastids 
(themselves derived from prokarydes) were symbiotically acquired 
by some of these protozoans to form the eukaryotic algae and the 
green plants. The cytoligical, biochemical and paleontological 
evidence for this theory is resented, along with suggestions for 
further possible experimentay verification. The implications of 
this scheme for the systematics of the lower organisms is 
discussed. 
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I Sandler H., Krotov V.P., Hines J., Magadev V.s.8 Benjamin B.A., 
Badekeva A.M., Halpryn B.M., STone H.L., Krilov V.S. 
Cardiovascular Results From A Rhesus Monkey Flown Aboard the 
Cosmos 1514 Spaceflight. Aviat. Space Environ. Med., 58 
4 
:0529-0536. 1987. 
ABSTRACT: Pressure and flow relationships to the head were 
measured before and during space flight by means of a chronically 
implanted cuff placed about the left common carotid artery in one 
of two rhesus monkeys flown aboard cosmos 1514. Measurements 
were obtained daily for 4 min every 2 h during the 5-d 
spaceflight and compared to identical recordings obtained during 
a 35 h pre-flight control period 9-d before flight and a 12 h 
period while on the launch pad. Mean arterial pressure 
demonstrated a 10% increase compared to control levels 
immediately on insertion into orbit and maintained a 16-27% 
increase over the first few fours of flight before returning to 
baseline levels. Blood flow velocity showed a marked increase 
(approximately 8 cm/s) compared to pre-flight control while on 
the launch pad vhich was maintained over the duration of the 
flight. Blood flow shoved reciprocal changes to pressure on 
orbital insertion. Cardiovascualr system changes persisted into 
the second day of flight and were most cleasrly indicated by a 
decrease in relative differences betveen blood flov to the head 
and total cardiac output as measured by impedance 
plethysmography. Signs of adaptation appeared on days 3-5 of 
flight. 
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Sartor G., Schersten B., Carlstrom S., Melander A., Norden A., n Tolerance Prevention Of Diabetes By Tolbutamide And Diet Persson G. Ten-Year Follow-Up Of Subjects With Impaired Glucose 
Regulation. Diabetes, 29:41-49. 1980. 
8 
ABSTRACT: In a diabetes detection survey carried out between 1962 
and 1965, 2477 (1.1%) O C  228,883 subjects had Clinistix-positive 
glucosuria after a carbohydrate-rich luncheon meal. Of these 
24778 578 displayed impaired tolerance to oral glucose without 
having manifest diabetes. From this group, 267 men were divided 
into five groups and subjected to the folloving treatments and 
controls: (a) diet regulation and 0.5 g tolbutamide t.i.d. 
(N=49), annual oral glucose tolerance test (OGTT); (b) diet 
regulation and one placebo tablet t.i.d. (N=48), anuual OGTT; (c) 
diet regulation only (N=50), annual OGTT; (d) no treatment 
(N=61), annual OGTT; and (e) no treatment, OGTT at follov-up 
(N=59 at follow-up). In addition, a control group was included 
1 
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comprised of men with normal OGTT ( N = 5 2 ) .  At follow-up, 29% of 
these without diet regulation and medication (group e; N=59) had 
developed diabetes. Of those on diet regulation, but without 
active medication (group b plus ggoup c, N = 9 8 ) ,  13% had diabetes. 
had progressed to diabetes. In this group, 80% of those later 
examined (N=ll) had serum tolbutamide concentrations in the 
therapeutic range. No individual with initially normal OGTT 
developed diabetes or impaired OGTT. The findings suggest that 
normal oral glucose tolerance signifies little risk of progress 
to impaired glucose tolerance and manifest diabetes, whereas 
impaired glucose tolerance is associated with a high risk of 
progression to diabetes. In addition, it seems possible that 
treatment with diet regulation, in combination with tolbuamide, 
may prevent or postpone progression from impaired glucose 
tolerance to manifest diabetes. 
N o  individual maintaining tolbutamide and diet regulation (N=23) b 
Sasaki M., Kurosaki Y., Mor1 A., Endo S. Patterns Of 
Sleep-Wakefulness Before And After Transmeridian Flight In 
Commercial Airline Pilots. Aviat. Space Environ. Med., 57 (12 
S~ppl.):B0029-B0042. 1986. 
ABSTRACT: The study investigated changes in sleep-wake rhythms 
due to time zone changes. The subjects vere 12 commercial 
airline cockpit crewmembers on active duty who spents their 
baseline nights in a sleep facility in Tokyo. After flying from 
Tokyo to San Francisco, they underwent two consecutive nights of 
sleep polysomnography and daytime sleep latency tests (MSLT1). 
During the San Francisco layover, slight changes in sleep quality 
were obsrved. REM sleep ( % I  vas decreased, while slow wave sleep 
( $ 1  tended to increase during the major sleeps. Subjective sleep 
quality assessments also exhibited a decrease in comparison to 
the baseline values. Daytime sleepiness as measured by MSLTs was 
generally greater in the latter half of the avake period during 
layover as compared with baseline. When the subjects vere 
divided into ttmorningtt or "eveningtt types, the daytime MSLTs of 
each type shoved different patterns. The former displayed a 
d e c r e a s i n g  L-shaped p a t t e r n .  These r e s u l t s  s u g g e s t  t h a t  f u r t h e r  
investigation of the individual differences in circadian phase 
position may be important for understanding the effects of 
multiple time zone flights. 
Sato M., Takahashi H. Fermentation Of C14-Labeled Cellobiose By 
Cellulomonas fimi. Agr. Biol. Chem., 31/4:0470-0474. 1967. 
ABSTRACT: Crude cell-free extracts from Cellulomonas fimi 
contains cellobiose phosphorylase which cleaves cellobiose into 
glucose and glucose-1-phosphate in the presence of inorganic 
phosphate. With the aid of this enzyme, tvo samples of 
C14-cellobiose labeled in reducing or non-reducing glucosyl 
moiety were prepared from uniformly labeled C14-glucose or C14 
glucose-1-phosphate as substrate, respectively. The labeled 
preparations have been shown to be radiochemically pure. 
Analyses of the anaerobic fermentation products from 
C14-cellobiose by resting cell suspensions showed that both 
glucose moieties were fermented almost equivalently. However, 
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relatively small difference in specific activities of the 
products revealed that significantly larger amounts of formic 
acid were produced form the reducing glucose moiety than from the 
other half of the molecule. Succ-knlc and lactlc acids appeared 
to be produced almost equally from both mpletles. 
Sawada Y.8 Fujii R., Igami I., Kawai A, ,  Kamiki T., Niwa M. Removal 
Of Endotoxin From Water By Microfiltration Through A Microporous 
Polyethylene Hollow-Fiber Membrane, App. Env. Micro., 51/4 
:0813-0820. 1986. 
ABSTRACT: The microporous polyethylene hollow-flber membrane has 
a unique microfibrile structure throughout its depth and has been 
found to possess the functions of filtration and adsorption of 
endotoxin in water. The menbrane has a maximum pore diameter of 
approximately 0.04 um, a diameter which is within the range of 
microfiltration. Approximately 10 and 20% of the endotoxin in 
tap water and subterranean water, respectively, polyethylene 
hollow-fiber membrane. Escherichia coli 0113 culture broth 
contained 26.4 % of endotoxin smaller than 0.025 um which was 
also removed. Endotoxin was leaked into the filtrate only when 
endotoxin samples were successively passed through the membrane. 
These results indicate that endotoxin smaller than the pore size 
of the membrane was adsorbed and then leaded into the filtrate 
because of a reduction in binding sites. Dissociation of 
3H-labeles endotoxin from the membrane was performed, resulting 
inthe removal of endotoxin associated with the membrane by 
alcoholic alkali at 78% efficiency. 
Schildkraur C.L., Marmur J., Doty P. Determination Of The Base 
Composition Of Deoxyribonucleic Acid From Its Buoyant Density In 
cSC1. J. Mol. Biol., 4:0430-0443. 1962. 
ABSTRACT: A comprehensive study of the buoyant density of DNA as 
a function of compositon has been made. The linear relation 
previosly reported has been confirmed. Based on a value of 1.710 
g cm -3 for DNA from Escherichia coli the folloving relation vas 
obtailned from the best fit of measurements on 51 different DNA 
samples: p=1.660 t 0.098 (GC) where p refers to buoyant 
density and (GC) to the mole fraction of guanine plus cytosine. 
On this basis the composition of DNA from 36 other sources, not 
previously reported, has been estimated. Several specific 
observations were made. Bimodal distributions in the 
density-gradient band patterns were found in DNA from calf thymus 
and salmon sperm. The DNA of the commonly studied T-even 
bacteriophages exhibits altered densities due to the presence of 
glucosylated hydroxymethylcytosine. The DNA of *X174 phage is 
abnormally heavier suggesting less base-pairing than normal 
denatured, single-stranded DNA. 
Schlegel H.G., Jannasch H.W. Enrichment Cultures. Ann. Rev. Micro., 
21:0049-0070. 1967. 
ABSTRACT: None 
Schroeder D.J., Collins W.E., Elam G.W. Effects of Some Motion 
' .  . I .  . .  ' ,  * 
BI 6 Y I  OGhAPHY L 1 STING I 
1 
1 
1 
I 
8 
t 
c 
8 
1 
8 
I 
I 
I 
I 
I 
4 
I 
Sickness Suppressants on Static and Dynamic Tracking Performance 
Aviat. Space Environ. Med., 56:0344-0350. 1985. 
ABSTRACT: Two studies examined the influence of three established 
antimotion sickness drugs on tracking performance in static 
(stationary) and dynamic (angular accelaration) conditions and on 
visual fixation ability during motion. In Study 1, 40 young men 
were randomly assigned in equal numbers to either a control 
(lactose placebo), dimenhydrinate (50 mq), promethazine 
hydrochloride (25 mg), OK mixture (25 mg promethazine plus 10 mg 
d-amphetamine) group. Study 11 used 30 new subjects equally 
divided into controls, dimenhydrinate (100 mg), and promethazine 
(50 mg) groups. Following practice, tests were conducted prior 
to, and 1, 2, and 4 h after durg ingestion. The depressant drugs 
had little effect of static tracking, but impaired dynamic 
tracking performance and reduced ability to maintain visual 
fixation on a localizer/glide slope instrument due to increased 
ocular nystagmus. The mixture of promethazine plus d-amphetamine 
produced none of these deleterious effects. 
Schultz J . E . ,  Weaver P . F .  Fermentaion and Anaerobic Respiration by 
Rhodospirillum rubrum and Rhodopseudomonas capsulata. J. 
Bacteriol., 149/1:0181-0190. 1982. 
ABSTRACT: Rhodospirillum rubrum and Rhodopseudomonas capsulata 
were able to grov anaerobically in the dark either by a strict 
mixed-acid fermentation of sugars or, in the presence of an 
appropriate electron acceptor, by an energy-linked anaerobic 
respiration. Both species fermented fructose vithout the 
addition of accessory oxidants, but required the initial presence 
of bicarbonate before fermentative growth could begin. Major 
products of R. rubrum fermentation were succinate, acetate, 
propionate, formate, hydrogen, and carbon dioxide; R. capsulata 
produce major amounts of lactate, acetate, succinate, hydrogen, 
and carbon dioxide. R. rubrum and R. capsulata were also capable 
of growing strictly through anaerobic, respiratory mechanisms. 
Nonfermentable substrates, such as succinate, malate, or acetate, 
supported grovth only in the presence of an electron acceptor 
such as dlmethyl sulfoxide or trlmethlamine oxide. Carbon 
dioxide and dimethyl sulfide were produced during growth of R. 
rubrum and R. capsulata on succinate plus dimethyl sulfoxide. 
Molar growth yields from cultures grown anaerobically in the dark 
on fructose plus dimethyl sulfoxide were 3.8 to 4.6 times higher 
than values obtained from grovth on fructose alone and were 56 to 
60% of the values obtained from aerobic, respiratory growth with 
fructose. Likewise, molar growth yields from anaerobic, 
respiratory growth conditions with succinate plus dimethyl 
sulfoxide were 51 to 54% of the valuse obtained from aerobic, 
respiratory grovth with succinate. The data indicate that 
dimethyl sulfoxide or trimethylamine oxide as a terminal oxidant 
is approximately 33 to 41 % as efficient as oxygen in conserving 
energy through electron transport-linked respiration. 
Schunk R.G. Space Station ECLSS Simplified Integrated Test Final 
Report. NASA,:0001-0127. 1987. 
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ABSTRACT: This report describes the Space Station ECLSS 
Simplified Integrated Test (SIT) that was conducted at the Core 
Module Integration Facility (CMIF) located in building 4755 of 
the Marshall Space Flight Center IMSFC). The test, which began 
on June 9 ,  1987, was 52 hours in duration vith approximately 42 
hours of integrated system operatioh. The primary objectives of 
this test were to verify proper operation of  ECLS subsystems 
functioning together in an integrated fashion as well to gather 
preliminary performance data for the partial ECLS system used in 
the test. The test was conducted inside of an open module 
simulator with nominal 3-man metabolic design loads imposed. In 
order to verify proper performance of the ECLS system, 250 
measurements were monitored continuously by on-site personnel and 
archived for later recovery by an automated data acquisition 
system. Additionally, water and gas samples were taken during 
the test to aid in verifying proper subsystem performance. All 
250 measurements were reviewed vith analyses of over 60 of these 
measurements and the water and gas samples selected for inclusion 
into this report. 
Sella L.8 Williamson D., Greensmith C., Balacko G., Brown D., Stackiv 
W. Bacteriological Characteristics of 15 Freshwater Beaches in 
Manitoba. Candian J. Public Health, 78:0181-0184. 1987. 
I 
I 
I 
ABSTRACT: During the summers of 1984 and 1985, a total of 6680 
samples of lake vater vere collected from 15 of the most popular 
beaches in Manitoba and tested for faecal coliforms, enterococci 
and Escherichia coli. The 30 day maximum geometric mean of 200 
faecal coliforms per 100 mL of vater recommended as the 
acceptable maximum limit in the 1983 Guidelines for Canadian 
Recreational Water for bather protection was achieved by beaches 
in all three geographic reginos. The United States Environmental 
Protedtion Agency (USEPA) criterion of 126 Escherichia cili per 
100 mL of water was satisfied by the beaches in the Whiteshell 
area and the east side of Lake Winnipeg, but not by beaches on 
the west side of Lake Winnipeg. The USEPA criterion of 33 
enterococci per 100 mL, as well as the enterococcus criteria 
proposed for Manitoba vere not m e t  by most beaches in all three 
regions. Before recommending changes to the national guidelines 
for recreational vater quality (i.e. adding enterococci 
criteria), it is important to document an associateion between 
illness and counts of a specific indicator bacteria, standardize 
the test procedures for this bacteria and to agree on the 
bacterial counts that vould relate to an acceptable risk to 
n 
I 
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bathers. 
Shadix Lac.# Frebis C.P. Bacteria Recoveries Using Standardized 
Methods. 
American Society for Microbiology, Atlanta, Georgia,l987. 
ABSTRACT: The proposed revisions to the total coliform 
regulations under the National Primary Drinking Water Regulations 
may specify that a heterotrophic bacteria count must be taken and 
that the bacterial density must be below a specified value to 
avoid interference vith the total coliform test. The Standard 
Plate count (PCA or TGE pour plate), has been used for years as a 
Poster Session from the 87th Annuai Meeting of the 
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useful procedure for determining the heterotrophic bacterial 
density of potable waters and for quality control studies of 
water treatment processes. 
changes in the bacteriological quslity of finished water 
throughout a distribution system.(l) Standard Methods (16 ed. 2 )  
states the problems in using the Standard Plate Count. All 
viable bacteria present in a water sample cannot be recovered 
with any single procedure growth medium, or set of physical 
condltions. Three Alternative methods and two new media are 
presented in Standard Methods (2) to improve recovery of 
heterotrophic bacteria. The purpose of this evaluation was to 
compare the heterotrophic bacteria recoveries using these new 
media and methods with recoveries obtained using the previously 
accepted method in order to assess heterotrophic bacteria levels 
in various drinking water samples. 
Sherertz R.J., Belani A., Kramer B.S., Elfenbein G.J., Weiner R.S., 
Sullivan M.L., Thomas R.G., Samsa G.P. Impact of Air Filtration 
ABSTRACT: Bone marrow transplant recipients were found to have a 
10-fold greater incidence of nosocomial Aspergillus infection 
that other immunocompromised patient population (p ,O.OOl)when 
housed outside of a high-efficiency particulate air (HEPA) 
filtered environment. Multivatiate analysis demonstrated that 
number of infections, age, and graft-versus-host disease severe 
enough to require treatment were independent risk factors for 
development of nosocomial Aspergillus infection in this group. 
The use of whole-wall HEPA filtration units with horizontal 
laminar flow in patient rooms reduced the number of Aspergillus 
organisms in the air to 0.009 colony-forming units/m3, which vas 
significantly lower than in all other areas of the hospital (p< 
0.03). No cases of nosocomial Aspergillus infection developed in 
39 bone marrow transplant recipients who resided in this 
environment throughout their transplantation period compated with 
14 cases of nosocomial Aspergillus infection in 74 bone marrow 
transplant recipients who were housed elsevhere (p,O.OOl). Thus, 
a l t h o u g h  bone rnarrov t r a n s p l a n t  r e c i p i e n t s  had a n  
order-of-magnitude greater risk of nosocomial Aspergillus 
infection than other immunocompromised hosts, this risk could be 
eliminated by using HEPA filters with horizontal laminar airflow. 
1 Shklair I.L., Keene H.J. A Biochemical Scheme For The Separation Of 
1 
I 
It also has been used for monitoring 
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1 on Nosocomical Aspergillus Infections. Am. J. MED., 831987. 
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The Five Varieties Of Streptoccus mutans. Archs. Oral Biol., 19 
:1079-1081. 1974. 
ABSTRACT: A biochemical scheme was developed for the separation 
of Streptococcus mutans into 5 biotypes, a-e, which correlated 
vith the recognized serotypes a-e. The biotype identification of 
the Strep. mutans was based on the fermentation of mannitol (with 
and without bacitracin), sorbitol, raffinose, melibiose, and the 
production of ammonia from arginine. Of 194 naval recruits found 
harbouring Strep. mutans, 189 (97.4%) were carriers of biotype c 
alone, or in combination with other biotypes. Biotypes a, d, and 
e were infrequently isolated and biotype b was not isolated from 
I 
I any of the subjects. 
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Simmons D . J . ,  Parvin C., Smith K.C., France P., Kazarian L. Effects 
Of Rotoposltloning on the Growth and Maturation of Mandibular 
Bone In Immobilized Rhesus Monkeys. Avlat. Space Environ. Med., 
57:0157-0161. 1986. 
ABSTRACT: A s  part of an ongoing effort to mimic the hypokinesia 
and hypogravity of spaceflight, the effects of 14 d 
immobilization and rotopositioning on mandibular bone osteon 
growth (radial rate of closure) vas assessed in 12 juvenile 
Rhesus monkeys by tetracycline labeling. The monkeys had been 
restrained in a supine position and rotated 908 every 30 min 
through a full 3608 arc for 14 d. Osteon grovth vas also 
assessed after the immobilized /rotopositioned animals had been 
permitted to recover in metabolism cages for periods of 28 and 56 
d. The closure rates of osteons in the cortex of the inferior 
border of the mandible were not abnormal during 
immobilization/rotopoitioning or during recovery. The regression 
line plots yielded slopes of: Controls=0.946-1.000; 
Immobilized/Rotopositioned= 1.045;28 d Recovery=0.833; 56 d 
Recovery= 0.829. Microradiographs indicated a normal 
distribution of osteons of different mineral density: lowly 
( 2 8 % ) ,  moderatly (5391, and highly mineralized (18%). Bone 
porosity values also remain within the normal range 
(18.3,6,4.1?+). These results suggested that 14 d 
immobilization/rotopositioning did not effect abnormal changes in 
the rates of bone formation and mineralization in the manidubular 
cortex of the juvenile Rhesus monkey. 
Sirnonetti J.A., Schroeder H.G. Evaluation Of Bacterial Grow Through. 
Brunsvick Technetics Membrane Products Division, San Diego, 
California,l984. 
ABSTRACT: A variety of different commercially available 
submicron-rated membrane filter cartridges vere inoculated with a 
knovn number of viable cells and placed in service on a simulated 
D.I. water point of use. Pseudomonas diminuta vas selected as 
the model organism. The effluent was monitored for cell count as 
a function of time under continouos as well as intermittent 
usage. Since the downstream bacterial counts varied considerably 
for the cartridges teated, laboratory experiments were conducted 
to obtain insight into the possible mechanisms which may be 
associated with the proliferation of bacteria through various 
types of membrane materials 
Sinha R.M., Ranganathan B. Cellulolytic Bacteria I R  Buffalo Rumen. J. 
Appl. Bacter., 54:OOOl-0006. 1982. 
ABSTRACT: The influence of three different feeds, wheat straw, 
sorghun and berseem, on total and cellulolytic bacterial counts 
in the buffalo remen at different time intervals from 0 to 8 
hours after feeding vas studied. 
maximum growth of rememen bacteria in general and celluloytic 
bacteria in particular. Wheat straw supported the poorest 
grovth. The types of celluloytic bacteria recovered from the 
rumen of adult buffaloes were Ruminococcus albus, R. 
Berseem feeding supported 
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flavefaciens, Bactercides succinogenes, Butyrivibrio 
fibrisolvens, Clostridium lochheadii, CI. longisporum and other 
Closiridium spp. Cellulolytic cocci vere present in smaller 
numbers than rod forms in the rumen of wheat-straw-fed buffaloes, 
whereas the cocci outnumbered rod forms in sorghum and 
berseem-fed buffaloes. 
I 
I Skotnickl M.L., Tribe D.E., Rogers P.L. R-Plasmid Transfer In 
Zymomonas mobilis. App. Env. Micro., 40/1:0007-0012. 1980. 
ABSTRACT: Conjugal transfer of three IncPl plasmids and one 
IncFII plasmid into strains of the ethanol-producing bacterium 
Zymomonas mobilis was obtained. These plasmids were transferred 
at high frequencies from E. coli and Ps aeruginosa into 2. 
mobilis and also between different 2. mobilis strains, using 
themembrane filter mating technique. Most of the plasmids were 
stably maintained in 2. mobilis, although there was some evidence 
of delayed marker expression. A low level of chromosomal gene 
transfer, mediated by plasmid R68.45, was detected between Z. 
mobilis strains. Genetic evidence suggesting that 2 .  mobilis 
may be more closely related to E. coli than to Pseudomonas or 
Slonim A.R., Roth A.J., Hearld B., London S.A., West A. Potable Water 
1 
1 
I Rhizobium is discussed. 
I Standazds For Aerospace Systems-1967. Life Support And Toxic 
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Hazards Division, Aerospace Medical Research Laboratories, 
Wright-Patterson Air Force Base, Ohio,1967. 
ABSTRACT: Many different types of engineering devices to produce 
vater from human waste, chamber atmosphere and oxygen-hydrogen 
fuel cells have been developed over the past decade. Such 
diversified techniques have resulted in water varying greatly in 
quality from one technique to another, between units of the same 
process, and within the same unit from day to day. Thus, potable 
vater standards were developed for guidance to (1) qualify all 
water producing techniques prior to evaluation for aerospace 
systems and (2) ascertain the safety of the vater for human 
consumption. Development of these engineering guidelines has 
been based on several criteria, including the results of over 300 
laboratory analyses of aerospace water systems. The recommeded 
standards are divided into two parts. The first deals with 
qualification of the technique and is subdivided into general 
requirements (performance goals) and specific requirements 
(limits of acceptability). The second part consists of 
procedures for monitoring the water from qualified units for 
potability. 
I 
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Smith H. The Determinants of Microbial Pathogenicity. Essays in 1 Microbiology, Dept. of MiCKObiOlOgy, Univ. of Birmingham, P.O. 
BOX 363, Birmingham B15 2TT8:0002-0032. . 
ABSTRACT: None 
Sneath P.H.A. Identification of Microorganisms. Essays In 
Microbiology, Department of Microbiology, Leicester University, 1 Leicester, :0002-0032. 1978. 
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ABSTRACT: None 
Snyder A.P., Wang T.T., Greenberg D . L  Pattern Recognition Analysis 
Of In Vivo Enzyme-Substrate Fluorescence Velocities In 
Microorganism Detection And Identification. App. Env. Micro., 
51/5:0969-0977. 1986. 
ABSTRACT: A spectrometric technique is presented that combines 
most of the important criteria necessary for efficient detection 
and identification of microorganisms. These criteria include 
simplicity of experimental design, various degrees of sensitivity 
and selectivity, convenience, and total reaction times of less 
than 15 min. The study takes advantage of the inherent 
extracellular enzymes present in living as opposed to dead, 
non-enzyme-producing organisms. Sequentially, these are 
harnessed in in vivo reactions with a substrate containing a 
select organic functional group that is known to be cleaved of 
hydrolyzed by a certain enzyme. The substrate is tailored so 
that one of the products can be induced to fluoresce, and by 
using a conventional spectrofluorimeter the rate at which the 
fluorescence appears can be recorded. By subjecting the same 
bacterial sample to a number of different enzyme substrates, a 
pattern of fluorescence response rates emerges from a 7 by 7 
microorganism-substrate matrix. Detection limits ranged from 3.6 
x 102 to 3.5 x 108 cells per ml for the Bacillus globiggii 
-indoxyl acetate and Escherichia coli-deacetylfluorescein pairs, 
respectively. The specificity and versatalitiy of the method for 
bacterial determination is demonstrated in probing different 
bacterial enzymes through their spectrally active metabolic 
products. 
Spain M.A., Middleditch B.S., Bafus D.A., Galen T. 
Dehydrohalogenation Of Atmospheric Contaminants In The Space 
Cabin. Aviat. Space Environ. Med., 56:0262-0264. 1985. 
ABSTRACT: A total of nine chlorinated ethanes and ethenes vere 
circulated over lithium hydroxide in a laboratory scale closed 
system simulator. System volume and lithium hydroxided 
temperature vere varied from that intended to maximize possible 
reactions to conditions approximating those of a space cabin 
environment. Of the nine compounds tested, seven were found to 
be dehydrohalogenated (viz., loss of hydrogen chloride) in the 
course of one of more experimental treatments. Of particular 
significance was the conversion of l82-dich1oroethane to 
chloroethene, a known carcinogen, and of trichloroethene to 
dichloroethyne, a highly toxic substance. It is therefore 
concluded that a potentially hazardous situation exists for the 
inhabitants of closed ecological systems such as spacecraft, one 
for which precautions must continue to be taken. 
Stafford D.A. The Effects Of Mixing And Volatile Fatty Acid 
Concentrations On Anaerobic Digester Performance. Biomass, 
:0043-0055. 1982. 
ABSTRACT: The literature on the effects of mixing and Volatile 
~ 
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Fatty Acid concentrations on anaerobic digestion is reviewed, and 
results of further experiments, carried out on laboratory scale 
digesters, reported. It is shown that mixing regimes for 
anaerobic digesters control the rate of biogas production. For 
impeller speeds of between 140 and 100 rpm, in a digester system 
treating sewage sludge, no improvement in gas yields was 
obtained. At the higher speed8, a slight reduction in gas 
production occurred, due possibly to shear forces separating the 
hydrolytic bacteria from their polymer substrates. Propionic 
acid concentrations, within digesters fed with sewage sludge, 
increased shortly after dosing and particularly when lactic acid 
was a feed additive. Acetate concentrations up to 4000 mg litre 
-1 did not inhibit gas production within digesters and could be 
stimulatory. Digesters showing (propionic t butyric 
acids):(acetic acid) ratios of less than 80:l produced good gas 
I 
I 
I 
c yields. 
Stafford D.A., Etheridge S.P. The Anaerobic Digestion Of Industrial 
Wastes, Farm Waste And Sewage Sludges. An Assessment Of Design 
Types And Performances. Inst. Chem. Eng. Symp. Ser.,:0141-0147. 
1983. 
ABSTRACT: The use of anaerobic digestion for the biological 
breakdown of waste organic materials to produce methane is 
developing commercially. Together with technological 
improvements in the process an increase in our knowledge on the 
microbiology of these systems can be linked with chemical 
enginerring "knowhow" and newer designs can be implemented for 
specific applications. Design types and their advantages are 
discussed with presentations of practical data when operating 
pilot plant reactors. These studies indicate that scale-up 
applications produce similar results to the innovative laboratory 
I 
I systems. 
Stafford D.A., Hughes D.E.  Energy From The Biomass. Int. Conf. I Future Energy Concepts, :0057-0060 .  1981. 
ABSTRACT: None 
I Stafford D.A., Kane-Maguire L. Extraction Of Biologically Useful 
Materials From Sewage Sludges. Processes Chem. Some Renew. Raw 
Mater. Symp.,:0029-0034. 1979. 
ABSTRACT: The extraction and use of the cellulosic and protein 
fractions of sewage sludges has potential for animal feedstuffs. 
The technology to derive these useful materials commercially is 
discussed. High grade protein can be chemicallly extracted 
directly or microbes can be grown on the hydrolysed cellulose 
fraction to produce single cell protein. I 
Starr D. Fingerprinting Microbes. one page torn from unknown 
journal,. 
ABSTRACT: A computerized device that identifies bacteria and 
I 
other microorganisms faster and more accurately than any previous I method. 
I Steffen J.M., Musacchfa X . J .  Spaceflight Effects On Adult Rat Muscle 
Protein, Nucleic Acids, And Amlno Acids. Am. J. PhySiOl., 251 
(Regulatory Integrative Comp. Physlol. 20):R1059-R1063. 1986. 
ABSTRACT: Exposure to conditions of weightlessness has been 
associated vith decrements in muscle nass and strength. The 
present studies were undertaken to determine muscle response at 
the cellular level. Male Sprague-Dawley rats (360-410 g) were 
exposed to 7 days of weightlessness during the Spacelab 3 shuttle 
flight (May 1985). Animals were killed 12 h postflight, and 
soleus (SI, gastrocnemius (GI, and extensor digitorum longus 
(ECL) muscles were excised. Muscle protein, RNA, and CNA were 
extracted and quantified. Differential muscle atrophy was 
accompanied by a significant (P < 0.05) reduction in total 
protein only in S muscles. There vere no significant changes in 
protein concentration (mg/g) in the muscles examined. In S 
muscles from flight animals, sarcoplasmic protein accounted for a 
significantly greater proportion of total protein that in ground 
controls (37.5 vs. 32.5%). Tissue concentration (nmol/g) of 
asparagine-aspartate, glutamine-glutamate, glycine, histidine, 1 and lysine were significantly reduced (from 17 to 63%) in S 
muscles from flight animals, but only glutamine-glutamate levels 
were decreased in the G and ECL. Muscle DNA content (ug) was I unchanged in the tissues examined, but S muscle DNA concentration (ug/mg) increased 27%. RNA content (ug) was significantly (P < 
0.025) reduced in S (-28%) and G(-22%) muscles following I spaceflight. These results identify specific alterations in rat 
skeletal muscle during short term (7-day) exposure to 
weightlessness and compare favorably vith observations previously 
obtained from ground-based suspension simulations. 
I 
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Stepaniak P.C., Furst J . J . ,  Woodard D. Anabolic Steroids As A 
Countermeasure Against Bone Demineralization During Space Flight. 
Aviat. Space Environ. Med, 57: 0174-0178. 1986. 
ABSTRACT: A progressive l o s s  of bone mass is consistently 
reported in humans exposed to weightlessness during space flight. 
The mechanism of this metabolic alteration is unknown but may be 
due in part to the effects of disuse osteoporosis along with the 
influence of elevated corticosteroid levels. With a goal toward 
mankind's permanent presence in space, effective countermeasure 
against bone demineralization vi11 be required. Synthetic 
anabolic steroids have been shown to prevent bone loss in 
ground-based immobilization studies and in excess corticosteroid 
states. These agents may efper a means of sloving or preventing 
bone loss thus facilitating long term space habitation. 
Formation, And Release of Mutagens By Man. Banbury Report 
7(Gastrointest. Cancer: Endog.Factors), :0247-0266. 1981. 
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I Stich H.F., Rosin M.P., San R.H.C.8 WU C.H., Powrie W.D. Intake, 
I ABSTRACT: None 
Stokes H.W., Dally E.L., Yablonsky M.D., Eveleigh D.E. Comparison Of 1 Plasmids In Strained Of Zymomonas mobilis. 1983. 
I ABSTRACT: Four strains of Zymomonas mobills vere examined for their resistance to antimicrobial agents and found to have 
similar resistance profiles. Pla2mid DNA vas extracted and 
purified by CsCl dye buoyant density centrifugation; molecular 
weights were determined by agarose gel electrophoresis and 
electron microscopy, All four strains harbored a large plasmid 
(46 x 106 Da) and a smalller plasmid (16-21 x 106 Da) whose 
molecular weight was strain dependent. Two strains, Agll and 
ATCC 10988, had smaller plasmids of unique molecular weight. 
Homology existed between the plasmids in the four stains as shown 
by cross-reaction in DNA-DNA blot hybridizations. Only one 
plasmid appeared unique to the host from which it was isolated. 
I 
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Stout J.E., Best M.G., Yu V.L. Susceptibility Of Members Of The I 
I 
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Family Legionellaceae To Therman Stress: Implications For Heat 
Eradication Methods In Water Distribution Systems. App. Env. 
Micro., 52/2:0396-0399. 1986. 
ABSTRACT: To ascertain the feasibility of heat inactivation as an 
eradication method applicable to all members of the family 
Legionellaceae, we tested the heat resistance of 75 isolates 
which represented 19 members of this family of organisms. The 
range of thermal death times at 60, 70, and 80 C were 1.3 to 
10.6, 0.7 to 2.6, and 0.3 to 0.7 min, respectively. These data 
suggest that the method of heat eradication will be effective 
against all members of the family Legionellaceae. 
Aromatic Compounds. J. Bacteriol., 87/4:0910-0919. 1964. 
Tabak H.H., Chambers C.W., Kabler P.W. Microbial Metabolism Of 
ABSTRACT: Bacteria from soil and related environments were 
selected or adapted to metabolize phenol, hydroxy phenols, 
nitrophenols, chlorophenols, methylphenols, alkylphenols, and 
arylphenols when cultured in mineral salts media with the 
specific substrate as the sole source of carbon. A 
phenol-adapted culture (substrate-induced enzyme synthesis 
proven) was challenged in respirometric tests vith 104 related 
. compounds; probable signlficant oxidative activity occurred with 
65. Dihydric phenols were generally oxidized; trihydric phenols 
were not. Cresols and dimethylphenols were oxidized; adding a 
chlorogroup increased resistance. Benzoic and hydroxybenzoic 
acids were oxidized; sulfonated, methOXylated, nitro, and 
chlorobenzoic acids were not; m-toluic acid was utilized but not 
the 0 -  and p- isomers. Benzaldehyde and p-hydroxybenzaldehyde 
were oxidized. In general, nitro- and chloro-substituted 
compounds and the benzenes were difficult to oxidize. 
I 
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Taub F.B. Some Ecological Aspects of Space Biology. Am. Biol. I Teacher, 25:412-421. 1983. 
ABSTRACT: This symposium was organized to bring together two 
comples groups: space biologists, who are attempting to develop 
closed ecological systems to sustain man during extended space 
missions, and ecologists, who for many years have been studying 
the ecological system on earth, man's normal life support system. 
1 
1 
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I Tavassoli M. Medical Problems Of Space Flight. Am. J. Med., 
ABSTRACT: Several conslstent medical problems have been 
encountered by astronauts during space flights. These include 
vestibular dysfunction, veight loss, increase in height, upward 
fluid shift, anemia, cardiovascular deconditioning, muscle 
atrophy, and bone loss. Almost all of these alterations can be 
attributed to the absence of gravitational force. Most are 
adaptive in nature and therefore reversible, but readaptation 
after returning to earth may cause further problems (e.q., In the 
case of vestibular dysfunction). The most recalcitrant and 
distubing of all these problems is the relentless bone loss 
associated with negative calcium balance. This problem appears 
to be irreversible, and critical demineralization can occur after 
two years in a weightless state. Unless its mechanism is 
elucidated and preventive measures are taken, the bone loss may 
prove to be the medically limiting factor for the duration of 
space flight. 
Skylab Environmental And Crew Microbiology Studies. Biomedical 
Results From Skylab, Chapter 8, Chapter 8,:0053-0063. . 
I ABSTRACT: The objectives of the Skylab microbiology studies were 
to detect the presence of potentially pathogenic micro-organisms 
on the crewmembers and their spacecraft and to obtain data vhich I would contribute to an understanding of the response of the 
crew's microbial flora to the space flight environment. These 
data were interpreted in light of the theories of microbial 
I simplification, intercrew transfer of medically important microorganisms, in-flight autoinfections, and postflight 
microbial shock, vhich have been proposed by various authors. 
I Taylor G.R.,'Neale L . S . ,  Dardano J.R. Immunological Analyses Of U.S. 
Space Shuttle Crevmembers. Aviat. Space Environ. Med., 57 
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Taylor G.R., Graves R.C., Brockett R.M., Ferguson J.K., Mieszkuc B.J. 
:0213-0217. 1986. 
ABSTRACT: We have previously reported changes in the 
immunoresponsiveness of "T" lymphocytes following space flight. 
Additional data collected before and after 11 Shuttle space 
flights show that absolute lymphocyte numbers, lymphocyte 
blastogenic capability, and eosinophil percent in the peripheral 
blood of crewmembers are generally depressed postflight. These 
responses resemble those associated with physical and emotional 
stress and may not be related to flight per se. Additional data 
from Space Shuttle flights 41B and 41D, involving 11 crewmembers, 
indicate a postflight decrease in cells reacting with IqBf' 
lymphocyte and monocyte monoclonal antibody tags. Further, the 
loss of 'rT" lymphocyte blast capability interacts with the 
decreased monocyte count (correlation coefficient = 0.697). This 
finding implies that the previously reported loss of blastogenic 
capability may be a function of decreased monocyte control, as 
noted in several nonspaceflight related studies. 
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Thompson N.L., Burghardt T.P., Axelrod D. Measuring Surface Dynamics 
of Biomolecules by Total Internal Reflection Fluorescence With 
Photobleaching Recovery or Correlation Spectroscopy. Biophys. J., 
33/3:0435-0454.  1981. - 
ABSTRACT: The theoretical basis of a new technique for measuring 
equilibrium adsorption/desorption kinetics and surface diffusion 
of fluorescent-labeled solute molecules at solid surfaces has 
been developed. The technique combines total internal reflection 
fluorescence (TIR) with either fluorescence photobleaching 
recovery (FPR) or fluorescence correlation spectroscopy (FCS). A 
laser beam totally internally reflects at a solid/liquid 
interface; the shallow evanescent field in the liquid excites the 
fluorescence of surface adsorbed molecules. In TIR/FPR, adsorbed 
molecules ace bleached by a flash of the focused laser beam; 
subsequent fluorescence recovery is monitored as bleached 
molecules exchange with unbleached ones from the solution or 
surrounding nonilluminated regions of the surface. In TIR/FCS, 
spontaneous fluorescence fluctuations due to individual molecules 
intering and leaving a well-defined portion of the evanescent 
field are autocorrelated. Under appropriate experimental 
conditions, the rate constants and surface diffusion coefficient 
can be readily obtained from the TIR/FPR and TIR/FCS curves. In 
general, the shape of the theoretical TIR/FPR and TIR/FCS curves 
depends in a complex manner upon the bulk and surface diffusion 
coefficients, the size of the illuminated or observed region, and 
the adsorption/desorption kinetic rate constants. The theory can 
be applied both to specific binding between immobilized receptors 
and soluble ligands, and to nonspecific adsorption processes. A 
discussion of experimental considerations and the application of 
this technique to the adsorption of serum proteins on quartz may 
be found in the accompanying paper (Burghardt and Axelrod. 1981. 
Biophys. 3. 3 3 : 4 5 5 ) .  
Tixador R., Richoilley G., Gasset G., Templies J., Bes J.C., Moatti 
N., Lapchine L. Study of Minimal Inhibitory Concentration of 
Antibiotics on Bacteria Cultivated in Vitro in Space (Cytos 2 
Experiment). Aviat. Space Environ. Xed., :748 -751 .  1985. 
ABSTRACT: The aim of the Cytos 2 experiment, carried out during 
the French-Soviet manned flight in July 1982, was to study the 
bacteria's sensitivity to antibiotics cultivated in vitro during 
the orbital flight, using the bacterial method of minimal 
inhibitory concentration (MIC). Tvo species of bacteria were 
tested with various antibiotics: Staphylococcus aureus with 
Oxacillin, Chloramphenicol and Erythromycin; Escherichia coli 
with Colistin and Kanamycin. The results show an increase in 
resistance to antibiotics particularly strong in E. coli and 
weaker in Staphylococcus aureus. Considering these results, we 
think that there might be a relationship between the increase in 
resistance to antibiotics and a stimulating effect on grovth rate 
by the factors of environmental space. 
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Tokarev V.F., Razsolov N.A., Mohler S . R . ,  Nicogossian A.E.T. Training 
of Aerospace Medicine Physicians In The Soviet Union And The 
United States Of America. Aviat. Space Environ. Med., 57 [ 
I :BIBLIOGRAPHY LISTING 
0376-0380. 1986. 
ABSTRACT: The union of Soviet Soc4alist Republics and the United 
Stated of America operate major aerospace medicine programs; each 
country has taken specific measures to assure the development of 
an adequate number of trained aerospace medicine physicians. 
This jointly prepared paper emphasizes the training of aerospace 
medicine physicians related to civil aerospace activities. Those 
working in the field of aerospace medicine will find of interest 
the aerospace medical approaches taken by the U.S.S.R. and the 
U.S.A. in achieving their respective aerospace objectives. 
Trunkey D.D., Frank I.C. . Trauma Care In Space. Emergency Nursing, 
1 
1 
1 12/3:0032A-O035A. 1986. 
4 Unknown. Process Design: Physics of Ultrafiltration Process. 
ABSTRACT: None 
ABSTRACT: None 
Vaidya M., Seeta R., Mishra C., Deshpand v.8 Rao M. A Rapid and 
Simplified Procedure For Purification Of A Cellulase From 
Fusarium lini. Biotech. Bioeng., XXVI:OO41-0045. 1983. 
ABSTRACT: An endo-B-1,l-GLUCANASE (EC 3.2.1.4) was obtained in 
high yields in purified form from a culture filtrate of Fisarium 
lini by an extremely simple method. The method consists of 
precipitation of the culture filtrate with ammonium sulphate (290 
q/L), followed by chromatography of the precipitated fraction on 
Biogel P-150. The purification is based on the unusual property 
of the enzyme being eluted after cytochrome C, even though its 
molecular weight is 2.8 X 10 (4) (by SDS PAGE). The yield of 
pure enzyme was 6.8 mg/L culture broth. The homogeneity of the 
enzyme was established by ultracentrifugation, isoelectric 
focusing, and electrophoresis in polyacrylamide gels containing 
SDS. The enzyme vas isoelectric at PH 8.3 and contained 2.9% 
carbohydrate. The Km value for carboxymethyl (CM) cellulose was 
11.6 mg/mL. The enzyme Shoved high viscosity reducing activity 
towards CM cellulose but very low activity vith Walseth cellulose 
and crystalline celluloses such as Avicel and cotton. The 
purified enzyme has activity towards xylan. The amino acid 
analysis showed a predominance of acidic and neutral amino acids 
and low contents of histidine, arginine, and methionine. 
One-half of the cysteine content was 1 residues/mol enzyme, and 
no free-SH group was detectable. 
Verostko C.E., Garcia R., Peirson D.L., Reysa R.P., Irbe R. Results 
On Reuse Of Reclaimed Shower Water. NASA TM 860983 ,. 
ABSTRACT: A microgravity whole body shower (WBS) and a waste 
water recovery system (WWRS) were used in a closed loop test at 
the Johnson Space Center. The WWRS process involved chemical 
pretreatment, phase change distillation and post-treatment. A 
preprototype Thermoelectric Intergrated Hollow Fiber Membrane 
Evaporation Subsystem (TIMES) was used for distillation after 
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pretreatment and the post-treatment was accomplished with 
activated carabon, mixed ion exchange resin beds and bactericide 
dispensing units. The purposes o f  this test vere to evaluate a 
NASA approved Shuttle soap for whole body showering comfort; 
evaluate the effects of the shower water on the WBS and the 
TIMES; and evaluate purification qualities of the recovered water 
in a closed loop operation. This paper describes the test 
hardware, the controls exercised for vhole body showerlng, shower 
water collection and chemical pretreatment for microorganism 
control, TIMES operation and recovered water post-treatment. 
During the closed loop test, samples were taken to evaluate the 
water quality for both chemical and microbial impurities at 
selected locations in the water purification process. The water 
was recycled five times, thus demonstrating the feasibility of 
reusing reclaimed shower water in Space Station. Chemical 
pretreatment effectively controlled microorganism growth in the 
raw shower water and the TIMES with post-treatment effectively 
reduced the organic impurities and provided adequate and positive 
disinfectant. 
1 
fi 
Verostko C.E., Price D.F., Garcia R., Pierson D.L., Sauer R. L., u 
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Reysa R.P. Test Results of a Shower Water Recovery System. SAE 
Technical Paper #871512,1987. 
ABSTRACT: A shover test was conducted recently at NASA-JSC in 
which vaste water was reclaimed and reused. Test subjects 
shovered in a prototype whole body shower following a protocol 
similar to that anticipated for Space Station. The waste water 
was purified using reverse osmosis followed by filtration through 
activated carbon and ion exchange resin beds. The reclaimed 
waste water was maintained free of microorganisms by using both 
heat and iodine. This paper discusses the test results, 
including the limited effectiveness of using iodine as a 
disinfectant and the evaluation of a Space Station candidate soap 
for showering. In addition, results are presented on chemical 
and microbial impurity content of water samples obtained from 
various locations in the water recovery process. 
Vico L., Chappard D., Bakulin A.V., Novikov V.E., Alexandre C. 
Effects of 7 Day Space Flight on Weight Bearing And Nonveight 
Bearing Bones In Rats (Cosmos 1667). The Physiologist, 30/1 # (Suppl) :S0045-S0046. 1987. 
ABSTRACT: Previous 3-week COSMOS spaceflights indicated a 
significant reduction of bone mass in weight- and 
non-weight-bearing bones probably due to a decrease in bone 
formation activity. On COSMOS 1667, 7 flight and 7 control male 
rats were studied by bone histomorphometric methods. 1) 
Weight-bearing bones: in proximal tibial metaphysis, the 
trabecular bone volume was markedly declined in flight animals. 
Trabeculae were decreased in number and thickness; this probably 
leads to an alteration of bone mechanical properties. Formation 
activity (reflected by osteoid seam thickness and osteoid surface 
measurements) was decreased at the trabecular and endosteal 
levels. Resorption actlvity (osteoclast number and active 
resorption surfaces measured by a histoenzumologic method) 
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remained unchanged. The imbalance that appeared to occur between 
these cellular actlvlties may be responsible for the loss of 
trabecular bone mass. In proxima? femoral metaphysis, trabecular 
bone volume was measured in area located under muscular 
insertions. Deleterious effects of weightlessness were not 
observed. Therefore, muscular tractory may have a protective 
effect on weight-bearing bones. 2 )  Non-weight-bearing bones: in 
thoracic and lumbar: vertebrae, no change was found neither in 
bone mass nor in bone cellular parameters. The short flight 
appeared to confirm that non-weight-bearing bones are not as much 
at risk as weight-bearing bones during spaceflight. Futhermore, 
marked differences observed between areas with and without 
muscular insertions, emphasize the most important role of 
mechanical factors in trabecular bone mass preservation. 
Novikov V.E., Bakulin A.V. . Effects of Weightlessness on Bone 
Mass and Osteoclast Number In Pregnant Rats After A Five-Day 
Spaceflight (Cosmos 1514). Bone, 8:0095-0103. 1987. 
ABSTRACT: Five pregnant growing rats vere orbited for 5 days 
aboard the Soviet COSMOS 1514 biologic satellite. The bone 
effects of weightlessness were studied and compared to those of 
five pregnant rats. Bone histomorphometric studies were 
performed to investigate the early effects of weightlessness in 
loaded (tibia-femur) and unloaded (thoracic and lumbar vertebrae) 
bones. A short exposure to veightlessness does not induce any 
change in bone mass and inner: structure in either type of bone. 
In unloaded bones, the number of osteoclasts per square 
millimeter of the trabecular surface significantly increased when 
measured after histochemical demonstration of tartrate-resistant 
acid phosphatase. It is likely that a stimulation of bone 
iesorption activity occurs in the trabeculae of unloaded bones 
during the early phase of a spaceflight. In tibia, osteoid seam 
thickness and total osteoclastic resorption surfaces at the 
endosteal  l e v e l  were not modified. 1 Voge V.M. A Comparison of U.S. Air Force And U.S. Navy Flight Surgeon 
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Vico L.8 Chappark D., Alexandre C., Palle s.8 Minaire P . 4  Riffat G., r 
P 
Philosophies. Military Medicine, 150:0542-0545. 1985. 
ABSTRACT: The author compares the Flight Surgeon 
utilization/training philosophies of the U.S. Air Force and the 
U.S. Navy. These two programs are compared as to general 
philosophies, basic and advanced training programs, continuing 
medical education opportunities, career oppcztunities, peer 
prestige, practice modalities, retention rates, and special 
aircrew member evaluations/follow-up. Some proposals for 
improving the programs are put forth. It is concluded that, in 
many ways, the aviation medicine problems faced by the USAF and 
the USN Flight Surgeons are quite similar. However, their 
programs, philsophies and aeromedical policies are seen to be 
quite divergent. Each service could learn fro4 the other. 
# 
Vogel J.M., Whittle M.W. Bone Mineral Changes: The Second Manned 3 Skylab Mission. Aviat. Space Environ. Med., 47/4:0396-0400. 
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ABSTRACT: The mineral content of the central os calcis, and 
distal radius and ulna was measured by the monenerqetic photon 
absorptiometric technique pre- ana postflight on the SL-3 
crewmen. No significant changes were observed in the radius and 
ulna. Only the SPT showed a loss in calcaneal mineral which 
slowly returned to preflight levels by the 87th postflight day. 
Fixation Of Living Material In The Microgravity Environment . 
Naturwissenschaften , 73:0435-0437. 1986. 
ABSTRACT: None 
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Volkmann D., Behrens H.M., Junk P. Flight Hardware For Chemical 
Walch M., Mitchell R. Hydrogen Uptake By Metals In The Presence Of 
Bacterail Films. Sixth International Biodeterioration Symposium, 
1984. 
ABSTRACT: None 
Wald s.8 Wilke C.R., Blanch H.W. Kinetics Of The Enzymatic Hydrolysis 8 Of Cellulose. Biotech. Bioeng., 26:0221-0230. 1984. 
ABSTRACT: Enzymatic hydrolysis of cellulose for sugar production 
offers advantages of higher conversion, minimal by-product 
formation, low energy requirements, and mild operating conditions 
over other chemical conversions. The development of a kinetic 
model, based on observable, macroscopic properties of the overall 
system, is helpful in design and economic evaluation of processes 
for sugar conversion and ethanol production. A kinetic model is 
presented, incorporating enzyme adsorption, product inihibition, 
and considers a multiple enzyme and substrate system. This model 
was capable of simulation saccharification of a lignocellulosic 
material, rice straw, at high substrate (up to 333 g/L) and 
enzyme concertrations (up to 9.2 FPU/mL) that are common to 
proposed process designs. 
Waldron C.R.8 Frein E.M., Evelelth D.E. Prevention of Phosphate 
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Interference in HPLC Sugar Analysis Studies. Biotech. Bioeng., 
25:2091-2092. 1983. 
ABSTRACT: The use of high performance liquid chromatography 
(HPLC) is a common tool for the separation and quantitation of 
saccharification products in cellulase research. Many of the 
columns used both commercial and homemade, employ the cation 
exchange resin Dowex(Amlnex)5DkX4. A problem with this procedure 
is the interference to the response of the refactometer by 
certain ions (e.g. phosphate and citrate). These inons are 
present in culture media and hence in crude extracellular enzyme 
preparations. Their removal via dialysis poses the question of 
the degree of loss of the cellulase enzyme via adsodrption to the 
dialysis membrane. These ions may also be used in the 
saccharification buffers and can produce peak responses with 
siaiiar retention times to the sugars being analyzed. Phosphate 
ion produces a peak with approximately the same retention time as 
cellobiose when the 50W-X4 resin Is used in its Ca2+#Pb2+, OK H+ 
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forms. Depending on the concentration of both the phosphate ion 
and the disaccharide, there can be interference with or even 
total obliteration of the cellobiuse peak. This interference can 
be eliminated by precipitation of the phosphate by the addltlon 
of heavy metals. 
Plasmid In Zymomonas mobilis Carrying Antibiotic Resistance. App. 
Env. Micro., 47/1:0198-0200. 1984. 
ABSTRACT: The cryptic plasmid pRUT41 from Zymomonas mobllls was 
examined for its biological properties. This plasmid was found 
to be conjugally transferred from 2. mobilis CP4 toE. coli BM21 
and to carry genes for antibiotic resistance (gentamicin, 
kanamycin, and streptomycin). Covalently closed circular plasmid 
DNA was isolated from eight transconjugants of E. coli BM21. 
These plasmids were identical in mobility on agarose gels and 
exhibited the same restriction patterns as the native pRUT41 
plasmid isolated from 2 .  mobilis. The plasmid location of the 
antibiotic resistance genes was further confirmed by transforming' 
E. coli BM21 with isolated pRUT41 plasmid from strain CP4 and 
with plasmids from the transconjugants of BM21. Resistance to 
streptomycin, kanamycin, and gentamicin was tightly linked and 
transferred together in all cases. 
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Walia S . K . ,  Carey V.C., All B.P., Ingram L.O. Self-Transmissible 
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Wallis C., Melnick J.L. An Instrument For The Immediate 
? 
Quantification Of Bacteria In Potable Waters. 
ABSTRACT: A new semi-automated instrument is described which 
quantifies the number of bacteria in potable waters within 3 
minutes, providing a permanent colorimetric record of the 
results. The bacterial-detection device can measure as few as 
100 CFU/ml in potable vaters. In brief, a 100-1000 ml sample of 
tap water is drawn thru a large surface, customized filter housed 
in the device, and bacteria, rust and humic acid in the water are 
concentrated there on. A reducing agent is used to remove the 
rust and humic acid from the filter. The filter is inverted and 
backflushed to elute the bacteria which are collected and 
reconcentrated onto a 7 mm diameter filter surface. The 
reconcetrated bacteria are stained, and the fiter fibers are 
preferentially decolorized without removing the dye from the 
bacteria. The color intensity of the filter surface is compared 
to a color guide to determine the amount of bacteria in the test 
8 
water. I c Wang D.C., Cooney C.L., Wang S.D., Gordon J., Wang G . Y . , .  Anaerobic 
Biomass Degradation to Produce Sugars, Fuels and Chemicals. 
Department of Nutrition and Fooc Scinece, Massachusetts Institute 
of Technology, Cambridge, MA 02139,1978. 
ABSTRACT: The degradation of cellulosic biomass by an anaerobic 
and thermophillic bacterium, Clostridium thermocellum, has been 
under investigation. It has been found that this organism is 
able to degrade cellulose and accumulate reducing sugars in the 
fermentation broth. The degradation of cellulose and the 
utilization of the sugars has been tested in mlxed-cultures where 
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the second organism is used to produce acetic acid. The direct 
production of a chemical (acetic acid) and a liquid fuel 
(ethanol) from cellulosic biomass-by a pure culture of C. 
thermocellum also appears possible. Although the conversion 
efficiency is quite good, the product concentration must be 
increased. A selection and adaptation technique has been used 
where a strain capable of toleratlnq 5 volume % ethanol has been 
1 
a isolated. 
Warzywoda M., Ferre V., Pourquie J. Development Of A Culture Medium a 
1 
For Large-Scale Production Of Cellulolytic Enzymes By 
Trichoderma reesei. Biotech. Bioeng., 25:3005-300. 1983. 
ABSTRACT: Culture filtrates of CL-847 strain of Trichoderma 
reesei grown on different carbon sources have been compared. The 
highest enzyme production is obtained with Watman CC 41 
cellulose: 17.9 mg/mL of soluble proteins and 13.7 units fo 
filter paper (FP) activity. Wood pulps gave lower production 
values and more viscous culture media. About one-third of 
maximal enzyme production is obtained on lactose as the sole 
carbon source. Addition of 0.5% cellulosic inducer to 6% lactose 
media enhances enzyme production up to the following levels: 14.1 
mg/mL of soluble proteins and 8.4 units of FP activity. 
1\ Waterfield M.D., Scrace D.T., Whittle N., Stroobant P., Johnsson A., 
Wasteson A., Westermark B., Heldin C.H., Huang J.F., Deuel T.F. 
Platelet-Derived Growth Factor Is Structurally Related To The 
@ Putative Transforming Protein P28 Of Simian Sarcoma Virus. Nature, 304/7:0035-0037. 1983. 
fi ABSTRACT: A partial amino acid sequence of human platelet-derived growth factor, the major mitogen in serum for cells of 
mesenchymal origin has been determined. A region of 104 
contiguous amino acids shows virtual identity with the predicted 
sequence of p28 sis, the putative transorming protein of simian 
sarcoma virus (SSV). This similarity suggests a mechanism for 
transformation by SSV and other agents, involving expressing of 
growth factors. 
t 
Watson R.D. Prevention Of Dust Exposure. Am. J. Indust. Med., 10 fl : 0229-0243. 1986. 
1 
ABSTRACT: Dust exposure on farms can be prevented by changes in 
work practices and by informing and educating farmers. 
Ventilation control during handling and prevention of growth of 
microbes are feasible measures and could be included in 
regulation schemes. Apart from information on existing work 
practices, an increased avareness of new technology is 
necessary. 
Wegmann H.M., Gundel A., Naumann M., Same1 A. ,  Schwartz E., Vejvoda 
M. Sleep, Sleepiness, And Circadian Rhythmicity In Aircrews 
Operating On Transatlantic Routes. Aviat. Space Environ. Med., 
4 
57 (12 S~ppl.):B0053-B0064. 1986. 
ABSTRACT: This study was performed on B-747 aircrews operation on 
1 
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regular passenger flights betveen Frankfurt and the U.S. vest 
coast ( 9  h time difference). In an initial phase, sleep behavior 
was surveyed by daily logs in 38 erewmembers. The results for 
the layover period indicate congruent sleep patterns with shifts 
in sleep onset distinctly less than 9 h. In comparison vith 
preflight control data, sleep duration was significantly 
prolonged and, on average, no sleep deficits were experienced 
before commencing the return flight. The main part of the study 
consisted of polygraphic sleep recordings and multiple sleep 
latency tests (MSLT) applied to four complete cockpit crews (12 
members total) in a baseline period, during layover, and after 
return to homebase. In addition, body temperature and ECG were 
continuously recorded. during layover, mean bed times were 
shifted by 4.5 h at maximum. Sleep was disturbed by early and 
prolonged avakenings which led to a reduction of sleep 
efficiency. In contrast, no sleep deficits nor increases in 
daytime sleepiness occurred. Night duty associated vith the 
return flight caused sleep deprivaton which conversely resulted 
in good sleep during the first night back in Germany. However, 
during the second night after return, impaired sleep was 
observed, at least in part caused by the rhythm disturbances. As 
predicted by our resynchronization model, ECG and rectal 
temperature recordings gave evidence for a desynchronization of 
the circadian system and an internal dissociation of different 
body functions. 
Whinnery J . E . ,  Burton R.R. tGz-Induced Loss Of Consciousness: A Case 4 For Training Exposure To Unconsciousness. Aviat. Space Environ. Med., 58:0468-0472. 1987. 
fl ABSTRACT: tGz-induced loss of consciousness (G-LOC) continues to be a threat to aircrew flying high-performance fighter aircraft. 
All avenues to prevent G-LOC, and to reduce the resulting 
incapacitation should G-LOC occur, must be explored. Research 4 has begun to accurately quantify all aspects of the G-LOC 
phenomenom. The emerging pattern from this research indicates 
that, theoretically, G-LOC incapacitation could be significantly 
reduce. Comparison of G-LOC with LOC induced by acute arrest of 1 cerebral circulation reveals that the G-LOC incapacitation could 
be reduced by as much as 17 s. Results also indicate that the 
relative incapacitation period (confusion and disorientation) 1 following unconsciousness could be reduced by at least 9 s for an 
individual who has previously experienced G-LOC. This suggests 
that exposure to G-LOC during centrifuge training could provide 1, this orientatione to G-LOC and potentially reduce the 
incapacitiation period should it occur inflight. This expposure 
may be likened to the current altitude-hyposia training 
requirement for aircrew. Experience to date supports the ! contention that such training may be accomplished vith an 
acceptable safety margin. 
8 Whinnery J.E., Glaister D.H., Burton R.R. tGz-Induced Loss Of 
Consciousness And Aircraft Recovery. Aviat. Space Environ. Med., 
58:0600-0603. 1987. 
ABSTRACT: Aircrew incapacitation resulting from very high onset 
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sustained +Gz stress has resulted in significant losses of 
aircraft and aircrew. Enhanced protection and training toward 
prevention of tGz-induced loss of consciousness (G-LOC) will 
continue to be vital. Techniques for reduction of the time of 
incapacitation, should G-LOC occur, must also be explored and 
developed. Current capabiltiy of aircraft autorecover as 
demonstrated by the Advanced Fighter Technology Intergration F-16 
(AFTI/F-16) promises to enhance safety from the acute 
incapacitation resulting form G-LOC (and spatial disorientation). 
Physiologic monitoring for determining G-LOC has certain 
advantages especially in the aerial combat arena. The optimum 
physiologic monitoring technique would be direct determination of 
failure of brain cell function at the cellular of subcellular 
level. Complete investigation of G-LOC is necessary to 
understand the phenomenon and to develop methods for physiologic 
monitoring of G-LOC. Intergration of physiologic monitoring 
techniques into aircraft autorecovery systems requires a broad 
approach for optimal development. 
c 
* White S.C. The Aerospace Medical Research Laboratory: A Leader In The 
Development Of Life Support. Aviat. Space Environ. Med., 57 (10 
Suppl) :A0044-A0048. 1986. 
ABSTRACT: The progress in the development of life support for the 
crewman parallels the changing flight envelope of the airplane 
and spacecraft. A constant in this history is man. In spite of 
elaborate attempts to refine the selection of the crev, the basic 
lists of requirements has not changed. Only the urgency and the 
need for providing the entire list of requirements have been 
seen. Generally, progress in the flight envelope has demanded 
more reliable and often more complex provisions to support the 
crew. The debate as to how this should be done has often 
centered on the argument about having man wear or carry the life 
support elements versus integration of these provisions into the 
vehicle. This debate initiated the concept of risks/benefits, a 
debate that has now reached all aspects of man's endeavors, 
including his medical care. This paper will disuss the major 
milestones of providing life support, some of the key 
contributors (a role that General Armstrong played in a great 
way), and how this has provided the base for the next steps in 
aviation and space operations. 
Performance Testing. No Date. 
ABSTRACT: None 
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Whitley K.M., McGriff C.F. Test Plan For VCD Subsystem Checkout And 
Willis C.E., Schultz J . R .  Spacecraft Water System Disinfection 
Technology: Past, Present, and Future Needs. SAE Technical 
Paper Series 871487,1987. 
ABSTRACT: The lessons of past and present manned space programs 
are clear. Successful design and operation of a spacecraft water 
system is contingent upon consideration of traditional saitary 
engineering principles in the context of unique mission 
requirements. However, the aerospace solution to the traditional 
1 
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terrestrial problem often requires an innovative desigh approach 
to succeed in the spacecraft environment. Future long duration 
space missions will require the same attention to basic 
principles, the same degree of innovation, and an extra measure 
of caution, because of the lack of terrestrial experience with 
direct human reuse of reclaimed water. I Wolfe R.S. Respiration In Methanogenic Bacteria. Diversity Of 
Bacterial Respiratory Systems 1, :0161-0186. 1980. 
ABSTRACT: None 
I 
Wolff H.S. Animal Experiments. Proc. R. SOC. Lond. B., 199 
:0479-0483. 1977. 
ABSTRACT: Towards the end of 1980 the first Spacelab will be 
launched. It represents the culmination of a major cooperative 
project between the nations subscribing to the European Space 
Sgency and N.A,S.A. The Spacelab module contains a laboratory 
inside which a wide range of experiments can be carried out in an 
environment which, apart from the absence of gravity,is not 
unlike that of a terrestrial laboratory. From the point of view 
of the life scientist it represents an opportunity to carry out 
experiments to investigate the effect of xero gravity or 
modulated gravity on biolgical preparations including amn. 
Thefirst mission will last seven days, but subsequent missions 
planned for the decade 1980-1990 may last up to thirty days. The 
purpose of the paper is to introduce participants to the 
facilities whech are available in Spacelab and to explain the 
procedure by which experiments may be proposed. There is also a 
discussion of the present funding arrangements int he United 
I 
3 
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1 Kingdom. 
Wolin M.J. The Rumen Fermentation: A Model For Microbial Interactions 
In Anaerobic Ecosystems. Division of Laboratories and 
Research, New York State Department of Health, Albany, New York 
12201, USA, :0049-0077 .  . 
8 ABSTRACT: A ruminant can be thought of as a fermentation factory. 
The animal ingets plant polymers (in grass, hay, corn, silage, 
etc.) which are the raw material for its fermentation. 
Preliminary processing occurs in the oral cavity and consists 
mainly of comminution of food by mastication. The plant material 
is then swallowed and transported to the ruminant's complex 
stomach. The stomach, called the rumen reticulum or, mcre 
simpley, rumen, is the site of fermentation. 
1 
Wood C.D., Manno J.E., Manno B.R., Redetzke H.M., Wood M.J., Mims 
M.E. Evaluation of Antimotion Sickness Drug Side Effects On 
Performance. Aviat. Space Environ. Med., 56:0310-0316. 1985. 
ABSTRACT: This project has employed a computerized pursuit meter 
which has a high correlation with operational performance to test 
the principal antimotion sickness drugs. Proficiency scores on 
the pursuit meter task were improved over placebo scores in 
subjects with d-amphetamine 10 mg and 5 mg, the combination of 
1 
1 
.. , .  
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promethazine 25 mg plus scopolamine 0.4 mg with d-amphetamine 10 
mg, and the combination of scopolamine 1 mg with d-amphetamine 10 
mg. Scores were not significantly different from placebo scores 
in tests with scopolamine 0.25 mg, 0.5 mg, or 0.6 mg; marezine 50 
mg; meclizine 50 mg; or dimenhydrinate 50 mg. This was also true 
for the combination of scopolamine 1 mg with d-amphetamine 5 mg, 
and that of promethazine 25 mg with d-amphetamine 10 mg. A 
statistically slgnlf lcant decrement of performance scores was 
seen with scopolamine 1 mg or 0.8 mg, and with Promethazine 25 mg 
oral or 25 mg I.M. The cornbination of promethazine 25 mg with 
scopolamine 0.4 mg, and that of promethazine 25 mg oral plus 25 
mg I.M. with d-amphetamine 10 mg, also gave significant 
decrements from placebo scores. These results indicate that 
selected doses and combination of antimotion sickness drugs can 
be used without loss of operational proficiency. 
8 
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Wood E.H. Contributions Of Aeromedical Research To Flight and 
Biomedical Science. Aviat. Space Environ. Med, 57/1O(Suppl.) 
:A0013-A0023. 1986. 
ABSTRACT: Pilot and plane capabilities to withstand high-Gz 
combat maneuvers are tactically important. Sustained 10-15 Gz 
capabilities of current and future planes outstrip safe 
physiologic limits in spite of the combined use of World War 11 
-vintage straining maneuvers and relatively ineffective anti-G 
suits to prevent losses of vision and consciousness. However, 
the extreme arterial pressure increases needed to maintain 
cerebral blood frow (e.f. 400 mm Hg at heart level during 
exposures to 13.5 G when sitting upright) carry risks of 
anatomic damages to the circulatory system and rupture of 
air-containing, essentially unprotectable, lungs. These could be 
minimized, and incapacitating losses of consciousness avoided, by 
use of horizontal positions designed to eliminate heart-to-head 
hydrstatic gradients. Development of a prone-position cockpit 
with a counterweighted, forward-looking head support plus 
optical-electronically aided all-directional visibility is the 
most physiologic, safest, and surest way to achieve this goal. 
Woodard E.D., Friedlander B., Lesher R . J . ,  Font W., Kinsey R., Hearne 
T.F. Outbreak of Hypersensitivity Pneumonitis in an Industrial 
Setting. JAMA, 259/13:1965-1969. 1988. 
ABSTRACT: Systoms consistent with hypersensitivity pneumonitis 
developed in several wokers in two multistory buildings in an 
industrial complex. A health questionnaire survey was conducted 
to determine the extent of the problem. Eightyseven percent of 
the population of 1050 employees completed the health 
questionnaire. Serological testing identified 152 positive 
precipitin reactors to the fungus Aureobasidium pullulans; 115 
reactors were symptomatic. The clinical and laboratory features 
at the time of the acute illness and during four years of 
follow-up are described. The agent, A pullulans, was identified 
as a contanimant of the heating-cooling ventilation units 
containing open waterspray chambers. Control was accomplished by 
replacement of the ventllatlon systems. A secondary source of 
antigen was found to be corrugated cardboard. Some sensitized 
. .  . . .  . -  
1 employees required removal from vork exposure to corrugated 
cardboard to prevent recurrent symptoms. 
Hlstomorphometrlc Analysls of Rat Skeleton Following 
Spaceflight. Am. J. Physiol. 252 (Regulatory Integrative Comp. 
Physiol. 21) :R0252-R0255. 1985. 
ABSTRACT: Male Sprague-Dawley rats vere placed in orbit for 7 
days aboard the space shuttle. Bone histomorphometry was 
performed in the long bones and lumbar vertebrae of flight rats 
and compared with data derived from ground-based control rats. 
Trabecular bone mass vas not altered during the 1st veek of 
weightlessness. Strong trends vere observed in flight rats for 
decreased periosteal bone formation in the tibial diaphysis, 
reduced osteoblast size in the proximal tibia, and decreased 
osteoblast surface and number in the lumbar vertebra. For the 
most part, histological indexes of bone resoption vere normal in 
flight rats. The results indicate that 7 days of veightlessness 
are not of sufficient duration to induce histologically 
detectable loss of trabecular bone in rats. Hovever, cortical 
and trabecular bone formatin appear to be diminished during the 
1st wk of spaceflight. 
Cytoplasmic Proteins Of Streptococcus mutans (Serotype C) And 
:0506-0512. 1984. 
- 
Wronskl T.J., Morey-Holton E.R., Doty S.B., Maese A.C., Walsh C.C. 
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YOtiS W.W., Zeb M., Kubak B., WU-YUan C., YOtiS E., McNulty J. 
1 Their Interaction With Fluoride. App. Env. Micro., 47/3 
ABSTRACT: The protein profile of the cytoplasmic proteins of 
Streptococcus mutans GS-5 vas determined by two-dimensional gel 
electrophoresis. Use of this recently developed, high-resolution 
analytical tool showed in excess of 140 cytoplasmic proteins. 
The profile consisted of mostly acidid components with PI values 
betveen 3.70 and 5.30 and relative moecular weights mainly in the 
13,000 to 90,000 range. With sodium dodecyl 
sulfate-polyacrylamide get electrophoresis, the proteins were 
resolved into 40-45 components. The binding of fluoride by the 
proteins reached a maximum value in 15 miln., and it vas linear 
vith exogenous F- doses of up to 60-80 ppm per mg of protein 
(60-80 ug/q). The proteins bound 22 to 138 times more F- from 
assay mixtures containing 1 mM CaC12 than from assay mixtures 
containing such ions as HgC12, ZnClZ, cUc12, MgC12, MnC12, or 
used as sources of F- (adjusted to 10 ppm of F- in all cases), 
the proteins bound 2.1, 1.8, 1.6, 1.4, and 0.3 ppm of F- per mg 
of protein, respectively. Initial fractionation of the plasma 
proteins by preparative column isoelectric focusing indicated 
that proteins vith PI values of 4.1 to 4.5 as vel1 as thaose vith 
pI values of 5.0 to 5.3 bound twice as muc F- as did the proteins 
# 
I 
1 SnC12. When NaF, SnFZ, NH4F8 CSF, (CH4)3NF8 and Na2P03F Were 
I utside these PI values. 
I 
Young L.R., Oman C.M., Watt D.G.D., Money K.E., Lichtenberg B.K. 
Spatial Orientation In Weightlessness And Readaptation To 
Earth's Gravity. Science, 225:0205-0208. 1984. 
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ABSTRACT: Unusual vestibular responses to head movements in 
weightlessness may produce spatial orientation illusions and 
symptoms of space motion sickness, An integrated set of 
experiments vas performed during Spacelab 1, as well as before 
and after the flight, to evaluate responses mediated by the 
otolith organs and semicircular canals. A variety of 
measurements were used, including eye movements, postural 
control, perception of orientatin, and susceptibility to space 
sickness. 
Young, R. B., McConnell, D. G., Suelterr, C. H., Phillips, T. A. . Normal and Dystrophic Embryonic Chicken Pectoralis Muscle 
Cultures: I. Cell Differentiation, Protein Synthesis, and 
Enzyme Levels. Muscle and Nerve, :0117-0124. 1981. 
ABSTRACT: Normal (line 2 0 0 )  and dystrophic (line 307) embryonic 
chicken pectoralis muscle cells were studied in cell culture over 
a period of 2 veeks. During the first 4 days, normal and 
dystrophic cultures exhibited similar developmental increases in 
the number of nuclei vithin multinucleated myotubes; hovever, 
dystrophic muscle cells degenerated approximately tvice as fast 
as normal cells once the initial burst of myoblast fusion vas 
complete. The apparent synthesis rate of nonmyofibrillar 
proteins vas similar in normal and dystrophic cells throughout 
development, but the apparent synthesis rates of myosin heavy 
chain and the myofibrillar protein fraction were 500-900 higher 
in dystrophic muscle cultures once maturity had been reached 
(days 6-14). The specific activities of creatine kinase and 
phosphofructokinase were not affected by the dystrophic 
condition; hovever, specific activity of AMP-deaminase vas 
depressed 25%-40% in the dystrophic muscle cultures. 
Young, R. B., SChneible, P. A. . Myosin Heavy Chain Concentration, 
Synthesis Rate and Degradation Rate in Normal and Dystrophic 
Chicken Muscle Cells in Culture. Euro. J. Cell Biol., 34 
~0075-0079. 1984. 
ABSTRACT: Myosin heavy chain concentrations, synthesis rates and 
degradation rates were studied in muscle cell cultures prepared 
from the breast muscle of 13-day normal (vhite leghorn) and 
dystrophic (line 307) chicken embryos. Muscle cells were studied 
after 7 days in culture, at which time they had reached a steady 
state vith respect to myofibrillar protein synthesis and 
degradation. The quantity of myosin heavy chain vas 10.5 t 0.9 
ug/culture (n=32) in normal cells and 8.10 t 1.2 ug/culture 
(n=31) in dystrophic cells. However, the myosin heavy chain 
synthesis rate vas 23 500 molecules/min/nucleus in normal cells 
and 39 900 molecules/min/nucleus in dystrophic cells, as 
deteermined by pulse labeling vith [3Hlleucine and measurement of 
the specific radioactivity of tRNA precursor pools. Myosin heavy 
chain half-lives rates were calculated to be 30.6 h in normal 
cells and 15.6 h in dystrophic cells when corrections were made 
for reutilization of [3H[leucine. Thus, dystrophic muscle 
cultures accumulate less myosin heavy chain, despite their faster 
synthesis rate, because of faster degradation of myosin heavy 
chain. 
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Yu V.L., Beam T.R., Lumlsh R.M., Vlckers R.M., Fleming J., McDermott 
C., Romanmo J. Routine Culturing f o r  Legionella in the Hospital 
Envlronment May Be a Goo3 Idea: A Three-Hospltal Prospective 
Study. Am. J. Med. Sci., 294:97-99. 1987. 
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ABSTRACT: The source for nosocomial Legionnaires' disease is the 
water distribution system. However, the implications for 
legionella contamination in a hospital without known 
Legionnaires' disease is unclear. Therefore, culturing for 
Legionella pneumophila in the environment has not been routinely 
recommended. The authors conducted a prospective pneumonia study 
in three hospitals, none of which was known to have a major 
problem with endemic legionellosis. The water system of Hospital 
1 was colonized with L. pneumophila, serogroup 1; Hospital 2 was 
colnized by L. pneumophila, serogroup 5 (which is rarely 
associated with disease); Hospital 3 was essentially free of L. 
pneumophila. Sputum culture on selective legionella media, 
direct fluorescent antibody testing, and serology were performed 
for all nosocomial pneumonias regardless of clinical impression. 
At the end of the study the incidence of nosocomial legionnaires' 
disease was found to be 9%, OS, and 0% in Hospitals 1, 2, and 3, 
respectively, In Hospital 1, monoclonal antibody subtyping 
confirmed that the patient isolates were identical to the 
environmental isolates. The authors conclude that environmental 
culturing, despite the absence of knovn Legionnaires'. disease, is 
useful. Positive cultures from the hospital water supply would 
mandate the introduction of legionella testing into the 
laboratory and stimulate physicaians to consider Legionnaires' 
disease when encountering nosocomial pnemonias. 
Zamost B.L., McClary D.O. The Effects Of Plant Growth Regulators On 
Cellulase Production By Trichoderma reesei . Biotech. Let., 5/3 3 : 0179-0184. 1983. 
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ABSTRACT: The plant growth regulators, indole-3-acetic acid (IAA) 
and gibberellic acid (GA3), were tested for their effects on 
spore germinaton and cellulase (B-1-4-endogluconase 1 producton by 
Trichoderma reesie. The addition of 10 -5 M IAA of GA3 enhanced 
cellulase production whereas higher concentration were 
inhibitory, both to spore germination and cellulase production. 
Zayed S.M.A.D., Mastafa I.Y., Farqhaly M.M., Attaby H.S.H., Adam 
Y.M., Mahdy R.M. Microbial Degradation Of Trifluralin By 
Aspergillus carneus, Fusarium oxysporum, And Trichoderma viride. 
J. Environ. Sci Health, B18/2:0253-0267. 1983. 
ABSTRACT: None 
Zdankiewicz E.M., Chu J. Phase Change Water Recovery For Space 1 
1 
Station Parametric Testing And Analysis. 
ABSTRACT: Vapor compression distillation (VCD) technology for 
phase change recovery of potable water from wastewater has 
evolved as a technically mature approach for use aboard the space 
station. A program to parametrically test an advance 
. '. * .  
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1 preprototype vapor compression life systems for the national aeronautics and space administration (NASA) Johnson Space Center 
(JSC) During 1985. In parallel v&th parametric testing, a 
hardware improvement program vas initiated to incorporate and 
verify certain key improvements into the advance preprototype 
VCDS following initial parametric tests. Specific areas of 
improvements included long-life, self-lubricated berings, a 
lightweight, highly-efficient compressor and a long-life 
magnetic drive. These improvements are now incorporated and 
verification testing started. The advance preprotype VCDS Was 
designed to reclain 95% of the available wastewater at a nominal 
water recovery rate of 1.36 KG/H (3.0 LB/HR) And 308 K (95 F) 
condenser temperature. While this performance was maintained for 
the initial testing, a 300% improvement in water production rate 
(4.1 KG/H(S.O LB/HR)) with a corresponding lower specific energy 
was achieved following incorporation of the improvements. The 
paper presents a summary of the results of the parametric test 
program conducted. Testing involved the characterization of key 
VCDS Performance factors (water production rate, water quality 
and specific energy) as a function of recycle loop solids 
concentration, distillation unit temperature and fluids pump 
speed. The objective of this effort was to expand the VCDS data 
base to enable defining optimum performance characteristics for 
flight hardware development. Based upon the parametric testing 
results which were obtained. Projections are made for a phase 
change water recovery subsystem for the space station based upon 
the VCD concept. The projected unit processes 18.1 KG/Day (40.0 I LB/Day) of vastevater, weighs 36.1 KG (79 LB), has a volume of only 0.21M3 (7.4 FT3) and requires only 84 W of electrical power 
for a specific energy of 76.8 W-H/KG (35 W-HR/LB). 
fl Zeikus. Use Of Co-Cultures In The Production Of Ethanol By The 
Fermentative Of Biomass . U.S. Patent 4,400,470,. 
ABSTRACT: Production of ethanol and enzymes by fermentation of 
biomamss vith co-culture of Clostridium thermocellum and C. 
thermohydrosulfuricum 
Zeikus J.G. Microbial Populations In Digesters. Anaer. Dig. Proc. 
8 
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Int. Symp.,:0061-0089. 1981. 
4 ABSTRACT: None 
Zeikus J.G. Thermophilic Bacteria: Ecology, Physiology And 1 
a 
Technology. Revievs, Departpent of Bacteriology, University of 
Wisconsin, Madison, Wisconsin 53706, USA,. 
ABSTRACT: Thermophilic bacteria are common in soil and volcanic 
habitats and have a limited species composition. Yet they 
possess all the major nutritional categories and metabolize the 
same substrates as mesophilic bacteria. The ability to 
proliferate at growth temperature optima well above 60 C is 
associated with ectremely thermally stable macromolecules. As a 
consequence of growth at high temperature and unique 
macromolicular properties, thermophilic bacteria can possess high 
metabolic rates, physically and chemically stable enzymes, and 
I 
lover growth but higher end product yields than similar 
mesophilic species. Thermophilic processes appear more stable, 
rapid and less expensive, and fadlitate reactant activity and 
product recovery. Thermophilic bacteria have application in 
chemical feedstock and fuel production, bioconversion of wastes, 
enzyme technology, and single cell protein production. This 
paper revievs the fundamental and applied aspects of thermophilic 
bacteria that are of potential industrial interest. 
I 
I 
Zeikus J.G. Microbial Intermediary Metabolism In Anaerobic Digestion. 
Anaerobic Digention, Proceedings Of The International Symposium, 
ABSTRACT: Effective biodegradation of oranic wastes into methane 
requires the coordinated metabolic activities of different 
microbial populations. The intermediary metabolism of 
multicarbon and uni- and dicarbon transforming bacteria is 
described in mono- and co-culture fermentations. The results of 
physiological and biochemical experiments are presented in order 
to explain the fundamentals of mixed culture metabolism and to 
identify key control parameters which influence the rate of 
organic degradation, the yield of reduced metabolites, and 
thermodynamic efficiency in the anaerobic digestion process. 
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SPACE MEDICINE 
This  b ib l iography was prepared i n  conjunct ion w i th  the  col loquium "Space Medl- 
c ine:  Newest F ron t i e r  of the  Health Sciences" he ld a t  the Nat ional  L ib ra ry  o f  
Medicine on November 13, 1986. The colloquium was one o f  a se r ies  he ld  i n  
ce lebra t ion  o f  the L i b r a r y ' s  sesquicentennial 
Because there i s  a l a rge  volume of l i t e r a t u r e  on space f l i g h t  which covers a l l  
d i s c i p l i n e s  o f  science, t h i s  s e l e c t i v e  bibl iography i s  l im i ted ,  f o r  the most 
pa r t ,  t o  references on the  biomedical aspects as they r e l a t e  t o  the  human f a c t o r  
i n  space f l i g h t  o r  the  space environment. These inc lude phys io log ica l ,  b i o l o g i -  
ca l ,  and behavioral funct ions.  There are a l i m i t e d  number of references o f  a 
more general nature r e l a t i n g  t o  equipment design, 1 i f e  support systems, environ- 
mental con t ro l ,  r a d i a t i o n  e f fec ts ,  1 i f e  sciences, and in te rna t i ona l  cooperation. 
I n  general, references t o  animal and c e l l  cu l tu re  s tud ies  have been excluded. 
This b ib l iography covers the  ten-year per iod from 1977 t o  the  present and 
inc ludes on ly  Engl ish language pub1 ica t ions .  Sources f o r  the references inc lude 
NLM's MEDLINE and CATLINE databases as wel l  as B IOSIS ,  EMBASE, Aerospace Oata- 
base, D isser ta t ion  Abstracts On1 ine,  Mental Heal th Abstracts, NASA RECON, 
PSYCHINFO, and Social SciSearch, A l l  types o f  pub l i ca t ions  have been included: 
monographs, journa l  a r t i c l e s ,  technica l  reports, conference proceedings, and 
d isser ta t ions .  This b ib1  iography i s  extensive bu t  n o t  exhaustive; the exclu- 
s i o n  o f  p a r t l c u l a r  i tems i s  no r e f l e c t i o n  on t h e i r  q u a l i t y  or usefulness. 
'Space Medicine" has been d iv ided i n t o  seven broad categor ies:  bone metabolism, 
the  cardiovascular system, general physiology, motion sickness, psychological /  
behavioral  aspects, r a d i a t i o n  e f f e c t s ,  and other. The l a t t e r  includes broad 
general pub l l ca t lons  as w e l l  as s p e c i f i c  ones which f a l l  outs ide the  categor ies 
1 1 s ted  above. 
For a comprehensive p u b l i c a t i o n  on the  pre-1977 aspects o f  space medicine, the 
reader i s  re fe r red  to:  
Foundations o f  space b io logy  and medicine: j o i n t  
USA/USSR pub l ica t ion .  Melvin Calv in  and Oleg G. 
' Gazenko, general ed i to rs .  Washington: S c i e n t i f i c  
and Technical In format ion Off ice,  Nat ional  Aero- 
nau t i cs  and Space Administrat ion, 1975. 3v. 
(NASA Special Pub1 l c a t i o n  no. 374; 
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APPENDIX E 
Task Statements 
1.0 Provide Support To The Mechanical Design And Integration Of Test 
These are preliminary design recommendations for the integration and 
material compatibility of water reclamation subsystems as they relate to 
microbial concerns. These criteria are based on an ideal system and as 
such are subject to change depending on actual design implementation. 
Systems As Related To Microbiological Concerns 
1.1 General 
A major microbiological concern in a water-related system is the 
attachment of bacteria to surfaces and subsequent biofouling. The degree 
of attachment is dependent upon surface area and the nutrient conditions 
present. Although these factors cannot be eliminated, steps can be taken 
to reduce their influence in most cases. A second concern involves the 
ability to detect bacterial presence quickly and accurately. Proper 
preventive measures should be taken and problem areas identified and 
detected quickly. Some general recommendations are outlined below. 
1.1.1 Bacterial Attachment and Biofilming 
Surface areas available for bacterial attachment should be minimized. 
Plumbing runs, number of elbows, and storage tank size should be reduced 
wherever possible. Joints should be welded by automatic orbital welding 
techniques to eliminate the creation of internal surface areas and 
subsequent attachment sites for bacteria. Component materials (Section 
1.2) and Subsystem Integration (Section 1.3) considerations are also 
important to reducing biofouling. 
In addition, nutrient concentrations available to support microbial 
growth should be reduced. Component materials should not contribute 
nutrients to the system. Growth-promoting factors may be reduced in the 
water supply by physical or chemical means. For example, organic carbon, 
the single most important factor in biofilm formation, can be reduced by 
reverse osmosis membranes UV irradiation and activated carbon beds. 
1.1.2 Holding Time 
A holding (storage period is needed in order to validate and verify 
the quality of water be f’ ore use. This time period is dictated by the time 
required to perform the necessary tests for verification. However, as long 
as a holding time is required it is not possible to verify the water 
quality just prior to use. In addition, a holding time requires not only 
the maintenance of water uality during the hold period but also during the 
the water. At the present time, the minimum time required is estimated to 
be 24 hours. Although it is conceivable that the chemical parameters can 
be concluded and reported within an eight hour shift, the microbiological 
arameters will require at least 24 hours. A holding time greater than 24 
[ours is In order to allow for the minimal holding time 
possible, viable plate counts should be performed on those parameters which 
can be completed within 24 hours and also provide the necessary information 
required for veriiication of water quality (Section 3.2). In addition, a 
near real-time method for total bacterial counts will be necessary. 
eriod as well. Final 9 y, the greater the holding time which is placed 
on t K e water prior to use the more tank capacity that is required to store 
recommended. 
1.1.3 Storage Tanks 
Storage tanks, with their large volumes of water, can be especially 
difficult to control. Limiting the size of the tank and minimizing storage 
time will effectively reduce the attachment of bacteria to tank walls and 
eliminate a major reservoir for bacterial contamination and growth. 
Refrigeration of the storage tanks and their contents will usually slow the 
process of bacterial growth and subsequent fouling. Direct heat 
sterilization of the tank and its contents will control bacterial 
development. In addition, heat sterilization can be mechanically validated 
and thus the sterility easily verified. At lower temperatures than is 
normally required for conventional heat sterilization a process known as 
tyndallization may be used. Tyndallization is a series of daily heat 
spikes which destroys vegetative cells resent and then allows for the 
subsequent germination of s ores whici may be present. These new 
vegetative cells are then destroyed ! y repeating the process. 
1.1.4 Control of problem areas 
Those areas which are especially prone to bacterial contamination such 
as sampling sites, replacement units (e.g. reverse osmosis unit, resin 
beds, activated carbon beds and articulate filters) and storage tanks will 
require s ecial considerations. Fhese areas should be easily accessible 
will serve to reduce system down time when a problem is encountered or 
components need to be cleaned or replaced. 
for perio B ic checking, routine maintenance and scheduled replacement. This 
1.2 Material Recommendations 
The choice of materials used in the construction of pharmaceutical and 
semiconductor water supplies remains the best source of information on 
system components. Wherever possible materials should be those which are 
flight approved. Listed below are recommendations applicable to the test 
system from these sources. 
1.2.1 Stainless steel (316L) 
Stainless steel (316L) is recommended for all applicable hardware 
components. Advantages are listed below: 
- low carbon content - low trace metal content - highly resistant to pitting and corrosion 
- able to tolerate high salt concentrztions - acceptable resistance to bacterial attachment 
1.2.2 Gaskets 
Use of Teflon gasket material is recommended. 
1.2.3 Storage Tanks 
Bellows tanks with an external 
tanks will eliminate the possibility of 
mechanism which would serve as a reservoir for 
piston are recommended. These 
water entrapment in the piston 
bacterial contamination. 
1.2.4 Valves 
Packless diaphagm valves are recommended in order to prevent 
water entrapment in the valve mechanism and a potential site for bacterial 
contamination. 
1.2.5 Activated Carbon 
Many grades of activated carbon are available. The highest 
quality anthracite is recommended. 
1.2.6 Material compatibility with disinfectant 
Care must be taken to ensure that the decontamination rocesses 
chosen are compatible with the hardware materials used. All K ardware 
materials (RO membranes, ion exchange resins, etc.) should be compatible 
with proposed pretreatment processes, other subsystem components and 
proposed disinfection procedures and/or agents. 
Stainless steel is suitable for disinfection with dry/moist heat 
rocedures. In addition, 316L stainless steel can withstand treatment with 
got water, chlorine, and iodine. Fiberglas-reinforced plastics (FRP) can 
tolerate hydrogen peroxide, ozone, and formaldehyde. Polyvinyl 
decaflouride (PVDF) compounds are resistant to gluteraldehyde and 
ultraviolet (W) light. 
1.3 System Design and Subsystem Integration 
The ability to produce acceptable product water depends on the 
integration of basic structural and implemented hardware designs to 
discourage bacterial growth. Listed below are some problems likely to be 
encountered and recommendations to help govern them. 
1.3.1 Stasis 
Any segment of pipe containing water that is not recirculated on 
a frequent basis provides an area for nutrient deposition and eventual 
bacterial growth. These areas, often referred to as a "dead legs" can 
potentially serve as internal sites for system contamination. 
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Distribution lines should be plumbed as close to the point of use as 
possible. This will decrease the physical length of pipe required and 
reduce the amount of dead space present when the system is not in use. 
Minimize the use of elbows, valves, and use points in order to reduce 
possible "dead legs". Also, electronic water level indicators instead of a 
sight tube is recommended to eliminate standing water. 
Recirculation or continuous operation is recommended to reduce static 
conditions and minimize "dead legs". 
Point of use sites such as hand washers serve as potential reservoirs 
for bacterial growth due to contaminants from skin oils, hair, and 
respiratory droplets. Circulating pumps at these sites help reduce standing 
water and thereby help to eliminate the build-up of required nutrients 
necessary for the propagation of microorganisms. Circulation within water 
storage tanks would help to reduce bacterial populations. Circulation 
reduces the settling of growth-promoting substrates from materials and 
water sources which normally provide a primary layer for biofilm formation. 
Circulation will ensure uniform mixing of chemical biocides, if employed. 
It allows for increased filtration and exposure to UV. irradiation (or 
disinfection). 
1.3.2 Tank Vent Filters 
1.3.2.1 Composition 
The composition of the filter should be of a hydrophobic 
membrane to reduce water entrapment on the surface. 
1.3.2.2 Placement 
Place the unit in a vertical osition to reduce further the 
possibility of water collection on the fi P ter and subsequent microbial 
growth. 
1.4 Sampling Ports 
Sampling ports as will use points provide a place of entry for 
contaminating microorganisms. The ability to control such areas is based 
on a combination of design considerations and physical treatments. 
Recommendations are listed below. 
1.4.1 Implementation of sterilization or disinfection 
procedures (Section 1.5). 
1.4.2 Circulation to prevent water stagnation. 
1.4.3 Elimination of gooseneck designs which may trap 
water. 
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1.5 Sterilization/Decontamination 
In order to retard bacterial growth the system should be sterilized or 
decontaminated at the onset as well as during actual usage. This may 
include separate cleaning of specific hardware especially susceptible to 
the growth of microorganisms. Periodic cleaning or replacement of some 
materials would also be indicated. Below are listed recommendations for 
sterilization and decontamination of the system. 
1.5.1 Routine removal of the outer length of outlet pi e for 
physical cleaning and sterilization (or disposal) would allow mec K anical 
cleaning of biofilm formation. 
1.5.2 Point of Use/Sampling Port Sterilization 
Routine point of use/sampling port sterilization or 
decontamination is recommended. These measures will help eliminate 
environmental contamination to the system. Below are presented several 
possible means to accomplish this. 
1.5.2.1 Ultraviolet (W) irradiation 
1.5.2.2 Routine and periodic treatment of the 
sampling ports with H202 or other 
acceptable disinfecting solution reduces 
the possibility of environmental 
contamination between uses. 
1.5.2.3 Microbial Check Valve (MCV) 
1.5.2.4 Flaming 
1.5.3 Sterilization of hardware 
1.5.3.1 R/O Membranes 
Reverse osmosis membranes can be treated with high 
temperature (95C) to remove bacteria attached to them. 
1.5.3.2 Activated Carbon Beds 
Activated carbon beds can be steam sterilized to reduce 
bacterial levels. 
1.5.3.3 Ion-exchange Resins 
Ion-exchange resins can be sterilized with a 0.5% solution 
of formaldehyde. Regeneration of the beds with 2% sulfuric acid and 4% 
sodium hydroxlde solutions will also help to control bacterial growth 
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1.6 Operational Requirements 
To operate efficiently, conditions must be maintained that will not 
overburden the system and cause premature failure of components. 
Recommendations for maintaining an efficient system are given below. 
1.6.1 Water pretreatment 
The R/O membrane and activated carbon bed are a major site for 
bacterial attachment due to 1) the large surface areas present and 2) the 
nutrient accumulation. Bacterial growth here will not only affect the 
efficiency of these components but all other subsystems downstream. 
Therefore, effective pretreatment of water entering these units will 
reatly extend the life of the of these subsystems by reducing the 
Eactenal burden placed upon them. 
1.6.2 Filters 
Periodic replacement of air filters, vent filters, prefilters and 
particulate filters will decrease the possibility of airborne 
contamination and reduce the particulate burden placed on the reclamation 
system. 
1.6.3 Continuous Operation 
Continuous or semi-continuous o eration, as opposed to batch 
processing, is recommended (Section 1.3.1f In addition to eliminating 
static conditions continuous operation will allow for increased observation 
of the system over an extended period of time to detect areas of weakness. 
It will also allow for the greater capacity for producing water if required 
for test evaluation and it will better simulate the operating conditions to 
be encountered aboard the Space Station. 
1.6.4 Constant Flow 
Maintenance of constant flow rates are recommended. Optimum flow 
rates of similar systems a r e ’  reported to be between 5-10 ft./sec. 
Maintaining a constant flow is reported to help reduce the number of free- 
floating bacteria and nutrients available for attachment to surfaces. 
2.0 Assist with the design of Human Subjects Test Protocols 
2.1 Test Subject Protocols 
The Boeing Aerospace Company (BAC) will identify potential subjects 
and route the names and contact information (work area, mail code, work 
phone number) to the BAC health nurse. The BAC health nurse will contact 
the potential subject and set up an ap ointment for initial screening. 
This initial screening will include a a escription of the project and 
completion of an informed consent form. The nurse will obtain a health 
questionnaire (HQ), a Duke University Health Profile (DUHP), and have the 
subject begin a symptom diary. The sub'ect will be iven an appointment 
routed to the examining physician by the health nurse. The subject will 
bring the diary to the EP on the day of the initial examination. 
At the initial examination, a full history and physical will be 
performed and recorded on the initial examination form. The laboratory 
will be drawn and the skin tests placed. When these results are available, 
the EP will indicate his/her opinion concernin the subject's medical 
invironmental Health Physician (EHP). Guidelines for this determination 
are outlined in 2.12 below. 
with the examining physician (EP), and t h e HQ and % UHP results will be 
ualification for involvement and route all t E e information to the 
For the subject selected to be involved in the test, an appointment 
will be made with the EP one week before he/she is scheduled to 
participate. At this time, the brief pre-test examination will be done and 
recorded on the form. When the 
results are available, the EP will again verify ualification, based on the 
guidelines presented in 2.14 below. The EP wi 7 1 then notify the EHP by 
telephone of the status of the subject, and route all the materials to the 
EHP. Each day of the testing, the EHP will notify the project manager of 
any changes in subject status. 
The repeat laboratory will also be drawn. 
Throughout the period from initial evaluation through testing and for 
six months beyond, the sub'ect will continue the symptom diary. Each 
later and six and twelve months later. These follow-up visits will include 
review of any intercurrent illnesses or symptoms and a brief physical 
examination as indicated. Each month after involvement for 24 months, the 
health nurse will obtain the records of any visit to a physician other than 
the EP and route them to the EP. All records will then be routed to the 
EHP on all subjects monthly. 
subject will be seen by the E! P one week after each involvement, one month 
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2.11 Initial Evaluation 
2.11 1 Name of personal physician 
2.112 Recent illnesses 
2.113 Past medical history 
2.113 1 Chronic illnesses (Hypertension, 
Diabetes, etc.) 
2.1 132 Regular medicines, including OCP's 
and OTC 
2.1133 Menstrual history 
2.1134 Regular cream, ointment, oil use 
2.1135 Other drugs, alcohol, tobacco 
2.1136 Active skin or hair disorder 
2.1137 Frequency of minor infectious 
diseases 
2.11371 Respiratory (colds, pharyngitis, 
bronchitis) 
2.11372 GI (gastroenteritis) 
2.1 1373 UTI (bladder, kidney) 
2.11374 GU (vaginitis, urethritis) 
2.11375 Skin (acne, im etigo, cellulitis, 
athlete's foot P 
2.114 Physical Exam 
2.1141 Skin 
2.1142 Heart 
2.1143 Lungs 
2.1144 Heart 
2.1145 Abdomen 
2.1146 GU (including pelvic) 
2.1 147 Neuro/Musculo Skeletal 
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2.115 Health Profile (DUHP) 
2.116 Laboratory 
2.1161 
2.1 162 
2.1163 
2.1164 
2.1165 
CBC 
U/A and culture 
Wet prep/GM Stain (if indicated) 
Serum pregnancy test 
Stool culture 
Special studies 2.1166 
2.117 Skin test anergy ack and PPD (Reading 
2.118 Begin symptom diary 
required in 48 rl ours) 
2.12 Disqualification Criteria for Initial Evaluation 
2.121 No personal physician 
2.122 Any chronic illness or regular medicine 
intake 
2.123 Frequent minor illnesses 
2.1231 > 4 colds&. 
2.1232 > 2GE/yr. 
2.1233 > 1 UTI/yr. 
2.1234 > 2 Vaginitis/yr. 
2.1235 > 1 Active Skin Infection/yr. 
2.124 Abnormal physical finding 
2.125 Poor DUHP score 
2.126 Abnormal lab 
2.13 Pre-Test Evaluation 
2.131 Review symptom diary 
2.132 Review recent menstrual history 
2.133 Review recent topical use 
2.134 Brief physical exam 
2.135 Laboratory 
2.1351 U/A and culture 
2.1352 Wet prep/GM stain (if indicated) 
2.1353 Serum pregnancy test 
2.1354 Urine drug screen (legal ramifications) 
2.1355 Special Studies 
2.14 Disqualification Criteria for Pre-test Evaluation 
2.141 Significant new symptoms of infection 
2.142 Testin4 likely to occur during menses (policy 
2.143 Any topical use on prohibited list 
2.144 Abnormal physical finding 
2.145 Positive urine culture ( > lO,OOO/ml of each 
2.146 Positive wet prep/GM stain 
2.147 Positive or indeterminate serum pregnancy test 
2.148 Positive urine drug screen (legal) 
decision) 
organism) 
2.15 Post-Test Evaluation 
2.151 Review symptom diary 
2.152 Review menstrual history 
2.153 Brief physical exam 
2.154 Repeat health profile (DUHP) 
2.155 Laboratory 
2.1551 U/A and culture 
2.1552 Wet prep/GM stain (if indicated) 
2.1553 Serum pregnancy test 
2.1554 Stool culture 
2.1555 Special studies 
2.16 Detection of Sick Subjects 
2.161 Continue symptom diary 
2.162 Monitor visits to personal physician (by 
permission) 
2.163 Subject notifies 
~ 
I 
I 
I 
1 
I 
I 
1 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
2.17 Medical Staffing Options for Project Evaluations 
2.171 Boeing/NASA Physician 
POSITIVE 
1) Good adherence 
to protocols 
2) Low additional 
cost 
2.172 Personal Physician 
1) High subject 
acceptability 
2) Awareness of 
involvement 
NEGATIVE 
1) Low subject 
acceptability ? 
2) Objectivity 
1) Objectivity 
2) High cost 
3) Low adherence 
to protocol 
2.173 Contract Physician 
1) Objectivity 
2) High adherence 
to protocol 
1) cost 
2.174 Responsibility for subject problems, accidents, 
injuries, exposure 
2.1741 Human subjects guidelines 
2.1742 JSC guidelines 
2.175 Certification process 
I 
I 
I 
I 
I 
I 
I 
I 
1 
2.2 Human Subject Guidelines 
2.21 Institutional Review Board 
There are several large policy issues that re uire early 
decisions in order to continue to work on further details. 
these is an approval of human subjects in general. The JSC Document 
provides the same categories of ''minimal" and "reasonable" risk that are 
used by the UAH Institutional Review Board. These are guidelines published 
by the Department of Health and Human Services that clearly outline what is 
to be done. In the JSC document, it is made clear that the testing of 
ground-based projects does not come under the JSC HRPPC review. It is 
stated that this review would be carried out by the Institutional Review 
Board "of the Institution at which the test procedure development takes 
It. This review board is a group of persons with widely diverse 
have not identified a MSFC IRB. An IRB should be desi ned for this review. 
UAH IRB, Dr. Crump can facilitate that process, as he is on the diversity- 
wide board. IRB for MSFC if 
one is needed. 
T 1 e first of 
glace ackgrounds which reviews protocols for human subjects. At this point, we 
If the MSFC legal department approves of delegating t E is authorit to the 
Dr. Crump could also facilitate designing an 
2.22 System Certification 
Certification prior to system use is another major policy 
issue. The JSC document makes it clear that the principal investigator for 
the project is the person whose signature certifies that 1) the system is 
safe, and 2) the subjects are medically qualified to participate. 
Certain1 , one role of the Medical Support Team is to delineate and accept 
must be specified, as it is clear that this person signs the "bottom line". 
The Medical Sup ort Team can be advisory to that principal investigator and 
can go on recorx as having recommended to the principal investigator that 
all is well. 
some o r this risk. However, the principal investigator for this project 
2.23 Subject Injury 
Concerning the issue of injury or harm to the test 
subjects, the JSC Document states that (in HRPPC reviews) since the 
subjects are NASA employees, NASA accepts responsibility under the Federal 
Employee's Compensation Act or the Federal Tort Claims Act. ,If Boeing 
employees are to be the subjects in our tests, this line of responsibility 
will have to be clarified before we can proceed. 
2.24 Supporting Documents (Appendix H) 
2.241 JSC HRPPC 
2.242 HHS 
2.243 UAHIRB 
2.244 Duke University Health Profile 
3.0 Interpretation and recommendations pertaining to water qua 
requirements. 
3.1 Identify current air/water quality requirements. 
3.1.1 Johnson Space Center Requirements 
The proposed requirements for potable and hygiene water 
specified by the Johnson Space Center (JSC) are presented in Table 3-1. 
3.1.2 Environmental Protection Agency (EPA) 
i ty 
as 
The current recommended priority pollutants as established by the 
EPA are presented in Table 3-2. 
3.1.3 State of Alabama 
The current State of Alabama requirements for drinking water are 
presented in Table 3-3. 
3.2 Recommend which chemical parameters should be monitored in order 
to verify water quality prior to use. 
The current parameters recommended for water quality verification are 
listed in Table 3-4. The chemical parameters recommended for routine 
monitoring are based on the identification of these compounds as toxic by 
the EPA, the recommendation by EPA that these compounds be monitored for 
pharmacutical products, the existence of standardized methods for their 
evaluation and the potential for rapid analysis (8 hours or less). 
3.3 Identify the instrumentation and methodology to be used for water 
quality verification. 
Based on the recommendations made pertaining to Section 3.2, Table 3-5 
lists the instrumentation and methods required for chemical parameter 
verification. 
3.4 Provide recommendations pertaining to microbiological monitoring 
of the potable and hygiene water loops in order to verify water quality. 
The current microbiology requirements are presented in Table 3-6. The 
arameters recommended for water quality verification are presented in 
!able 3-7. The microbiological parameters recommended are based on 
standard microbiological rocedures, current water quality requirements and 
the need for rapid resu P ts (6-24 hours). Determination of total bacteria 
will be conducted by an epifluorescence method in order to facilitate rapid 
results (4-6 hours . Conventional viable plate counts requiring a maximum 
plate count (72-120 hours) will be used for after the fact verification and 
identification of isolates as required. Le ionellae, fungi and yeast will 
be monitored routinely at a frequency to % e determined at a later time. 
incubation of 24 i ours will also be conducted. The standard heterotrophic 
1 Specific recommendations pertaining to viral monitoring will also be addressed at a later time, 
5 
b 
3.5 Development of a method for total bacterial counts. 
In order to detect the presence of bacteria on a near real-time basis 
a direct method for their detection and enumeration must be developed. It 
is recommended . that an epifluorescence method be used. At present, 
personnel at the CSLS are reviewing current methods and will make a final 
recommendation upon completion of this review. It is estimated that 
approximately $4,000.00 in equipment upgrades and four man-months will be 
required for method development. Table 3-8 summarizes the current methods 
for enumeration and the current recommendations. 
3.6 Provide information pertaining to laboratory analysis required 
The information outline below details pertinent information regarding 
for Leeionella and AIDS screening. 
the Legionellae and HIV (AIDS) virus. 
3.6.1 Legionellae 
k General 
1. gram negative rod 0.3-0.9 x 2-20 um 
2. usually motile 
3. Ten( 10) species determined by 1984 (Leeionella 
symposium) nine(9) of which had been implicated 
in human disease (legionellosis) 
4. More than one serogroup in some species 
5. Incubation is at 35C for 4-7 days in a humid 
environment usually requiring 2.5% C02 
B. Nomenclature 
1. Partial list of s ecies 
* a. L.meumo&liq(pneumonia;also called 
Lgionnaires disease;less severe infection 
termed Pontiac Fever) 
b. bozemanii pneumonia) 
c. L. micdadei (pneumonia) 
2. Species a,d,e,g,h and j have been isolated from 
environmental sources (water and soil) 
4 
C. Habitats 
1. Pertaining to our areas of interest 
a. water heaters, especially those at low 
temperatures ( c 55C) 
b. water storage tanks 
c. potable water distribution outlets 
1. shower heads 
2. faucets 
3. showers 
d. evaporator condensers 
e. air compressor lines (at water separator) 
f. "dead legs" in piping 
D. Ecological interactions 
1. Interaction with other organisms 
a. Studies indicate bpeumophilia, may derive 
many of its nutnbonal requirements from 
various species of een and blue- een algae. 
Legionellae m cooling towers where conditions 
favoring algal growth i.e. direct or indirect 
sunlight, warmth and moisture are present. 
Dissemination of the organism in aerosols may 
also be enhanced by protection from desiccation 
due to the mucilage produced by the algae. 
mtracellularly in some freshwater protozoans 
such as tetrahymena yriformis which normally 
protected from certain enwonmental factors. 
grow within vacuoles of ameba ubiquitous to the 
same aquatic environment and therefore may also 
protected as above. 
This may help exp r ain the prepon C Y  erance of 
b. 4 pneumoDhilia has been shown to grow 
feed on bacteria. In t E is way the bacteria are 
c. Certain species of the bacteria also appear to 
E. Sampling from Environmental Sites 
1. Water 
,\ 
I 
a. The volume of water sampled is dependent on site 
1. Potable water sources including holding tanks, 
cooling tower blowdowns and circulating pumps 
require at least 2-3 one(1) liter volumes 
2. Water condensers require about 3 one hundred 
(100) ml. volumes 
3. Other sites must be assessed individually based 
on probability of isolation 
b. All samples should be collected in sterile poly- 
pro lene containers 
after allowing steady flow for two(2) minutes 
. 
c. Pota gY e water from faucets should be collected 
generate r from evaporative condensers, cooling 
d. Samples are processed within 30 hours 
The abili of legionellae to survive in aerosols 
towers, etc. indicates that sam@ing at any aerosol 
generating site should be considered. 
2. Air 
a. Methods 
1. The use of an air sampler such as a six-stage 
Andersen unit at a rate of 0.0283 cubic 
millimeters per minute for 10 minutes (ambient 
air) up to 24 minutes (&/water lines). In 
general, a selective media for air impact is 
not recommended but is necessary here to 
reduce background organisms. Examples of such 
media are listed below. 
2. A glass im inger containing 0.25% yeast extract 
set to co lf ect air at a rate of 0.0108 cubic 
millimeters per minute for 10 minutes may also 
be considered. The broth can be stained by 
direct fluorescence antibody procedures and 
lated on a selective media for examination of 
Pegionella-like organisms. 
F. Isolation from Environmental Sites 
F 
li 
I 
i 
I 
1 
1. A varie of isolation techniques have been used to 
select B or Legionellae from environmental 
sources by reducing the number of background 
organisms. 
a. Buffered charcoal-yeast extract (BCYE) agar 
b. BCYE supplemented with antibiotics 
c. BCYE containing cysteine and ferric yrophosphate 
e. Heat pretreatment of the water sample 
f. Any combination of the above 
containing a-ketoglutarate 
d. Acid pretreatment of the water samp P e 
2. Althou h useful for initial isolation, only a and c 
shod % be considered for subculturing, as some studies 
have shown even 24 hour cultures become sensitive to 
these procedures 
3. Incubation time requires 4-7 days 
Procedures involved in the identification of 
Legionellae include both colonial characterization 
and specific antigen-antibody responses. 
1. Colony Characterization 
G. Identification 
a. Colonies are presum tively identified on 
b. Their specific requirement for G steine is 
selective media by t R eir ground glass appear- 
used as a determinant i.e. will o 3 y see a 
ence 
colony on media containing a cysteine source 
2. Antigen-Antibody Reactions 
a. Based primarily on F. Lb., isolates are confirmed 
b. Other LegionelIae species and serogrouping within 
by direct fluorescent monoclonal antibody assays 
for L pneumoDhilia 
all species requires a olyclonal antibody not 
commercially availab P e 
di K erentiation within the genus 
3. Because of the unusual abundance of branched-chain 
fatty acids, a library of known Le ionellae species 
fatty acid profiles may serve as a % asis for the 
se aration from non-legionella organisms as well as 
H. Environmental Control 
C 
The detection of Le 'onellae does not necessarily mean 
infect is de endent u on concentrations of the bacteria 
can be employed to reduce the possibility of supporting 
its growth. 
it is also a reservoir 7 or the organism. The ability to 
usually in t f: e form o P aerosols. Regardless, strategies 
1. Material/Design 
a. Dead legs in pi ing or any area of stasis will 
b. Some investi ators have found rubber gaskets in 
legionellae even after chlorination procedures 
because of the inability to reach these areas 
adequately. Replacement with inert materials 
discourage initial colonization in these areas 
increase the a E ility of the bacteria to grow 
shower hea 8 s, tap faucets and fittings to harbor 
2. Disinfection 
a. Because legionellae has shown a symbiotic 
existence with other organisms standard methods 
such as chlorination to reduce these organisms 
will also affect owth of the bacteria 
b. Ultraviolet(UV. !tlight is effective in removing 
legionellae from water sources and would be of 
greatest use in areas of low flow or stasis 
c. Because low hot water temperatures (38-46C) favor 
colonization of legionellae elevation to 70C will 
eliminate most if not all activity. Even at a 
temperature of 60-63C the electron transport system 
of the organism is compromised 
1 
c 
1 
li' 
1 
3.6.2 AIDS 
Testing of the HIV (AIDS) Virus in Hygiene Loop Studies 
Routine monitoring for the AIDS virus from the various ECLSS sources 
A. The virus is transmissible through very limited means 
1. Sexual intercourse with an infected person 
2. Blood contamination including transfusion and the 
sharing of needles, razors, etc. by drug users 
3. Passage from an infected mother to her fetus or 
through breastmilk 
is not recommended for the following reasons: 
B. The virus is infectious in only certain body fluids 
1. Blood 
2. Semen and vaginal secretions 
3. Breast milk 
C. The virus is environmentally unstable 
D. There is no evidence supporting the transmission of 
AIDS through any of the following routes: 
2. Sneezing 
3. Sweat exposure 
4. Saliva exposure 
5. Teardrop exposure 
6. Urine exposure 
1. coughing 
E. Studies of transmission of the virus to close but non- 
sexual contacts of AIDS patients living in the same 
household and sharing household items, facilities and 
washing items continue to support the absence of 
transmssion of the virus in this setting 
F. The virus is extremely sensitive to commonly used 
disinfectants including household bleach at a 1:lO 
dilution, alcohol, hydrogen peroxide, paraformaldehyde 
and heat (56C for l0min.) 
G. The virus has only been recovered from blood or serum 
and commercial test kits are designed to look for 
antibody to the virus in these fluids. No other sources 
have been recognized by the Center for Disease Control 
(CDC) as viable recovery sites 
3.7 Determine what arameters should be determined on a real-time, 
near real-time and delaye B time basis in order to drink the potable water 
or to use the hygiene water. 
Table 3-9 illustrates the analysis frequency possible for water 
uality verification. These are optimum fre uencies possible and are 
Iirectly related to laborato equipment avai 1 able, number of samples 
collected and number of qualified 7 aboratory personnel available. 
little information toward verifying water quality (due to f ow sensitivity 
3.8 Explain what value results obtained from real time monitoring 
Results obtained from real time (on line) monitorin will provide 
and limited parameters currently available). It will, however, be useful 
in the operation of the reclamation system and identification of upset 
conditions. 
will provide in determining whether the water is usable. 
3.9 Development and justify comprehensive air/water quality 
requirements for recycled air and water. 
Recommendations concerning air/water quality requirements were made 
and a delineation of specific requirements were outlined by three general 
categories. A current listing of these compounds are presented at the end 
of ths  section. 
3.7.1 Primary Requirements 
3.7.2 Secondary Requirements 
3.7.3 Mission Specific Requirements 
3.10 Determine the short and long term effects oftoxicants. 
Not fully addressed at this time. 
Table 3-1 
WATER QUALITY REQUIREMENTS 
PHYSICAL PARAMETERS 
TOTAL SOLIDS ( q / l )  100 
TASTE & ODOR (TTN/TON) 3 
TURBIDITY (NTU) 1 
COLOR, TRUE (Pt /Co uni ts)  15 
PARTICULATES (max s i  ze -m i  cron s ) 40 
DISSOLVED GAS (free @ 35OF) None 
FREE GAS (@ STP) None 
PH 6.0-8.0 
INORGANIC CONSTITUENTS (mg/l ) 
AMMONIA 
ARSENIC 
BARIUM 
CADMIUM 
CALCIUM 
CHLORIDE 
CHROMIUM 
COPPER 
IODINE (TOTAL) 
I RON 
LEAD 
MAGNESIUM 
MANGANESE 
MERCURY 
NICKEL 
POTASSIUM 
SEL EN I UM 
SILVER 
SU L FAT E 
SULFIDE 
ZINC 
NITRATE (N03-N) 
BACTERICIDE (mg/l) 
RESIDUAL IODINE (minimum) 
RESIDUAL IODINE (maximum) 
0.5 
0.01 
1 .o 
0.01 
30 
250 
0.05 
1 .o 
15 
0.3 
0.05 
50 
0.05 
0.002 
0.05 
' 10 
340 
0.01 
0.05 
250 
0.05 
5.0 
0.5 
4.0 
5 0 0  
15 
3 
40 
5.0-8.0 
1 
TBD 
TBD 
0.5 
0.01 
1.0 
0.01 
30 
250 
0.05 
1.0 
1 5  
0 . 3  
0.05 
50 
0.05 
0.002 
0.05 
10 
340 
0.01 
0.05 
250 
0.05 
5.0 
0 .5  
6.0 
~~ -~ 
WATER QUALITY REQUIRMENTS (continued) 
QUALITY PARAMETERS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
AESTHETICS (mg/l ) 
CATIONS 
AN IONS 
c02 
MICROBIAL 
BACTERIA (CFU/lOOml) 
TOTAL COUNT 
ANAEROBES 
AEROBES 
GRAM NEGATIVE 
GRAM POSITIVE 
ENTERIC 
E-COLI 
VIRUS ( PFU/ 1 OOml ) 
YEAST &,MOLD (CFU/lOOml) 
RADIOACTIVE CONSTITUENTS (pCi/l ) 
ORGANIC PARAMETERS (ug/l ) 
TOTAL ACIDS 
CYANIDE 
HALOGENATED HYDROCARBONS 
PHENOLS 
TOC (Less Non-Toxicants) 
TOTAL ALCOHOLS 
TOTAL ORGANIC CARBON (TOC) 
ORGANIC CONSTITUENTS (mg/l ) 
SPECIFIC TOXICANTS 
Note 1: The maximum contaminant 
30 
30 
15 
1 
1 
1 
1 
1 
1 
1 
1 
1 
Note 1 
500 
200 
10 
1 
100 
500 
500 
TBD 
1 
1 
TBD 
TBD 
TBD 
TBD 
1 
1,000 
TBD 
10,oco 
TBD 
leve ls  f o r  rad ioac t i ve  mater ia l  i n  
potable and personal hygiene water sha l l  conform t o  Nuclear Regulatory 
Commission (NRC) regu la t ions  (10CFR20, e t  al.)  f o r  con t ro l  o f  dose t o  
the  p u b l i c  from the  extant  1200t man-made radionucl ides.  These maxi- 
mum contaminant l e v e l s  are l i s t e d  i n  the Federal Register, Vol. 51, 
No. 6, 1986, Appendix B, as Table 2 (Reference Level Concentrations) 
Column 2 (Water). 
1 
I 
I 
I 
Table 3-2 
Compound 
VOLA1 I L E S  
S P E C I F I C  T O X I C A N T S  
P R I M A R Y  R E Q U I R E M E N T S  
S o u r c e  A m t  
d e t e c t e d  
* A c e t y l  b e n z e n e  1 
3 
A c r o l e i n  
A c r y l o n i t r i l e  
B e n z e n e  
A l k y l b e n z e n c  4 
B r o m o c h l o r o m c t h a n e  1 
B r o m o c h l o r o p r o p a n e  1 
B r o m o f o r m  
B r o m o m e t h a n c  1 
d i b r o m o m e t h a n e  3 
B r o m o d i c h l o r o m e t h a n e  
C a r b o n t e t r a c h l o r i d e  
C h l o r o b e n z e n e  3 
C h l o r o d i b r o m o m e t h a n e  
C h l o r o e t h a n c  
2 - c h l o r o c t h y l  v i n y l  e t h e r  
C h l o r o f o r m  4 
3 
C h l o r o m e t h a n e  1 
D i b r o m o c h l o r o m e t h a n e  
D i c h l o r o b u t a n c  1 
1 , l - d i c h l o r o e t h a n c  
1 , 2 - d i c h l o r o c t h r n c  
1 , l - d i c h l o r o c t h y l c n e  
t r a n s  1 , 2 - d i c h l o r o e t h y l e n c  
D i c h l o r o f l u o r o m e t h a n e  1 
1 , 2 - d i c h l o r o p r o p a n e  
1 , 3 - d i c h l o r o p r o p e n e  1 
1 , 2 - d i c h l o r o p r o p y l e n c  
D i m e t h y l b e n z c n e -  
m e t h a n a m i n e  1 
e t h y l  b e n z e n e  
m e t h y l  b r o m i d e  
m e t h y l  c h l o r i d e  
m e t h y l e n e  c h l o r i d e  8 
p r o p a - d i - e n e  c h l o r i d e  4 
1 , 1 , 2 , 2 - t e t r a c h l o r o e t h a n c  
t e t r a c h l o r o e t h y l e n e  
t o  1 u e n c  
1 , 2 - t r a n s - d i c h l o r o e t h y l e n e  
l , l , l - t r i c h l o r o e t h a n c  
t r i c h l o r o e t h y l e n e  
t r i c h l o r o f l u o r o m e t h a n e  1 
v i n y l  c h l o r i d e  
16 ( 2 0 p p b  e s t  a m t )  
3 0  
5 0  
5 0 0  
5 0 0  
100 
1 0  
5 
10 
4 
1 0 0  
5 0 0  
5 0  
100 
2 3 0  
2 0 0  
3 0  
5 0  
ORIGINAL PAGE IS 
OF POOR QUALITY 
PRIMARY R E P U I R E U E N T S  ( C O N T . )  
C o m p o u n d  S o u r c e  Ant 
d e t e c t e d  
A C I D  C O M P O U N D S  
* 
0 - c r e s o l  8 
p - c h l o r o - m - c r e s o l  
4 , 6 - d i n i t r o c r e s o l  
p h e n o l  8 
3 
2 - c h l o r o p h e n o l  
d i c h l o r o p h e n o l  4 
2 , 4 - d i c h l o r o p h e n o l  
2,4,6-trichlorophenot 1 
4 
p e n t a c h l o r o p h e n o l  
4 - c h l o r o - 3 - m e t h y l p h e n o l  
2 , 4 - d i m e t h y l p h e n o l  
2 - n i t r o p h e n o l  4 
4 - n i t r o p h e n o l  
2'4-dinitrophenol 
2 - m e t h y l d i n i t r o p h e n o l  1 
m e t h y l p h e n o l  4 
2 - m e t h y l  phenol 1 
4 - m e t h y l  p henol 1 
c h l o r o m e t h y l p h e n o l  4 
phenol, 2,6-di 
phenol, 
p h e n o l  c m p d s  4 
p h e n o l  c m p d s  (6) 2 
- t - b u t y l - 4 - m e t h y l -  1 
4-(l,l-dimethylethyl)1 
p h e n o l  c m p d s  ( 8 )  6 
phenol,2,6-di 
- t - b u t y l - 4 - m e t h y l -  8 
p h e n o l  ( c a r b o l i c  acid) 4 
p h e n o l ,  c h l o r o -  adduct 4 
phenol, d i c h l o r o m e t h y l  4 
phenol, t - butyl 4 
160 
1 5 0  
3 
55 
2 0 0  
25 
3 0  
2 6 5  
4 0  
1000 
6 5 0  
10 
16 ( 2 0 p p b  est a m t )  
13 
2,200 
600 
2 7 5  
150 
4 6 0  
1 0 0  
100 
150 
I 
c 
E 
1 
m 
4 
I 
I 
II 
I 
I 
s 
I 
C 
Compound 
EASE/NEUTRALS 
a c e n a p h t h e n e  
a c e n a p h t h y l e n e  
a n t h r a c e n e  
b e n t  i d i  n e  
b e n z o - a - a n t h r a c e n e  
P R I M A R Y  R E Q U I R E M E N T S  ( C O N T . )  
S o u r c e  A m t  D e t .  
1 
1 b e n z o - a - p y r e n e  
b e n z o - b - f l u o r a n t h e n e  
3 , 4 - b e n z o f l u o r a n t h e n e  
b e n z o ( g , h , i ) p e r y l e n e  
b e n z o ( k ) f l u o r a n t h e n e  1 
b i s ( 2 - c h l o r o  e t h o x y ) m e t h a n e  
b i s ( 2 - c h l o r o e t h y 1 ) e t h e r  
b i s ( 2 - c h l o r o i s o p r o p y 1 ) e t h e r  
4 - b r o m o p h e n y l  p h e n y l  e t h e r  
b u t y l b e n r y l  p h t h a l a t e  
2 - c h l o r o  n a p h t h a l e n e  
4 - c h l o r o p h e n y l  p h e n y l  e t h e r  
c h r y s c n e  
d i b e n z o ( a , h ) a n t h r a c e n e  
1 , 2 - d i c h l o r o b e n z e n e  
1 , 3 - d i c h l o r o b e n z e n e  
1 . 6 - d i c h 1 o r o b e n z e n e  
3 , 3 * - d i c h l o r o b e n z i d i n d  
d i e t h y l  p h t h a l a t e  
d i m e t h y l  p h t h a l a t e  
d i - n - b u t y l  p h t h a l a t e  
2 , 4 - d i n i t r o  t o l u e n e  
2 , b - d i n i t r o  t o l u e n e  
d i - n - o c t y l  p h t h a l a t e  
1 
1 , 2 - d i p h e n y l h y d r a z i n e  ( a s  a z o b e n z e n e )  
f l o u r a n t h e n e  
f L u o r e n e  
h e x a c h l o r o b e n z e n e  
h e x a c h l o r o b u t a d i e n e  
h e x a c h l o r o c y c l o p e n t a d i e n e  
h e x a c h l o r o e t h a n e  
i n d e n o ( l , 2 , 3 - o d ) p y r e n e  
i s o p h o r o n e  
* 2 - m e t h y l  n a p h t h a l e n e  
n a p h t h a l e n e  
n i t r o b e n z e n e  
N - n i t r o s o d i m e t h y l a m i n e  
1 
1 
1 0 0  
1 0 0  
4 0  
1 0 0  
200 
240 
9 
4 0  
1 0 0  
N - n i t r o s o d i - n - p r o p y l a m i n e  
N - n i t r o s o d i p h e n y l a m i n e  
p h e n a n t h r e n e  
ORIGINAL PAGE IS 
Of POOR QUALITY 
Compound 
P R I M A R Y  R E Q U I R E M E N T S  ( C O N T . )  
S o u r c e  A m t  D e t .  
B A S E / N E U T R A L S  ( C O N T . )  
p h t h a l a t e ,  d i e t h y l  p e n t y l -  1 49  
p h t h a l a t e  e s t e r s  ( 2 )  6 3 5 0  
p h t h a l a t e  e s t e r s  1 1 4 0 - 1 5 , 0 0 0  
p h t h a l a t e  e s t e r  cmpds ( 4 )  3 75 
p h t h a l a t e  e s t e r  cmpds ( 3 )  8 20 
p h t h a l a t e ,  b i s ( 2 - e t h y l  h e x y l ) -  8 103 
p h t h a l a t e ,  b i s ( 2 - e t h y l  h e x y l ) -  1 4600  
p y r e n e  
l 1 2 , 4 - t r i c h l o r o b e n z e n e  
2 , 3 , 7 , 8 - t e t r a c h t o r o d i b e n t o - p - d i o x i n  
P E S T I C I D E  COMPOUNDS 
A l d r i n  
a l p h a - B H C  
b e t  a - B H C  
gamma - B H C  
d e l  t a -BHC 
c h l o r o d a n e  
4 4' - D D D  
4 ,4 ' -DDE 
4 ,4 ' -DDT 
d i e l d r i n  
e n d o s u l f a n  I 
e n d o s u l f a n  1 1  
e n d o s u l f a n  s u l f a t e  
e n d r i n  
e n d r i n  a l d e h y d e  
h e p t a c h l o r  
h e p t a c h l o r e p o x i d e  
t o x a p h e n e  
P C B -  1 0 1 6  
PCB-1221  
P C B -  1232  
PCB-1242 
PCB-1248  
PCB-1254 
PCB-1260  
Inorganics 
Arsenic 
Barium 
Cadmium 
Chromium 
Lead 
Mercury 
Nitrate 
Selenium 
Silver 
Fluoride 
TABLE 3-3 
STATE OF ALABAMA 
DRINKING WATER STANDARDS 
Primary Standards 
Organics 
Endrin 
Lindane 
Methoxy 
Toxaphene 
2,4 D 
2,4,5,TP Silvex 
Trihalomethanes 
Volatile Organic Carbons 
Benzene 
1,4 dichlorobenzene 
Carbontetrachloride 
1,2 dichloroethane 
1,l dichloroethylene 
Trichloroethylene 
Vinyl chloride 
1,1,1 trichlorethene 
Secondary Standards 
Chloride 
Color 
Copper 
Iron 
Manganese 
Sulfate 
Total Dissolved Solids 
Zinc 
.05 mg/l 
1.0 mg/l 
0.01 mg/l 
0.05 mg/l 
0.05 mg/l 
0.002 mg/1 
10.0 mg/l 
0.01 mg/l 
0.05 mg/l 
4.0 mg/l 
.0002 mg/l 
.004 mg/l 
. 005  mg/l 
0.01 mg/l 
0.1 mg/l 
0.1 mg/ 1 
0.1 mg/ 1 
250 mg/l 
0.3 mg/l 
0.5 mg/l 
250 mg/1 
500 mg/l 
5.0 mg/l 
15 NTU 
1 mg/l 
TABLE 3-4 
RECOMMENDATIONS FOR MONITORING 
PHYSICAL 
CONDUCTIVITY 
COLOR 
TURBIDITY 
PH 
INORGANIC 
Non-Metals 
Ammonia 
Chloride 
Bromide 
Iodide 
Nitrate 
Phosphate 
Sulfate 
Metals 
Arsenic 
Barium 
Cadmium 
Chromium 
Copper 
Iron 
Lead 
Manganese 
Mercury 
Selenium 
Silver 
Zinc 
ORGANICS 
CYANIDE 
TOC 
TOX 
Total Toxic Organics (TTO) 
MICROBIOLOGICAL 
TOTAL BACTERIA 
TOTAL COLIFORMS 
HETEROTROPHS 
NON-SAPROPHYTIC 
TABLE 3-5 
METHODS AND INSTRUMENTATION FOR WATER QUALITY VERIFICATION 
PARAMETER METHOD INSTRUMENTATION 
PHYSICAL 
CONDUCTIVITY 
COLOR 
PH 
TURBIDITY 
INORGANIC 
Non-Metals 
Ammonia 
Chloride 
Bromide 
Iodide 
Nitrate 
Nitrogen, Total 
Phosphate 
Sulfate 
Metals 
Arsenic 
Barium 
Cadmium 
Chromium 
Copper 
Iron 
Lead 
Magnesium 
Manganese 
Mercury 
Nickel 
Potassium 
Selenium 
Silver 
Zinc 
ORGANICS 
EPA 120.1 
EPA 110.3 
EPA 150 
EPA 180 
EPA 350.2 
EPA 300.0 
EPA 300.0 
EPA 300.0 
EPA 300.0 
EPA 351.3 
EPA 300.0 
EPA 300.0 
EPA 206.3 
EPA 200.7 
EPA 213.2 
EPA 200.7 
EPA 200.7 
EPA 200.7 
EPA 239.2 
EPA 200.7 
EPA 200.7 
EPA 245.1 
EPA 249.2 
EPA 258.1 
EPA 270.3 
EPA 272.2 
EPA 200.7 
Cyanide EPA 335.2 
Halogenated Hydrocarbon EPA 612 
Organic Acids 
Organic Alcohols 
Pesticides EPA 608 
Phenols EPA 6.04 
TOC EPA 415.2 
Total Toxic Organics EPA 624, 625 
Cond. Meter 
w-VIS 
pH Meter 
Nephelometer 
w-VIS 
Ion Chromatograph 
Ion Chromatograph 
Ion Chromatograph 
Ion Chromatograph 
w-VIS 
Ion Chromatograph 
Ion Chromatograph 
AAH 
ICP 
AAG 
ICP 
ICP 
ICP 
AAG 
ICP 
ICP 
Hg Analyzer 
AAG 
AAF 
AAH 
AAG 
ICP 
w-VIS 
GC/ECD 
HPLC 
HPLC 
GC/ECD 
GC/FID 
TOC Analyzer 
GC/MS 
TABLE 3-6 
MICROBIOLOGICAL REQUIREMENTS 
Drinking Water 
State of Alabama 
Total Coliforms 
Fecal Coliforms 
Recreational Waters 
American Public Health Association 
Total Plate Count 
Turbidity 
<4 CFU/lOO ML 
<1 CFU/100 ML 
<lo0 CFU/ML 
1 NTU 
8 
I 
TABLE 3-7 
RECOMMENDATIONS FOR MICROBIOLOGICAL MONITORING 
BACTERIA 
TOTAL BACTERIA 
TOTAL COLIFORMS 
HETEROTROPHS 
NON-SAPROPHYTIC 
LEGIONELLAE 
FUNGI AND YEAST 
VIRUSES 
To Be Determined 
TABLE 3-8 
METHODS FOR ENUMERATION 
VIABLE PLATE COUNTS 18-120 HOURS 
DIRECT MICROSCOPIC COUNTS 4 HOURS 
FLUORESCENCE MICROSCOPY 6 HOURS 
SCANNING ELECTRON MICROSCOPY 8-12 HOURS 
PARTICLE C3UNTS 4 HOURS 
RECOMMENDATION: 
FLUORESCENCE MICROSCOPY 
REQUIREMENTS: 
APPROXIMATELY $4,000 UPGRADE OF PHASE MICROSCOPE AND 4 MAN- 
MONTHS LABOR 
TABLE 3-9 
SAMPLING FREQUENCY REQUIRED FOR WATER QUALITY VERIFICATION 
PARAMETERS 
PHYSICAL 
Conductivity 
Color 
PH 
Turbidity 
INORGANIC 
Non-Metals 
Ammonia 
Chloride 
Bromide 
Iodide 
Nitrate 
Phosphate 
Sulfate 
Metals 
Arsenic 
Barium 
Cadmium 
Chromium 
Copper 
Iron 
Lead 
Manganese 
Mercury 
Selenium 
Silver 
Zinc 
ORGANICS 
REAL-TIME 
Cyanide 
TOC 
TOX 
Total Toxic Organics (TTO) 
BACTERIA 
Total Bacteria 
Total Coliforms 
Heterotrophs 
Non-Saprophytic 
Legionellae 
X 
X 
X 
X 
NEAR REAL DELAYED 
TIME (24 HRS) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
J?UNGI AND YEAST 
Compound 
V O L A T  I LES 
S P E C I F I C  T O X I C A N T S  
P R I M A R Y  R E Q U I R E M E N T S  
S o u r c e  A m t  
d e t e c t e d  
1 A c e t y l  b e n z e n e  
A c r o l e i n  
A c r y l o n i t r i l e  
B e n z e n e  
B r o m o c h l o r o m e t h a n e  1 
B r o m o c h l o r o p r o p a n e  1 
B r o n o f  o rm 
Bromomethane  1 
B r o m o d i c h l o r o m e t h a n e  
C a r b o n t e t r a c h l o r i d e  
C h l o r o b e n z e n e  
C h l o r o d i b r o m o m e t h a n e  
C h l o r o e t h a n e  
2 - c h l o r o e t h y l  v i n y l  e t h e r  
C h l o r o f o r m  
C h l o r o m e t h a n e  1 
D i b r o m o c h l o r o m e t h a n e  
D i c h l o r o b u t a n e  1 
1 , l - d i c h l o r o e t h a n e  
1 , 2 - d i c h l o r o e t h a n e  
1 , l - d i c h l o r o e t h y l e n e  
t r a n s  1 8 2 - d i c h l o r o e t h y l e n e  
D i c h l o r o f l u o r o m e t h a n e  1 
1 , 2 - d i c h l o r o p r o p a n e  
1 , 2 - d i c h l o r o p r o p y l e n e  
D i m e t h y l b e n z e n e -  
e t h y l  b e n z e n e  
m e t h y l  b r o m i d e  
m e t h y l  c h l o r i d e  
m e t h y l e n e  c h l o r i d e  
l 8 1 , 2 , 2 - t e t r a c h l o r o e t h a n e  
t e t r a c h l o r o e t h y l e n e  
t o l u e n e  
l 8 2 - t r e n s - d i c h l o r o e t h y 1 e n e  
l , l , l - t r i c h l o r o e t h a n e  
t r i c h l o r o e t h y l e n e  
t r i c h l o r o f l u o r o m e t h a n e  1 
v i n y l  c h l o r i d e  
l 8 3 - d i c h 1 o r o p r o p e n e  1 
m e t h a n a m i n e  1 
16  
5 0 0  
5 0 0  
100 
100 
5 0 0  
5 0  
1 0 0  
230 
5 0  
Compound 
P R I M A R Y  R E Q U I R E M E N T S  ( C O N T . )  
S o u r c e  A m t  
d e t e c t e d  
B 
I 
8 
A C I D  C O U P O U N D S  
p - c h l o r o - m - c r e s o l  
4 , 6 - d i n i t r o c r e s o l  
* 
* 
p h e n o l  
2 - c h l o r o p h e n o l  
2 , 4 - d i c h l o r o p h e n o l  
2 , 4 , 6 - t r i c h l o r o p h e n o l  1 
p e n t a c h l o r o p h e n o l  
4 - c h l o r o - 3 - m e t h y l p h e n o l  
2 , 4 - d i m e t h y l p h e n o l  
2 - n i t r o p h e n o l  
4 - n i t r o p h e n o l  
2 , 4 - d i n i t r o p h e n o t  
2 - m e t h y l d i n i t r o p h e n o l  1 
2 - m e t h y l  p h e n o l  1 
4 - m e t h y l  p h e n o l  1 
p h e n o l ,  2 , 6 - d i  
p h e n o l  , 
- t - b u t y l - 4 - m e t h y l -  1 
4 - ( l 8 l - d i m e t h y l e t h y 1 ) l  
p h e n o l  cmpds ( 8 )  6 
p h e n o 1 8 2 , 6 - d i  
p h e n o l  cmpds 4 
p h e n o l  cmpds ( 6 )  2 
- t - b u t y l - 4 - m e t h y l -  8 
, 
200 
4 0  
650 
1 0  
16  
13 
2,200 
600 
275 
150 
p h t h a l a t e  
p h t h a l a t e  
p h t h a l a t e  
* p h t h a l a t e  
p y r e n e  
1 , 2 , 4 - t r i c h  
2 ,3 ,7 ,8 -  t e t  
P R I M A R Y  R E Q U I R E M E N T S  ( C O N T . )  
S o u r c e  A m t  O e t .  
1 100  
Compound 
a c e n a p h t h e n e  
a c e n a p h t h y l e n e  
a n t h r a c e n e  
b e n z i d i n e  
b e n z o - a - a n t h r a c e n e  
b e n z o - a - p y r e n e  
b e n z o - b - f l u o r a n t h e n e  
3 . 4 - b e n z o f l u o r a n t h e n e  
b e n z o ( g , h , i ) p e r y l e n e  
b e n z o ( k ) f l u o r s n t h e n e  1 
b i s ( 2 - c h l o r o  e t h o x y l m e t h a n e  
bis(2-chloroethy1)ether- 
b i s ( 2 - c h l o r o i s o p r o p y 1 ) e t h e r  
b i s ( 2 - e t h y l h e x y 1 ) p h t h a l a t e  8 
4 - b r o m o p h e n y l  p h e n y l  e t h e r  
b u t y l b e n z y l  p h t h a l a t e  
2 - c h l o r o  n a p h t h a l e n e  
4 - c h l o r o p h e n y l  p h e n y l  e t h e r  
d i b e n z o ( a , h ) a n t h r a c e n e  
1 , 2 - d i c h l o r o b e n z e n e  
1 , 3 - d i c h l o r o b e n z e n e  
1 , 4 - d i c h l o r o b e n z e n e  
3 , 3 ' - d i c h l o r o b e n z i d i n e  
d i e t h y l  p h t h a l a t e  
d i m e t h y l  p h t h a l a t e  
d i - n - b u t y l  p h t h a l a t e  
2 , 4 - d i n i t r o  t o l u e n e  
2 , 6 - d i n i t r o  t o l u e n e  
d i - n - o c t y l  p h t h a l a t e  
1 , 2 - d i p h e n y l h y d r a z i n e  ( a s  a z o b e n z e n e )  
f l o u r a n t h e n e  
f l u o r e n e  
h e x a c h l o r o b e n z e n e  
h e x a c h l o r o b u t a d i e n e  
h e x a c h l o r o c y c l o p e n t a d i e n e  
h e x a c h l o r o e t h a n e  
i n d e n o ( l , 2 , 3 - o d ) p y r e n e  
i s o p h o r o n e  
* 2 - m e t h y l  n a p h t h a l e n e  
n a p h t h a l e n e  
n i t r o b e n z e n e  
N - n i t r o s o d i m e t h y l a m i n e  
N - n i t r o s o d i - n - p r o p y l a m i n e  
N - n i t r o s o d i p h e n y l a m i n e  
p h e n a n t h r e n e  
c h  r y s e n e  1 
1 
1 
1 
100  
4 0  
103  
100  
4 0  
100  
d i e t h y l  p e n t y l -  1 49  
e s t e r s  ( 2 )  6 3 5 0  
e s t e r s  1 1 4 0 - 1 5 , 0 0 0  
b i s ( 2 - e t h y l  h e x y l ) -  8 103  
o r o b e n z e n e  
a c h l o r o d i b e n z o - p - d i o x i n  
1 
1 
8 
P R I M A R Y  R E Q U I R E M E N T S  ( C O N T . )  
P E S T I C I D E  C O M P O U N D S  
A l d r i n  
a l p h a - B H C  
b e t  a - B H C  
gamma - B H C  
d e  1 t a - B H C  
c h l o r o d a n e  
4 , 4 ' - D D D  
4 , 4 ' - D D E  
4 , 4 '  - D D T  
d i e l d r i n  
e n d o s u l f a n  I 
e n d o s u l f a n  1 1  
e n d o s u l f a n  s u l f a t e  
e n d r i n  
e n d r i n  a l d e h y d e  
h e p t a c h l o r  
h e p t a c h l o r e p o x i d e  
t o x a p h e n e  
P C B - 1 0 1 6  
P C B - 1 2 2 1  
P C B - 1 2 3 2  
P C B - 1 2 4 2  
P C B -  1 2 4 8  
P C B -  1 2 5 4  
P C B -  1 2 6 0  
S E C O N D A R Y  R E Q U I R E M E N T S  
Compound S o u r c e  A m t .  T o x i c i t y  
A c e t i c  A c i d  5 3 0 0  o r 1  hmn TDLo 1 4 7 0  u g  G I T  
i h l  hmn TDLo 816ppm/3min  
a c e t i c  a c i d ,  p h e n y l  4 4 0 0  
a c e t a t e ,  e t h a n o l  e t h o x y  1 180  
a c e t a t e ,  v i n y l  1 5 0  
a c e t o n e  3 3 3 0 0  o r 1  hmn T C L o  500ppm Eye  
a c e t o n e  cmpds ( 2 )  4 2 5 0 p p b  
a c r y l a t e ,  3 - m e t h o x y - b u t y l  3 130ppm 
d i a c e t o n e  a l c o h o l  1 19PPb 
a z e p i n - 2 - o n e ,  h e x a h y d r o  1 SL1 73PPb 
a n i l i n e  1 2OPPb 
1 SL3 4.3ppm 
2 - n i t r o a n i l i n e  1 2OOppb 
3 - n i t r o a n i l i n e  1 2OOppb 
4 - n i t r o a n i l i n e  1 2OOppb 
a d i p a t e ,  t e t r a m e t h y l e n e  1 6PPb 
amide ,  b u t y l  b e n z e n e s u l f o n  1 6PPb 
a m i d e ,  N , n - d i - n - b u t y l f o r m -  1 60PPb 
amide ,  N - m e t h y l - N - e t h y l  f o r m - 1  1 , 1 0 3 p p b  
4 - c h l o r o a n i l i n e  1 1 OOppb 
amide ,  N , n - d i m e t h y l  f o r m -  1 5 4 1 p p b  
a m i d e s  ( 4 )  1 3 1 9 0 p p b  
a m i d e s  ( 2 )  2 4OOppb 
A d i p i c  A c i d  o r 1  r a t  LDLo 36001119 
amine ,  d i m e t h y l  o r 1  r a t  L D S 0  6981119 
amine ,  N , n - d i m e t h y l  b e n z y l -  1 8OPPb 
amine ,  d i - n - b u t y l  1 74PPb 
a m i n e s  (2) 1 2OOppb 
a l c o h o l  cmpds ( 2 )  3 5 0 0 0 p p b  
a l k e n e  ( C 2 9 H 5 8 )  3 1 OPPb 
B u t y r i c  A c i d  
b u t y r a t e s ,  3 - h y d r o x y  
- t r i m e t h y l p e n t y l i s o  1 
1 - b u t a n a m i n e ,  n - b u t y l -  1 
b u t a n o a t e , 2  m e t h o x y m c t h y l - 2 -  1 
2 - b u t a n o n e  1 
b u t a n o n e ,  3 - m e t h y l - 2 -  1 
b e n z o i c  a c i d  1 
3 
b e n z o i c  a c i d  cmpds ( 2 )  4 
6 
b e n z a l d e h y d e  3 
b e n z a l d e h y d e  cmpds ( 3 )  4 
b e n z y l  a l c o h o l  1 
b e n z i s o x a z o l e  1 
o r 1  r a t  L D S 0  29401119 
300ppb 
1 8 0 p p b  
9 0 0 p p b  
5 0 0 p p b  o r 1  r a t  L D S 0  3040mg 
8 4 8 p p b  
3 0 0 0 p p b  
1 5 0 p p b  
lOOOppb o r 1  r a t  L O g o  1300mg 
1 5 0 p p b  
4 7 0 0 p p b  o r 1  r a t  L O s 0  1330mg 
1 OOppb 
55PPb 
6OPPb 
S E C O N D A R Y  REPUIREWENTS ( C O N T . )  
Compound S o u r c e  A m t .  T o x i c i t y  
c a p r y l i c  a c i d  1 
c y a n u r a t e ,  t r i a l l y l i s o -  1 
c a r b o x y l i c  a c i d s  4 
c a r b o x y l i c  a c i d s  2 
c a r b o x y l i c  a c i d s  3 
c a r b o x y l i c  a c i d s  ( 5 )  7 
c a r b o x y l i c  a c i d s  ( 5 )  1 
u n k n o u n  c a r b o x y l i c  a c i d s  1 
c a p r o l a c t a m  1 
c a r b o n  d i s u l f i d e  1 
c a r b o x y l i c  a c i d  cmpds ( 4 )  6 
C a p r - o i c  A c i d  
2 7 3 p p b  i v n  mus L D S O  600mg 
12PPb 
40, lOOppb 
92,21  Oppb 
8 1 , 5 0 0 p p b  
3 ,500ppb 
52 ,000ppb 
43, OOOppb 
2 ,633ppb 
15,  OOOppb 
1 4 -  7 2 2 p p b  
o r 1  r a t  LDLo 3000mg 
D e c a n a  1 o r 1  r a t  L D S O  37301719 
D o d e c y l  a l c o h o l  i p r  r a t  LOso 800mg 
d e c a n  cmpds ( 2 )  4 2 8 0 p p b  
d o d e c a n o l  3 1 OOppb 
d i b e n z o f u r a n  1 2 0  
d i m e t h y l - b e n z e n e  m e t h a n o l  1 16PPb 
d i o x a l a n e  cmpds 3 6 0 0 p p b  
e t h e r ,  e t h y l  p r o p y l  1 34PPb 
e t h e r ,  
e t h y l e n e  g l y c o l  m o n o b u t y l -  1 1 OOppb 
e t h e r ,  
p - c h l o r 6 p h e n y l  m e t h o x y i s o b u t y l  4 4 0 0 p p b  
e t h e r s ,  g l y c o l  ( 2 )  1 5 5 0 p p b  
3 9OOppb 
f u r f u r y l  a l c o h o l  5 200 o r 1  r a t  L D s 0  2751119 
H e p t a n o i c  A c i d  
4 - h e p t a n o n e  
h e p t a n o n e  cmpds ( 2 )  
h e x a n o l ,  2 - e t h y l - l -  
h e x a n o l ,  5 - m e t h y l - l -  
2 - h e x a n o n e  
c y c l o h e x a n o n e  
Hexanol 
o r 1  mus L D S 0  160mg 
6 1 OOppb 
4 60PPb 
orL r a t  L D s 0  7 2 0 m g  
6 1 OOppb 
1 1 5 0 p p b  
1 50PPb 
1 3 5 PPb 
i s o p h o r o n e  1 3PPb 
l a c t o n e  cmpds 3 1 3 0 p p b  
m o r p h o l i n e ,  4 - e t h y l  1 4 7 0 p p b  
m o r p h o l i n e ,  n - e t h y l  1 4 0 0 p p b  
n o n a n e d i o a t e ,  
n o n a n e d i o i c  a c i d  
b i s ( 2 - e t h y l  h e x y l ) -  
o c t a n o a t e ,  m e t h y l -  
1 
1 
3 
1 , lOOppb 
6PPb 
2OOppb 
I 
I 
1 
I 
1 
I 
I 
S E C O N D A R Y  R E Q U I R E M E N T S  (CONT.) 
Compound S o u r c e  A m t .  l o x  i c i t y  
p a l m i t i c  a c i d  7 10  i v n  mus L D S 0  57mg 
p e n t a n e ,  2 , 3 - d i m e t h y l -  1 5 0  
4 - m e t h y l - 2 - p e n t a n o n e  1 5 0  
2 - m e t h y l - 2 , 4 - p e n t a n e d i o l  1 410  
p e n t e n e ,  4 , 4 - d i m e t h y l - l -  1 100  
p h o s p h a t e ,  d i e t h y l  p e n t y l -  1 6 7  
p h o s p h a t e ,  t r i e t h y l -  1 12  
p h o s p h a t e ,  t c r t a m e t h y l p y r o -  1 2 
p h o s p h a t e ,  t e t r a m e t h y l p y r o -  2 100  
1 - p r o p e n e  1 100  
p e n t a n e ,  2 , Z 8 4 - t r i m e t h y l -  1 100  
p r o p i o n i c  a c i d  1 6 ,000 -17 ,222  o r 1  r a t  L D S 0  1510mg 
p r o p y l e n e  g l y c o l  1 3 0 0  
p y r r o l i d i n e ,  N - m e t h y l -  1 7 1  
p y r r o l i d o n e  1 1 0 0  
P y r r o l i d i n e  o r 1  r a t  L D S O  800mg 
s t y r e n e  
s a l i c y l i c  a c i d  
1 50  i h n  hmn TCLo 376ppm 
6 3 5 0 0 0 0  o r 1  r a t  L D S O  8911119 
t h i o p h e n e ,  
t e t r a h y d r o - 1 , l - d i o x i d e  1 15 
t h i o u r e a  1 3 0 0 - 5 0 0  
t h i o u r e a ,  t e t r a m e t h y l  1 35  
u r e a  
U n d e c a n o i c  A c i d  
n - u n d e c a n e  
1 *16 ,000  
4 2 0 0  
i v n  mus L D S O  140mg 
v a n i  1 l a n  6 200 o r 1  r a t  L D S O  1580mg 
Xy 1 eno  1 
x y l e n e s ,  t o t a l  
o r 1  mus L D S O  1070mg 
1 50  
4.0 Assist in determining the design specifications required as related 
to the Technical Demonstration Program 
This topic has not been addressed. 
5.0 Develop data base of all microorganisms recovered from previous 
This topic was not addressed. An outline is presented below 
subsystem testing 
indicating pertinent areas which must be defined. 
5.1 Biochemical Characterization of Unknowns 
5.2 Identification of Presumptive Organisms 
5.3 FAME profiling of isolates 
5.4 Establish data base of isolates with respect to source 
5.5 Identify isolates which potentially represent health 
r isks 
5.6 Characterize isolates based on susceptibly/resistance 
to antimicrobials 
6.0 Estimates of health risk of individual microbes to test subjects 
This topic was not addressed. The completion of 5.0 above must first 
be completed. 
7.0 Assist with setting limits for safety of test subjects 
This topic was addressed in 3.0 above. 
8.0 Health monitoring of test subjects 
8.1 Delineation of parameters to monitor well subjects 
This topic was addressed in 2.15 above. 
8.2 Guidelines for managing sick subjects 
This topic was addressed in 2.16 above. 
9.0 Assist in the preparation of test plans 
9.1 Microbiological 
This topic was in progress when funding ran out. 
9.2 Chemical 
This topic was not addressed. 
10.0 Assist in the development of a QA/QC program to assure the 
validity, accuracy and precision of the analyses 
This topic was not addressed but is related to both 9.1 and 9.2 above. 
I 
I 
I 
11.0 Assist in developing test plans required for future "man in 
the loop" testing 
This topic was not addressed. 
I 
I 
B 
I 
I 
APPENDIX F 
Supporting Documents 
NIH PHS HHS I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
PROTECTION 
OF 
HUMAN SUBJECTS 
CODE OF FEDERAL REGULATIONS 
45 CFR 46 
Revised as of March 8, 1983 
i 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
NATIONAL RESEARCH ACT 
PUBLIC LAW 934348 
JULY 12,1974 
INSTITUTIONAL REVIEW BOARDS; ETHICS GUIDANCE PROGRAM 
SEC. 212. (a) Part I of title I V  of the Public Health Service Act, as 
amended by section 103 of this Act, is amended by adding at  the end the 
following new section: 
" INSTITUTIONAL REVIEW BOARDS; ETHICS GUIDANCE PROGRAM 
"SEc. 474. (a) The Secretary shall by regulation require that each entity 
which applies for a grant or contract under this Act for any project or 
program which involves the conduct of biomedical or behavioral research 
involving human subjects submit in or with its application for such grant or 
contract assurances satisfactory to the Secretary that it has established (in 
accordance with regulations which the Secretary shall prescribe) a board (to 
be known as an 'Institutional Review Board') to review biomedical and 
behavioral research involving human subjects conducted at or sponsored by 
such entity in order to protect the rights of the human subjects of such 
research. 
"(b) The Secretary shall establish a program within the Department 
under which requests for clarification and guidance with respect to ethical 
issues raised in connection with biomedical or behavioral research involving 
human subjects are responded to promptly and appropriately. " 
(b) The Secretary of Health, Education, and Welfare shall within 240 
days of the date of the enactment of this Act promulgate such regulations as 
may be required to carry out section 474(a) of the Public Health Service 
Act. Such regulations shall apply with respect to applications for grants and 
contracts under such Act submitted after promulgation of such regulations. 
THE CODE OF FEDERAL REGULATIONS, 
45 CFR 46, IMPLEMENTS THESE AMENDMENTS 
TO THE PUBLIC HEALTH SERVICE ACT'. 
salus ubi rnulri consiliurii 
I 
CODE OF FEDERAL REGULATIONS 
TITLE 45 
PUBLIC WELFARE 
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
NATIONAL INSTITUTES OF HEALTH 
OFFICE FOR PROTECTION FROM RESEARCH RISKS 
PART 46-PROTECT'ION OF HUMAN SUBJECTS 
REVISED AS OF MARCH 8, 1983 
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PART 46-PROTECTION OF 
HUMAN 
SUBJECTS 
I' Subpart A-Basic HHS Policy for 
Protection of Human Research 
'Subjects 
46.101 
46.102 
46.103 
46. I 0 4  
46.105 
46.106 
46. IO7 
46.108 
46.109 1 46.1 IO 
I 
lo what do these regulations apply? 
Definitions. 
Assurances. 
Section reserved. 
Section reserved. 
Section reserved. 
IRB membership. 
IRB functions and operations. 
IRB review of research. 
Expedited review procedures for 
certain kinds of research involving no 
more than minimal risk. and for minor 
changes in  approved rerearch. 
Criteria for IRB approval of 
research. 
46. I I 1  
46. I12 Review by institution. 
46. I 13 
approval of research. 
46. I14 Cooperative research. 
46. I I 5  IRB records. 
46. I16 General requirements for informed 
46.117 Documentation c f  informed 
46. I I8 
P 
Suspension or termination of IRB 
consent. 
consent. 
Applications and proposals lacking 
definite plans for involvement of human 
subjects. 
46. I19 Research undertaken without the 
intention of involving human subjects. 
46.120 Evaluation and disposition of 
applications and proposals. 
46. I2 I 
30-day delay requirement. 
46.122 Use of federal funds. 
46.123 Early termination of research 
funding; evaluation of subsequent 
applications and proposals. 
Investigational new drug or device 
a 
46. I24 Conditions. 
Subpart B-Additional Protections I Pertaining to Research, 
I In Vitro Fertilization 
Development, and Related 
Activities Involving Fetuses, 
Pregnant Women, and Human 
46.201 Applicability I 46.202' Purpow. 
46.203 Definitions. 
46.204 Ethical Advisory Boards. 
46.205 Additional duties of the In'rtitutional 
Review Boards in  connection with 
activities involving fetuses, pregnant 
women. or human in vitro fertilization. 
46.206 General limitations. 
46.207 Activities directed toward pregnant 
46.208 Activities directed toward fetuses in  
46.209 Activities directed toward fetuses ex 
women 1S SUbJCClS. 
utero as subjects. 
utero. including nonviable fetuses. 8s 
subjects. 
fetal material. or the placenta. 
requirements. 
46.210 
46.21 I 
Activities involving the dead fetus. 
Modification or waiver of Specific 
Subpart C-Additional Protections 
Pertaining to Biomedical and 
Behavioral Research Involving 
Prisoners as Subjects 
Sec . 
46.301 Applicability. 
46.302 Purpose. 
46.303 Definitions. 
46.304 Composition of Institutional Review 
Boards where prisoners are involved. 
46.305 Additional duties of the Institutional 
Review Boards where prisoners are 
involved. 
prisoners. 
46.306 Permitted activities involving 
Subpart D-Additional Protections 
for Children Inrolred u Subjecta in 
Reaeuch 
sec. 
46.401 To what do thae regulations apply? 
46.402 Definitions. 
46.403 IRE du t ia  
46.404 Research not involving grater than 
46.405 Rcvuch  involving grater than 
mininul risk. 
m i n i d  risk but presenting the prospect 
of direct benefit to the individual subjects. 
minimal risk and no prospect of direct 
benefit to individual subjcsts, but likely to 
yield generalizable knowledge about the 
subject's diwrder or condition. 
46.407 R a u r c h  not otherwire approvable 
which praents UI opportunity to 
undentmd. prevent, or alleviate a serious 
problem affecting the health or welfare of 
children. 
parents or gurdiuu and for ament by 
children. 
46.406 Rcvuch  involving grater than 
46.408 Requinmrnts for pennirrion by 
46.m Wudr 
Authorlty: 5 U.S.C. 301; Sec. 474(8). 88 
Stat. 352 (42 U.S.C. 289/-3(a)). 
Subpart A-Basic HHS Policy for 
Protection of Human Research 
Subjects 
Source: 46 FR 8386. January 26. 1981.48 FR 
9269, March 4. 1983. 
0 46.101 
regulations apply? 
(a) Except as provided in 
paragraph (b) of this section, this 
subpart applies to all research 
involving human subjects conducted 
by the Department of Health and 
Human Services or funded in whole 
or in part by a Department grant, 
contract, cooperative agreement or 
fellowship. 
( 1 )  This includes research 
conducted by Department employees, 
except each Principal Operating 
Component head may adopt such 
nonsubstantive. procedural 
modifications as may be appropriate 
from an administrative standpoint. 
(2) I t  also includes research 
conducted or funded by the 
Department of Health and Human 
Services outside the United States, 
but in appropriate circumstances, the 
Secretary may, under paragraph (e) of 
this section waive the applicability of 
some or all of the requirements of 
these regulations for research of this 
type. 
(b) Research activities in which the 
only involvement of human subjects 
will be i n  one or more o f t  e 
following categories are p7i exempt rom 
these regulations unless the research 
is covered by other subparts of this 
part: 
( 1 )  Research conducted in 
established Qr commonly accepted 
educational settings. involving 
normal educational practices, such as 
( i )  researsh on regular and special 
education instructional strategies, or 
(i i)  research on the effectiveness of or 
the comparison among instructional 
techniques, curricula, or classroom 
management methods. 
( 2 )  Research involving the use of 
educational tests (cognitive, 
diagnostic, aptitude, achievement). if 
To what do these 
45 CFR 46 Page 5 
information taken from these sources 
is recorded in such a manner that 
subjects cannot be identified, directly 
or through identifiers linked to the 
subjects. 
(3) Research involving survey or 
interview procedures. except where 
all of the following conditions exist: 
(i) responses are recorded in such a 
manner that the human subjects can 
be identified, directly or through 
identifiers linked to the subjects, (ii) 
the subject's responses, if they 
became known outside the research, 
could reasonably place the subject at 
risk of criminal or civil liability or be 
damaging to the subject's financial 
standing or employability, and (iii) 
the research deals with sensitive 
aspects of the subject's own behavior, 
such as illegal conduct, drug use. 
sexual behavior. or use of alcohol. 
All research involving survey or 
interview procedures is exempt, 
without exception, when the 
respondents are elected or appointed 
public officials or candidates for 
public office. 
(4) Research involving the 
observation (including observation by 
participants) of public behavior, 
except where all of the following 
conditions exist: ( i )  observations are 
recorded in such a manner that the 
human subjects can be identified,, 
directly or through identifiers linked 
to the subjects, ( i i )  the observations 
recorded about the individual, if they 
became known outside the research, 
could reasonably place the subject at 
risk of criminal or civil liability or be 
damaging to the subject's financial 
standing or employability, and ( i i i )  
the research deals with sensitive 
aspects of the subject's own behavior 
such as illegal conduct, drug use. 
sexual behavior, or use of alcohol. 
( 5 )  Research involving the 
collection or study of existing data, 
documents, records, pathological 
specimens, or diagnostic specimens, 
if these sources are publicly available 
or if the information is recorded by 
the investigator in such a manner that 
subjects cannot be identified, directly 
or through identifiers linked to the 
subjects. 
statute (and except to the extent 
specified in paragraph (i)), research 
and demonstration projects which 
are conducted by or subject to the 
approval of the Department of 
Health and Human Services, and 
which are designed to study, 
evaluate, or otherwise examine: (i) 
programs under the: Social Security 
Act, or other public benefit or 
service programs; (ii) procedures for 
obtaining benefits or services under 
those programs; (iii) possible changes 
in or alternatives to those programs 
or procedures; or (iv) possible 
changes in methods or levels of 
payment for benefits or services 
under those programs. 
(c) The Secretary has final 
authority to determine whether a 
particular activity is covered by these 
regulations. 
(d) The Secretary may require that 
specific research activities or classes 
of research activities conducted or 
funded by the Department, but not 
otherwise covered by these 
regulations, comply with some or all 
of these regulations. 
(e) The Secretary may also waive 
applicability of these regulations to 
specific research activities or classes 
of research activities, otherwise 
covered by these regulations. Notices 
of these actions will be published in 
the Federal Regisrer as they occur. 
(0 No individual may receive 
Department funding for research 
covered by these regulations unless 
the individual is affiliated with or 
sponsored by an institution which 
assumes responsibility for the 
research under an assurance satisf ing 
individual makes other arrangements 
with the Department. 
regulations will in no way render 
inapplicable pertinent federal, state, 
or local laws or regulations. 
(6) Unless specifically required by 
the requirements of this part, or t K e 
(g) Compliance with these 
(h)  Each subpart of these 
regulations contains a separate 
section describing to what the subpart 
applies. Research which is covered 
by more than one subpart shall 
comply with all applicable subparts. 
(i) If, following review of 
proposed research activities that are 
exempt from these regulations under 
paragraph @)(a), the Secretary 
determines that a research or 
demonstration project presents a 
danger to the physical, mental, or 
emotional well-being of a participant 
or subject of the research or  
demonstration project, then federal 
funds may not be expended for such 
a project without the written, 
informed consent of each participant 
or  subject. 
4 46.102 Definitions. 
(a) "Secretary" means the 
Secrztary of Health and Human 
Services and any other officer or 
employee of the Department of 
Health and Human Services to whom 
authority has been delegated. 
(b) ' 'Department ' ' or ' 'HHS ' *  
means the Department of Health and 
Human Services. 
(c) "Institution" means any public 
or private entity or agency (including 
federal, state, and other agencies). 
representative" means an individual 
or judicial or other body authorized 
under applicable law to consent on 
behalf of a prospective subject to the 
subject's participation in the 
procedure(s) involved in the research. 
(e) "Research" means a 
systematic investigation designed to 
develop or contribute to generalizable 
knowledge. Activities which mfet 
this definition constitute "research" 
for purposes of these regulations, 
whether or not they are supported or 
funded under a program which is 
considered research for other 
purposes. For example, some 
"demonstration" and "service" 
programs may include research 
activities. 
(d) "Legally authorized 
Page 6 
(f) "Human subject" means a 
living individual about whom an 
investigator (whether professional or 
student) conducting research obtains 
(1) data through intervention or 
interaction with the individual, or (2) 
identifiable private information. 
"Intervention " includes both 
physical procedures by which data are 
gathered (for example, venipuncture) 
and manipulations of the subject or 
the subject's environment that are 
performed for research purposes. 
"Interaction" includes ~ 
communication or interpersonal 
contact between investigator and 
subject. "Private information " 
includes information about behavior 
that occurs in a context in which an 
individual can reasonably expect that 
no observation or recording is taking 
place, and information which has 
been provided for specific purposes 
I by an individual and which the 
individual can reasonably expect will 
not be made-public (for example. a 
medical record). Private information 
must be individually identifiable 
(i.e., the identity of the subject is or 
may readily be ascertained by the 
investigator or associated with the 
information) in order for obtaining 
the information to constitute research 
involving human SUbJeCtS. 
(g) "Minimal risk" means that the 
risks of harm anticipated in  the 
proposed research are not greater, 
considering probability and 
magnitude, than those ordinarily 
performance of routine physical or 
psychological examinations or tests. 
(h) "Certification" means the 
i
c 
I 
II 
8 
I 
P 
P o the Department in accordance with 
k 
E 
P n accordance with 8 46.101(b)). 
ncountered in daily life or during the 
fficial notification by the institution 
the requirements of this part that a 
esearch project or activity involving 
uman subjects has been reviewed 
eview Board (IRB) in accordance 
ith the approved assurance on file at 
HS. (Certification is required when 
partment and not otherwise exempt 
and apptoved by the Institutional 
,the research is funded by the 
45 CFR 46 
0 46.103 Assurances. 
research covered by these regulations 
shall provide written assurance 
satisfactory to the Secretary that it 
will comply with the requirements set 
forth in these regulations. 
(b) The Department will conduct or 
fund research covered by these 
regulations only if the institution has 
an assurance approved as provided in 
this section, and only if the institution 
has certified to the Secretary that the 
research has been reviewed and 
(a) Each institution engaged in 
approved by an IRB provided for in 
the assurance, and will be subject to 
continuing review by the IRB. This 
assurance shall at a minimum include: 
( I )  A statement of principles 
governing the institution in the 
discharge of its responsibilities for 
protecting the rights and welfare of 
human subjects of research conducted 
at or sponsored by the institution, 
regardless of source of funding. This 
may include an appropriate existing 
code, declaration, or statement of 
ethical principles, or a statement 
formulated by the institution itself. 
This requirement does not preempt 
provisions of these regulations 
applicable to Department-funded 
research and is not applicable to any 
research in an exempt category listed 
in § 46.101. 
( 2 )  Designation of one or more 
IRBs established in accordance with 
the requirements of this subpart, and 
for which provisions are made for 
meeting space and sufficient staff to 
support the IRB's review and 
recordkeeping duties. 
(3)  A list of the IRB members 
identified by name; earned degrees; 
representative capacity; indications of 
experience such as board 
certifications, licenses, etc., 
sufficient to describe each member's 
chief anticipated contributions to IRB 
deliberations; and any employment or 
other relationship between each 
member and the institution; for 
example: full-time employee, part- 
time employee, member of governing 
panel or board, stockholder, paid or 
unpaid consultant. Changes in IRB 
membership shall be reported to the 
Secretary. 1 
(4) Written procedures which the 
IRB will follow ( i )  for conducting its 
initial and continuing review of 
research and for reporting its findings 
and actions to the investigator and the 
institution: ( i i )  for determining which 
projects require review more often 
than annually and which projects 
need verification from sources other 
than the investigators that no material 
changes have occurred since previous 
IRB review; (iii) for insuring prompt 
reporting to the IRB of proposed 
changes in a research activity, and for 
insuring that changes in approved 
research.'during the period for which 
IRB approval has already been given, 
may not be initiated without IRB 
review and approval except where 
necessary to eliminate apparent 
immediate hazards to the subject; and 
(iv) for insuring prompt reporting to 
the IRB and to the Secretary I of 
unanticipated problems involving 
risks to subjects or others. 
(c) The assurance shall be executed 
by an individual authorized to act for 
the institution and to assume on 
behalf of the institution the 
obligations imposed by these 
regulations. and shall be filed in such 
form and manner as the Secretary 
may prescribe. 
assurances submitted in accordance 
with these regulations through such 
officers and employees of the 
Department and such experts or 
consultants engaged for this purpose 
as the Secretary determines to be 
appropriate. The Secretary's 
evaluation. will take into 
consideration the adequacy of the 
proposed IRB in light of the 
anticipated scope of the institution's 
research activities and the types of 
subject populations likely to be 
(d) The Secretary will evaluate all 
I Repons should be filed with the Office 
for Protection from Research Risks. htion81 
Institutes of Health, Dcprnment of Herlh 
and Human Services, Bethesdr. Maryland 
20205. 
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involved, the appropriateness of the 
proposed initial and continuing 
review procedures in  light of the 
probable risks, and the size and 
complexity of the institution. 
the Secretary may approve or 
disapprove the assurance, or enter 
into negotiations to develop an 
approvable one. The Secretary may, 
limit the period during which any 
particular approved assurance or class 
of approved assurances shall remain 
effective or otherwise condition or 
restrict approval. 
submission to HHS of an application 
or proposal. an institution with an 
approved assurance covering the 
proposed research shall certify that 
the application or proposal has been 
reviewed and approved by the IRB. 
Other institutions shall certify that the 
application or proposal has been 
approved by the IRB within 30 days 
after receipt of a request for such a 
certification from the Department. If 
the certification is not submitted 
within these time limits, the 
application or proposal may be 
returned to the institution. 
4 46.104 [Resenedl 
4 46.105 [Reservedl 
0 46.106 [Resenedl 
4 46.107 IRB membership. 
(a) Each IRB shall have at least 
five members, with varying 
backgrounds to promcte complete and 
adequate review of research 'activities 
commonly conducted by the 
institution. The IRB shall be 
sufficiently qualified through the 
experience and expertise of its 
members, and the diversity of the 
members ' backgrounds including 
consideration of the racial and 
cultural backgrounds of members and 
sensitivity to such issues as 
community attitudes, to promote 
respect for its advice and counsel in 
safeguarding the rights and welfare of 
human subjects. In addition to 
(e) On the basis of this evaluation, 
(0 Within 60 days after the date of 
possessing the professional 
competence necessary to review 
specific research activities, the IRB 
shall be able to ascertain the 
acceptability of proposed research in 
terms of institutional commitments 
and regulations, applicable law, and 
standards of professional conduct and 
practice. The IRB shall therefore 
include persons knowledgeable in 
these areas. If an IRB regularly 
reviews research that involves a 
vulnerable category of subjects, 
including but not limited to subjects 
covered by other subparts of this part, 
the IRB shall include one or more 
individuals who are primarily 
concerned with the welfare of these 
subjects. 
(b) No IRB may consist entirely of 
men or entirely of women, or entirely 
of members of one profession. 
(c) Each IRB shall include at least 
one member whose primary concerns 
are in nonscientific areas; for 
example: lawyers, ethicists, members 
of the clergy. 
(d) Each IRB shall include at least 
one member who is not otherwise 
affiliated with the institution and who 
is not part of the immediate family of 
a person who is affiliated with the 
institution. 
(e) No IRB may have a member 
participating in the IRB's initial or 
continuing review of any project in 
which the member has a conflicting 
interest, except to provide 
information requested by the IRB. 
(0 An IRB may, in its discretion, 
invite individuals with competence in 
special areas to assist in the review of 
complex issues which require 
expertise beyond or in addition to that 
available on the IRB. These 
individuals may not vote with the 
IRB. 
4 46.108 IRB functions and 
operations. 
In order to fulfill the requirements 
of these regulations each IRB shall: 
(a) Follow written procedures as 
provided in 9 46.103(b)(4). 
(b) Except when an expedited 
review procedure is used (see 
5 46.110). review proposed research 
at convened meetings at which a 
majority of the members of the IRB 
are present, including at least one 
member whose primary concerns are 
in nonscientific areas. In order for the 
research to be approved, it shall 
receive the approval of a majority of 
those members present at the 
meeting . 
(c) Be responsible for reporting to 
the appropriate institutional officials 
and the Secretary any serious or 
continuing noncompliance by 
investigators with the requirements 
and determinations of the IRB.  
0 46.109 IRB review of research. 
(a) An IRB shall review and have 
authority to approve, require 
modifications in (to secure approval), 
or disapprove all research activities 
covered by these regulations. 
information given to subjects as part 
of informed consent is in accordance 
with 5 46.116. The IRB may require 
that information, in addition to that 
specifically mentioned in 5 46.116, 
be given to the subjects when in the 
IRB's judgment the information 
would meaningfully add to the 
protection of the rights and welfare of 
subjects. 
(c) An IRB shall require 
documentation of informed consent or 
may waive documentation in 
accordance with 5 46. I 17. 
(d) An IRB shall notify 
investigators and the institution in 
writing of its decision to approve or 
disapprove the proposed research 
activity, or of modifications required 
to secure IRB approval of the 
research activity. I f  the IRB decides 
to disapprove a research activity, it 
shall include in its written notification 
I Reports should be filed with the Office 
for Protection from Research Risks. National 
Institutes of Health. Deprnmcnt of Health 
and Human Services. Bethesda, Maryland 
20205. 
(b) An IRB shall require that 
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a statement of the reasons for its 
decision and give the investigator an 
opportunity to respond in person or in 
writing. 
(e) An IRB shall conduct 
continuing review of research covered 
by these regulations at intervals 
appropriate to the degree of risk, but 
not less than once per year, and shall 
have authority to observe or have a 
third party observe the consent 
process and the research. 
Q46.110 Expedited review 
procedures for certain kinds of 
research involving no more than 
minimal risk, and for minor 
changes in approved research. 
I 
CI 
1 
B 
1 
1 
si 
1 
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P 
u 
(a) The Secretary has established, a and published in the Federal 
Regisrer, a list of categories of 
research that may be reviewed by the 
IRB through an expedited review 
procedure. The list will be amended, 
as appropriate, through periodic 
republication in the Federal 
R, gister . 
of the research appearing on the list 
through an expedited review 
procedure, if the research involves no 
more than minimal risk. The IRB may 
also use the expedited review 
procedure to review minor changes in 
previously approved research during 
the period for which approval is 
authorized. Under an expedited 
review procedure, the review may be 
carried out by the IRB chairperson or 
by one or more experienced reviewers 
designated by the chairperson from 
among members of the IRB. In 
reviewing the research, the reviewers 
may exercise all of the authorities of 
the IRB except that the reviewers may 
not disapprove the research. A 
research activity may be disapproved 
only after review in accordance with 
the non-expedited procedure set forth 
in 0 46.108(b). I (c) Each IRB which uses an 
expedited review procedure shall 
adopt a method for keeping all 
members advised of research 
(b) An IRB may review some or all 
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proposals which have been approved 
under the procedure. 
(d) The Secretary may restrict. 
suspend, or terminate an institution's 
or IRB's use of the expedited review 
procedure when necessary to protect 
the rights or welfare of subjects. 
446.11 1 Criteria for IRB 
approval of research. 
(a) In order to approv'c research 
covered by these regulations the IRB 
shall determine that all of the 
following requirements are satisfied: 
( I )  Risks to subjects are 
minimized: ( i )  By using procedures 
which are consistent with sound 
research design and which do not 
unnecessarily expose subjects to risk, 
and (ii)  whenever appropriate, by 
using procedures already being 
performed on the subjects for 
diagnostic or treatment purposes. 
in relation to anticipated benefits. if 
any, to subjects, and the importance 
of the knowledge that may reasonably 
be expected to result. In evaluating 
risks and benefits, the IRB should 
consider only those risks and benefits 
that may result from the research (as 
distinguished from risks and benefits 
of therapies subjects would receive 
even if not participating in the 
research). The IRB should not 
consider possible long-range effects 
of applying knowledge gained in the 
research (for example, the possible 
effects of the research on public 
policy) as among those research risks 
that fall within the purview of its 
responsibility . 
equitable. In making this assessment 
the IRB should take into account the 
purposes of the research and the 
setting in which the research will be 
conducted. 
(4) Informed consent will be 
sought from each prospective subject 
or the subject's legally authorized 
representative. in accordance with, 
and to the extent required by 
8 46.116. 
(2) Risks to subjects are reasonable 
(3) Selection of subjects is 
(5) Informed consent will be 
appropriately documented, in 
accordance with, and to the extent 
required by 9 46.117. 
plan makes adequate provision for 
monitoring the data collected to 
insure the safety of subjects. 
(7) Where appropriate, there are 
adequate provisions to protect the 
privacy of subjects and to maintain 
the confidentiality of data. 
subjects are likely to be vulnerable to 
coercion or undue influence, such as 
persons with acute or severe physical 
or mental illness, or persons who are 
economically or educationally 
disadvantaged, appropriate additional 
safeguards have been included in the 
study to protect the rights and welfare 
of these subjects. 
(6) Where appropriate, the research 
(b) Where some or all of the 
Q 46.112 Review by institution. 
regulations that has been approved by 
an IRB may be subject to further 
appropriate review and approval or 
disapproval by officials of the 
institution. However, those officials 
may not approve the research if it has 
not been approved by an IRB. 
Research covered by these 
Q 46.113 Suspension or  
termination of IRB approval of 
research. 
An IRB shall have authority to 
suspend or terminate approval of 
research that is not being conducted 
in accordance with the IRB's 
requirements or that has been 
associated with unexpected serious 
harm to subjects. Any suspension or 
termination of approval shall include 
a statement of the reasons for the 
IRB's action and shall be reported 
promptly to the investigator, 
appropriate institutional officials, and 
the Secretary. 
~~ 
I Reports should be filed with the Office 
for Protection from Research Risks, National 
Instituter of Health. Department of Health 
and Human Services. Bethesda. Muyland 
20205. 
4 46.114 Cooperative research. 
Cooperative research projects are 
those projects, normally supported 
through grants, contracts, or similar 
arrangements, which involve 
institutions in addition to the grantee 
or prime contractor (such as a 
contractor with the grantee, or a 
subcontractor with the prime 
contractor). In such instances, the 
grantee or prime contractor remains 
responsible to the Department for 
safeguarding the rights and welfare of 
human subjects. Also, when 
cooperating institutions conduct some 
or all of the research involving some 
or all of these subjects, each 
cooperating institution shall comply 
with these regulations as though i t  
received funds for its participation in 
the project directly from the 
Department, except that in complying 
with these regulations institutions 
may use joint review, reliance upon 
the review of another qualified IRB, 
or similar arrangements aimed at 
avoidance of duplication of effort. 
0 46.115 IRB records. 
appropriate an IRB. shall prepare and 
maintain adequate documentation of 
IRB activities, including the 
following: 
reviewed, scientific evaluations, if 
any, that accompany the proposals, 
approved sample consent documents, 
progress reports submitted by 
investigators, and reports of injuries 
to subjects. 
shall be .in sufficient detail to show 
attendance at the meetings; actions 
taken by the IRB; the vote on these 
actions including the number of 
members voting for, against, and 
abstaining; the basis for requiring 
changes in or disapproving research; 
and a written summary of the 
discussion of controverted issues and 
their resolution. 
(3) Records of continuing review 
activities. 
(a) An institution, or where 
(1) Copies of all research proposals 
(2) Minutes of IRB meetings which 
(4) Copies of all correspondence 
between the IRB and the 
investigators. 
required by 9 46.103(b)(3). 
as required by 9 46.103(b)(4). 
findings provided to subjects, as 
required by 0 46.1 16(b)(5). 
(b) The records required by this 
regulation shall be retained for at 
least 3 years after completion of the 
research. and the records shall be 
accessible for inspection and copying 
by authorized representatives of the 
Department at reasonable times and 
in a reasonable manner. 
( 5 )  A list of IRB members as 
(6) Written procedures for the IRB 
(7) Statements of significant new 
4 46.116 General requirements 
for informed consent. 
Except as provided elsewhere in 
this or other subparts, no investigator 
may involve a human being as a 
subject in research covered by these 
regulations unless thc investigator has 
.obtained the legally effective 
informed consent of the subject or the 
subject's legally authorized 
representative . An investigator shall 
seek such consent only under 
circumstances that provide the 
prospective subject or the 
representative sufficient OppOrtUnity 
to consider whether or not to 
participate and that minimize the 
possibility of coercion or undue 
influence. The information that is 
given to the subject or the 
representative shall be in language 
understandable to the subject or the 
representative. No informed consent, 
whether oral or written. may include 
any exculpatory language through 
which the subject or the 
representative is made to waive or 
appear to waive any of the subject's 
legal rights, or releases or appears to 
release the investigator, the sponsor, 
the institution or its agents from 
liability for negligence. 
(a) Basic elements of informed 
consent. Except as provided in 
paragraph (c) or (d) of this section, in 
seeking informed consent the 
following information shall be 
provided to each subject: 
(1 )  A statement that the study 
involves research, an explanation of 
the purposes of the research and the 
expected duration of the subject's 
participation, a description of the 
procedures to be followed, and 
identification of any procedures 
which are experimental; 
(2) A description of any reasonably 
foreseeable risks or discomforts to the 
subject; 
(3) A description of any benefits to 
the subject or to others which may 
reasonably be expected from the 
resfarch; 
(4) A disclosure of appropriate 
alternative procedures or courses of 
treatment, if any, that might be 
advantageous to the subject: 
( 5 )  A statement describing the 
extent, if any, to which 
confidentiality of records identifying 
the subject will be maintained; 
(6) For research involving more 
than minimal risk, an explanation as 
to whether any compensation and an 
explanation as to whether any 
medical treatments are available if 
injury occurs and, if so. what they 
consist of, or where further 
information nray be obtained; 
contact for answers to pertinent 
questions about the research and 
research subjects' rights, and whom 
to contact in the event of a research- 
related injury to the subject; and 
(8) A statement that participation is 
voluntary, refusal to participate will 
involve no penalty or loss of benefits 
to which the subject is otherwise 
entitled, and the subject may 
discontinue participation at any time 
without penalty or loss of benefits to 
which the subject is otherwise 
entitled. 
(b) Additional elements of 
informed consent. When appropriate, 
one or more of the following elements 
of information shall also be provided 
to each subject: 
(7) An explanation of whom to 
II lo - 
(1) A statement that the particular 
treatment or procedure may involve 
risks to the subject (or to the embryo 
or fetus, if the subject is or may 
become pregnant) which are currently 
unforeseeable; 
(2) Anticipated circumstances 
under which the subject’s 
participation may be terminated by 
the investigator without regard to the 
subject’s consent; 
subject that may result from 
participation in the research; 
(4) The consequences of a 
subject’s decision to withdraw from 
the research and procedures for 
orderly termination of participation 
by the subject; 
(5) A statement that significant 
new findings developed during the 
course of the research which may 
relate to the subject’s willingness to 
continue participation will be 
provided to the subject; and 
(6) The approximate number of 
subjects involved in the study. 
(c) An IRB may approve a consent 
procedure which docs not include, or 
which alters, some or all of the 
elements of informed consent set 
forth above, or waive the requirement 
to obtain informed consent provided 
the IRB finds and documents that: 
project is to be conducted by or 
subject to the approval of state or 
local government officials and is 
designed to study, evaluate, or 
otherwise examine: (i) programs 
under the Social Security Act, or 
other public benefit or service 
programs; (ii) procedures for 
obtaining benefits or services under 
those programs; (iii) possible changes 
in or alternatives to those programs 
or procedures; or (iv) possible 
changes in methods or levels of 
payment for benefits o r  services under 
those programs; and 
practicably be carried out without the 
waiver or alteration. 
(d) An IRB may approve a consent 
procedure which does not include, or 
(3) Any additional costs to the 
(1) The research or demonstration 
c 
(2) The research could not 
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which alters, some or all of the 
elements of informed consent set 
forth above, or waive the 
requirements to obtain informed 
consent provided the IRB finds and 
documents that: 
( 1) The research involves no more 
than minimal risk to the subjects; 
( 2 )  The waiver or alteration will 
not adversely affect the rights and 
welfare of the subjects; 
practicably be carried out without the 
waiver or alteration; and 
subjects will be provided with 
additional pertinent information after 
participation. 
(e) The informed consent 
requirements in these regulations are 
not intended to preempt any 
applicable federal, state, or local laws 
which require additional information 
to be disclosed in order for informed 
consent to be legally effective. 
(0 Nothing in these regulations is 
intended to limit the authority of a 
physician to provide emergency 
medical care, to the extent the 
physician is permitted to do so under 
applicable federal. state, or local law. 
0 46.117 Documentation of 
informed consent. 
(a) Except as provided in  
paragraph (c) of this section, 
informed consent shall be 
documented by the use of a written 
consent form approved by the IRB 
and signed by the subject or the 
subject’s legally authorized 
representative. A copy shall be given 
to the person signing the form. 
(b) Except as provided in 
paragraph (c) of this section, the 
consent form may be either of the 
following: 
( 1) A written consent document 
that embodies the elements of 
informed consent required by 
8 46.116. This form may be read to 
the subject or the subject’s legally 
authorized representative, but in any 
event, the investigator shall give 
either the subject or the representative 
(3) The research could not 
(4) Whenever appropriate, the 
adequate opportunity to read it before 
it is signed; or 
(2) A “short form” written 
consent document stating that the 
elements of informed consent 
required by 0 46.116 have been 
presented orally to the subject or the 
subject’s legally authorized 
representative. When this method is 
used, there shall be a witness to the 
oral presentation. Also, the IRB shall 
approve a written summary of what is 
to be said to the subject or the 
representative. Only the short form 
itself is to be signed by the subject or 
the representative. However, the 
witness shall sign both the short form 
and a copy of the climmary, and the 
person actually obtaining consent 
shall sign a copy of the summary. A 
copy of the summary shall be given to 
the subject or the representative, in 
addition to a copy of the “short 
form. ” 
(c) An IRB may waive the 
requirement for the investigator to 
obtain a signed consent form for some 
or all subjects if i t  finds either: 
( 1) That the only record linking the 
subject and the research would be the 
consent document and the principal 
risk would be potential harm resulting 
from a breach of confidentiality. Each 
subject will be asked whether the 
subject wants documentation linking 
the subject with the research, and the 
subject’s wishes will govern; or 
(2) That the research presents no 
more than minimal risk of harm to 
subjects and involves no procedures 
for which written consent is normally 
required outside of the research 
context. 
In cases where the documentation 
requirement is waived, the IRB may 
require the investigator to provide 
subjects with a written statement 
regarding the research. 
0 46.118 Applications and 
proposals lacking definite plans for 
involvement of human subjects. 
Certain types of applications for 
grants, cooperative agreements, or 
contracts are submitted to the 
Department with the knowledge that 
subjects may be involved within the 
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period of funding, but definite plans 
would not normally be set forth in the 
application or proposal: These 
include activities such as institutional 
type grants (including bloc grants) 
where selection of specific projects is 
the institution's responsibility; 
research training grants where the 
activities involving subjects remain to 
be selected; and projects in which 
human subjects' involvement will 
depend upon completion of 
instruments, prior animal studies, or 
purification of compounds. These 
applications need not be reviewed by 
an IRB before an award may be 
made. However, except for research 
described in 9 46.101(b), no human 
subjects may be involved in any 
project supported by these awards 
until the project has been reviewed 
and approved by the IRB, as provided 
in these regulations, and certification 
submitted to the Department. 
4 46.119 Research undertaken 
without the intention of involving 
human subjects. 
funded by the Department) is 
undertaken without the intention of 
involving hJman subjects, but it is 
later proposed to use human subjects 
in the research, the research shall first 
be reviewed and approved by an IRB, 
as provided in these regulations, a 
certification submitted to th6 
Department, and final approval given 
to the proposed change by the 
Department. 
0 46.120 Evaluation and 
disposition of applications and 
proposals. 
(a) The Secretary will evaluate all 
applications and proposals involving 
human subjects submitted to the 
Department through such officers and 
employees of the Department and 
such experts and consultants as the 
Secretary determines to be 
appropriate. This evaluation will take 
into consideration the risks to the 
subjects, the adequacy of protection 
against these risks, the potential 
benefits of the proposed research to 
In the event research (conducted or 
the subjects and others, and the 
importance of the knowledge to be 
gained. 
the Secretary may approve or 
disapprove the application or 
proposal. or enter into negotiations to 
develop an approvable one. 
0 46.121 Investigational new drug 
or device W a y  delay requirement. 
When an institution is required to 
prepare or to submit a certification 
with an application or proposal under 
these regulations, and the application 
or proposal involves an 
investigational new drug (within the 
meaning of 21 U.S.C. 355(i) or 
357(d)) or a significant risk device (as 
defined in 21 CFR 812.3(m)), the 
institution shall identify the drug or 
device in the certification. The 
institution shall also state whether the 
30-day interval required for 
investigational new drugs by 21 CFR 
312. ](a) and for significant risk 
devices by 21 CFR 812.30 has 
elapsed, or whether the Food and 
Drug Administration has waived that 
requirement. If the 30-day interval 
has expired, the institution shall state 
whether the Food and Drug 
Administration has requested that the 
sponsor continue to withhold or 
restrict the use of the drug or device 
in human subjects. If the 30-day 
interval has not expired, and a waiver 
has not been received, the institution 
shall send a statement to the 
Department upon expiration of the 
interval. The Department will not 
consider a certification acceptable 
until the institution has submitted a 
statement that the 30-day interval has 
elapsed, and the Food and Drug 
Administration has not requested it to 
limit the use of the drug or device, or 
that the Food and Dmg 
Administration has waived the 30-day 
interval. 
0 46.122 Use of Federal funds. 
Federal funds administered by the 
Department may not be expended for 
research involving human subjects 
unless the requirement of these 
(b) On the basis of this evaluation, 
tegulations, including all subparts of 
these regulations. have been satisfied. 
4 46.123 Early termination of 
research hnding; evaluation of 
subsequent applications and 
proposals. 
(a) The Secretary may require that 
Department funding for any project 
be terminated or suspended in the 
manner prescribed in applicable 
program requirements, when the 
Secretary finds an institution has 
materially failed to comply with the 
terms of these regulations. 
(b) In making decisions about 
funding applications or proposals 
covered by these regulations the 
Secretary may take into accounI, in 
addition to all other eligibility 
requirements and program criteria, 
factors such as whether the applicant 
has been subject to a termination or 
suspension under paragraph (a) of this 
section and whether the applicant or 
the person who would direct the 
scientific and technical aspects of an 
activity has in the judgment of the 
Secretary materially failed to 
discharge responsibility for the 
protection of the rights and welfare of 
human subjects (whether or not 
Department funds were involved). 
4 46.124 Conditions. 
With respect to any research 
project or any class of research 
projects the Secretary may impose 
additional conditions prior to or at the 
time of funding when in the 
Secretary's judgment additional 
conditions are necessary for the 
protection of human subjects. 
Subpart B-Additional Protections 
Pertaining to Research 
Development, and Related 
Activities Involving Fetuses, 
Pregnant Women, and Human in 
Vitro Fertilization 
SOURCE: 40 FR 33528. A u t .  8. 1975, 43 FR 
l758.  January 1 I ,  1978. 43 FR 
5lSS9, November 3. 1978 
(a) The regulations in  this subpart 
0 46.201 Applicability. 
are applicable to all Department of 
Health, Education, and Welfare 
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grants and contract supporting 
research, development, and related 
activities involving: ( I  The fetus, (2) 
pregnant women, and (3) human in 
virro fertilization. 
construed as indicating that 
compliance with the procedures set 
forth herein will in any way render 
inapplicable pertinent State or local 
laws bearing upon activities covered 
by this subpart. 
(c) The requirements of this 
subpart are in addition to those - 
imposed under the other subparts of 
this part. 
0 46.202 Purpose. 
provide additional safeguards in 
reviewing activities to which this 
subpart is applicable to assure that 
they conform to appropriate ethical 
standards and relate to important 
societal needs. 
8 46.203 Definitions. 
(b) Nothing in this subpart shall be 
It is the purpose of this subpart to 
As used in this subpart: 
(a) "Secretary" means the 
Secretary of Health, Education, and 
Welfare and any other officer or 
employee of the Department of 
Health, Education, and Welfare to 
whom authority has been delegated. 
(b) ' 'Pregnancy ' * encompasses the 
period of time from confirmation of 
implantation (through any of the 
presumptive signs of pregnancy, such 
as missed menses, or by a medically 
acceptable pregnancy test), until 
expulsion or extraction of the fetus. 
(c) "Fetus" means the product of 
conception from the time of 
implantation (as evidenced by any of 
the presumptive signs of pregnancy, 
such as missed menses, or a 
medically acceptable pregnancy test), 
until a determination is made, 
following explusion or extraction of 
the fetus, that it is viable. 
(d) "Viable" as it pertains to the 
fetus means being able, after either 
spontaneous or induced delivery, to 
survive (given the benefit of available 
medical therapy) to the point of 
independently maintaining heart 
beaf and respiration. The Secretary 
may from time to time, taking into 
account medical advances, publish in 
the FEDERAL R EGISTER guidelines 
to assist in determining whether a 
fetus is viable for purposes of this 
subpart. If a fetus is viable after 
delivery, it is a premature infant. 
(e) "Nonviable fetus" means a 
fetus ex utero which, although living, 
is not viable. 
(0 "Dead fetus" means a fetus ex 
utero which exhibits neither 
heartbeat, spontaneous respiratory 
activity, spontaneous movement of 
voluntary muscles, nor pulsation of 
the umbilical cord (if still attached). 
(g) "In vitro fenilizatiqn" means 
any fertilization of human ova which 
occurs outside the body of a female, 
either through admixture of donor 
human sperm and ova or by any other 
means. 
0 46.204 Ethical Advisory 
Boards. 
(a) One or more Ethical Advisory 
Boards shall be established by the 
Secretary. Members of these board(s) 
shall be so selected that the board(s) 
will be competent to deal with 
medical, legal, social, ethical, and 
related issues and may include. for 
example, research scientists, 
physicians, psychologists. 
sociologists, educators, lawyers, and 
ethicists, as well as representatives of 
the general public. No board member 
may be a regular, full-time employee 
of the Department of Health, 
Education, and Welfare. 
the Ethical Advisory Board shall 
render advice consistent with the 
policies and requirements of this Part 
as to ethical issues, involving 
activities covered by this subpart, 
raised by individual applications or 
proposals. In addition, upon request 
by the Secretary, the Board shall 
render advice as to classes of 
applications or proposals and general 
policies, guidelines. and procedures. 
(c) A Board may establish, with 
the approval of the Secretary, classes 
of applications or proposals which: 
(b) At the request of the Secretary, 
(1) Must be submitted to the Board, 
or (2) need not be submitted to the 
Board. Where the Board so 
establishes a class of applications or 
proposals which must be submitted, 
no application or proposal within the 
class may be funded by the 
Department or any component thereof 
until the application or proposal has 
been reviewed by the Board and the 
Board has rendered advice as to its 
acceptability from an ethical 
standpoint. 
involving human in virro fertilization 
may be funded by the Department or 
any component thereof until the 
application or proposal has been 
reviewed by the Ethical Advisory 
Board and the- Board has rendered 
advice as to its acceptability from an 
ethical standpoint. 
0 46.205 Additional duties of the 
(d) No application or proposal 
Institutional Review Boards In 
connection with activitlcs 
Involving fetuses, pregnant 
women, or human in vitro 
fertillution. 
(a) In addition to the 
responsibilities prescribed for 
Institutional Review Boards under 
Subpart A of this part, the applicant's 
or offeror's Board shall, with respect 
to activities covered by this subpart, 
cany out the following additional 
duties: 
( 1 )  Determine that all aspects of 
the activity meet the requirements of 
this subpart; 
consideration has been given to the 
manner in which potential subjects 
will be selected, and adequate 
provision has been made by the 
applicant or offeror for monitoring 
the actual informed consent process 
(e.g.. through such mechanisms, 
when appropriate, as participation by 
the Institutional Review Board or 
subject advocates in: (i) Overseeing 
the actual process by which 
individual consents required by this 
subpart are secured either by 
approving induction of each 
individual into the activity or 
(2) Determine that adequate 
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verifying. perhaps through sampling, 
that approved procedures for 
induction of individuals into the 
activity are being followed, and (ii) 
monitoring the progress of the 
activity and intervening as necessary 
through such steps as visits to the 
activity site and continuing evaluation 
to determine if any unanticipated 
risks have arisen); 
responsibilities as may be assigned by 
the Secretary. 
(b) No award may be issued until 
the applicant or offeror has certified 
to the Secretary that the Institutional 
Review Board has made the 
determinations required under 
paragraph (a) of this section and the 
Secretary has approved these 
determinations, as provided in 
0 46.120 of Subpart A of this part. 
(c) Applicants or offerors seeking 
support for activities covered by this 
subpart must provide for the 
designation of an Institutional Review 
Board, subject to approval by the 
Secretary, where no such Board has 
been established under Subpart A of 
this part. 
(3) Carry out such other 
j 46.206 General limitations. 
(a) No activity to which this 
subpart is applicable may be 
undertaken unless: 
and nonpregnant individuals have 
been completed; 
( 2 )  Except where the purpose of 
the activity is to meet the health 
needs of the mother or the particular 
fetus, the risk to the fetus is minimal 
and, in all cases, is the least possible 
risk for achieving the objectives of 
the activity. 
(3) Individuals engaged in the 
activity will Rave no pan in: (i) Any 
decisions as to the timing, method, 
and procedures used to terminate the 
pregnancy, and (i i )  determining the 
viability of the fetus at the 
termination of the pregnancy; and 
(4) No procedural changes which 
may cause greater than minimal risk 
to the fetus or the pregnant woman 
will be introduced into the procedure 
( I )  Appropriate studies on animals 
for terminating the pregnancy solely 
in the interest of the activity. 
(b) No inducements, monetary or 
otherwise, may be offered to 
terminate pregnancy for purposes of 
the activity. 
[40 FR 33S28, Aug. 8 .  197% u amended at 
40 FR S1638. Nov. 6, I9751 
0 46.207 Activities directed 
toward pregnant women as 
subjects. 
(a) No pregnant woman may be 
involved as a subject in an activity 
covered by this subpart unless: (1 )  
The purpose of the activity is to meet 
the health needs of the mother and the 
fetus will be placed at risk only to the 
minimum extent necessary to meet 
such needs, or (2) the risk to the fetus 
is minimal. 
(b) An activity permitted under 
paragraph (a) of this section may be 
conducted only if the mother and 
father are legally competent and have 
given their informed consent after 
having been fully informed regarding 
possible impact on the fetus, except 
that the father's informed consent 
need not be secured i f  (1)  The 
purpose of the activity is to meet the 
health needs of the mother; ( 2 )  his 
identity or whereabouts cannot 
reasonably be ascertained; (3) he i s  
not reasonably available; or (4) the 
pregnancy resulted from rape. 
0 46.208 Activities directed 
toward fetuses in utero as 
subjects. 
(a) No fetus in utero may be 
involved as a subject in  any activity 
covered by this subpart unless: ( I )  
The purpose of the activity is to meet 
the health need5 + the particular fetus 
and the fetus will be placed at risk 
only to the minimum extent necessary 
to meet such needs, or (2) the risk to 
the fetus imposed by the research is 
minimal and the purpose of the 
activity is the development of 
important biomedical knpwledge 
which cannot be obtained by other 
means. 
(b) An activity permitted under 
paragraph (a) of this section may be 
conducted only if the mother and 
father are legally competent and have 
given their informed consent, except 
that the father's consent need not be 
secured i f  ( I )  His identity or 
whereabouts cannot reasonably be 
ascertained, (2) he is not reasonably 
available. or (3) the pregnancy 
resulted from rape. 
0 46.209 Activitles directed 
toward fetuses ex utero, 
including nonviable fetuses, as 
subjects. 
(a)  Until i t  has been ascertained 
whether or not a fetus ex utero is 
viable, a fetus ex utero may not be 
involved as a subject in an activity 
covered by this subpart unless: 
( 1 )  There will be no added risk to 
the fetus resulting from the activity, 
and the purpose of the activity is the 
development of important biomedical 
knowledge which cannot be obtained 
by other means, or 
(2) The purpose of the activity is to 
enhance the possibility of survival of 
the particular fetus to the point of 
viability. 
(b) No nonviable fetus may be 
involved as a subject in an activity 
covered by this subpart unless: 
( I )  Vital functions of the fetus will 
not be artificially maintained, 
( 2 )  Experimental activities which 
of themselves would terminate the 
heartbeat or respiration of the fetus 
will not be employed, and 
(3) The purpose of the activity is 
the development of important 
biomedical knowledge which cannot 
be obtained by other means. 
(c) In the event the fetus ex utero 
is found to be viable, it may be 
included as a subject in the activity 
only to the extent permitted by and in 
accordance with the requirements of 
other subpans of this part. 
(d) An activity permitted under 
paragraph (a) or (b) of this section 
may be conducted only if the mother 
and father are legally competent and 
have given their informed consent, 
except that the father's informed 
consent need not be secured i f  ( I )  his 
identity or whereabouts cannot 
reasonably be ascertained, (2) he is 
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not reasonably available, or (3) the 
pregnancy resulted from rape. . 
0 46.210 Activities involving the 
dead fetus, fetal material, or the 
placenta. 
Activities involving the dead fetus, 
mascerated fetal material, or cells, 
tissue, or organs excised from a dead 
fetus shall be conducted only in 
accordance with any applicable State 
or local laws regarding such 
activities. 
0 46.211 Modification or waiver 
of specific requirements. 
Upon the request of an applicant or 
offeror (with the approval of its 
Institutional Review Board). the 
Secretary may modify or waive 
specific requirements of this subpart. 
with the approval of the Ethical 
Advisory Board after such 
opportunity for public comment as 
the Ethical Advisory Board considers 
appropriate in the particular instance. 
In making such decisions. the 
Secretary will consider whether the 
risks to the subject are so outweighed 
by the sum of the benefit to the 
subject and the importance of the 
knowledge to be gained as to warrant 
such modification or waiver and that 
such benefits cannot be gained except 
through a modification or waiver. 
Any such modifications or waivers 
will be published as notices in the 
FEDERAL REGISTER 
Subpart C-Additional Protections 
Pertaining to Biomedical and 
Behavioral Research Involving 
Prisoners as Subjects 
Source: 43 FR 53655. Nov 16. 1978 
0 46.301 Applicability. 
(a) The regulations in this subpart 
are applicable to all biomedical and 
behavioral research conducted or 
supported by the Department of 
Health, Education, and Welfare 
involving prisoners as subjects. 
construed as indicating that 
compliance with the procedures set 
forth herein will authorize research 
involving prisoners as subjects, to the 
extent such research is limited or 
(b) Nothing in this subpart shall be 
barred by applicable State or local 
law. 
(c) The requirements of this 
subpart are in addition to those 
imposed under the other subparts of 
this part. 
0 46.302 Purpose. 
Inasmuch as prisoners may be 
under constraints because of their 
incarceration which could affect their 
ability to make a truly voluntary and 
uncoerced decision whether or not to 
participate as subjects in research, it 
is the purpose of this subpart to 
provide additional safeguards for the 
protection of prisoners involved in 
activities to which this subpart is 
applicable. 
0 46.303 Definitions. 
As used in this subpart: 
(a) "Secretary" means the 
Secretary of Health, Education, and 
Welfare and any other officer or 
employee of the Department of 
Health, Education, and Welfare to 
whom authority has been delegated. 
Department of Health, Education, 
and Welfare. 
individual involuntarily confined or 
detained in a penal institution. The 
term is intended to encompass 
individuals sentenced to such an 
institution under a criminal or civil 
statute, individuals detained in other 
facilities by virtue of statutes or 
commitment procedures which 
provide alternatives to criminal 
prosecution or incarceration in a 
penal institution, and individuals 
detained pending arraignment. trial, 
or sentencing. 
(d) "Minimal risk" is the 
probability and magnitude of physical 
or psychological harm that is 
normally encountered in the daily 
lives, or in the routine medical, 
dental. or psychological examination 
of heal thy persons. 
0 46.304 Composition of 
(b) "DHEW" means the 
(c) "Prisoner" means any 
Institutional Review Boards 
where prisoners are involved. 
In addition to satisfying the 
requirements in 0 46.107 of this part, 
an Institutional Review Board, 
carrying out responsibilities under 
this part with respect to research 
covered by this subpart, shall also 
meet the following specific 
requirements: 
(exclusive of prisoner members) shall 
have no association with the prison(s) 
involved, apart from their 
membership on the Board. 
Board shall be a prisoner, or a 
prisoner representative with 
appropriate background and 
experience to serve in that capacity, 
except that where a particular 
research project is reviewed by more 
than one Board only one Board need 
satisfy this requirement. 
0 46.305 Additional duties of the 
(a) A majority of the Board 
(b) At least one member of the 
Institutional Review Boards 
where prisoners are involved. 
(a) In addition to all other 
responsibilities prescribed for 
Institutional Review Boards under 
this part, the Board shall review 
research covered by this subpart and 
approve such research only if it finds 
that: 
( 1)  The research under review 
represents one of the categories of 
research permissible under 
4 46.306(a)(2); 
accruing to the prisoner through his 
or her participation in the research, 
when compared to the general living 
conditions, medical care, quality of 
food. amenities and opportunity for 
earnings in the prison, are not of such 
a magnitude that his or her ability IO 
weigh the risks of the research against 
the value of such advantages in the 
limited choice environment of the 
prison is impaired; 
(3) The risks involved in the 
research are commensurate with risks 
that would be accepted by 
nonprisoner volunteers; 
(4) Procedures for the selection of 
subjects within the prison are fair to 
(2) Any possible advantages 
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all prisoners and immune from 
arbitrary intervention by prison 
authorities or prisoners. Unless the 
principal investigator provides to the 
Board justification in writing for 
following some other procedures, 
control subjects must be selected 
randomly from the group of available 
prisoners who meet the characteristics 
needed for that particular research 
project; 
language which is understandable to 
the subject population; 
(6) Adequate assurance exists that 
parole boards will not take into 
account a prisoner's participation in 
the research in making decisions 
regarding parole, and each prisoner is 
clearly informed in advance that 
participation in the research will have 
no effect on his or her parole; and 
(7) Where the Board finds there 
may be a need for follow-up 
examination or care of participants 
after the end of their participation, 
adequate provision has been made for 
such examination or care, taking into 
account the varying lengths of 
individual prisoners' sentences, and 
for informing participants of this fact. 
(b) The Board shall carry out such 
other duties as may be assigned by 
the Secretary. 
(c) The institution shall certify to 
the Secretary, in such form and 
manner as the Secretary may require, 
that the duties of the Board under this 
section have been fulfilled. 
(5) The information is presented in 
0 46.306 Permitted research 
involving prisoners. 
(a) Biomedical or behavioral 
research conducted or supported by 
DHEW may involve prisoners as 
subjects only i f  
thesonduct of the research has 
certified to the Secretary that the 
Institutional Review Board has 
approved the research under 9 46.305 
of this subpart; and 
( I )  The institution responsible for 
(2) In the judgment of the 
Secretary the proposed research 
involves solely the following: 
effects, and processes of 
incarceration. and of criminal 
behavior, provided that the study 
presents no more than minimal risk 
and no more than inconvenience to 
the subjects; 
Structures or of prisoners as 
incarcerated persons, provided that 
the study presents no more than 
minimal risk and no more than 
inconvenience to the subjects; 
(C) Research on conditions 
particularly affecting prisoners as a 
class (for example, vaccine trials and 
other research on hepatitis which is 
much more prevalent in prisons than 
elsewhere; and research on social and 
psychological problems such as 
alcoholism, drug addiction and sexual 
assaults) provided that the study may 
proceed only after the Secretary has 
consulted with appropriate experts 
including experts in penology 
medicine and ethics, and published 
notice, in the FEDERAL R EGlSTEK 
of his intent to approve such research; 
or 
(D) Research on practices, both 
innovative and accepted, which have 
the intent and reasonable probability 
of improving the health or well- 
being of the subject. In cases in 
which those studies require the 
assignment of prisoners in a manner 
consistent with protocols approved by 
the IRB to control groups which may 
not benefit from the research, the 
study may proceed only after the 
Secretary has consulted with 
appropriate experts, including experts 
in penology medicine and ethics, and 
published notice, in the F E D E R A L  
R EGIST ER, of his intent to approve such 
research. 
(b) Except as provided in 
paragraph (a) of this section, 
biomedical or behavioral research 
conducted or supported by DHEW 
shall not involve prisoners as 
subjects. . 
(A) Study of the possible causes, 
(B) Study of prisons as institutional 
Subpart D-Additional Protection8 
for Children Involved as Subjecta ln 
Research. 
Source: ba FR 9818, March a. 1983 
846.401 To what do these 
regulations apply? 
research involving children as 
subjects, conducted or supported by 
the Department of Health and 
Human Services. 
(1) This includes research 
conducted by Department 
employees, except that each head of 
an Operating Division of the 
Department may adopt such 
nonsubstantive, procedural 
modifications as may be appropriate 
from an administrative standpoint. 
(2) It also includes research 
conducted or supported by the 
Department of Health and Human 
Services outside the United States, 
but in appropriate circumstances, the 
Secretary may, under paragraph (e) 
of 3 46.101 of Subpart A, waive the 
applicability of some or all of the 
requirements of these regulations for 
research of this type. 
(b) Exemptions (1). (2), (5) and (6) 
as listed in Subpart A at 946.101@) 
are applicable to this subpart. 
Exemption (4). research involving 
the observation of public behavior, 
listed at $46.101@), is applicable to 
this subpart where the investigator(s) 
does not participate in the activities 
research involving survey or 
interview procedures, listed at 
946.101(b) does not apply to research 
covered by this subpart. 
(c) The exceptions, additions, and 
provisions for waiver as they appear 
in paragraphs (c) through (i) of 
9 46.101 of Subpart A are applicable 
to this subpart. 
(a) This subpart applies to all 
being observed. Exemption (3), - 
Q 46.402 Definitions. 
Subpart A shall be applicable to this 
subpart as well. In addition, as used 
in this subpart: 
The definitions in $46.102 of 
. 
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(a) “Children” are persons who 
have not attained the legal age for 
consent to treatments or procedures 
involved in the research, under the 
applicable law of the jurisdiction in 
which the research will be 
conducted. 
(b) “Assent” means a child’s 
aflirmative agreement to participate 
in research. Mere failure to object 
should not, absent affirmative 
agreement, be construed as assent. 
(c) “Permission” means the 
agreement of parent@) or guardian to 
the participation of their child or 
ward in research. 
(d) “Parent” means a child’s 
biological or adoptive parent. 
(e) “Guardian” means an 
individua1 who is authorized under 
applicable state or local law to 
consent on behalf of a child to 
general medical care. 
ff 46.403 IRB duties. 
assigned to IRBs under this part, 
each IRE shall review research 
covered by this subpart and approve 
only research which satisfies the 
conditions of all applicable sections 
of this subpart. 
In addition to other responsibilities 
ff 46.40) Research not involving 
greater than minimal risk. 
HHS will conduct or fund 
research in which the IRB finds that 
no greater than minimal risk to 
children is presented, only if the IRE 
finds that adequate provisions are 
made for soliciting the assent of the 
children and the permission of their 
parents or guardians, as set forth in 
8 46.408. 
ff 46.405 Research involving greater 
than minimal risk but presenting the 
prospect of direct benefit to the 
indiddual subjects. 
HHS will conduct or fund 
research in which the IRB finds that 
more than minimal risk to children is 
presented by an intervention or 
procedure that holds out the 
prospect of direct benefit for the 
individual subject, or by a 
monitoring procedure that is likely to 
contribute to the subject’s well-being 
only if the IRB finds that: 
(a) The risk is justified by the 
anticipated benefit to the subjects; 
(b) The relation of the anticipated 
benefit to the risk is at least as 
favorable to the subjects as that 
presented by available alternative 
approaches; and 
for soliciting the assent of the 
children and permission of their 
parents or guardians, as set forth in 
g 46.408. 
(c) Adequate provisions are made 
Q 46.406 Research involving greater 
than minimal risk and no prospect of 
direct benefit to individual subjects, 
but likely to yield generalizable 
knowledge about the subject’s disorder 
or condition. 
research in which the IRB finds that 
more than minimal risk to children is 
presented by an intervention or 
procedure that does not hold out the 
prospect of direct benefit for the 
individual subject, or by a 
monitoring procedure which is not 
likely to contribute to the well-being 
of the subject, only if the IRB finds 
that: 
(a) The risk represents a minor 
increase over minimal risk; 
(b) The intervention or procedure 
presents experiences to subjects that 
are reasonably commensurate with 
those inherent in their actual or 
expected medical, dental, 
psychological, social, or educational 
situations; 
(c) The intervention or procedure 
is likely to yield generalizable 
knowledge about the subjects’ 
disorder or condition which is of 
vital importance for the 
understanding or amelioration of the 
subjects’ disorder or condition; and 
(d) Adequate provisions are made 
for soliciting assent of the children 
and permission of their parents or  
guardians, as set forth in 0 46.408. 
HHS will conduct or fund 
0 46.407 Research not otherwise 
approvable which presents an 
opportunity to understand, prevent, or 
alleviate a serious problem affecting 
the health or welfare of children. 
HHS will conduct or fund 
research that the IRB does not 
believe meets the requirements of 
$ 6  46.404, 46.405, or 46.406 only if: 
(a) The IRB finds that the research 
presents a reasonable opportunity to 
further the understanding, 
prevention, or alleviation of a serious 
problem affecting the health or 
welfare of children; and 
consultation with a panel of experts 
in pertinent disciplines (for example: 
science, medicine, education, ethics, 
law) and following opportunity for 
public review and comment, has 
determined either: ( 1 )  That the 
research in fact satisfies the 
conditions of $ 9  46.404, 46.405, or 
46.406. as applicable, or ( 2 )  the 
following: 
(i) The research presents a 
reasonable opportunity to further the 
understanding, prevention, or 
alleviation of a serious problem 
affecting the health or welfare of 
children; 
in accordance with sound ethical 
principles; 
(iii) Adequate provisions are made 
for soliciting the assent of children 
and the permission of their parents or 
guardians, as set forth in 9 46.408. 
8 46.408 Requirements for 
permission by parents or guardians 
and for assent by children. 
(a) In addition to the 
determinations required under other 
applicable sections of this subpart, 
the IRE shall determine that 
adequate provisions are made for 
soliciting the assent of the children, 
when in the judgment of the IRB the 
children are capable of providing 
assent. In determining whether 
children are capable of assenting, the 
IRE shall take into account the ages, 
maturity, and psychological state of 
the children involved. This judgment 
(b) The Secretary, after 
(ii) The research will be conducted 
- 
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may be made for all children to be 
involved in research under a 
particular protocol, or for each child, 
M the IRB deems appropriate. If the 
IRB determines that the capability of 
some or all of the children is so 
limited that they cannot reasonably 
be consulted or that the intervention 
or procedure involved in the 
research holds out a prospect of 
direct benefit that is important to the 
health or well-being of the children 
and is available only in the context of 
the research, the assent of the 
children is not a necessary condition 
for proceeding with the research. 
Even where the IRE determines that 
the subjects are capable of assenting, 
the IRE may still waive the assent 
requirement under circumstatlces in 
which consent may be waived in 
accord with 0 46.116 of Subpart A. 
determinations required under other 
applicable sections of this subpart, 
the IRB shall determine, in 
nccurdance with and to the extent 
that consent k required by P 46.1 16 of 
Subpart A, that adequate provisions 
are made for soliciting the permission 
of each child's parents or guardian. 
Where parental permission is to be 
obtained, the IRB may find that the 
permission of one parent is sufficient 
for research to be conducted under 
09 46.404 or 46.405. Where research 
k covered by 5 5  46.406 and 46.407 
and permission is to be obtained from 
(b) In addition to the 
parents, both parents must give their 
permission unless one parent is 
deceased, unknown, incompetent, or 
not reasonably available, or when 
only one parent has legal 
responsibility for the care and 
custody of the child. 
(c) In addition to the provisions for 
waiver contained in 0 46.116 of 
Subpart A, if the IRB determines that 
a research protocol is designed for 
conditions or for a subject population 
for which parental or guardian 
permission is not a reasonable 
requirement to protect the subjects 
(for example, neglected or abused 
children), it may waive the consent 
requirements in Subpart A of this 
part and paragraph (b) of this section, 
provided an appropriate mechanism 
for protecting the children who will 
participate as subjects in the research 
is substituted, and provided further 
that the waiver is not inconsistent 
with federal,state or local law. The 
choice of an appropriate mechanism 
would depend upon the nature and 
purpose of the activities described in 
the protocol, the risk and anticipated 
benefit to the research subjects, and 
their age, maturity, status, and 
condition. 
(d) Permission by parents or 
guardians shall be documented in 
accordance with and to the extent 
required by 8 46.117 of Subpart A. 
assent is required, it shall also 
(e) When the IRE determines that 
determine whether and how assent 
must be documented. 
$46.409 W d .  
(a) Children who are wards of the 
state or any other agency, institution, 
or entity can be included in research 
approved under 0 P 46.406 or 46.407 
only if such research is: 
(1) Related to their status as wards; 
or 
(2) Conducted in schools, camps, 
hospitals, institutions, or similar 
settings'in which the majority of 
children involved as subjects are not 
wards. 
(b) If the research is approved 
under paragraph (a) of this section, 
the IRB shall require appointment of 
an advocate for each child who is a 
ward, in addition to any other 
individual acting on behalf of the 
child as guardian or in loco parentis. 
One individual may serve as 
advocate for more than one child. 
The advocate shall be an individual 
who has the background and 
experience to act in, and agrees to act 
in, the best interests of the child for 
the duration of the child's 
participation in the research and who 
is not associated in any way (except 
in the role as advocate or member of 
the XRB) with the research, the 
investigator(s), or the guardian 
organization. 
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. NOTICES 
HUMAN SUBJECTS 
Viable Fetus 
Elsewhere in this issue of the 
is amending 45 CFR Pan 46 by, 
guidelines to assist in determining whether a 
Minimum Criteria Identifying the FEDERAL REGISTER, the Secretary is lor p u ~ o s e r  Of Ibis subpart. 
This notice is published in 
among other things, adding a new accordance With # 46.203d). For 
On March 13. 1975. regulations Subpan B to additional purposes of Subpart B. the guidelines 
were published in the FEDERAL 
R EGlSTER(40 FR 11854) relating to the development, and related 
protection of human subjects in 
research, development, and related and in vitro fehilitation. following: 
activities supported by Departmeirt of 1 Health, Education, and Welfare 
grants and contracts. These 
protections pertaining to research, 
involving fetuses, pregnant women, 
Section 46.203(d) of Subpan B 
The Secretary may from time to time. 
indicating that a fetus other than a 
dead fetus within the meaning of 
5 46.203(f) is viable include the 
an estimated gestational age of 20 weeks or 
more and a body weight of 500 grams or 
more. 
FEOERAL REQISTER, VOL 40, 
AUGUST 8, 1975 
m 
provides inter alia as follows: 
regulations are at 45 CFR taking into account medical advances. 1 Part 46. publish in the FEDEIAL REGISTER 
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RESEARCH A C T I V I T I E S  W H I C H  MAY BE R E V I E W E D  
T H R O U G H  EXPEDITED R E V I E W  PROCEDURES 
Research a c t i v i t i e s  i n v o l v i n g  n o  more t h a n  m i n i m a l  r i s k  - a n d  i n  w h i c h  t h e  
o n l y  i n v o l v e m e n t  of  human s u b j e c t s  w i l l  be i n  o n e  o r  more of t h e  
f o l l o w i n g  c a t e g o r i e s  ( c a r r i e d  o u t  t h r o u g h  s t a n d a r d  m e t h o d s )  may be 
r e v i e w e d  by t h e  I n s t i t u t i o n a l  R e v i e w  Board t h r o u g h  t h e  e x p e d i t e d  r e v i e w  
p r o c e d u r e  a u t h o r i z e d  i n  46 .110  of  4 5  CFR P a r t  46 .  
( 1 )  C o l l e c t i o n  o f :  h a i r  a n d  
n a i l  c l i p p i n g s ,  i n  a 
n o n d i s f i g u r i n g  m a n n e r ;  
d e c i d u o u s  t e e t h ;  a n d  p e r m a n e n t  
t e e t h  i f  p a t i e n t  c a re  i n d i c a t e s  
a n e e d  f o r  e x t r a c t i o n .  
(2) C o l l e c t i o n  of exc re t a  
a n d  e x t e r n a l  s e c r e t i o n s  
i n c l u d i n g  swea t ,  u n c a n n u l a t e d  
s a l i v a ,  p l a c e n t a  r emoved  a t  
d e l i v e r y ,  a n d  amniot ic  f l u i d  a t  
t h e  time of r u p t u r e  of t h e  
membrane  p r i o r  t o  or  d u r i n g  
l a b o r .  
( 3 )  R e c o r d i n g  of  d a t a  from 
s u b j e c t s  18 years  of age o r  
o lde r  u s i n g  n o n i n v a s i v e  
p r o c e d u r e s  r o u t i n e l y  employed  
i n  c l i n i c a l  p r a c t i c e .  T h i s  
i n c l u d e s  t h e  u s e  o f  p h y s i c a l  
s e n s o r s  t h a t  a r e  a p p l i e d  e i t h e r  
t o  t h e  s u r f a c e  of t h e  body or  
a t  a d i s t a n c e  and do  n o t  
i n v o l v e  i n p u t  o f  mat te r  o r  
s i g n i f i c a n t  amounts  o f  e n e r g y  
i n t o  t h e  s u b j e c t  o r  an  i n v a s i o n  
of t h e  s u b j e c t ' s  p r i v a c y .  I t  
a l s o  i n c l u d e s  s u c h  procedures  
a s  w e i g h i n g ,  t e s t i n g  s e n s o r y  
a c u i t y ,  e l e c t r o c a r d i o g r a p h y ,  
e l e c t r o e n c e p h a l o g r a p h y ,  
t h e r m o g r a p h y ,  d e t e c t i o n  of 
n a t u r a l l y  o c c u r r i n g  
r a d i o a c t i v i t y ,  d i a g n o s t i c  
e c h o g r a p h y ,  a n d  
e l e c t r o r e t i n o g r a p h y .  It  does 
n o t  i n c l u d e  e x p o s u r e  t o  
e l e c t r o m a g n e t i c  r a d i a t i o n  
o u t s i d e  t h e  v i s i b l e  r a n g e  ( f o r  
e x a m p l e ,  x - r a y s ,  m i c r o w a v e s ) .  
(4) C o l l e c t i o n  of blood 
s a m p l e s  by v e n i p u n c t u r e ,  i n  
a m o u n t s  n o t  e x c e e d i n g  4 5 0  
DL!.S. Government P r ' n t i n p  O'fjcc : 1 9 6 8  - 2 0 1 - 7 7 8 / R O S 4 2  
m i l l i l i t e r s  i n  a n  e i g h t - w e e k  
p e r i o d  a n d  no more o f t e n  t h a n  
two times per week,  from 
s u b j e c t s  18 y e a r s  of ages o r  
o l d e r  a n d  who are  i n  good 
h e a l t h  a n d  n o t  p r e g n a n t .  
( 5 )  C o l l e c t i o n  of b o t h  
s u p r a -  a n d  s u b g i n g i v a l  d e n t a l  
p l a q u e  and  c a l c u l u s ,  p r o v i d e d  
t h e  p r o c e d u r e  is n o t  more 
i n v a s i v e  t h a n  r o u t i n e  
p r o p h y l a c t i c  s c a l i n g  of t h e  
t e e t h  a n d  t h e  process i s  
accompl ished  i n  a c c o r d a n c e  w i t h  
accepted p r o p h y l a c t i c  
t e c h n i q u e s .  
(6) Voice r e c o r d i n g s  made 
fo r  research p u r p o s e s  s u c h  as 
i n v e s t i g a t i o n s  of s p e e c h  
defec ts .  
(7) Moderate exerc ise  by 
h e a l t h y  v o l u n t e e r s .  
( 8 )  T h e  s t u d y  of e x i s t i n g  
d a t a ,  d o c u m e n t s ,  r eco rds ,  
p a t h o l o g i c a l  s p e c i m e n s ,  or  
d i a g n o s t i c  s p e c i m e n s .  
o r  g r o u p  b e h a v i o r  o r  
c h a r a c t e r i s t i c s  of i n d i v i d u a l s ,  
s u c h  a s  s t u d i e s  of p e r c e p t i o n ,  
c o g n i t i o n ,  game t h e o r y ,  or t e s t  
d e v e l o p m e n t ,  where t h e  
i n v e s t i g a t o r  does n o t  
m a n i p u l a t e  s u b j e c t s '  b e h a v i o r  
a n d  t h e  research  w i l l  n o t  
i n v o l v e  stress t o  s u b j e c t s .  
(10)  Research on d r u g s  o r  
d e v i c e s  fo r  which a n  
i n v e s t i g a t i o n a l  new d r u g  
e x e m p t i o n  or a n  i n v e s t i g a t i o n a l  
d e v i c e  e x e m p t i o n  is n o t  
r e q u i r e d .  
( 9 )  Research o n  i n d i v i d u a l  
s o u r c e :  46 FR 8392 
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a r e  
1NTRODUCTION 
f l i g h t  invest igat ions,  domestic or foreign, invo lv ing human subjects which 
funded, sponsored, or implemented by National Aeronautics and Space Admin- 
i s t r a t i o n  (NASA), conducted i n  NASA f a c i l i t i e s ,  a i r c r a f t  or spacecraft,  or 
which i nvo l ve  NASA p a r t i c i p a t i o n  t o  any degree, must be approved by t h e  NASA- 
Johnson Space Center (JSC), hrnan Research Pol icy  and Procedures Conmittee 
(HRPPC). The a u t h o r i t y  for t h i s  requirement i s  NMI 7100.8A and implementing 
NASA/JSC p o l i c y  i ns t ruc t i ons .  The HRPPC has the r e s p o n s i b i l i t y  f o r  ensuring 
the medical safety, health, and well-being of  a l l  human subjects i n  a l l  pre- 
f l i g h t ,  i n f l i g h t ,  and p o s t f l i g h t  a c t i v i t i e s  and ear ly  supporting ground-based 
i n v e s t i  gat i ons associated w i th  human f 1 i ght experiments or Detai 1 ed Supp lemen- 
t a l  Objectives (DSOs).  This r e s p o n s i b i l i t y  extends t o  hrman i nves t i ga t i ve  
r o l e s  whether as  subject or  operator (experimenter). 
The r e s p o n s i b i l i t y  of HRPPC a l s o  Includes a l l  JSC human inves t i ga t i ons ,  
whetner conducted on s i t e  o r  o f f  s i t e  (e.y., medical centers, hospi ta ls ,  
etc.), i n  which JSC personnel p a r t i c i p a t e  as subjects, P r inc ipa l  Invest igators  
( P I S )  o r  Co-Principal I nves t i ga to rs  (Co-PIS). JSC-funded human research a t  
a l l  o ther  i n s t i t u t i o n s  i n  which no JSC personnel par t i ’c ipat ion i s  d i r e c t l y  
invo lved,  sha l l  be reviewed by the I n s t i t u t i o n a l  Review Board (IR8) of the 
i n s t i t u t i o n  performing the research as prescribed i n  the J X  procurement docu- 
ment (see a r t i c l e  G, JSCM 510OA, Rev. 14). It i s  recognized t h a t  some i n s t i t u -  
t i o n s  w i l l  require t h a t  t h e i r  own IRb also review the use of f l i g h t  personnel 
a s  t e s t  subjects a t  t h e i r  i n s t i t u t i o n s .  Such a review does not supplant the 
review by the JSC/HHPPC. This dup l i ca t i on  of  e f f o r t  i s  unavoidable, because 
two d i f f e r e n t  sets of requirements must be met. 
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Thls Issuance I s  designed t o  d e t a l l  the documentatlon requlrements and the 
b a s l s  f o r  these requirements I n  order t o  f a c l l l t a t e  the approval process and 
a l l o w  the  i nves t i ga to rs  t o  devote t h e i r  energies t o  the conduct o f  t h e i r  
studles. The Comnittee has learned from past experience tha t  provlding the 
requi red documentation can be somewhat d i f f i c u l t ;  however, f a l l u r e  on the p a r t  
o f  t h e  PI t o  provide appropr iate documentatlon i n  a usable fonn can lead t o  
disapproval of some experimental protocols, d l s r u p t i o n  of t r a i n i n g  schedules, 
and unnecessary loss of time. Therefore, the Corni t tee urges a l l  persons 
associated w i th  human research t o  adhere t o  the l e t t e r  and s p i r i t  o f  the 
requirements set f o r t h  I n  t h i s  document. 
2.0 WORK I N G  PRINCIPLES FOR THE HRPPC 
A. Ensuring the health, well-being, and safety of  human research sub- 
j e c t s  i s  the fundamental bas is  f o r  the e n t i r e  process. The Comnittee approves 
only those invest igat ions i nvo l v iny  "minimal" or "reasonable r i s k . "  "Minimal 
r i s k "  means tha t  the harm o r  discomfort an t i c ipa ted  i n  the proposed research 
i s  not  greater, considering prohabi 1 i t y  and magnitude, than that  encountered 
i n  the  d a i l y  l i v e s  of healthy ind iv iduals ,  inc lud ing the recoynired r i s k s  i n -  
herent I n  a chosen occupation, such as spaceflight and ground support .  
Examples o f  "minimal r i s k "  are found i n  Appendix 1. "Reasonable r i s k "  means 
t h a t  the r i s k s  of harm an t i c ipa ted  i n  the proposed research a r e  greater than 
those o r d i n a r i l y  encountered i n  d a i l y  l i f e  or dur ing the performance of rou- 
t i n e  tes ts ,  but considered t o  be proper when weighed against the ant ic ipated 
bene f i t s  o r  importance of the knowledge t o  be gained from the research. 
B. The HRPPC does not dupl icate the e f f o r t s  o f  the Space Transportation 
System (STS) Payload Safety Review Panel i n  i t s  revlew of  i n f l i g h t  equipment 
o r  t he  e f t o r t s  of Safety, W e l l a b i l i t y  and Qual i ty Assurance (SWSVA) i n  i t s  
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rev iew o f  ground-based equipment, but the Comnittee does require documentation 
of  such safety analyses, 
C, Space f l i g h t  personnel are viewzd i n  the special l l g h t  of  t h e i r  i n -  
volvement i n  a mission. They w i  11, on many occasions, act as test  subjects or 
operators o f  t e s t s  i n  an environment p o t e n t i a l l y  invo lv ing more r i s k  than t h a t  
on Ear th due t o  the unusual aspects o f  space f l i g h t  such as microgravity, a l -  
t e r a t i o n s  i n  atmospheric conposi t ion and pressure, mu l t i p le  tasks being pe r -  
formed by a s ing le subject, confined l i v i n g  condi t ions,  t imel ine constraints,  
and remoteness from medical survei l lance. Because of  these factors,  a more 
vigorous review process i s  required f o r  spacef l ight  experiments than f o r  sim- 
i l a r  ground-based Invest igat ions.  
D. Protocols submitted t o  t h i s  Corn i t tee a r e  of two types: Master and 
Training. A Master Protocol consists of a de ta i l ed  descr ipt ion of  a l l  aspects 
o f  an i n v e s t i g a t i o n  and i s  used f o r  Spacelab studies, mid-deck experiments, 
De ta i l ed  Supplemental Objectives (USUS), and ground-based invest igat ions.  The 
Master Protocol i s  the f i r s t  document t o  be submitted t o  the Comnittee f o r  
approval. A Training Protocol consists of a deta i led descr ipt ion of the  
a c t i v i t i e s  of a spec i f ic  t r a i n i n g  tou r  and w i l l  general ly be used only by 
Spacelab invest igators .  It w i l l  inc lude object ives o f  the speci f ic  tour as 
w e l l  as a d a i l y  schedule of the t r a i n i n g  procedures (protocols)  and equipment 
t o  be used. The b a s i s  f o r  t h i s  requirement i s  that  Spac.elab l i f e  sciences 
experiments are expected t o  be evolut ionary i n  nature; the experiences from 
t r a i n i n g  tours and baseline data c o l l e c t i o n s  are expected t o  mandate changes 
i n  protocols .  Therefore, the HRPPC requires t h a t  the exact protocol f o r  each 
t r a i n i n g  tour/basel ine data c o l l e c t i o n  be reviewed and approved on a tour-by- 
t o u r  basis. Training protocol  approvals i n  any event are v a l i d  f o r  only a 
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12-month period. The P I  must submit a statement t o  the HRPPC 30 days p r i o r  t o  
the e x p i r a t i o n  o f  t h e  12month pe r iod  tha t  no changes have been made and 
request an approval renewal 
E. A1 though ground-based t ra in ing /base l i ne  data co l l ec t i ons  are l i k e l y  
t o  i nvo l ve  less r i s k  than i n - f l i g h t  experiments, the HRPPC requires that t h e  
r i g o r  and d i s c i p l i n e  necessary fo r  space f l i g h t  experimentation be i n s t i t u t e d  
t o  the extent poss ib le  dur ing the ground-based phases t o  ensure f a m i l i a r i t y  
w i th  these procedures dur ing f l i g h t ,  
F. The Comrlittee meets r e g u l a r l y  i n  executive session and u t i l i z e s  w r i t -  
ten documentation exc lus ive ly  i n  i t s  evaluat ion of protocols. Verbal assur- 
ances or  explanations are not acceptable. 
G .  A l l  members o f  the HRPPC a re  vot ing members. The Chairman w i l l  vote 
only i n  the event of a t i e .  A member w i l l  abstain from vot ing only i n  case o f  
c o n f l i c t  o f  i n te res t .  A quorum of the Committee shal l  consist o f  the Chair- 
person and s i x  addi t ional  members. Members of the Comnittee w i l l  inc lude s i x  
l i f e  s c i e n t i s t s  appointed by the  Chairperson ( inc lud ing a secretary-recorder), 
and a representat ive from each of the fo l lowing organizations: Chief Counsel ; 
D i r e c t o r  of Safety,  H e l i a b i l i t y  and Quali ty Assurance; and the  Astronaut 
Of f ice.  The Conmiittee w i l l  a lso include one "lay" or non- l i f e  sciences member 
and w e  non-NASA, f u l  I - t ime, federal  employee. Up t o  three ad hoc members i n  
specia l ized d i s c i p l i n e s  may be added t o  the Corni t tee on a temporary basis as 
deemed appropriate by the Chairperson. 
I-
3.0 PHOCEDUHt3 All0 HEOUIHEHCNTS FOK INVESTICATIUhb 
A. Invest igators  snal l  prov ide t o  the Corni t tee 20 loose- leaf  copies of 
a complete Master Protocol o f  p r e f l i g h t ,  i n - f l i g h t ,  and p o s t f l i g h t  a c t i v i t i e s .  
(For Spacelab studies, these should 
Master Protocols should be submitted 
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be rooted through the Mission Manager.) 
no l a t e r  than 6 months p r l o r  t o  a m i r -  
sion, f o r  o r i g i n a l  approval. The format presented i n  Appendix 2 sha l l  be em- 
ployed. It i s  designed t o  e l i c i t  e f f i c i e n t l y  the appropriate Information re -  
q u i r e d  by the Comnittee t o  grant approval and a l  so t o  emphasize t o  the inves- 
t i g a t o r s  c e r t a i n  r e s p o n s i b i l i t i e s  tha t  must be considered when dealing w i t h  
human subjects. I f  the protocol  changes, t he  invest igator  must provide 
dated replacement pages w i t h  the changed sections ind icated by bars i n  the 
margin as shown here and dated a t  the bottom of the page. The replacement 
pages w i l l  be submitted t o  the Comnittee by the Mission Manager. 
B. As a matter o f  general pract ice,  a l l  human research protocols p r i o r  
t o  submission t o  the HHPPC w i l l  have been approved by the SA S c i e n t i f i c  Mer i t  
Review Committee ( f o r  JSC invest igat ions) ,  peer reviewed, and submitted t o  one 
o r  more of  the fo l lowiny coinliittees as appropriate: 
1) JSC Radiat ion Satety Comnittee; 
2) Medical Isotopes Operations Subcommittee; 
3)  STS Payload Safety  Review Panel ( f o r  i n - f l i g h t  equipment); 
4 )  Satety Kel iab i  l i t y  and Quali ty Assurance ( f o r  yround-based equip- 
ment). 
C. A t  l e a s t  6 weeks p r i o r  t o  a t r a i n i n g  tour,  the invest igator  s h a l l  
p rov ide  the HRPYC w i t h  20 copies o f  the Training Protocol t o  be used i n  the  
tour .  I f  the experiment i s  t o  f l y  i n  the mid-deck o r  Spacelab, the Training 
Protocol  w i l l  be routed through the Mission Manager t o  the HRPPC. On t h e  
o the r  hand, i f  a US0 i s  involved, i t  w i l l  be submitted t o  the HRPPC by a rep- 
resen ta t i ve  of the Science Management Review Comnittee (SMRC). The headings 
and contents o f  t h i s  protocol  are de ta i l ed  i n  Appendix 3. Again the format i s  
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designed t o  improve t h e  e f f i c i e n c y  of In fo rmat ion  t r a n s f e r  and the  e l im ina -  
t i  on of unnecessary paperwork. 
0 .  A l l  p ro toco ls ,  t r a i n i n g  tours ,  and DSOs submit ted t o  the  Comnittee 
must be signed and dated by t h e  P I .  
E. A f t e r  i n i t i a l  approval of a DSO, resubmi t ta l s  of tne same US0 can be 
i n  t h e  form o f  a l e t t e r  or  memorandum t o  the  Comnittee, s t a t i n g  any changes o r  
problems w i t h  the LISU and the  date of the o r i g i n a l  approval by the  Corn i t tee .  
F. Once the Secretary  of t h e  Human Research P o l i c y  and Procedures Com- 
m i t t e e  has received a s a t i s f a c t o r y  and complete Master Protocol  and/or sub- 
sequent T ra in ing  Pro toco l  s f o r  speci f i c  t ou rs ,  the i n v e s t i g a t o r  w i  11 be o f f  i - 
c i a l l y  informed i n  w r i t i n g  of the  meeting date a t  which the  p r o t o c o l  w i l l  be 
reviewed. 
G. Tne Cormi t tee meets on the  f i r s t  and t h i r d  Thursday of each nonth. 
A l though the  Committee works on ly  from w r i t t e n  documentation, i t  may be d e s i r -  
a b l e  t o  have a representa t ive ,  who i s  i n t i m a t e l y  t a r n i l i a r  w i th  the study and 
i t s  p r o t o c o l ,  a v a i l a b l e  t o  answer quest ions regarding d e t a i l s  o f  the  p r o t o c o l  
and t o  deal w i t h  ac t i ons  requ i red  by the HHPPC. 
ti. If the p r o t o c o l  i s  deeiiied d e l i c i e n t  i n  some category, the  PI w i l l  be 
informed d i r e c t l y  or  through the  l l i s s i o n  Manager if add i t i ona l  i n fo rma t ion  i s  
requ i red .  Upon r e c e i p t  by the Secretary  of the Coinmittee, the new in fo rma t ion  
w i l l  be reviewed a t  t h e  next scheduled meeting, if i t  i s  rece ived 10 working 
days be to re  such a meeting. I t  i s  imperat ive,  there fore ,  t ha t  t h e  process of 
p r o t o c o l  review be i n i t i a t e d  a t  l e a s t  6 weeks before the  a n t i c i p a t e d  t r a i n i n g  
t o u r  i n  order t o  a l l o w  f o r  the  poss ib le  exchange of quest ions and answers. 
-
I 
I 
I 
i 
m 
I 
I 
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I, I f  the protocol  i s  approv.ed a t  t he  i n i t i a l  or  subsequent meeting, the 
P I  w i l l  be informed of such approval. I n  some cases, where minor 
d e f i c i e n c i e s  are found, the approval may be q u a l i f i e d  wi th some s t i p u l a t i o n  
t h a t  requires follow-up reports. Ord ina r i l y ,  these should be sent t o  the 
Secretary w i t h i n  2 weeks a f t e r  the completion o f  the t r a i n i n g  tour. (For 
Spacelab invest igat ions,  such repo r t s  should be routed through the Mission 
b n a g e r .  ) 
3 .  During the conduct of human research, a l l  a c t i v i t i e s  w i l l  be fmnedi- 
a t e l y  suspended (unless such suspension would endanger the subject),  and the 
Center D i r e c t o r  and the Chdirman, A l ternate Chairman, or Crew Surgeon immedi- 
a t e l y  informed i n  the event o f :  
(1) Any i n j u r y  t o  or i l l n e s s  of a subject ;  
( 2 )  Any change i n  the environment o r  the subject 's response t h a t  
could lead t o  some medical disturbance; 
Any substantive change from the approved protocol .  ( 3 )  
Furthermore, any one of the fo l l ow ing  i n d i v i d u a l s  has the au tho r i t y  t o  te rm i -  
nate the t e s t  and i n s i s t  on a review of the circumstances p r i o r  t o  the resump- 
t i o n  of  t e s t  a c t i v i t i e s :  1) Pr inc ipa Inves t i ga to r ;  2) Medical O f f i c e r ;  3) 
Test Engineer o r  Di rector ;  4) Test Subject; o r  5) Mission Manager. A 
dec i s ion  t o  terminate the t e s t  by any one of  the above i s  binding upon the 
o the r  responsible i nd i v idua l  s. 
K. A Medical O f f i ce r  of t h e  HHPPC W i l l  a t tend as many t r a i n i n g  tours a s  
deemed necessary by the HHPPC. The O f f i c e r  W i l l  receivc the minutes from 
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t r a i n i n g  debr ie f ing sessions. The Medical O f f i c e r  may be the Crew Surgeon or 
other  F1 i g h t  Surgeon, an HRPPC member, or  an appropr iate representat lve I 
1 designated by the HRPPC. 
L. As ind icated above, the Medical O f f i c e r  at tending a t r a i n i n g  session 
may terminate any experimental procedure tha t  he/she determines t o  be unsafe 
o r  presents a medical hazard t o  the experimental subject. Minor equipment and 
procedure changes may be approved by the Medical O f f l c e r  during the t r a i n i n g  
tour.  Any changes t h a t  the representat ive wishes t o  defer t o  the f u l l  HRPPC 
I 
I 
w i l l  delay t h a t  po r t i on  of the t r a i n i n g  u n t i l  t he  HRPPC has ruled on the chan- 
ges . I 
I 
I 
1 
I 
1 
H. I f ,  dur ing a t r a i n i n g  tour,  there i s  any (even minor) anomalous i n c i -  
dent i n v o l v i n g  human subjects, the inc ident  must be reported v i a  telephone 
wi th in  24 hours, and a w r i t t e n  Inc ident  Report submitted w i th in  one week t o  
the  Chairman. Such inc idents  might include adverse reactions t o  drugs o r  
e lec t rode  paste, trauma, eye i r r i t a t i o n s ,  equipment f a i l u r e  (anomalous opera- 
t i o n ) ,  animal b i t e s  or scratches, hematomata, etc. 
N. A l l  human research requ i r i ng  data c o l l e c t i o n  aboard t h e  KC-135 w i l l  
be reviewed and approved by the HHPPC a t  least  6 weeks p r i o r  t o  the scheduled 
flight. This approval appl ies as wel l  t o  a l l  payloads which may be poten- 
t i a l l y  hazardous t o  the heal th  of the crew and/or invest igators ,  such as those 
u t i l i z i n g  t o x i c  or rad ioact ive substances. 
I 
I 
1 
0. The Mission Manager of a given in tegrated payload involv ing human 
I n v e s t i g a t i o n s  w i l l  ensure t h a t  the Science Manager presents the t o t a l  
medical /experimental requirements for  the In tegrated payload t o  the HRPPC. 
This a c t i v i t y  w i l l  be coordinated w i th  the crew f l i g h t  surgeon, and w i l l  
[ 
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i nc lude  medical operational ( c l l n i c a l )  b l o o d j f l u i d  requirements, as wel l  as 
t o t a l  crew t ime scheduling requirements f o r  , a l l  phases o f  the mission (i.e., 
pre-, in- ,  and p o s t f l i g h t  periods) . 
P. Research i nvo l v ing  STS f l i g h t  personnel- requires t h a t  the NASA HUMAN 
RESEARCH MINIMAL R ISK INFORMED CONSENT FORM 1416, acknowledging "minimal 
r i s k s "  be completed (Appendix 4). I n  some cases, Wen the C m i t t e e  fee l s  a 
study involves "reasonable r i sk " ,  the crewmembers w i l l  be asked t o  complete 
the NASA HUMAN RESEARCH REASONABLE RISK INFORMED CONSENT FORM 1416A (Appendix 
5). This form w i l l  also be used for JSC studies, inc lud ing those funded, 
sponsored, or  implemented by JSC, using t e s t  subjects other than c r e m b e r s .  
E i t h e r  the NASA HUMAN RESEARCH MINIMAL R I S K  INFORMED CONSENT FORM 1416 o r  NASA 
HUMAN RESEARCH REASONABLE R I S K  INFORMED CONSENT FORM 1416A must be signed by 
the STS f l i g h t  personnel involved i n  the research, before the s t a r t  o f  any 
t r a i n i n g  tour .  These forms must then be sent t o  the Chairman of HRPPC and a 
copy t o  the F l i y h t  Medicine C l i n i c .  
Q. No crew t r a i n i n g  or  ground-based inves t i ga t i on  i s  pennitteu t o  can- 
mence unless a Master  Protocol has received o r i y i n a l  approval, the de ta i l ed  
procedures have been approved 6 weeks p r i o r  t o  a t r a i n i n g  tour, and consent 
forms have been obtained fran the human subjects and f i l e d  w i th  the HRPPC. 
R. Studies invo lv ing animals must adhere t o  the guidel ines wtrich are 
o u t l i n e d  i n  Appendices 6 and 7. Appendix 6 describes animal handling proce- 
dures f o r  p r e f l i g h t  crew t r a i n i n g  a c t i v i t i e s .  F l i g h t  simulations and space 
f l i g h t  procedures are described i n  Appendix 7. 
S. If animals are used i n  an experiment, the invest igator  must inc lude 
the fo l l ow ing  information i n  Section 8 of the Master Protocol: 
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(1) Precautions to  be used t o  malntain the Specif lc Pathogen-Free 
(SPF) status and tes ts  used t o  ascertain SPF status pr ior  to t ra ln lng or  
I 
I f l i g h t .  
( 2 )  Potent ia l  biohazards fran cold-blooded vertebrates must be 
I analyzed. 
I 
II 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
1 
1 
I 
I 
11 
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4.0 APPENDIX 1 
EXAMPLES OF RESEARCH A C T I V I T I E S  INVOLVING NO MORE THAN "MINIMAL RISK" 
The f o l l  owing research a c t i v i t i e s  (performed by standard methods) are consid- 
ered t o  invo lve no more than "minimal r isk" .  
(1) C o l l e c t i o n  o f  h a i r  and n a i l  c l ipp ings,  i n  a nondisf igur ing manner; decid- 
uous teeth;  and permanent teeth i f  pa t i en t  care indicates a need fo r  
ex t rac t i on .  
(2 )  Col 1 ect  ion o f  excreta and external secret tons i ncl uding sweat, uncannu- 
l a t e d  sa l iva,  placenta removed a t  del ivery,  and amniotic f l u i d  a t  the 
t ime o f  rupture of the membrane p r i o r  t o  or during labor. 
( 3 )  Recording of data f ra  subjects 18 years o f  age or older using noninva- 
s i v e  procedures rou t i ne l y  employed i n  c l i n i c a l  pract ice.  This includes 
the use of physical sensors t h a t  a r e  a p p l i d  e i t h e r  t o  the surface o f  the 
body or  a t  a d istance and do not involve input  of m a t t e r  or s i g n i f i c a n t  
amounts of energy i n t o  the subject, o r  an invasion o f  the subject 's p r i -  
vacy. It also includes such procedures as weiyhiny, t es t i ng  sensory 
acui  t y  , e l  ec t roca r d  1 ograp hy , e l  ectroencephal oyrayhy , the rmograp hy , detec- 
t i o n  of  n a t u r a l l y  occurr ing r a d i o a c t i v i t y ,  d iagnost ic echosonography, and 
electroret inoyraphy. It does not include exposure t o  electromaynetic 
r a d i a t i o n  outside the v i s i b l e  range ( fo r  example, x-rays, microwaves). 
(4 )  C o l l e c t i o n  of blood samples by venipuncture, i n  mounts not exceediny 450 
m i l l i l i t e r s  i n  an 8-week per iod and no more than trJo times per week, from 
subjects 18 years of age o r  older and M o  are i n  good heal th and not 
pregnant. 
I 
I 
I 
I 
1 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
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Co l lec t i on  of  both supra- and subgingival dental plaque and calculus, 
provided the procedure i s  not more invas ive than rout ine prophylact ic 
scal i ng o f  the teeth, and the process i s  accanpl ished fn  accordance wfth 
accepted prophylactic techniques. 
Voice recordings made for research purposes such as invest igat ions o f  
speech defects a 
Moderate exerci se by heal t hy  vol unteers . 
The study of ex i st ing  data , documents, records, pathol ogical specimens, 
or  diagnost ic specimens. 
Research on ind iv idual  or group behavior or  character is t ics  o f  i nd i v id -  
uals, such as studies of perception, cogni t ion,  game theory, or t e s t  
devel oyment, where the invest igator  does not  manipulate subjects' behav- 
i o r  and the research w i l l  not involve s t ress t o  subjects. 
Research on drugs or devices fo r  which an invest igat ional  exmpt ion  i s  
not required. 
1 13 
5.0 APPENDIX 2 m 
i 
I 
I 
0 
I 
E 
I 
I 
HUW RESEARCH W T E R  PROTOCOL* 
Spacelab or Shuttle F1 ight Designat ion 
Experiment Designation 
Funct i onal obj ect i ve Des f gnat i on 
2. ORGANIZATION CONDUCTIW THE RESEARCH 
Normally the i n s t i t u t i o n  w i th  which the P I  i s  a f f i l i a t e d .  
3. INVESTIGATORS 
A. L i s t  a l l  invest igators  s t a r t i n g  wi th  the P I ,  t h e i r  addresses, and 
phone numbers. Attach a Curriculum Vitae fo r  each inves t i ga to r  a t  the end of 
the protocol .  
B. L i s t  technical  personnel who w i l l  aid i n  and/or conduct the research. 
Attach q u a l i f i c a t i o n s  a t  the end of the protocol. The Canmittee i s  i n te res ted  
i n  the q u a l i f i c a t i o n s  o f  t he  technical s t a f f  t ha t  w i l l  be i n te rac t i ng  w i t h  the 
t e s t  subjects, because they w i l l  be operating equipment or  performing pro- 
cedures on them. 
4. HYPOTHESIS( ES) 
The hypotheses should be c l e a r l y  and succ inc t l y  stated. The Committee 
must consider s c i e n t i f i c  mer i t  as a factor  i n  weighing r i s k s  vs. bene f i t s .  
This sumnary should abstract the d e t a i l s  t o  be included i n  Section 5. 
* A l l  headings o r  statements i n  bold are t o  be included i n  tne protocol and i n  
the order l i s t e d .  
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5, PlRPOsE OF RESEARCH 
This sect ion may be handled by attachment (as an appendix) o f  in format ion sub- 
m i t t e d  i n  the o r i g i n a l  proposal. However, the invest igator  should ensure t h a t  the 
fo l l ow ing  in format ion i s  included: 
A. HISTORICAL BACKGROUW 
A b r i e f  background statement should t race  development o f  key fac to rs  o r  p r i n -  
c i p l e s  which led t o  formulation of the hypothesis. Reference t o  pe r t i nen t  scien- 
t i f i c  l i t e r a t u r e  i s  essent ia l  .* 
8. NEW IEORMTIOII EXPECTED 
6. JUSTIFICATION FOR USE ff tU)(Aw SUWECTS 
Exp la in  why humans are a necessary pa r t  o f  the study. 
7. STUDY PLAN AND SCHEDULE 
Give an overview of what w i l l  be accomplished during p r e f l i g h t  t ra in ing/base- 
1 fne data c o l l e c t i o n  sessions, i n - f l  i g h t  experimentation, and p o s t f l  i g h t  data 
acqu is i t i ons .  For example, f a m i l i a r i z a t i o n  with the concepts o f  the experiment, 
procedures t o  be learned, equipment t o  be used, data co l lect ion,  etc. 
A. cv\TES/DURATION 
Give as close an approximation as possible. Detai led schedules f o r  
Spacelab invest igat ions should be included i n  Tra in iny Protocols. 
80 PLACE(S) W TRAINIWTEST 
*Not required f o r  a DSO. 
c. suB3ECTS 
Provide names, if known, o r  f l i g h t  personnel des 
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gnation; e.g., Mis- 
s i o n  Spec ia l i s t  (MS) MS1, MS2, Payload Spec ia l i s t  (PS) PS1, PS2, PS Backup, 
C m a n d e r  (COR), P i l o t  (PLT) . 
8. EXPERIUENTAL PROTOCOLS AND EQUIPENT 
This sect ion contains some of the most important information used by the 
Committee. It i s  fran t h i s  sect ion t h a t  the Committee may i d e n t i f y  po ten t i a l  
problems tha t  might be overlooked by the invest igators.  Experience has shown 
t h a t  incompleteness of t h i s  sect ion i s  one o f  the major reasons f o r  HRPPC d i s -  
approval. 
A. 
Describe p r e f l i g h t  t r a i n i n y  and basel ine data c o l l e c t i o n  i n  terms o f  step- 
ident i - 
ground - 
PREFLIGHT TRAINING AND BASELINE M T A  COLLECTION 
by-step procedures and equipment used. All equipment items must be 
f ied.  I n  those instances where any hardware i s  used for t r a i n i n g  or  
based test ing,  the P I  i s  responsible f o r  providing de ta i l ed  descr ip t  
hazard analyses as an attachment t o  the protocol submittal.  The P I  
responsible f o r  maintaining conf igurat ion control  o f  the hardware t o  
ons and 
i s  also 
prevent 
any modi f icat ions tha t  would compromise the hazard analyses. Inspection 
records must be provided t o  assure the hardware conf igurat ion and t o  assure 
adherence t o  t e s t  requi rements/procedures. Functional t e s t  and check-out o f  
equipment u t i 1  i z i n g  non-f l  iyht-crew personnel i s  required. A l l  equipment 
whether canmercial , modif ied canmercial or  custom designed, used i n  f i t  and 
funct ionai  t e s t i n g  must be inspected by the SRi3QA. These resul ts ,  together 
with equipment safety c e r t i f i c a t i o n  must be submitted by the P I  t o  the HRPPC 
p r i o r  t o  f l i y h t  crew usage. 
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80 I I I F L I W T  ACTIVITIES 
L i  s t  step-by-step procedures and q u i  pment used, approxlmate durat lon of 
the test ing,  how many f l i g h t  personnel are necessary, and how many times the 
experiment w i l l  be performed . 
C. #)STFLIGHT ACTIVITIES 
I f  p o s t f l i g h t  test ing of flight personnel Is necessary, note how many 
times the t e s t  w l l l  be done, when, where, and what procedures and equipment 
w i l l  be used. 
9 .  HAZARDS M U Y S E S  AND SAFETY PRECAUTIONS 
Deta i l  the conceivable hazards that  mlght be encountered during the study 
and the precautions that w i l l  be taken t o  avoid them. For research invo lv ing 
animal hand1 i ng , 1 i s t  precautions employed f o r  m i  nimi ziny zoonoses ( see page 9 
of handbook) 
A. PREFLIGHT ACTIVITIES 
1. POTENTIAL HAZARDS 
2. PROTECTION TO MINIMZE RISKS 
3. ASSESSQNT OF RESIDUAL RISKS 
I. IN-FLIGHT ACTIVITIES 
1. HITENTIAL HAZARDS 
2. PROTECTION TO MINIMIZE RISKS 
3. ASSESSMENT W RESIDUAL RISKS 
C. POSTFLIBIT ACTIVITIES 
1. POTENTIAL HAtARDS 
2. PROTECTION TO MINIMIZE RISKS 
3. ASSESSENT OF RSSIWAL RISKS 
10. POSSIBLE INCONVENIEIICES OR DISamFORTS TO SUWECTS 
L i s t  addi t ional  factors t h a t  do not f a l l  i n t o  the category 
t h a t  should be considered. 
11. EXTENT W PHYSICAL EXANINATIONS 
I n  many cases, re l iance on the annual physical examinat 
personnel i s  a l l  t h a t  need be stated. I f  a special physical 
on fo r  f l i g h t  
kxaminat ion o r  
special  t e s t  Is required, describe i t  and s ta te  why i t  i s  needed. 
12. AVAILABILITY OF A PHYSICIAN AND CEDICAL FACILITIES 
13. REQUIRED STATWNTS FOR MUAN RESEARCH SUBJECTS 
A. The subject w i l l  be free t o  withdraw from t he  research a t  any time. 
[Except . ..(describe any circumstances under which i t  would be hazardous or  
unwise t o  do so.)] 
8. The i d e n t i t y  of human subjects w i l l  not be released t o  the general 
pub l i c  wi thout h i s  o r  her consent unless s p e c i f i c a l l y  required by law. 
C. There W i l l  be no addi t ional  wage, salary, or other renu- 
n e r a t i o n  of  any fonn paid, given, o r  i n  any manner del ivered t o  the t e s t  sub- 
j e c t s  o f  t h i s  invest igat ion where the subjects a r e  NASA employees o r  NASA con- 
t r a c t o r  enployees and the terms of the contracts w i th  NASA provide f o r  par- 
t i c i p a t  ion as subjects i n  approved experiments. 
0. The human research Subjects are NASA employees, NASA contractor  em- 
ployees or  independent contractors, and the t r a i n i n g / t e s t i n g  i s  par t  o f  t h e i r  
employment o r  contractual circumstances. Therefore, NASA i s  responsible f o r  
compensation f o r  i n j u r y ,  death, o r  property damage t o  the extent required by 
the  Federal Employees Canpensation Act o r  the Federal Tort Claims Act. 
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14 REQUIRED ATTACHMENTS 
A. Include informat ion concerning the human research t o  be communicated 
t o  the  subjects i n  the course o f  obtaining t h e i r  informed consent. Alony wi th  
a signed consent form, a t tach  a summary, signed by the subject, descr ib ing i n  
layman's terms t h e  procedures the  subject w i l l  underyo. Should the subject be 
f low on the KC-135 airplane, include the fol lowing statement i n  the summary: 
"Since t h e  KC-135 i s  considered t o  be a publ ic a i r c r a f t  within the meaning o f  
the f e d e r a l  Av iat ion Act o f  1958, as mended, and as such, does not hold a 
c u r r e n t  airworthiness c e r t i f i c a t e  issued by the Federal Av iat ion Administra- 
t i o n  (FAA),  any i nd i v idua l  manifested to board the KC-135 should determine 
before boarding whether h is /her  personal l i f e  o r  accident insurance provides 
coverage under such conditions." 
8. If required, a t tach the appropriate JSC Consent Forr t o  be employed 
(see Appendices 4 8 5) .  Specify the appendix designation i n  t h i s  section. I f  
not required, so state. 
C, Attach a copy of the  Approval by the P I ' S  I n s t i t u t i o n a l  Review 
Board (Human Research or  Eth ics Committee). Speci fy the appendix designation. 
0. Attach a copy of the I n s t i t u t i o n a l  Safety Authority's most recent 
S p c i  fy appendix designation( 5) .  c e r t i f i c a t i o n  of a1 1 ground-based equipment. 
E. If external r a d i a t i o n  sources or  radionucl ides are enployed (see 
Appendix 8 ) ,  t h e i r  use must have the approval of the 3SC Radiation Safety Can- 
m i t t e e .  Attach a copy of the Approval of the JSC Radiation Safety Ctmittee, 
Speci fy appendix designation. 
F, Research use of drugs f o r  Indicat ions not i n  the package i n s e r t  i s  
subJect t o  Federal Drug Administrat ion (FDA) r e s t r i c t i o n s .  Pr ior  t o  shipping 
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t h e  drug i n  i n t e r s t a t e  comnerce, e i t h e r  I t s  sponsor ( the manufacturer) or the 
c l i n i c a l  i nves t i ga to r  nust f i l e  form FDA 1571, 'Notice of Claimed Invest iga-  
t ional  Exenption For A Mew Drug (IND)" wi th  the FDA. The FOA regulat ions also 
r e q u i r e  each c l i n i c a l  i nves t i ga to r  who uses i nves t i ga t i ona l  drugs i n  humans t o  
f i l e  wi th  the sponsor o f  the Invest igat ional  New Drug ( I N D )  e i t h e r  form FDA 
IS72 o r  form FDA 1573, OStaternent of Invest lgator '  (See Section 12.0 Appendix 
9). At tach a copy of each form t h a t  has been f i l e d  and proof of submission 
date (e.g, c e r t i f i e d  m a i l  r e c e i p t )  or a statement o f  not having received a 
w r i t t e n  rep l y  from the FDA 60 days a f te r  the submission of forms. Attach a 
copy of the FDA reply,  if i t  had been received. 
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6.0 APPENDIX 3 
TRAININ6 PROTocoC+ 
Spacelab Designation 
Experlmecrt # 
Training Tour # 
Location o f  Tninlng 
Dates o f  Training 
Sbjec ts  
10 TITLE 
2, ORWIUTIOW CO~UCTIffi THE RESEARCH 
3. INUESTIGATORS AND TECHNICAL PERSONNEL 
L i s t  the name of the P I ,  address, and phone number. Reference t o  the 
Master Protocol may be made for other invest igators and technical personnel. 
I f  chanyes have been made, note the changes and supply qual i f icat ions i f  not 
already on f i l e .  
4. OBJECTIVES OF THIS TOUR 
Stat ing the objectives of the sQecif ic t ra in ing  session will  aid those 
who are conducting the tour t o  focus on what they wish t o  accomplish and help 
the Committee t o  understand the i n ten t  of  an ind iv idual  t ra in ing  tour. Relate 
the object ives t o  the resul ts o f  previous t ra in ing  tours ( i f  any). 
5. #TAILED DAILY SCHEDULE Of TRAININ6 ACTIVITIES 
The schedule will provide the Camnittee an idea of the in tens i ty  and 
durat ion o f  each day of t ra in ing  as well as the step-by-step procedures and 
* A l l  headings i n  bold are t o  be included i n  the protocol as l i s ted .  
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equipment t o  be employed. Reference can be made t o  the Master Protocol f o r  
d e t a i l s ,  but  each step must be l i s t e d  and any dev iat ion frun the Master Proto- 
c o l  must be noted. I f  substantive o r  permanent changes from the Master Proto- 
c o l  have been made, supply dated and marked replacement pages f o r  the Master 
Protocol .  (See page 5 o f  t h i s  handbook.) 
6 .  H A W S  
Restate a l l  o f  the po ten t i a l  hazards fo r  the speci f ic  t r a i n i n g  tour  as 
ex t rac ted  fran the Master Protocol. 
7. IFORHED CONSENT FOM 
I f  required, at tach the appropriate consent form t o  be used. L i s t  i n f o r -  
mat ion t o  be provided t o  the Subjects. Reference may be made t o  Master Proto- 
c o l  . I f  a consent form i s  not requi red, so state.  
8. M I D I T I O W  ATTACHMENTS 
A. Updated Safety C e r t i f i c a t e s  ( inspect ion and c e r t i f i c a t i o n  o f  ground- 
based equipment should be p e r f o n e d  annual l y ) .  
6 .  Updated I R B  Cer t i f i ca tes .  
C. Q u a l i f i c a t i o n s  o f  New Personnel 
I 
3 
t 
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7.0 APPENDIX 4 
NASA HUMAN RESEARCH 
MINIMAL R I S K  
INFORMED CONSENT FORM 
1. I, the undersigned, do v o l u n t a r i l y  g ive my informed consent f o r  my p a r t i -  
c i p a t i o n  as a t e s t  subject t o  the fo l lowing tes t ,  experiment, o r  other 
evaluat ive procedure. 
NAM OF EXPERIMENT 
TRAINING TOUR NUMBER 
FLIGHT TO WHICH ASSIGNED 
NAN OF DESIGNATED PRINCIPAL INVESTIGATOR 
N A M  OF RESPONSIBLE NASA PROJECT SCIENTIST 
I understand t h a t :  
(a )  This procedure i s  par t  o f  an experiment approved by NASA. 
(b )  I an performing these dut ies as p a r t  o f  my employment, w i th  
( c )  This procedure has been reviewed and approved by the JSC Human Re- 
search Pol i c y  and Procedures Cmmittee (HRPPC) and determined tha t  
the procedure involves no more than minimal r i s k  t o  the Subject. 
(d )  "Minimal r i s k "  means t h a t  the harm or discomfort ant ic ipated i n  the 
proposed research i s  not greater, considering p r o b a b i l i t y  and magni- 
tude, than those encountered i n  the d a i l y  l i v e s  o f  healthy indiv idu- 
als, i nc lud iny  the recognized r i s k s  inherent i n  a chosen occupation, 
such as syacefl  i g h t  and ground support . 
( f )  I am med ica l l y  q u a l i f i e d  t o  p a r t i c i p a t e  i n  the procedure. 
( 9 )  I may withdraw from the procedure a t  any time unless, as recomnended 
by the P r i n c i p a l  Invest igator,  o r  h is/her designee, the withdrawal 
i s danyerous or  impossible. 
(h)  I n  the event o f  physical i n j u r y  r e s u l t i n y  from the procedure and 
c a l l i n g  f o r  immediate action o r  a t t e n t i o n  t h a t  NASA w i l l  provide, o r  
cause t o  be provided, the necessary treatment. I also understand 
t h a t  NASA w i l l  pay f o r  any claims of i n j u r y ,  loss o f  l i f e  or p r o p  
e r t y  damage t o  the extent required by the Federal Employees' Compen- 
sat ion Act o r  the Federal Tort Claims Act. My agreement t o  p a r t i c i -  
pate sha l l  not be construed as a release of NASA o r  any t h i r d  party 
frm any f u t u r e  l i a b i l i t y  which may a r i se  from, or  i n  connection 
with, the above procedures. 
2. I ,  the undersigned, the Pr inc ipa l  Invest igator  o f  the experiment desly- 
nated above, c e r t i f y  that :  
(a )  I have accurately described the procedure t o  the tes t  subject. 
(b) Tne t e s t  set-up involves minimal r i s k  t o  the tes t  subject. A11 
equipment used has been inspected and c e r t i f i e d  for safe and proper 
operation . 
(c) The t e s t  subject i s  medical ly q u a l i f i e d  t o  par t i c ipa te .  
( d )  The t e s t  protocol has not been changed from that  approved by the 3SC 
Human Research Pol i c y  and Procedures Camni t t e e  (HRPPC) . 
APPROVED : 
Test Subject 
~ ~ 
Date 
Pr inc ipa l  Inves t iga tor  Date 
Pro jec t  Sci ent i s t  Date 
This consent form i s  v a l i d  for a 60-day period from the date o f  signature by 
the subject and the Pr inc ipa l  Invest igator  (which dates should be ident ica l ) .  
A siyned, dated copy of the form should be forwarded t o  the JSC Human Research 
P o l i c y  and Procedures Committee, M a i l  Code SA, Lyndon B. Johnson Space Center, 1 Houston, Texas 77058. 
I 
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8.0 APPENDIX 5 
1. I, the undersigned, do v o l u n t a r i l y  g ive my Informed consent f o r  my par- 
t i c i p a t i o n  as a t e s t  subject I n  the fo l lowing tes t ,  experiment, or  o ther  
evaluat ive procedure: 
NAFE OF EXPERIMENT 
TRAI  N I  NG TOUR NUMBER 
FLIGHT TO WHICH ASSIGNED 
NAME OF DESIGNATED PRINCIPAL INVESTIGATOR 
N A E  OF RESPONSIBLE NASA PROJECT SCIENTIST 
I understand tha t :  
( a )  
( b )  I am performing these du t i es  as a pa r t  o f  my employment, w i t h  
This procedure i s  par t  of an experiment approved by NASA. 
( c )  This  procedure has been reviewed and approved by the JSC Human and 
Research Pol i c y  Procedures Canmi t t e e  (HRPPC) and determined t h a t  the 
procedure involves reasonable r i s k  t o  the  subject 
( d )  "Reasonable r i s k "  means tha t  the r i s k s  o f  harm ant ic ipated i n  the 
proposed research are greater than those o r d i n a r i l y  encountered i n  
d a i l y  l i f e  o r  during the performance of rout ine tests ,  but con- 
sidered t o  be proper when weiyhing the ant ic ipated bene f i t s  and the 
importance of the knowledye t o  be gained fran the research. 
(e )  The procedure has been explained t o  me p r i o r  t o  the execution o f  
t h i s  form. I was af ford& an opportuni ty t o  ask questions, and a l l  
questions asked were answered 
( f )  I an medical ly q u a l i f i e d  t o  p a r t i c i p a t e  i n  the procedure. 
( 9 )  I may withdraw from the procedure a t  any t ime unless, as recommended 
by the Pr inc ipa l  Invest igator ,  o r  h is/her designee, the withdrawal 
i s  dangerous o r  impossible 
( h )  I n  the event of physical i n j u r y  r e s u l t i n g  fran the procedure and 
c a l l i n g  for immediate act ion or  a t t e n t l o n  t h a t  NASA w i l l  provide, o r  
cause t o  be provided, the necessary treatment. I also understand 
t h a t  NASA w i l l  pay f o r  any claims o f  i n j u r y ,  l oss  of l i f e  o r  prop- 
e r t y  damage t o  the extent  required by the Federal Employees' Canpen- 
pate shal l  not be construed as a release o f  NASA or any t h i r d  pa r t y  
fi.a any fu ture l i a b i l i t y  which may a r i se  fran, or  i n  connection 
with, the above procedures. 
sat ion Act o r  the Federal Tor t  C l a i m s  Act.  
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2. 1, the undersigned, the Pr inc ipa l  Investigator of  the experiment desig- 
nated above, c e r t i f y  that: 
(a)  I have accurately described the procedure t o  the tes t  subject. 
(b) The t e s t  set-up involves reasonable r i s k  t o  the tes t  subject. A l l  
equipment used has been inspected and c e r t i f i e d  for safe and proper 
operation. 
(c )  The t e s t  subject i s  medical ly qual i f ied t o  part ic ipate.  
(d )  The t e s t  protocol has not been changed fran that  approved by the JSC 
Human Research Pol i c y  and Procedures C m i  t t e e  (HRPPC) . 
APPROVED : 
Test Subject Da te  
Pr inc ipa l  Investigator Date 
Pro jec t  Sc ient is t  
This consent form i s  va l id  for  a 60-day period from the date of  siynature by 
the subject and the Pr inc ipa l  Invest iyator (which dates should be ident i -  
ca l ) .  A signed, dated copy of the form should be forwarded t o  the JSC Human 
Research Policy and Procedures Canmittee, Mail Code SA, Lyndon B. Johnson 
Space Center, Houston, Texas 77058 . 
26 
9.0 APPENDIX 6 
GUIDELINES RELATIVE TO USE OF EXPERIMENTAL ANIHALS 
DURING PREFLIGHT CREW TRAINING A C T I V I T I E S  
These guide l ines s p e c i f i c a l l y  address the t r a i n i n g  a c t i v i t i e s  a t  the home 
i n s t i t u t i o n s  (medical centers /un ivers i t ies)  of the P I  conducting experiment- 
s p e c i f i c  t r a i n i n g  and s i m i l a r  t r a i n i n g  a c t i v i t i e s  a t  per t inent  NASA f a c i l  i- 
t i e s  . Guide1 ines r e l a t i v e  t o  animal standards and procedures for t r a i n i n g  
s imulat ions u t i 1  i t i n g  the f l i g h t  Research Animal Holding F a c i l i t y  (RAHF), 
a l t i t u d e  chamber simulat ions (closed environments), and actual space f l i g h t  
are addressed i n  a- separate appendix, 
1. A l l  animal holding f a c i l i t i e s  o r  breeding colonies w i l l  general ly 
adhere t o  the guide1 ines and recommendations of the American Associat ion of 
Laboratory Animal Science (AALAS) and the American Association f o r  Accelera- 
t i o n  of Laboratory Animal Care (AAALAC) . 
2 .  The Speci f ic  Pathogen-Free (SPF) c r i t e r i a  f o r  r a t s  a r e  given i n  Enclo- 
sure 1. C e r t i f i c a t i o n  by r e l i a b l e  commercial suppl iers that  t h e i r  animals are 
f ree o f  these pathogens i s  acceptable t o  the C m i t t e e .  Periodic inspect ion 
o f  t he  animals for  c l i n i c a l  signs o f  i l l n e s s  by animal handlers i s  required. 
Should animal s become c l  i n ica l  l y  ill , they should be excl uded from the colony 
and a l l  reasonable attempts made t o  establ ish an e t i o l o g i c  diagnosis. I n  
these circumstances, the remaining animals must be r e c e r t i f i e d  pathoyen-free, 
or, a l t e r n a t i v e l y ,  a new supply secured fran the vendor. 
27 
3. For t r a i n i n g  n i t h  r a t s  a t  the above f a c l l l t l e s ,  acceptable laboratory  
a t t i r e  i s  recanmended. Ord lnar l ly ,  t h i s  means only a laboratory coat. The 
use of  surgical  masks and gloves I s  crew optlonal . 
SQUIRREL MONKEYS 
Spec i f i c  Pathogen-Free (SPF) c e r t l f i c a t l o n  w i l l  be v a l i d  f o r  a period o f  6 
months. Should hands-on t r a i n l n g  w i th  squi r re l  monkeys be requlred a t  any o f  
the above f a c i l l t i e s ,  the SPF c r i t e r i a  for  space f l i g h t  animals shal l  apply 
(Enclosure 2). It must be re-emphasized here tha t  the crew w i l l  not be per- 
m i  t ted t o  come I n  contact w i th  Herpesvi rus saimi r i - pos i  t l ve  squi r r e l  monkeys 
a t  any time. 
The r i s k  o f  amphibian zoonosis i s  almost non-existent. Acceptable labora- 
to ry  a t t i r e  i s  recommended, v iz . ,  a laboratory coat. Other protect ive meas- 
ures are crew opt ional .  
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SPF CRITERIA FOR RATS 
MICROORGANISM 
CULTURE S I  TE/HATER IAL 
OR 
IOE N T I  F ICAT ION TEST 
BACTERIA : 
S t  rep tobac i  11 us moni 1 i f ormi s 
S t  reptococcus pyogenes 
Sal monel 1 a sp. 
Lep tosp i ra  sp. 
Campy1 obacter  sp. 
VIRUSES: 
Lymphocyt i c cho r i omeni ny i t i  s v i  r u  s 
FUNGI : 
A1 1 Dermatophytes 
ECTOPARASITES: 
ENDOPARASITES: 
Or a1 
Oral, Nasal 
Fecal 
Urine 
Fecal 
B1 ood (Serol ogy) 
Skin ( C l i n i c a l  Inspect ion)  
Skin, Ha i r  
Feces, Caecal Contents 
Enclosure 1 
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SPF CRITERIA  FOR SQUIRREL MONKEYS 
MI C ROORGAN I SM 
BACTERIA : 
S h i g e l l a  sp. 
Sal monel 1 a sp. 
Streptococcus pneumoniae 
Hycobacteri urn tubercul os1 s 
Pasteurel 1 a mu1 toc ida 
Campy1 obacter sp. 
Leytospi  r a  sp. 
S t  reptococcus pyogenes 
VIRUSES: 
Lymphocytic chor iomeningi t is  v i r u s  
Herpes tamarinus 
Herpesvirus saimi r i  
E NUOPARAS I TES: 
T r i  c homona s 
Acanthocephl ans 
Strongyl  oides 
Entamoeba h i s t o l y t i c a  
Henoprotozoa 
FUNG I : 
A1 1 Dermatophytes 
CULTURE SITVMTERIM 
OR 
IDENTIFICATION TEST 
Fecal 
Fecal 
Oral , Fecal 
Skln Test, X-Ray 
Nasal , Fecal 
Fecal 
Ur i ne 
Oral , Nasal 
B1 ood (Serol cyy) 
B1 ood ( Serol ogy) 
81 ood (Serology) 
Oral 
Feces 
Feces 
Feces 
B1 ood 
S k l  n 
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Enclosure 2 
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10.0 APPENDIX 7 
GUIDELINES RELATIVE TO USE OF EXPERIMENTAL ANIMALS DURING CREW 
TRAINING SIMULATIONS UTILIZING THE FLIGHT RESEARCH ANIMAL 
HOLDING FACILITY (RAHF) AND GENERAL PURPOSE WORK STATION 
(GPWS) , ALTITUDE CHAMBER SIMULATIONS (CLOSED ENVIRONMENTS) 
AND ACTUAL SPACEFLIGHT 
Th is  memorandum sumnarires the HRPPC's c u r r e n t  requirements and r e c m e n -  
da t i ons  regard ing sub jec t  standards and procedures as viewed i n  the  context  of 
pas t  adv isory group meetings on t h i s  and re la ted  top i cs .  
(1) A l l  animal ho ld ing  f a c i l i t i e s  and/or breediny co lon ies  w i l l  genera l l y  
adhere t o  the gu ide l i nes  and recamendations o f  the  American Associat ion o f  
Laboratory  Animal Science (AALAS) and the American Associ a t  i o n  f o r  Accel era- 
t i o n  of Laboratory  Animal Care (AAALAC). 
( 2 )  Only Spec i f i c  Pathogen-Free (SPF) r a t s  and s q u i r r e l  monkeys w i l l  be 
u t i l i z e d  f o r  subject  t r a i n i n g  and f l i g h t  a c t i v i t i e s .  The SPF c r i t e r i a  f o r  
r a t s  are y iven  i n  Enclosure 1, and fo r  squ i r re l  monkeys i n  Enclosure 2. The 
r i s k  o f  amphibian zoonosis i s  almost non-existent, t he re fo re  no special c e r t i -  
f i c a t i o n  i s  requi red.  
( 3 )  Other animal species proposed f o r  approved f l i g h t  experiments w i l l  be 
considered by t h e  Committee on an i nd i v idua l  bas is .  
( 4 )  The f o l l  owi ng general guide1 i nes w i  11 be f o l l  owed where appl i c a b l  e : 
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A. Standard Microbio log ica l  Practices 
1. Work surfaces W i l l  be decontaminated w i th  a su i tab le  d i s i n -  
f ec tan t  a f t e r  use o r  a t  l e a s t  da i l y .  
2. A l l  waste l i q u i d s ,  sol ids,  t lssues, syringes and needles w i l l  
be placed i n  durable, leakproof, puncture-resistant, sealed containers f o r  
eventual autoclaving, inc inerat ion,  or other appropriate decontamination/dis- 
posal procedure pos t - t ra in ing  , post-simulat ion or  p o s t f l  ight .  Such ma te r ia l s  
w i l l  not  be transported between Spacelab and Orbi ter .  
3. Hypodermic needles and syringes sha l l  be used only f o r  the 
parenteral i n j e c t  ion o r  asp i ra t i on  of  f l u i d s  from laboratory  animals and d ia -  
phragm bo t t l es .  Only needle-locking syringes or disposable needle syr inge 
u n i t s  (i.e., the needle i s  i n teg ra l  t o  the syringe) are t o  be used f o r  the 
i n j e c t i o n  o r  asp i ra t i on  of f l u ids .  Needles should not be bent, sheared o r  
removed f ran  the syr inye fo l lowing use. Needles should not be replaced i n  the 
p l a s t i c  sheath o r  guard p r i o r  t o  disposal. Needle and syringe should be 
promptly placed i n  puncture-proof container f o r  eventual decontamination , 
preferably by autoclaving, before f i n a l  discard. 
4. Personnel w i l l  use appropriate a n t i s e p t i c  wet wipes or other  
ava i l ab le  means f o r  cleaning hands a f t e r  hand1 ing  animals, when depart ing the 
laboratory,  and especia l ly  before eating. 
5. Laboratory coat  {or equivalent) w i l l  be worn when animals are 
handled . 
t 
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8. Animal C e r t i f i c a t i o n  
1. Animals w i l l  be c e r t i f i e d  SPF by t he  supp l ie r  for  the pro- 
sc r ibed organisms l i s t e d  i n  Enclosures 1 and 2. The r a t s  w i l l  be housed 
together  i n  p a i r s  i n  f i l t e r e d  cages. One animal or each p a i r  w i l l  be sampled 
f o r  m ic rob ia l  screening 72 hours p r i o r  t o  crew contact .  Presumptive r e s u l t s  
w i l l  be ava i l ab le  i n  24 hours and d e f i n i t i v e  r e s u l t s  i n  72 hours. The crew 
w i l l  n o t  be exposed t o  e i t h e r  animal i n  a given cage i f  the sampled animal 
c u l t u r e s  are p o s i t i v e  fo r  a proscr ibed oryanism. Rat v i r a l  serology w i l l  be 
completed two weeks p r i o r  t o  crew exposure according t o  es tab l i shed pro toco ls .  
2. The S q u i r r e l  Monkeys w i l l  be screened fo r  proscr ibed organisms 
a t  six-month i n t e r v a l  5 .  The f l  i y h t  animals selected w i l l  have v i r a l  serology 
screeniny completed one month be fore  use and W i l l  be cu l tu red  f o r  proscr ibed 
b a c t e r i a  96 hours p r i o r  t o  crew contact. A l l  m ic rob io log i ca l  t e s t  r e s u l t s  
w i l l  be forwarded t o  the  Committee as pa r t  of the  Operational Readiness Review 
(ORR) . 
3 .  SPF c e r t i f i e d  Squ i r re l  Monkeys w i l l  a t  a l l  times be housed i n  
t h e i r  ow dedicated v i v a r i m  apar t  f ran  other  n o n - c e r t i f i e d  sub-human p r i -  
mates. The dedicated v ivar ium w i l l  be provided w i t h  a separate v e n t i l a t i o n  
system so as t o  preclude contamination frm o the r  animals. 
C. Research Animal Hold ing F a c i l i t y  (RAHF) and General Purpose Work 
S t a t i o n  (GPWS) I n f l i g h t  Guidel ines 
1. .With the  improved i n t e y r i t y  o f  animal enclosures and associ- 
a t e d  f l i g h t  procedures, THE ROUTINE USE OF LABORATORY ATTIRE I S  NOT REQUIRED. 
. 
~ ~- 
~ ~ 
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I f  ananalous s i tua t ions  should develop which produce free contaminants, a l l  
cremembers w i l l  use su i tab le  p ro tec t ive  measures (viz., surgical masks) u n t i l  
the p a r t i c u l a r  experiment o r  procedure i s  terminated and the contaminant 
removed from the spacecraft. This precaution i s  necessary i n  the closed 
microgravi  t y  envi rorment , since contamination does not remain lWa1 l z e d  i n  the 
continuous atmosphere of the Spacelab and Orbi ter .  
Pa r t i cu la r  care should be exercised during the fol lowing pro- 
cedures : 
a. Rats: Waste tray and food canister changeout; cage 
removal ; condensate b o t t l e  changeout; GPWS operations involv ing animals. 
b. Squirrel  Monkeys: Waste tray changeout; ur ine canis ter  
changeout; food cani s te r  changeout; blood sample col 1 ect lon . 
2 .  HEPA f i l t r a t i o n  system of the RAHF and GWPS w i l l  f i l t e r  a l l  
p a r t i c l e s  greater than 0.3 microns. 
3.  Biological  SMlpleS fran animals shal l  not contaminate the 
spacecraft o r  crew a t  any time including co l lec t ion ,  t ransport  and storaye 
procedures. 
4. Animals transported between the RAHF and GPWS must be enclosed 
i n  a c a r r i e r .  
5. Equipment and procedures for  the housiny, transport,  and 
experimental protocol must preclude any p o s s i b i l i t y  o f  animal escape i n t o  the 
spacecraf t  . 
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SPF C R I T E R I A  FOR RATS 
MICROORGANISM 
BACTERIA : 
S t r e p t o b a c i l l u s  mon i l i f o rm is  
Spi r i  11 um m i  nus 
Streptococcus pneumoniae 
-
Streptococcus pyoyenes 
B a c i l l u s  p i l i f o r m i s  
Co ry n e b a c t e r i urn k u t s c her i 
Salmonel 1 a 3p. 
Pas teu re l l  a pneumotropica 
Leptospi ra  sp. 
Campy1 obacter sp. 
VIRUSES: 
Lymphocytic chor 
Rat parvov i ruses 
Rat coronavi rus 
S i  a1 odacryadeni t 
Sendai v i r u s  
FUNGI : 
A1 1 Demiatophytes 
ECTOPARASITES: 
E NDOPARAS I TE S : 
omeni ng i t i  s v i  rus 
s v i r u s  
CULTURE SITE/WATERIAL 
oft lOENTIFICATION TEST 
O r  a1 
O r  a1 
Oral, Nasal 
Oral, Nasal 
L i ve r  ( Invoke w i th  Cortisone) 
Fecal, Oral 
Feca 1 
Oral, Nasal 
U r  i ne 
Fecal 
B1 ood ( Serol oyy) 
B1 ood (Serol ogy) 
81 ood ( Serology) 
81 ood ( Serology) 
81 ood ( Serol ogy) 
S k i n  
Skin, Hair  
Feces, Caecal Contents 
Enclosure 1 
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SPF CRITERIA  FOR SQUIRREL WNKEYS 
MICROORGANISH 
B ACTER I A : 
S h i g e l l a  sp. 
Sal monel 1 a sp 
Streptococcus pneumoniae 
Mycobacterium tubercu los is  
Pasteurel 1 a mu1 t o c i d a  
Campy1 obacter sy. 
Leptospira sp. 
Streptococcus .pyogenes 
V I RUSES : 
Lymphocytic chor iomeningi t is  v i r u s  
Herpes tamarinus 
Herpesvi rus saimi r i  
E NDOPARASI TE S: 
Trichomonas 
Acanthocephl ans 
Strongyloides 
Entamoeba h i s t o l y t i c a  
Hemoyrot ozoa 
FUNGI : 
A1 1 Dermatophytes 
CULTURE SITE/MTERIAL 
IDENTIFICATION TEST 
Fecal 
Fecal 
Oral , Fecal 
Skin l e s t ,  X-Ray 
Nasal, Fecal 
Fecal 
Urine 
Oral, Nasal 
81 ood ( Serology) 
81 ood (Serol oyy)  
B1 ood (Serology) 
Oral 
Feces 
Feces 
Feces 
B1 ood 
Skin 
Enclosure 2 
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SPF C R I T E R I A  FOR MACACA MULATTA 
I 
I 
I 
I 
VIRUSES 
Herpesv i rus s imf ae 
Yaba 
Yaba-1 i ke v i  ruses (OrTeCu, BEMP, and 
Monkey pox 
Heasl es (Rubeola) 
Lymy ho c y t  i c  c ho r i aneni ng i t i s 
Rab i es 
Tanapox ) 
SA1 OS (SRV-1, SRV-E) 
H I V  
STLV I 1 1  
PARASITES 
Hmenol epsi s - nana 
Entamoeba h i  s t o l  y t i c a  
G i a r d i a  i n t e s t i n i  t i s  
G i a r d i a  lambl ia  
Balant id ium co l  i 
Trichomonas homi n i  s 
Ascar is  sp. 
Strongyl  oides sp. 
Aca n t  hocep ha1 a ns 
-
BACTERIA 
Mycobacteriun tubercu los is  
Shigel la  sy. 
Salmonel 1 a sp. 
Pasture1 1 a mu1 toc ida 
Yersi n i a  pseudotubercul os1 s 
Yersi n i  a enterocol i t i c a  
S t  reptococcus pyogenes 
Campy1 obacter sp. 
SQ IKOCHETES 
Leptospira sp. 
Fungi : 
A1 1 dermatophytoses 
I 
! .I 
Enclosure 3 
GUIDELINES FOR 
RAOIONUCLIOE USE I N  SPACE FLIGHT PAYLOADS 
The la rge  number of permutations of radionucl ide type, amount, chemical and 
phys ica l  form, and degree of containment requires t h a t  each experiment Invo lv -  
i n g  radionucl ides be evaluated on i t s  own meri t .  Nonetheless, some general 
gu ide l i nes  can be set forth. These guidel ines are not hard and fas t  and may 
be waived i f  other  safety features or procedures a r e  deemed adequate. 
1. No payload containing rad ioact ive mater ia l  or other sources of i o n i z i n g  
r a d i a t i o n  s h a l l  create a s i t u a t i o n  whereby: 
a.  Radiat ion leve ls  which, i f  an i nd i v idua l  were continuously present i n  
the area, could r e s u l t  i n  the Ind i v idua l ' s  receiving a dose i n  excess 
of 2 m i l l i r e m s  i n  any 1 hour, o r  
b. Radiat ion l e v e l s  which, i f  an i nd i v idua l  were continuously present i n  
the area, could r e s u l t  i n  the i n d i v i d u a l ' s  receiving a dose i n  excess 
of 100 m i l l i r e m s  i n  any 7 consecutive days, o r  i n  excess of 5,000 m i l -  
l i rems i n  a 365-day period. 
2. No payload or  experiment, by design, shal l  cause quant i t ies  of rad ioac t i ve  
ma te r ia l  t o  be released i n t o  an occupied space which could r e s u l t  i n  u n i -  
form a i r  concentrations I n  excess o f  the values speci f ied i n  Appendix B, 
t a b l e  I, column 1 of t i t l e  10, Code o f  Federal KegulatiOnS, p a r t  20. For 
c a l c u l a t i o n  purposes, the volume of  the crew compartment i s  65 m3 and t h a t  
of the Spacelab i s  77  m3, 
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The maximun permiss ib le  dose and the  maximun p e m i s s l b l e  concentrat ions o f  
rad ionuc l i des  as recanmended are p r i m a r i l y  f o r  the  purpose o f  keeping t h e  
average dose t o  the  creunembers as low as reasonably achievable and not 
because o f  t he  l i k e l i h o o d  o f  s p e c i f i c  i n j u r y  t o  an i nd i v idua l .  
3. General r u l e s  f o r  safe use o f  r a d i o a c t i v e  m a t e r i a l s  s h a l l  be fol lowed: 
a. Wear d isposable gloves and a su rg i ca l - t ype  mask a t  a l l  t imes w h i l e  
handl ing rad ioac t i ve  l i q u i d s  o r  powders. The gloves should prevent 
-- - . -  -contamination o f  the hands where a mask should reduce chances o f  
i n h a l a t i o n  and/or inges t ion .  
b. Do no t  eat  o r  d r i n k  i n  any area where r a d i o a c t i v e  mater ia l  i s  being 
used . 
c. Wipe a l l  work surfaces a f t e r  use o f  r a d i o a c t i v e  mater ia ls .  
d. P rac t i ce  good personal hygiene hab i t s  by always thoroughly c lean iny  
hands a f t e r  hand1 i n g  rad ioac t i ve  sources. 
e. Never mouth-pipette l i q u i d s  conta in iny  rad ioac t i ve  mater ia ls .  To the  
maximun extent  poss ib le  minimize handl ing and t rans fe rs  o f  r a d i o a c t i v e  
m a t e r i a l s  i n  f l i g h t .  
f. Dispose o f  rad ioac t i ve  waste on ly  i n  speci f i c a l  l y  designated recepta- 
c l e s  t h a t  are p roper ly  shielded and labeled.  
g. Confine rad ioac t i ve  so lu t ions ,  specimens, powders, and waste i n  double 
containment, p l a i n l y  i d e n t i f i e d  and labeled.  Containment must be 
leakproof  and puncture r e s i s t a n t .  (Hood, glove box, o r  vented 
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workbench could be considered one o f  the containers, bu t  not  stowage 
bins.) 
h. A l l  t ransfers  o f  rad ioac t i ve  l i q u i d s  should be accomplished by the 
"buddy system." The ind iv idual  performing the t r a n s f e r  wlll be 
assisted by an ass is tant  t o  catch o r  t r a p  droplets, aerosols, etc., 
w i th  absorbent mater ia l  t o  ensure t h a t  no t rap  droplets  or aerosols 
are released i n t o  the occupied areas. 
4. Contingency plans for a l l  conceivable off-nominal s i t ua t l ons  shal l  be 
devel oped and tested . 
5. I n d i v i d u a l s  t ra ined i n  Health Physlcs shal l  be involved w i th  the stowage, 
the post-mission hand1 ing o f  payloads u t i 1  i r i n g  rad ioact ive ma te r ia l s  
capable of producing rad ioact ive contamination, and post-mission survey 
f o r  contamination of the spacecraft . 
Adherence t o  the guidel ines i s  important for rad io log i ca l  p ro tec t i on  of  the 
Operator and other cremembers i n  the Spacelab or  crew capartment.  Moreover, 
such adherence i s  important i n  minimizing contanination bui ldup i n  the space- 
c r a f t  which can i n t e r f e r e  w i th  other invest igators '  experiments. 
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NOT tCE OF CLAIMED INVESTIGATIONAL EXEMPTION 
FOR A NEW DRUG 
W T I :  N o h l m 4  k -ped 01 ~ J Y  W t t t d  
I complete ctrtement hu been rccdwd. 
121 CFR 312.1(#)(2)). I 
Name bf Sponsor Date 
Address Telephone ( ) 
Name of Investigational Drug 
FOR A DRUG: FOR A BIOLOGIC: 
Food And Drug Administration 
Office of New Drug Evaluation (HFN-106) 
5600 Fishers Lane 
RockviUe, Maryland 20857 
Food and Drug Administration 
Office of Biologics (HFN-823) 
8800 Rockville Pike 
Bethesda, Maryland 20205 
Dear Sir: 
The sponsor, , submits 
this notice of claimed investigational exemption for a new drug under the provisions of section SOS(i) of the Federal 
Food, Drug, and Cosmetic Act and Q 3 12.1 of Title 2 1 of the Code of Federal Regulations. 
Attached hereto in triplicate are: 
1. The best avulable descriptive name of the drug. including to the 
extent known the chemical name 8nd structure of m y  newdrug sub- 
stance. md 8 statement of how it is to k administered. (If the drug hrs 
only 1 code nunc. enough informrtion should be supplied to identify 
the dny.) 
2. Complete list of Components of the drug, including any reason- 
rble J tematcs  for inactive components. 
3. Complete statement of quantitative composition of drug. includ- 
& rusonable variations th81 may k expected durvlg the investip- 
tIon8l s t y c .  
4. Description of source and preparation of. any newdrug sub- 
stances uwd as components. including the name m d  address of each 
suppkr  or processor. other than the sponsor, or each newdrug sub- 
strncc. 
5. A statement of the methods, facilities. md controls used for the 
manufactunng. processing. and prcking of the new drug to establish 
and m a n u m  appropriate standards of identity. strength, quality, and 
purity as needed for safety and to give signficancc to clinical mvestip. 
tionr made with the drug. 
6. A statement covering all information rvailablc to the sponsor 
derived from preclinical investigations and any clinical studies and 
erpcrwwe uith the drug as follows: 
8. Adequate information about the preclinical invcstyltions. in- 
cluding studies made on laboratory rnimrls. on the basis of which the 
sponsor has concluded lhat it is rcasonrbly safe to initiate clinical 
investigations with the drug: Such information should include idcnti- 
fication of the person who conducted erch investigation; identification 
and qualifications of the individuals who evoluatcd the results and 
concludcd thrt it i s  reasonably ufe to initiate clinical investigations 
with the dNg and a statement of where the investig#tionr were con- 
ducted and where the records u e  rvdr51c for inspc;:LI; and enough 
detrils about the investigations to permit scientific review. The pre- 
dinicd investigations shall not be considered 8dCqUrte to justify 
clinical testing unless they givc proper attention to the conditions of 
the proposed clinical testing. When this information. the outline of the 
plan of clinical pharmacology. or any progress report on the clinical 
pharmacology, indicates 8 need for full review of the preclinical drta 
bcforc a dinicd trial is undertaken, the Department will notify the 
sponm to submit the complete preclinical data and to ei thhdd clinical 
trials uncil the review is completed rnd the sponsor notified. The Food 
urd D N ~  Administration will be prcpucd to confer with the sponsor 
ccnccmiq thL action. 
b. If the &ug has been mrrketed commercially or investigated (e.g. 
outside the United States). complete information about such distnbu- 
lion or investigation shall be submitted, rlong with 8 complete bibli- 
oqaphy of m y  publicrtions 8boUt the drug. 
c. If the drug is 8 combination of previously invatieted or mar- 
keted drugs, an rdcquatc summary of preexisting information from 
preclinicrl r d  clinical investigatlons rnd experience with its compo- 
nents, including all reports available to the sponsor suggesting side- 
effects. contrrindications. rnd ineffectiveness in use of such amp 
nents: Such summary should include an adequate bibliqnphy of 
publicrtions about the components and may incorporate by reference 
any informrtion concerning such components previously submittcd 
by the sponsor lo the Food and Drug Administrrtion lndude 8 sate-  
men1 of the expected phumacolo~crl  effects of the combmrtion. 
d. If the drug is a radioactive drug, sumcicnt data must be anilablc 
from rrumrl studies or previous human studies to allow a rewnablc 
calculation of radiation absorbed dose upon administration to a human 
being. 
7.  A toul (one in u c h  of the three  copies O f  chc notice) of all 
informrtiond material, including lrkl  and labeling. which is to k 
supplied to u c h  investigator: Thii shall include an rccuratc description 
of the prior investigations and experience rnd their results pcrtincni 
to the safety and possible usefulness of the drug under the conditmnr 
of the investigation. It shall not represent that the safety or uufulncs\ 
of the drug has k e n  established for the purposes lo  be investigatcd 
It lhrU describe 8U relevant hazards, conulindicrtions, ridciffcctr. 
and precautions suggested by prior investiptions and experience with 
the drug under investigation and related drugs for the informatm 
of clinical investigators. 
8. The saentxu mining m d  experience considered rppropririe 
by the sponsor to qualify the investiptors u suitable experts to investi- 
g t e  the safety of the drug, bearing in mind whrt is known about the 
phlmracologial wtion of the drug and the phase of the investigational 
proprm thrt is to be undertaken. 
9.  The names m d  8 summary of the training m d  expuiencc of 
each investigator and of the individual charged with monitoring the 
propeu of the investigation md eniurting the evidence of d a y  m d  
effectivemu of the drug 8s it is received hom the investiptorr. to- 
p t h e r  with r rtrtcment th8l the sponsor has obtrined from a c h  
investigator 1 completed m d  signed form, u provided in subpmyrph 
(12) or (13) of this pusgxrph. m d  lhat the investiplor is qurLirKd 
by rientific training m d  expedcnce u m appropriate expert to under- 
FORM FDA 1671 ( l o r n )  PREVIOUS EDITION ARE OBSOLETE. ORIGINAL PAGE IS 
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thc )hue G. the wertiptlon outllnei. .. .OC'~*.. io  of rhr 'NOdU 
of Chimed lmu t ip t iona l  Exemption for a New Drug." (In cnrcbl 
'tuatbnr. p h u  3 imcstiptors may k added md thla form m p p b  
nted by npid unnmunication methods. and the dgncd Form FD 
1573 shall k obtained promptly thereafter.) 
IO. An outline of any phase or phases of the p l ~ d  investlgationr 
d a description of the institutional revkw committee. u follows: 
a. Clinical phumacology. This is ordinarily divided into two phars:  k hrsc I starts when the new drug is rust introduced into man - only 
animal and in vitro data art available -with the purpose of determining 
uman toxicity, metabolism. absorption, elimlnrtion, and other phu- 
nacoloyical action, preferred route of administration, and safe dosage I ange; phase 2 c o v m  the initial trials on a Umited number of patients 
for specific d i v u c  control or prophylaxis purport .  A general outline 
of these phases shall bc submitted, identifying the invedigator or invest- 
tors, the hospitals or research facilities where the clinical pharmr- 
ology will k undertaken, any expert committees or panels to be 8" tilied. the maximum number of subjects to be involved, and the esti- 
mated duration of thcrc early phases of investigation. Modification of 
e experimental d e w  on the basis of experience pined need k 
ported only in the progress reports on there euly phases. or in the 3 evelopment of the plan for the clinical trial. phau 3. The fist two 
phases may overlap and, when indicated, may require additional animal 
data before these phases can be completed or phue can be undertaken. 
uch M a l  tests shall be designed to take into account the expected 
uration of administration of the drug to human beings. the rp POUP1 
d physical status. as for example, infants, pregnant women, prc- 
menopauvl women, o f  those human beings to whom the drug may be 
ministered. unku this has b e a d y  been done in the original animal 
udits. If a drug b a radioactive drug, the clinical pharmacology phase 
ust include studies which will obtain sufficient data for d o s h e w  
c culations. Thw studies should evaluate the excretion, whole body 
retention. and organ dbuibution of the radioactive materi.l. 
b. Clinical trial. This phase 3 provides the useummt of the drug's 
fety and effectivcneu and optimum dosage schedules in the diagnosis. II. atrnent. or proplryllsis of groups of subjects involving a given discuc 
or condition. A reasonable protocol is developed on the basis of the 
facts accumulated in the earlier phases. including completed and rub- 
'ttrd animal studies. This p h w  is conducted by lepuate groups fol- 
ing the same protocol (with reasonable vuirtions and alternatives k rmitted by the plan) to produce well-controlled clinical data. For this 
phase, the following data shall be submitted: 
L The names and addresses of the investigators. (Additional investi- 
ii. The specifu nature of the investigations to be conducted, to- 
gether with infonnatlon or case report forms to show the rope md 
detail of the planned clinical obscrvations and the clinical laboratory 
1s to k mode and reported. 
iii. The approximate number of subjects (a reasonable range of 
jectr is permissible and additions may be made), and criteria pro- 
iv. The estimated duration of the clinical trial and the intcndr. 
exceeding 1 year, at which progress reports showing the results of 
investigations SIII k submitted to the Food and Drug Adrninistra- 
c. Institutional re>;iew board (IRB). The sponsor must give assur- 
e that an I R B  that complies with the requirements set forth in P u t  
of this chapter wi l l  be responsible for the initial and continuing 
E 
a 
t 
tors may be added.) I
posed for subject ~ l e s t i o n  by age. sex. and condition. 
6 
6.. 
b 
INDICATE AUTHORITY 
I 
I 
n*ln md approtd of tbs propod dinlcrl study. T& rponwr mud 
r l r ~  p d r  wunnca that the I.rcwton rpI to the IRB 9 
c h u y c a  in the rctivlty a d  dl uamtlclpatd problems lnmb 
b~ hks to human subjects or others. and that the hverti@ton wm not 
mrke my changes in the rc#uch  wlthout IRB appronl, except where 
neceuuy to eliminate apparent immedlate hazard to the human rub- 
jects. FDA will regard the riplng of the Form FDA-IS71 u providing 
the mcessuy assurances above. 
(The notice of claimed investigational exemption m y  be limited 
to MY one or more phucr. pro*ided the outline of the additional 
phue or p h w s  ia submitted before such additional phues begin. A 
limitation on UI exemption does not predude continuing a rubject 
on the drug from phase 2 to phase 3 without interruption while the 
plan for phase 3 is being developed.) 
Ordinarily. a plan for clinial trLl will not be regarded u rasoanrble 
unless. among other things, it provider for more than one independent 
competent investigator to maintain adequate case hbtorler of an ade- 
qurte number of subjects, designed to record obsenationi and permit 
waluation of MY and aU dircernibk effects attributable to the drug in 
each individual treated. rnd comparable records on any individuals 
employed u controls. These records shall be individual records for each 
subject maintained to include adequate infomution pertaining to each. 
including age. scx. conditions trated. d o u p ,  frequency of dminiltn- 
tion of the drug. results of dl relevant clinical obserntionr and Inborn- 
tory exminations made, adequate information concerning any other 
treatment given and a full statement of m y  adverse e f k t s  and useful 
results o b m e d .  together with UI opinion as to whetha such effects 
or results are attributable to the drug under investigation. 
11. A statement that the sponsor will notify the Food and Drug 
Administration if the investigation is dirontinued, and the r e w n  
therefor. 
12, A statement that the sponsor will notify each investigator if 
a newdrug application is approved, or if the investigation is discon- 
tinued. 
13. If the drug u to be sold. a full explanation why =le is required 
md should not be regarded as the commercialization of a new drug for 
which an application is not approved. 
14. A statement that the sponsor assures that diniul  studies in 
humans will not be initiated prior to 30 days aner the date of receipt 
of the notice by the Food and Drug Administration and that he will 
continue to withhold or to restrict clinical studies if requested to do so 
by the Food and D N ~  Administration prior to the expiration of such 
M drys. If such request is made, the sponsor will be provided specific 
information u to the deficiencies and will be afforded a conference on 
request. The 30day delay may be waived by the Food and Drug 
Adminiitration upon a rhowing or' pod reason for such waiver; and 
for investigations subject to institutional review committee approval 
u described in item 1Oc above, and additional statement rssuring that 
the investigation will not be initiated prior to approval of the study by 
such committee. 
IS. When requcsted by the agency. an environmental impact 
andy i repor t  pursuant to 4 25.1 of thisihaptcr. 
16. A statemcnt that dl nonclinical laboratory studies have been, 
or will be, conducted in compliance with the good laboratory practice 
rcgulationr ret forth in Part SS of this chapter, or, if such studies have 
no1 been conducted in compliance with such regulations, 8 statement 
that dewriber in detail all differences between the practices u r d  in 
mnducting the study and those requucd in the regulationr. 
very truly yours. 
I)R!@INAL PAGE IS 
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(This notice may be amended or supplemented from time to time on the buis of the experience pined with the new drug Progress reports m y  be used 
t o r a t e  the notice.) 
ALL NOTICES AND CORRESPONDENCE SHOULD BE SUBMITTED IN TRIPLICATE. 
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NAME OF DRUG 
STATEMENT OF INVESTIGATOR porn Appmwd 
(Crinid Phannocob~) OM8 NO. 3 %ROO31 
I 
Deu sir: 
The undersigned. I 
subrmts this statement as required by section SOS(i) of the Federal Food, Drug, and Cosmetic Act and 5 312.1 of Title 21 of the CO& of 
Federal Regulations as a condition for receiving and conducting c h i d  pharmacology with a new drug limited by Federal (or U n i t 4  
States) law to investigational use. 
1. A STATEMENT OF THE EDUCATION A N D  TRAINING THAT OUALIFIES ME FOR CLINICAL PHARMACOLOGY 
TO: SUPPLIER OF THE DRUG: (Name andaddrest. lnelude ZIPCode)  
ORIGINAL PAGE IS 
OF POOR QUALITY 
NAME OF INVESTIGATOR ( h i n t  or Type1 
DATE 
!. THE NAME A N D  ADDRESS OF THE MEDICAL SCHOOL, HOSPITAL. OR OTHER RESEARCH FACILITY WHERE THE C-LINICA 
PHARMACOLOGY WILL BE CONDUCTED 
3. I f  the experimenW project b to be conducted on imtitution- 
dized subjects or is conducted by an individual affiliated with n 
institution which agrm to assume mponsibilitv for tho smdy. 
.PUMCO must be given that  an institutional review committee is 
rnpomib le for initial and continuing m iew and approval of the 
propced clinical studv. The momtarship must be comprisud of 
sufficient membeo of varying bckground. that is, I8wvers 
dergvmrn, or Iavmen as wll as scientists, to assure complete and 
adequate review of the research prok t .  The mcmbenhip must 
powcrr not only broad competence to comprehend the nature of 
the poject. but also other competencies necessary to judpc the 
nrptability of the project or activity in terms of institution.l 
regulations. relevant law, standards of profatiand practia, and 
community acceptance. Assurance must be pmented that the 
investigator has not participated in the selection of committee 
members; that the review committee does not allow participation 
in its review and conclusions bv any individud involved in the 
conduct of the research activitv under m i r w  (except to provide 
information to the committee); that the investigator will report to 
the committee for review any emergent problems, miour adverse 
rextions. or proposed procedural changes which mw affect the 
status of the investigetion and that no such change will be m d e  
without committee approval except where necessary to etimicute 
apparent immediate haurda; that mviewr of the studv will be 
conducted by the review committee at intenrala appropriate to the 
degra of risk, but not exceeding 1 year, to assun that the 
mearch project is being conducted in compl ina  with the 
committee's underatanding and recommendationc; that the review 
committee H provided dl the informaion on the research pr-t 
neumary for ia complete n v i m  of the project; and that the 
nvicrr committee maintains adequate documentation of its 
rtivitin and dewlop rdequne procedulsr for reporting its 
findings to tho institution. The documents m.intained tho 
committee YI to include the cum- and qudifiations 01 
committee members, mor& of information providcd to aubbu 
in obtaining informed consent, committee discuasion on urktan. 
tiw issun Md their molution, committee recommabtions. m d  
&tad mports of succasive mime I) they are performed. Copin 
of all docurmna are to be retained for a period of 3 your past me 
completion or dirontinurocb of the nu& and are to be made 
auailable upon mquat to 6 1 y  authorized reprcrentatiws of the 
Food and Drug Administration. IFworrMe recommendations by 
the committee are subject to further appropriate mviw and 
rejection by institution officials. Unfmrable mcomnmndations, 
restrictions, or conditions m y  not be owrruled by the institution 
officials.) Procedures for the ocprnization and operation of 
institutional roview committees ON contained in guidelines iaud 
pursuant to Chqmr 140 of the G m t r  Administration Manual of 
the US. Department of HeJth, Education, md Welhn, nnillMa 
from the US. Government Printing Office. It ia r o c o m d e d  that 
these guidelines be follovnd in establishing institutional review 
c o m m i t t e n  and that t h  mmitteer function according to tho 
procedures described thwein. A siqring of the Form FD-1572 will 
bs regarded as providing the rbom necessary assurance; howwet, 
if the institution h a  on fik with the Department of Health. 
Education, Md Welfare, Division of Rowarch Grants, National 
Institutes of Health, an "mpted (pneral assurance," and the 
uma committee is to  review tho proposed study using tha same 
pmcedures, this is rrapmb in lieu of tho abow oarurnas urd a 
statement to this effect should be provided with the siwed 
FD-1572. (In addition to sponsor's continuing responsibility to 
monitor t h  nu*, the food md Drug Administration will 
undertake investigations in institutions periodidly to datermine 
whether the committees am operating in accord with the 
aasunnces given by tho sponsor.) 
RY FD 1572 (In61 PREVIOUS EDITION MAY BE USED UNTIL SUPPLY IS EXHAUSTED. 
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1. THE ESTIMATED DURATION OF THE PROJECT A N 0  TME MAXIMUM NUMBER OF SUBJECTS TMAT WlLL BE I N V O L V E D  
1. A GENERAL OUTLINE OF THE PROJECT TO BE UNDERTAKEN (Modl~ca~onLpennlt tcd on me ba~&ofexperlrnceplned dthol 
advance prbmlrJlon of ammdmenta to the general outtine. but wlth the approwl of nhe review commlttrr ud upon nottfiaffon of the 
ORIGINAL PAGE IS 
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5. THE UNDERSIGNED UNDERSTANDS THAT THE FOLLOWING CONDITIONS GENERALLY APPLICABLE TO NEW DRUGS FOF 
INVESTIGATIONAL USE GOVERN HIS RECEIPT AND USE OF THIS INVESTIGATIONAL DRUG 
Tho sponsor is r q u i r o d  to supply tho invrt igotor w i th  full 
information concorning tho preclinical invrtig.tion tha justi- 
f i a  C l i n i d  phormrology. 
b. Tho invntigator is rauirmd to mdntain o d q u n o  rworda Of  
tho disoosition of all rao ip ts  of tho drug. including datn.  
quantity, Jnd US. by  wbira. and if tho clinical p h u m a o l o W  
is orspondod. tarminotod, discontinuod. or complo td .  to 
rnurn to tho spomor m y  unusod supply of tho drug. I f  tho 
investigational drug is ubjoct to tho comprohonsivo Drug 
Abuw Prwont ion and Control Act of 1970. d . s u o t e  pro. 
cautions must bo cakon, including scorogo of tho invrtigational 
drug in a sauroly Igckod, substantially cons t ruc td  cobinot. or 
0th- ucuroly lockd,  wbstont id ly C O ~ W N C ~ ~  ondourn 
acoas to which is limitod. to prwont choft or divorsion of tho 
wbatamo into illegal channols of distribution. 
c. Tho invosttgltor is rwu i rod  to p r w u o  and maintain adquato  
c&a htsrorion dn ignd IO r u o r d  all Oburvatiorn and 0 t h ~  data 
portinoot t o  tho clinical phormrology. 
4 Tho inv.rtigatOr is roquirrd to furnish his r.poRs to mo 
sponsor who is rnponaiblo for collecting and woluoting tho 
roults. and prownting v o g r o u  reports to tho Food and Drug 
AdminiatrotiQn at oppropriato intorvola. not oxcooding 1 y u r .  
Any dvorsa  o f f a t  which m y  roosonobly bo rogardod n 
cwsod by. O r  ia probably c a u s d  by, tho n.w.drug shall M 
r.portod to tho sponsor promptly: and if tho d v o r u  o f f u t  is 
alarming it shall bo r.poRod immdiotoly.  A n  doquofa  roport 
of tho clinical DhormrOlogy should bo furnishd to cho 
sponsor shortly aftor complotion. 
a Tho i m a t i g o t o r  shall maintain tho m o d s  of dheosition of cho 
drug and tho c n o  r O p O R S  d u c r i b d  above for 4 period of 2 
y u n  following tho doto tho now-drug application k o p p r w d  
for tho drug; or if no oppllcrtlon Is to b o  filod or is approud 
until 2 yoon aftor tho invrt ignt ion h dirontinud end tho 
Food and Drue Administration so notifiod. Upon tho twurt 
of wiontifieolly troinod and p a i f i c d l y  umqrizod omploya 
of tho Doportmont. ot rooaon&lo t imr,  tho invrt igotor wi l l  
m d o  auch ruords ~ o i l . b l o  for impation md copying. Tho 
noma of tho wbica n o d  not bo dkulgod un lns  tho records 
of tho PaRicuIor aubjata roquin mol. dotoilod study of tho 
CWI. or unloa thoro is ronon to b.(iwo that mo ruords do 
not roprnont a t u o l  ffudir or do not r o p n w n t  rbrJ r n u l a  
obtoinod. 
Tho invr t igo tor  c o R i f i r  that tho drug wi l l  bo odministorod 
Only  to subjuts undor his purOru( supuvision or undor tho 
wporvision of tho following invrtigators rosponsiblo 10 him, 
1. 
arm (hat tho drug will not bo uppl id to n y  o t h r  invostigator 
or to any clinic for administration to u b j r a .  
Q Tho invrt igotor cor t i f ia  thot ho wi l l  inform n y  pation- or 
MY porsom u s d  os controls. or thoir roorosrrtotivr. mot  
drum or0 k ing usod tor invrtig.tionol putpan, n d  wll l  
obtoin tho c o n u n t  of tho NbiUb. or thoir ropronntat ivr .  
oacopt whwo this ia not h a i b l o  or. in r)lo invrtigotor's 
profoasionol judgment. ia contrwy to mo bat intorats of tho 
wbiutr 
h. Tho invostlgator is raquird to anurn tho spomor t h a t  for 
inv r t lga t iom involving institutiorulizod ubiua tho rtudia 
wlll not bo initiotod until tho institutional twim committoo 
hn  n v i o w d  ond approval tho atudv. (Tho organization and 
praoduro  mquiromonu for uch c a n m i t t r  lhould bo 
o r p l o i n d  to tho invrt i - tor  by tho oonaor m m forth in 
Form FO-1171, dlvision 10. unit c.) 
Very truly yours. 
\ 
Name of Investigator 
Address 
L 
3 6 P A R l M E N T  OF HLALTH AN0 HUMAN SERVICES 
C U D L K  WEALTH SERVICE 
F O O D  A N 0  DRUG ADYlNlSlRATION 
L . 0 0  F S H E R S  LANE 
STATEMENT OF INVESTIGATOR 
MARYLAND 2-17 
NAME OF DRUG 
Irom Appro1 
OllB No. IF 
urn d ~hl. fa
. I t ~ - 3 1 ,  
~~~ ~ 
Dear Sir: 
submits this statement a s  required by section 505(i) of the Federal Food, Drug, and Cosmetic Act a 
Title 21 of the Code of Federal Regulations a s  a condition for receiving and conducting clinical in1 
with a new drug limited by Federal for United Stares) law to investigational use. 
The undersigned, 
1. 
L. 
STATEMENT OF EOUCATION AN0 EXPLRltNCE 
C O L L E G E S .  U N I V E R S I T I E S .  A N 0  M E D I C A L  O R  OTHER P R O F S S S l O N A L  S C H O O L S  ATTENDED. W I T H  D A T E S  O F  A 
D E G R E E S ,  A N 0  O A T E S  D E G R E E S  WERE A W A R D E D  
). P O S T G R A O U A T E  M E D I C A L  OR O T H E R  P R O F E S S I O N * L  T R A I N I N G  (Indleate date., NIM. 01 inatllutlon., and mtwa 
~~~ ~ ~~ ~ ~ . T E A C t i I N G  O R  R E S E A R C H  E X P E R I E N C E  (lndfcatc dates. instffuluon., and b r h f  d*.crfptlon of experfwnce) 
I. E a P L R I E N C E  IN  M E D I C A L  P R A C T I C E  O R  O T W E R  P R O F E S S I O N A L  E X P E R I E N C E  ( ldlcate data., fn.t/tufioruf afffl 
01 praetlca, or other p o l e s s i o r v l  erpcrlcnce) 
, R E P R E S E N T A T I V E  L I S T  O F  P E R T I N E N T  M E D I C A L  OR O T H E R  S C I E N T I F I C  P U O L I C A T I O N S  (hdfCate t111aa 01 a r t k  
publkallona and volume, wee number, and date) 
FORM FDA 1573 (4’791 PREVIOUS EDITION M A Y  BE USED UNTIL SUPPLY IS EXHAUSTED. 
41 ORIGINAL PAGE IS 
OF POOR QUALITY 
a. If the investigation is to be conducted on institutiond- 
ized subjects or  is conducted by an Individual affiliated 
with an institution which agree t o  assume responsibility 
for the study, assurance must be given that an institu- 
tional revicw coiniiiittce is rcsponsible for initial and con- 
tinuing review and approval of the proposed clinical 
study. The mcmbenhip must be comprised of sufficient 
members of  varying background, that is, lawyers, clergy- 
men. or laymcn as well 3s scientists, to assure complete 
and adequate rcvicw of the rcsearch project. The member- 
ship must posscss not only broad competence to compre- 
hend the nature of the project. but 3150 other compe- 
tencies neccssary to judgc the acceptability of the project 
or activity in tcriiis of institutional regulations, relevant 
law, standards of profcssiond practice,and community ac- 
ceptance. Assurancc must be presented that the investiga- 
tor has not participicd in tlic sc’lcction of committce 
members; that thc rcbiew ioiiiiiiittec does not allow par- 
ticipation in its rcview and conclusions by m y  individual 
involved in the conduct of the research activity under 
=view (except to provide information to the committee), 
that die investigator will rcport to the committee for re- 
view any emergeiil problCliiS. serious adversc reactions. or 
proposed proccdural chaiigcs wliicli aiay aflcct the status 
of the investigatioii aiid that no such change will bu made 
without conimittce approval cxccpt where necessary to 
eliminate apparent iiiinicdiatc hazards; that reviews of the 
study will be conducted by thc revicw committee at intcr- 
vals appropriitc to die degree of risk, but not exceeding 1 
year. to assure that dic research project is being con- 
ducted in coiiipliaiice with the committee’s understanding 
and recommendations; that the revicw committee is pro- 
vided all the information on the research project necessary 
for its complctc revicw of the project; and that the review 
committee tiiaiiitains adequatc docunirntation of its activ- 
ities and develops adcquate procedures for reporting its 
findings to the institution. Thc dwunients maintained by 
the committee are to include tlie names and qualifications 
of committee members, rccords of information provided 
to subjects in obtaining inlonned consent, committee dis- 
cussion on substantive hues and their nsolutik, cunmit- 
tee recommendations, and dated reports of successive re 
views as they are performed. Copies of dl d o c u m n u  M 
to be retained for a period of 3 years past the completion 
or discontinuance of the study and are to be made avail- 
able upon request to duly authorized representatives of 
the Food and Drug Administration. (Favorable recom- 
mendations by the committee are subject to further a p  
propriate review and rejection by institution officials. Un- 
favorable recommendations, rcstric tions, or conditions 
may not be overruled by the institution officials.) Pro- 
cedures for the organization and operation of institutional 
review committees are contained in guidelines issued pur- 
sumt to Chapter 140 of the Grants Administration Man- 
ual of the U.S. Department of Health, Education, and 
Welfare, available from the U.S. Government Printing 
Office. It is recommended that these guidelines k fol- 
lowed in establishing institutional review committees and 
that the committees function according to the procedures 
described therein. A signing of the Form FD 1573 will be 
regarded 1s providing the above necessary assurances; 
however, if the institution has on file with the Depart- 
ment of Hcalth, Education, and Welfare. Division of Re- 
search Grants, National Institutes of Health, an “accepted 
general assurance,” and the same committee is to review 
the proposed study using the same procedures, this is ac- 
ceptable in lieu of the above assurances and a statement to 
this effect should be provided with the signed FD 1573. 
(In addition to sponsor’s continuing responsiblity to mon- 
itor the study, the Food and Drug Administration will 
undertake investigations in institutions periodically to de- 
termine whether the committees are operating in accord 
with the assurances given by the sponsor.) 
b. A description of any clinical laboratory facilities that 
will be used. (If this information has been submitted to 
the sponsor and reported by him on Form FD 1571, ref- 
erence to the previous submission will be adequate). 
1. m e  investigational d n q  will be used by the undersigned or under his supervision in accordance with the plan of 
nvestigation described as follows: (Outline the plan of investigation including approximation of the number of subjects 
D be treated with tlie dnig and the number to be employed as connds. i/any; clinical uses to be investigated; 
.haracreristics of subjects by age. sex and condition; the kind of clinical observations and lcrbomtoty tests to be 
mdertaken prior to. duririg. aiid after administration of the drug; the estimated dumtion of the investigation; and a 
iescription or copies of report forms to be used to maintain an adequate record of the observations and test results 
) b t a ~ e d .  mis plan may include reasonable alternates and variations and should be supplemented or amended when any 
ignificant change in direction or scope of the investigation is undertaken.) 
ORIGINAL PAGE IS 
OF POOR QUALITY 
4. THE UNDERSIGNED UNDERSTANDS THAT THE FOLLOWING CONDITIONS, GENERALLY APPLICABLE 
TIONAL DRUG: 
To NEW DRUGS FOR INVESTIGATIONAL USE, GOVERN HIS RECEJPTS AND USE OF THIS INVESTIGA. 
a. The sponsor is required to supply the investigator with 
full information concerning the preclinical investigations 
that justify clinical trials, together with fully informative 
material describing any prior investigations and experience 
and any pobsible hazards, contraindications, sidecffects, 
and precautions to be taken into account in the course of 
the investigation. 
b. The investigator is required to maintain adequate rec- 
ords of the disposition of all receipts of the drug, includ- 
ing dates, quantities, and use by subjects, and if the inves- 
tiga t ion is terminated, suspended, discontinued, or 
compte ted, to re turn to the sponsor any unused supply of 
the dmg. If the investigational drug is subject to the Com- 
prehensive Drug Abuse Prevention and Control Act of 
1970, adequate precautions must be taken including stor- 
age of the investigational drug in a securely locked, sub- 
stantidy constructed cabinet, or other securely locked 
substantially constructed enclosure, access to which is 
limited, to prevent theft or diversion of the substance into 
illegal channels of distribution. 
c. The investigator is required to prepare and maintain 
adequate and accurate case histories designed to record all 
observations and other data pertinent to the investigation 
on each individual treated with the drug or employed as a 
control in the investigation. 
d. The investigator is required to furnish his reports to 
the sponsor of the drug who is responsible for collecting 
and evaluating the results obtained by various investiga- 
tors. The sponsor is required to present progress reports to 
the Food and Drug Administration at  appropriate inter- 
vals not exceeding 1 year. Any adverse effect that may 
reasonably be regarded as caused by, or probably caused 
by, the new drug shall be nported to the sponsor 
promptly, and if the adverse effect is alarming, it shall 
be reported immediately. An adequate report of the inves- 
tigation should be furnished to the sponsor shortly after 
completion of the investigation. 
e. The investigator shall maintain the records of dispe 
dtion of the drug and the casc histories described above 
for a period of 2 years following the date a new-drug 
application is approved for the drug; or if the application 
is not approved, until 2 years after the investigation is 
discontinued. Upon the request of a scientifically trained 
and properly authorized employee of the Department. at 
reasonable times, the investigator will make such records 
available for inspection and copying. The subjects’ names 
need not be divulged unkss the records of particular in- 
dividuals require a more detailed study of the cases, or 
unless there is reason to believe that the records do not 
represent actual cases studied, or do not represent actual 
results obtained. 
f. The investigator certifies that the drug will be adminis- 
tered only to subjects under his  personal supervision or 
under the supervision of the following investigators re- 
sponsible to him, 
~- 
and that the drug will not be supplied to any other investi- 
gator or to any clinic for administration to subjects. 
g. The investigator certifies that he will inform any sub 
jects including subjects used as controls, or their repre- 
sentatives, that drugs are being used for investigational 
purposes, and will obtain the consent of the subjects, or 
their representatives, except where this is not feasible or, 
in the investigator’s professional judgment, is contrary to 
the best interests of the subjects. 
h. The investigator is required to assure the sponsor that 
for investigations involving institutionalized subjects, the 
studies will not be initiated until the institutional review 
committee has reviewed and approved the study. (The 
organization and procedure requirements for such a com- 
mittee should be explaineu to the investigator by the 
sponsor as set forth in Form FD 157 I ,  division 10, unit c. 
Vcry truly yours. 
(Afame of lnvrttigator) 
(Addrcssj 
ORIGINAL PAGE IS 
OF POOR QUALITY 
(This form should bc supplemenid w amended from time to time if new subjets are added 
01 if signijicatt chungos crc tmde in rhc plan of invcrtigution) 
NASA-JSC 
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I. 
AI inst i tut ion of higher education is eligible t o  receive funds for 
research fran the D e p a r m t  of Health arrd Human Services (HHS) only i f  the 
inst i tut ion complies with certain policies designed t o  protect h m  re- 
search subjects. 
IMS approval of an insti tutional assurance, which is  a written document 
c m i t t i n g  the insti tution to  policy and proce6iral requirements in re- 
search. Specifically, the assurance must include a statement of principles 
f e t h e  protection of human subjects of research conducted a t  or sponsored 
by the inst i tut ion (regardless of funding source), designation of an insti- 
tutional review board (LRB) with certain prescribed research review 
functions, an identification of IBR mehers, and written procedures to be 
followed by the IRB in carrying out its functions. The purpose of t h i s  
doament is t o  put in place a t  The University of Alabama in Huntsville the 
foregoing policies, procedures, and mechanisms as the predicate for an 
approved assurance. 
This e l ig ib i l i ty  is secured in i t i a l ly  by subinission for 
11. 
INSTI"I'IOl4A.L REVlEiJ BOARD - SmUm AND WJX 
A. Es tab l i shmt  and Caposition. 
referred t o  as the "UHSRC") has been established as the Institutional Review 
Board (hereinafter referred to as the 111Ri3'') for The University of Alabara 
in EIuntsville. 
diverse backgrounds possessing the professional competence to $ r a t e  
cmplete and adequate review of research act ivi t ies  and ascert 5 1  ac- 
ceptability in terms of institutional cannitments and regula&is, appli- 
cable law and standards of professional conduct and p rd t i ce .  
Representation on the UHSRC shall include: 
1. The Use of Kman Subjects i n  Research Connittee (hereinafter 
- - -  
2. The UHSRC shall be cmposed of a t  least  f ive ( 5 )  mahers, with 
3. 
a. Menandwanen, 
b. 
c. 
ci .  
Representation of more than one profession, 
A t  least  one member whose primary concerns are 
non-scientific, i.e., lawyer, e th ic i s t ,  clergy member, 
A t  least  one member who is not aff i l ia ted with UAH, either 
personally or by irmediate familial relationship. 
4. No person shall serve as a member of the UHSRC where such service 
t m l d  constitute a conflict of interest involving the proposed research 
pro j ec t under review. 
5 .  The UHSRC w i l l  invite individuals v i th  specific competencies to 
ass i s t  in its review of canplex issues. Within the scope of their  
invitation, these invited individuals w i l l  serve as full ORmbers of the 
UHSRC, except that they shall not have a vote. 
B. Function and Operation. 
convened meetings at c*hich a majority of merbers are present, which shall 
include at least one rriier whose prbary concerns are in nm-scientific 
areas. 
of a majority of those d e r s  present at the meeting. 
University officials and the Secret 
Services (hereinafter referred to as HIS") any serious or continuing 
non-canplimce by investigators with the requiremnts and determinations of 
the UHSRC. 
i- 
1. The UHSRC shall follow written procedures for full review at 
In order for research to be approved it shall receive the approval 
The UHSRC shall be responsible for reporting to the appropriate 2. 
of the Deparbwnt of 'rlealth and Humn ar): 
3. The follaJing definitions apply through-out these procedures : 
a. "Certification" means the official notification by the 
University to  the HIIS in accordance with the re.quirements of 
the a3plicable federal regulations that a research project or 
activity involving tnanan subject has been reviewed and 
approved by the UHSRC in accordance kith the approved assur- 
ance on file at HHS. 
b. 'Timan Subject" means a living individual about whm an 
investigator conducting research obtains either date through 
intervention or interaction with the individual, or 
identifiable private i n f o m  t ion. 
"Interaction" includes camarnication or interpersonal contact 
between investigator and subject. 
"Intervention" includes both physical procedures by which 
data are gathered in manipulation of the subject or subject's 
enviroment that are performed for research purposes. 
''Minimal Risk" means that the risks of ham anticipated in 
the proposed research are not greater, considering 
probability and magnitude, than those ordinarily encountered 
in daily life or during the performance of routine physical 
or psychological examinations or tests. 
"Private Information" includes informtion about behavior 
that occurs in a context in which an individual can 
-reasonably expect that no observation or recording is taking 
place and information which has been provided for specific 
purposes by an individual in which the individual can rea- 
sonably expect will not be mde public. Private information 
must be individually identifiable in order for obtaining the 
information to  constitute research involving htlman subjects. 
"Research" means a systematic investigation designed to 
c. 
d. 
e. 
f. 
g. 
- 2 -  - 
develop or contribute to generalizable knowledge. Activities 
which met this definition constitute "research" for purposes 
of these procedures, whether or not they are supported or 
funded under a progrm which is considered "research" for 
other purposes. 
C. Records 
The UHSRC shall maintain the follorjing records: 
1. A statanent of principles governing the University in the dis- 
charge of its responsibilities for protecting the right and welfare of hman 
subjects of research conducted at, or sponsored by, the University, regard- 
less of source of funding. 
University as its IRE3 and that provisions have been made for meting space 
and sufficient staff to support review m d  record keeping duties. 
2. Records reflecting that the UHSRC has been designated by the 
3. A list of the UHSRC rnembers identified by nam, earned degrees, 
representative capacity, indications of experience such as board certifica- 
tion, licenses, etc. sufficient to describe each members chief anticipated 
contributions to the UHSRC deliberations and any employment or other rela- 
tionship between each member and the institution. 
membership shall be reported to the Secretary of HHS. 
Changes in the UIISXC 
4 .  \kitten procedures which the UHSRC w i l l  follaxl: 
a. For conducting its initial <and contjnuing review of research 
and for reporting its findings m d  actions to the investiga- 
tor and to the University; 
For determining which pzJjects require review more often 
than annually and which projects need verification frm 
sources other than the investigators that no material changes 
have occurred since previous review by the UHSRC; 
For insuring pranpt reporting to the UHSRC of proposed 
changes in a research activity, and for insuring thz: changes 
in approved research, during the period for which UHSRC 
approval has already been given may not be initiated without 
UHSRC review and approval except where necessary to eliminate 
apparent inmediate hazards to the subject; and 
b. 
c. 
d. For insuring pranpt reporting tc the UEXC a d  to the 
Secretary of "S of unanticipated problems involving risks to 
subjects or others. 
5 .  The assurance which shall be executed by an individual authorized 
to act for the University and to assme on behalf of the University the 
obligations imposed by applicable federal regulations. 
sixty (60) days after the date of submission to IMS of an application or 
6. Copies of all applications or proposals submitted to HHS. Within 
- 3 -  
proposal, the U€ISRC shall certify that the applicatim or proposal has been 
reviemd and approved. 
111. 
INSTITUTIObX REVIEW BC!>F! REVIEW PROCESS 
A. Exmpt &vim. 
proc3ss of the LTHSRC. 
infc..med consent unless the Secretary of HHS specifically determines that 
the project presents a danger to the physical, mntal, or emotional 
well-being of a participant of the project. 
training grant nature that may eventually involve h m m  subjects do not 
require UHSRC review for the initial request for funds. 
activities that are not exanpt as listed beluw must have UHSRC review and 
HIIS certification before h m  subjects are actually involved in the proj- 
ect. 
1. Certain research activities are considered exempt fran the usual 
As listed below, these activities do not require 
Projects of an institutional or 
HocJever, any 
2. The following activities are considered exempt frcm LJHSRC review: 
a. Research to be conducted in established or ccmnonly accepted 
educational settings, involving normal educational practices, 
such as 
i. 
ii. research on the effectiveness of, or the cqarism 
research.on regular or special educational instructional 
strategies, or 
among, instructional techniques, curricular, or 
classroan managmnt methods. 
b. Research tyhich trill involve the use of educational tests 
(cognitive, diagnostic, aptitude, achievement), if the 
information taken frm these sources is t o  be recorded in 
such a manner that subjects cannot be identified, directly or 
through identifiers linked to the subjects. 
Research which will involve survey or interview procedures. 
No exemption can be given under t h i s  subsection if 
i. 
ii. 
c.  
the research involves children as subjects, or 
the subjects could be identified directly or through 
identifiers linked to the subjects and 
m b e r  One. The subject's responses if hown outside 
the research could place then at risk of civil or 
criminal liability, - danage their financial standing or 
employability, or 
W e r  M. The research deals with sensitive areas 
- 4 -  
such as illegal conduct, drug or alcohol use or sexual 
behavior. 
d. Rescarch which will involve sunrey or intervial of elected or 
appointed officials or candidates for public office. 
Research which wil l  involve the observation (including 
observation by participats) of public behavior. No 
exemption can be given under this subsection 
i. 
e. 
for research involving children in which the 
investigator participates in the activities being 
observed. 
ii. if the subjects could be identified directly or through 
identifiers linked to the subjects @ 
Number One. 
the research could place them at risk of civil or 
criminal lisbility, &age their financial standing or 
anployability or 
W e r  lbo. 
such as illegal conduct, drug or alcohol irse or sexual 
behavior. 
- 
The subject's responses if knom outside 
- - 
The research deals with sensitive areas 
f. Research which w i l l  involve the collection or study of 
existing data, doments, records, pathological specimens or 
diagnostic specimens if these sources are publicly available 
or if the information is to be recorded by the investigc:or 
in such a manner that subjects cannot be identified, directly 
or through identifiers linked to the subjects. 
B. b-edited Review. 
Fxpedited review is allowed of research activities which involve no 
mre than m i n i 1  risks to human subjects and which can be placed in one or 
more or the ten categories noted below. 
research involving children except for collections which are part of the 
usual diagnostic or therapeutic regirr.cn of children. 
ities may be considered for expedited review: 
Expedited revicw is not allatJed for 
The following activ- 
1. 
deciduous teeth; and permanent teeth if patient care indicates a need for 
extraction. 
Collection of excreta and external secretions of sweat, un- 
Collection of hair 'and nail clippings in a nm-disfiguring manner; 
cannu o ated saliva, placenta reimal at delivery and anniotic fluid at the 
time of rupture of mexrbranes prior to or during labor. 
noninvasive procedures routinely employed in clinical practice. This 
includes the use of physical sensors that are applied either to the ourface 
of the body or at a distance and do not involve input of matter of 
3. Recording of data fran subject 18 years of age or older using 
I 
- 5 -  
significant amounts of energy into the subject or an invasion of the sub- 
ject's privacy. 
sensory acuity, electrocardiography , electroencephalography, themgraphy , 
detection of naturally occurring radioactivity, diagnostic echography , and 
electorretinography. It does not include exposure to electranagnetic 
radiation outside the visible range (for exanple, x-rays, microwaves). 
Collection of blwd sqles by venipuncture, in mounts not 
exceeding 450 milliliters in an eight-t.;eek period and no more often than tm 
times per week, frcxn subjects 18years of age or older m d  who are in good 
health and not pregnant. 
calculus, provided the procedure is not more invasive than routine 
prophylactic scaling of the teeth and the process is accomplished in ac- 
cordance with accerted prophylactic techniques. 
of speech defects. 
It also includes such procedures as reighing, testing 
4 .  
5 .  Collection of both supra- and subgingival dental plaque and 
6. Voice recordings made for research purposes such as investigations 
7. 
8. 
Moderate exercise by healthy volunteers. 
The study of existing data, domnts, records, pathological 
Research on individual or group behavior or characteristics of 
specimens, or diagnostic specimens. 
individualstsuch as studies of perception, cognition, game theory, or test 
development, where the investigator does not manipulate subjects' behavior 
and the research w i l l  not involve stress to subjects. Research involving 
sensitive matters such as sexual or political behavior may require full 
review. Expedited review is not appropriate if the subject's responses, if 
h a m  outside the research, could place then at risk of civil or criminal 
liability or damage their financial standing or employability. 
exemption or an investigational device exemption is not required. 
one or mre werienced reviewers designated by the chair person fran among 
members of the UHSRC. 
review. Prmosals aDp roved in this manner will be discussed at the next 
regular meetin 
the rights or welfare of subjects. 
c. Full Review. 
ing the use of human subjects will be required for all non-exanpt research 
projects hich do not qualify for an -edited review, 
9 .  
10. Research on drugs or devices for which an investigational new drug 
The expedited review may be carried out by the UHSRC chair person or by 
'Ihese reviewers exercise all the authorities of the 
.& UHSRC for approval of research, but disapproval requires subsequent full 
$ suspended or t z z x h e  Secretary of HHS tvhen necessary to protect . The use of the expedited review may be 
1. In general, full review of all proposed research projects involv- 
a. In the event research is undertaken without the intention of 
involving human subjects, but it is later proposed to use 
- 6 -  
b a n  subjects in the research, at the time of the proposal 
to use human subjects the research shall then be reviewed 
and approved by the UHSRC and a certification submitted to, 
and approved by, the HHS. 
Cooperative research projects are those projects, nomally 
supported through grants, contracts, or similar arrangments, 
which involve institutions in addition to the grantee or 
prime contractor. In the case .>f a cooperative research 
project in which the University is the grantee or prim 
contractor, then the University Will remain resFmsib1e to 
HHS for safeguarding the rights and welfare of human sub- 
jects. 
tion in a cooperative research project, the University will 
canply with these procedures as though it received funds for 
its participation in the project directly from HHS. 
involving cooperative research projects, the University may 
use joint review, reliance upon the review of another qual- 
ified LRE or similar arrangements aimed at avoidance of 
duplication of effort. 
b. 
Also, when the University joins w i t h  another institu- 
In cases 
2. Criteria for approval of research. 
a. In order to approve research covered by these procedures the 
LWSRC shall determine that a l l  of the following requiraEnts 
are satic -ied: 
i. risks to subjects are minimized: 
b b e r  h e .  - By using procedures which are consistent 
with som research design and which do not 
unnecessarily expose subjects to risks, and 
ii . 
k b e r  Tim. Whenever appropriate, by using procedures 
already being performed on the subjects for diagnostic 
or treatment purposes. 
risks to subjects are reasonable in relation to 
anticipated benefits, if any, to subject, and the 
importance of the knowledge that m y  reasonably be 
expected to result. 
the UHSRC will consider only those risks and benefits 
that may result fran the research (as distinguished fran 
risks and benefits of therapy subjects would receive 
eves if not participsting in the research). The UHSRC 
will not consider possible long-range effects of apply- 
ing knowledge gained in the research (for example, the 
possible effects of the research on public policy) as 
among those research risks that fall within the purview 
of its responsibility. 
In evaluating risks and benefits, 
iii. selection of subjects is equitable. In making this 
assessmt the UHSRC will take into account the purposes 
o f  the research and the setting in which the research 
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w i l l  be conducted. 
iv. informed consent will be sought fran each prospective 
subject or the subject's legally authorized representa- 
tive, in accordance with, the provisions of Section 111 
(C) (3) 
v. informed consent will be appropriately docmented, in 
accordance w i t h  the provisicns of Section 111 (C ) (3 ) .  
v i .  where appropriate, the research plan makes adequate 
provision for monitoring the data collected to inswe 
the safety of subjects. 
vii. where appropriate, there are adequate provisions to 
protect privacy of subjects and to maintain the con- 
fidentiality of data. 
b. Where sane or all of the subjects are likely to be vulnerable 
to coercion or undue influence, such as persons with acute or 
severe physical or mental illness, or persons who are ecmm- 
ically or educationally disadvantaged, appropriate additional 
safeguards nust be included in the study to protect the 
rights and welfare of these subjects. 
3. Znfomed consent. 
a. Ejtcept as provided elsaYhere in these procedures, no 
investigator may involve a h m  being as a subject in 
research covered by these procedures unless the investigator 
has obtained the legally effective inforred consent of the 
subject or the subject's legally authorized representative. 
An investigator shall seek such consent only under circum- 
stances that provide the prospective subject or the represen- 
tative sufficient opportunity to consider whether or not to 
participate and that minimize the possibility of coercion or 
undue influence. 
subject or the representative shall be in language under- 
standable to the subject or the representative. No informed 
consent, whether oral or written, may include any exculpatory 
language through which the subject or the representative is 
made to waive or appear to waive any of the subject's legal 
rights, or releases or appears to release the investigator, 
the sponsor, the institution or its agents frm liability for 
negligence. 
Except as provided elsewhere in this section, in seeking 
informed consent the following information shall be pruvided 
to each subject: 
Zhe information that is given to the 
b. 
i. a statement that the study involves research, an explan- 
ation of the purposes of the research and the expected 
duration of the subject's participation, a description 
- 8 -  
ii . 
iii. 
iv . 
V. 
vi. 
vii . 
of the procedures to be follmed, and identification of 
any procedures which are experimental; 
a description of any reasonably foreseeable risks or 
discdorts to the subject; 
a description of any benefits to the subject or to 
others which may reasonably be expected fran the re- 
search; 
a disclosure of appropriate alternative procedures or 
cuurses of treatment, if any, that might be advantageous 
to the subject; 
a statement describing the extent, if any, to which 
confidentiality of records identifying the subject w i l l  
be maintained; 
for research involving more than minimal risks, an 
explanation as to whether any conlpensation and an 
explanation as to whether any medical treatments are 
available if injury occurs and, if so, what they consist 
of, or where further information m y  be obtained; 
an explanation of whan to contact for answers to 
pertinent questions about the research and research 
subject's rights, and whan to contact in the event of a 
research-related injury to the subject; and 
viii.a statement that participation is voluntary, refusal to 
participate will involve no penalty or loss of benefits 
to which the subject is othendse entitled, and the 
subject may disc0ntir.w participation at any time 
without penalty or loss of benefits to which the subject 
is otherwise entitled. 
c. When appropriate, one or more of the following elements of 
information shall also be provided to each subject: 
i. a statement that the particular treatment or procedure 
may involve risks to the subject (or to the d r y 0  or 
fetus, if the subject is or may becane pregnant) which 
are currently unforeseeable; 
ii. anticipated circumstances under which the subject's 
participation may be terminated by the investigator 
without regard to the subject's consent;- 
iii. any additional cost to the subject that may result fran 
participation in the research; 
iv. the consequences of a subject's decision to withdraw 
fran the research and procedures for orderly termination 
of participation by the subject; 
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v. a staterrent that significrmt new findings developed 
during the course of the research which may relate t o  
the subject's willingness to continue participation will 
be provided to  the subject; and 
the approximate nucber of subjects involved in the 
study. 
vi. 
The IWSRC rray approve a consent procedure which does not 
include, or which alters, s a w  or all of the elemnts of 
informed consent set forth above, or waive the requirement to 
obtain inforned consent provided that the UHSRC finds and 
docments that: 
d. 
i. 
. 
the research or dmstration project is to be conducted 
by or subject to the approval of state or local 
g w e m m t  officials and is designed to study, evaluate, 
or otherwise examine: 
Number he: 
other pub1 ic benefit or service program; 
W e r  M: 
senrices under those progrms; 
Programs under the Social Security Act, or 
Procedures for obtaining benefits or 
h!er Three: Possible changes in or alternatives to 
those programs or procedures; or 
M e r  Four: Possible changes in methods or levels of 
payment tor benefits for services under those program; 
and 
ii. the research cuuld not practicably be carried out 
without the waiver or alteration. 
e. The UHSRC may approve a consent procedure which does not 
include, or which alters, scue or all of the elanents of 
informed consent set forth &me, or waive the requirements 
to obtain informed consent provided the USHRC finds and 
d m t s  that: 
i. the research involves no mre than minimal risk to the 
sub j ec ts ; 
the waiver or alteraticn id1 not adversely effect the 
rights and welfare of the subject; 
without the waiver or alteration; and 
ii. 
iii. the research could not practicably be carried out 
iv. 
Nothing in these procedures is intended to limit the 
whenever appropriate, the subjects will be provided with 
additional pertinent infonnation after participation. 
f. 
- 10 - 
authority of a physician to provide emergency medical care, 
to the extent the physician is permitted to do so under 
applicable federal, state or local law. 
g. Except as otherwise provided, informed consent shall be 
documented by the use of a written consent form approved by 
the UHSRC aqd signed by the subject or subject's legally 
authorized representative. A copy shall be given to the 
person signing the form. 
h. Except as otherwise provided, the consent form may be either 
of the following: 
i. a written consent document that &dies the elements of 
informed consent required by Section III(C) (3) of these 
procedures. l h i s  form may be read to the subject or the 
subject ' s legally authorized representative, but in any 
event, the investigator shall give either the subject or 
the representative adequate opportunity to read it 
before it is signed; or 
, 
ii . a "short form" written consent docranent stating that the 
elements of informed consent required by Section 
III(C)(3) have been presented orally to the subject or 
the subject's legally authorized representative. When 
this rrethod is used, there shall be a witness to the 
oral presentation. 
include those items contained in a written sumnary, 
which has received the prior approval of the UIISRC, of 
what is to be said to the subject or the representative. 
Only the short form itself is to be signed by the 
subject or the representative. Htxever, the witness - 
shall sign both the short form and a copy of the sumna- 
ry, and the person actually obtaining consent shall sign 
a copy of the srnrmary. A copy of the sl;rrmary shall be 
given to the subject or the representative in addition 
to a copy of the "short form." 
Also, the oral presentation shall 
i. The UHSRC may waive the requirement for the investigator to 
obtain a signed consent form for some or all of the subject 
if it finds either: 
i. that the only record linking the subject and the re- 
search w u l d  be the consent document and the principal 
risk m l d  be potential ham resulting fran a breach of 
confidentiality. Each subject will be asked whether the 
subject wants doamentation linking the subject with the 
research, and the subject's wishes will govern; or 
ii. that the research presents no more than minimal risk of 
harm to subjects and involves no procedures for which 
written consent is normally required outside of the 
research context. 
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j .  Tn cases where the domntaticm requirement for informed 
consent is waived, the UHSRC tray require the investigator to 
provide such subjects with a written statement regarding the 
research. 
4. The UHSRC shall have authority to suspend or terminate approval of 
research that is not being ccnducted in accordance with UHSRC's requirexents 
or that has been associated with unexpected serious harm to subjects. 
suspension or teimination of approval shall include a statement of the 
reasons for the UHSRC's action and shall be reported pranptly to the investi- 
gator, appropriate institutional officials, and the Secretaq of "s at the 
Office for Protection f r a n  Research Risks, National Institutes of Health, 
Department of Health and Rman Services, Bethesda, Mayland, 20205. 
Any 
5 .  Procedures. 
Iv. 
SPECIN, FEQ- - RESJ3ARCI-I INVOLVIEX: FETUSES, P R . E " T  WIAEJ 
AND " IN VITRO FERTILIZATION -- 
A. 
pregnatfwanen, and hman in vitro fertilization. 'Ihis includes-mitoring 
the actual informed consenrpEZEZs and m y  extend to approval of procedures 
for induction of individuals into the activity. 
through a specific Ethical Advisory Board, has the responsibility for final 
revini of these activities. 
The UHSRC has special responsibilities in research involving fetuses, 
The Secretary of EIS, 
B. 
of research projects involvir~ fetuses, pregnant waren and human in vitro 
fertilization; 
In general, the follcwing criteria mst be satisfied for UHSRC approval 
-- 
1. Appropriate studies on animals and nonpregnant individuals must 
have been canpleted. 
2. The risk to the fetus is minimal. 
3. 
4. 
5 .  
The investigator must have no role in determining viability of the 
No inducements may be made for pregnancy termination. 
Maternal and paternal inforued consent is required, except that 
fetus or decision-making at the terrnination of the pregnancy. 
the paternal consent need not be secured if: 
a. the identity or whereabouts of the father cannot reasonably 
be ascertained, 
b. the father is not reasonably available, or 
c. 
Ex utero fetuses m y  be involved if no added risks results fran 
the pregnancy resulted frm rape. 
6. 
the activity and if the purpose of the activity is to obtain knowledge which 
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cannot be obtained by other mthods or to enhance the possibility of sur- 
vival of the fetus. 
7. Nowviable ex utero fetuses can be involved mly i f  the activity 
does not affect v i t a l  functions and there is  no way to  obtain the knowledge 
in  any other way. 
Dead f e t a l  mzterial may be included in studies in accordance with 
s ta te  and local law. 
8. 
C. 
of "s m y  modify or waive these criteria, with the approval of the Ethical 
Advisory Board. This w i l l  be done after an appropriate opportunity for 
public carment, and consideration will be given to  whether the risk to  the 
subject are so out weighed by the sum of the benefit as to warrant such 
action. 
Upon the request of an applicant and with UHSRC approval, the Secretary 
V. 
SPECIAL REQUIREklENI'S - RESFARCH INVOLVING CHTLDREN 
A. For purposes of this part of the procedures, the following definitions 
shall apply: 
1. 
consent t o  t r e a m n t s  or procedures involved in the research, which under 
the Law of the State of Alabama a t  the time of the E !option of these proce- 
dures is nineteen (19) years of age. 
research. 
be construed as assent. 
"Children" are persons who have not attained the legal age for 
2. "Assent" means a child's affirmative agrement to  participate in 
lkre failure to object should not, absent a f f i m t i v e  agreement, 
3. "Permission" means the agreement of parent(s) or guardian t o  the 
participation of their  child or ward in research. 
4. 
5 .  
this state  to  consent on behalf of a child t o  general medical care, 
B. The UHSRC w i l l  approve research not involving greater than minimal  r isk 
t o  children only i f  the UHSRC finds that adequate provisions are made for 
soliciting the assent of the children and the pennissim of their parents or 
guardians as described below. 
C. The UHSRC w i l l  approve research in  which the UHSRC finds that mre than 
minimal r isk to  children-is presented by an intervention or procedure that 
holds out the prospect of direct benefit for the individual subject, or by a 
mnitoring procedure that is likely t o  contribute to  the subject's w e l l -  
being, m l y  i f  the UHSRC finds that: 
"Parent" mans a child's biological or adoptive parent. 
"Guardian" means an indivickal who is authorized under the l a w  of 
1. The r i sk  is  justified by the anticipated benefit to the subject; 
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2. The relation of 
favorable to the subjects 
proaches; and 
the anticipated benefit to the risk is at least as 
as that presented by available alternative ap- 
3. 
children and pernlission of their parents or guardiais as set forth below. 
D. The UHSRC w i l l  approve research involving Freater than minimal risks 
and no prospect of direct benefit to individual subjects, but likely to 
yield generalizable knowledge about the subject's disorder or Condition, 
only if the UHSRC finds t k t  : 
Adequate pro\isions are made for soliciting the assent of the 
1. 
2. 
The risk represents a minor increase Over minimal risk; 
The intervention or procedure presents experiences to subjects 
that are reasonably cammsurate with those inherent in their actual or 
expected mdical, dental, psychological, social, or educational situations; 
knowledge about the subject's disorder or condition which is of vital 
importance for the understanding melioration of the subject's disorder or 
condition; and 
3. The intervention or procedure is likely to yield generalizable 
4. 
If research is not otherwise approvable pursuant to the provisions of 
Adequate provisions are made for soliciting assent of the children 
and pemissim of their parents or guardians as set forth below. 
E. 
Sections V(B)- (D) ,  then the UHSRC will approve the proposed research only 
if: 
1. The UHSRC finds that the research presents a reasonable oppor- 
tunity to further the understanding, preventicn, or alleviation of a serious 
problem affecting the health or welfare of children; and 
2. The proposed research has been approved by the Secretary of HHS. 
Requirenents for permission by parents or guardian and for assent by F. 
children. 
1. In addition to the determinations required under other applicable 
sections of these procedures, the UHSRC shall determine that adequate 
provisions are made for soliciting the assent of the children, when in the 
judgrent of the UHSRC the children are capable of providing assent. 
determining whether children are capable of assenting, the UHSRC shall take 
into account the ages, maturity, and psychological state of the children 
involved. 
research under a particular protocol, or for each child, as the UHSRC deems 
appropriate. If the LWSRC determines that the capability of s m e  or all of 
the children is so limited that they cannot reasonably be consulted without 
the interventional or procedure involved in the research holds aut a pros- 
pect of direct benefit that is importat to the health or well-being of the 
children a d  is available only in the context of the research, the assent of 
the children is not a necessary csndition for proceeding with the research. 
men where the UHSRC determines that the subjects are capable of assenting, 
In 
This judgerit may b: uade for all children to be involved in 
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the UHSRC m y  still waive the assent requirmnts under circumstances in 
which consent may be waived in accordance with Section 
2. In addition to the determinations required under other applicable 
sections of these procedures, the LWRC shall &termine, in accordance with 
, that 
adequate provisions are mde for soliciting the permission of: each child's 
parents or guardian. Where parental permission is to be obtained, the UHSRC 
may find that the permission of one parent is sufficient for research to be 
conducted under Sections V(B) or V(C) .  Glhere research is covered by Section 
V(D) and V(E) and permission is to be obtained fran parents, both parents 
rmst give their pemission unless one parent is deceased, unknown, in- 
canpetent, or-not reasonably available, or when mly one parent has legal 
responsibility for the care and custody of the child. 
and to the extent that consent is required by Section 
3. In addition to the provisions for waiver contained in Section 
if the UHSRC determines that a research protocol is designed for 
conditions or for'a subject population for which parental or guardian 
permission is not a reasonable requirement to protect the subjects (for 
exanple, neglected or abused children), it may waive the consent require- 
ments, provided an appropriate mechani.m for protecting the children who 
w i l l  participate as subjects in the research is substituted, and pruvided 
further that the waiver is not inconsistent with federal, state or local 
law. The choice of an appropriate mechanism would depend upon the nature and 
purpose of the activities described in the protocol, the risk and anticipat- 
ed benefit to the research subjects, and their age, maturity, status and 
condition. 
4 .  Permission by parents or guardians shall be documented in accor- 
5 .  \&en the UHSRC deternines that assent is required, it shall also 
dance with and to the extent required by Section 
determine whether and how assent rmst be docurrented. 
. 
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1: 
Duke-UNC Health Profile 
Instructions: 
Here are a number of questions about your health and feelings. Please read each question 
carefully and check ( 4 ) your best answer. You should answer the questions in your own way. 
There are no right or wrong answers. 
DURING THE PAST WEEK: How much (rouble have you had with: 
None .Some A lot None Some A Lot 
part of your body ...... - - - 
1) Eyesight .............. - - __. 13) Hurting or aching in any 
2) Hearing .............. - - - 
3) Talking ............... - ___ - your body ............ - - - 
4) Tasting food .......... - - - 15) Indigestion ........... - __ ___ 
5) Appetite ............. - __ __ 16) Fever ................ - - - 
14) Itching in any part of 
6) Chewing food ........ - __ - 17) Getting tired easily ..... - - - 
7) Swallowing ........... - - - 18) Fainting .............. - - __ 
8) Breathing ............ - - - 19) Poor memory . . . . . . . . .  - - - 
9) Sleeping ............. - - - 20) Weakness in any part of 
your body ............ - - - 
10) Moving your bowels ... - - - 
11) Passing waterlurinating - - - 21) Feeling depressed or sad - - __ 
22) Nervousness .......... - - - 
12) Headache ............ - - - 
DURING THE PAST MONTH how much trouble have you had with: 
None Some ALot None Some A l o t  
23) Undesired weight loss ... - - - 25) Unusual bleeding .... - - - 
24) Undesired weight gain . . - - - 26) Sexual performance 
(Havingsex) ......... - - - 
-~ 
DURING THE PAST WLEK bow often did you: 
Not at All 14  Days 5-7 Days 
27) Do your usual work (either inside or outside the home) .... 
28) Get your work done as carefully and accurately as usual ... 
29) Socialize with other people (talk or visit with friends or 
relatives) ........................................... 
30) Take part in social, religious or recreation activities (meetings, 
31) Care for yourself (bathe, dress, feed yourself) ............. 
church,movies,sports,parties) . . . . . . . . . . . . . . . . . . . . . . . . .  
DURING THE PAST WEEK: 
None 1-4 Days 5-7 Days 
32) How many days did you stay inyour home because of sickness, 
33) How many days were you in bed most of the day because of 
injury or health problems? ............................ 
sickness, injury or health problems? .................... 
TODAY would you have any physical trouble or difficulty: 
34) Peeling an apple ..................................... 
35) Combing your hair ................................... 
36) Walking to the bathroom .............................. 
37) Walking up a flight of stairs ............................ 
38) Running the length of a football field ................... 
39) Running a mile ....................................... 
40) Running 5 miles ...................................... 
None Some A lot 
B 
I 
1 
I 
I 
I 
I 
1 
I 
I 
B 
I 
I 
I 
I 
I 
I 
I 
I 
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I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
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I 
I 
I 
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DAILY HEALTH RECORD 
DAY # 7 
An example Health Record is 
included in your folder 
DAY O F  THE WEEK - 
TIME --------- 
7 HOW did you feel physically todry? fPuf an ' X '  m fhe bor whrch best describes how you felf) 
TERRIBLE WONDERFUL 
872 
name the 
illness 
~nlury. name parl 
31 body hurt and 
'ype of injury 
OM you hrve any rvmPtomr or dlseomforlr today? /Fill out the char/ below horn letf fo righf lor each 2 Syrnpforn or set 01 syrnplorns) 
Not Illness or inrury. 
write what you think 
caused the symp- 
toms 
0 5 No symptoms or Go lo Ouesiron 6 
discomtorts at a11 * 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
1 
I 
SYMPTOM CHART 
O 1 Very Serious 
0 3 Somewhat Serious 
P 5 Not Very Serious 
CI 1 Veryserious 
0 3 Somewhat Serious 
0 5 Not Very Serious i 
NUMBERS 
BELOW 
CAN BE USED 
IN Os 3 AND 4 
1 
2 
3 
4 i  
2s SYMPTOMS6 
DISCOMFORTS 
Write symptoms of thc 
same health problem ci 
m e  box. 
I 2b CAUSE 
2c SERIOUSNESS 
In your opinion. hot 
serious was this conditioi 
or set of symptoms today 
0 1 .  Very Serious 
0 3 Somewhat Seriou: 
I 0 5 Not Very Serious 
O 1 Very Serious 
0 3 Somewhat Serious 
0 5 Not Very Serious 
0 1 Very Serious 
I 
0 3 Somewhat Serious 
0 5 Not Very Serious 
I I 1 
I 
I 
I 
I 
I 
~~ ~~ 
Triggers of symptoms and hcahh care 873 
3 Because of today's symptoms. did you cut down on the things you usually do? 
6 ' Yes fl 5 No GotoOuestion4 
Answer 3a through 3e 
3a. Did you stay in bed? E No S Yes 
3b. Did you cut down on 
household chores or 
errands? 0 No 0 Yes e 
3c. Did you miss work? 0 No C Yes 
3d. Did you miss school? 0 No C Yes e 
30. Did you cut down on 
olher activities you 
planned to do (sports. 
clubs, church etc.)? 0 No G Yes 
For whlch symptom. illneSS. or 
inlury' iWrrte m number lrom 
symprom chart. quesfron 21 
4 Did you seek medical or dental helg about today's symptoms? 
3 '  yes 3 5 No e Go lo Ouestion 5 
Answer 4a through 4e 
4a. Did you make an appoint- 
ment with a doctor or 
dentist? L' No C: Yes 
4b. Did you telephone a clinic, 
doctor's oflice or dentist s 
office and get advice? Z No 2 Yes 
4c. Did you visit a clinic. 
doctor's or dentist's oflice 
or an emergency room? i2 No I C Yes 
4d. Did you get admitted to 
a hospital? e NO t Yes 
40. Was there anything else 
you did? [IF YES: what 
was that?) 0 No 0 Yes 
For Wnch symptom. Illness. or 
injury' fWrtre In number from 
sympfom chart. question 21 
~ 
a74 Lois M. VERBRUGGE 
i 
1 
I 
I 
I 
I 
1 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
3 Did you lrlk wllh myono else lodry - such 18 relrtlves. nelghbors, frbnds - rboul your symploms? 
0 5. No e Go to Ouesfron 6 
5r. Who did you lrlk with? (Check all boxes lhar apply  I 
0 A Your husbandfwife 
0 B 
0 C 
0 0. 
0 E 
Other member of your household 
Relative not living with you 
Neighbor. coworker. friend (who is not a relative of household member) 
Other person (druggist. minister. priest. etc )Who did you speak with' 
--- .- - - . . .- - - - 
6 Did you vlslt or telephone r CllnlC, doctor or dentlsl's office. or hospital todry for any reason besides 
symptoms you mlghl have hod lodry?  
0 5 No Go fo Ouesfron 7 
ORIGINAL PAGE IS 
OF POOR QUALITY 
Triucrs or sympiomr and h i i h  care 
7b REASONS FOR TAKING 
PILLS, MEDICINE TREAT- 
MENTS 
(Check all boxes fhdl apply I 
A To treat symptoms bothering 
you today 
B For other health problem not 
bothering you today 
C To prevent illness or to 
become more healthy in 
general 
D Other reasons 
ORIGlNAL PAGE IS 
OF. POOR QUALITY 
7C SYMPTOM OR CONDITION 
What was the symptom. health 
Droblem. or other reason for tak- 
r ig  pills. medicine. or treatment? 
Did you take m y  pills. medicine. or treatment) lor your herllh todoy - lo trerl 0 symptom. prevent 7 illness. Or to become more healthy in generrl? iFdl ouf fhe chart below from /e11 lo fJQh/) 
P ' Yes 
7a PILLS. MEDICINE. TREAT, 
MENTS 
I f  pills or medicine. write the 
brand name from the label and 
the type of drug Use one box for 
each pill. medicine or treatment 
1 
0 5 No  pills. medicine 01 Go fo 
treatment taken at all Question 8 
O A  O B  O C  G O  
Go to 7c 
O A  C B  O C  Z D  
Go to 7c I) 
= A  U B  E C  I D  
Go to 7c 
E A  C7B C C  5 0  
Go 10 7c 
3 A  O B  O C  Z D  
Go io 7c 0 
8 How were your spirits loday? P u f  an “X”m the b o x  whrch best describes how you /elf today) 
6 7 8 
TERRIBLE WONDERFUL 
9 Did anything happen - for better or worse - to make today different than usual? 
0 5 No e Go lo Ouesrron 10 P Yes 
9a. What happened? Check all boxes lhaf apply ) 
fl A 
0 B Trip or vacation 
C Emergency 
0 0 
0 E 
0 F 
0 G Guests 
0 H Other What happened’ 
Birthday. holiday or special social event 
Trouble with family or friends 
Something extra nice wlth family or friends 
A lot of extra work 
qo Any other comments: __ - _ _ _  - _ -  
REMINDER: 
IF you had any symptoms today 
Be sure you answered Oueslions 1 ,  2. 3.4. 5 .6  7 .8 .  and 9 
IF you had no symptoms today 
Oe sure you answered Oueslions 1 .2 .6 .  7.8. and 9 
APPENDIX D 
MEDICAL EVALUATION, SUBJECTS 
FOR WATER RECOVERY TEST, MSFC 
NAME : 
LAST FIRST MIDDLE 
ADDRESS 
AGE DATE OF BIRTH 
WORK AREA WORK PHONE 
HOME PHONE MAIL CODE 
IN CASE OF EMERGENCY, CONTACT: 
PHONE 
PERSONAL PHYSICIAN 
PHONE ADDRESS 
INITIAL EVALUATION 
- -  NL ABNL COMMENTS 
PMH 
CHRONIC ILLNESSES 
MEDS 
MENSTRUAL HISTORY 
RECENT ILLNESSES 
TOPICAL USE 
HABITS (D, T, A) 
SKIN/HAIR DISORDER 
MINOR ILLNESS FREQUENCY 
PHYSICAL EXAM 
SKIN 
HEENT 
LUNGS 
HEART 
ABD 
GU 
NEURO/MS 
HEALTH PROFILE 
LABORATORY 
ROUTINE 
SPECIAL 
SKIN TEST 
PPD 
ANERGY 
SYMPTOM DIARY 
INITIAL EVALUATION (CONTINUED) 
- -  NL ABNL COMMENTS 
I have examined the above named subject and believe he/she 
(is) 
at MSFC. 
(is not) qualified to be involved in the water recovery test 
M.D. LA- 
DATE 
I s  
1 
I 
1 
I 
3 
8 
I 
I 
1 
I 
E 
I 
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I 
1 
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I 
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APPENDIX D 
MEDICAL EVALUATION, SUBJECTS 
FOR WATER RECOVERY TEST, MSFC 
NAME : 
LAST FIRST MIDDLE 
ADDRESS 
AGE DATE OF BIRTH 
WORK AREA WORK PHONE 
HOME PHONE MAIL CODE 
IN CASE OF EMERGENCY, CONTACT: 
PHONE 
PERSONAL PHYSICIAN 
ADDRESS PHONE 
PRE-TEST EVALUATION 
- -  NL ABNL COMMENTS 
SYMPTOM DIARY 
MENSTRUAL HISTORY 
TOPICAL USE 
PHYSICAL EXAM 
LABORATORY 
ROUTINE 
- -  SPECIAL 
I have examined the previous named subject and believe 
he/she (is) (is not) qualified to be involved in the water 
recovery test at MSFC. 
- M.D. 12- 
DATE 
APPENDIX E 
2.12 Disqualification Criteria for Initial Evaluation 
2.121 No personal physician 
2.122 Any chronic illness or regular medicine intake 
2.123 Frequent minor illnesses 
2.1231 > 4 colds/yr 
2.1232 > 2 GE/yr 
2.1233 > 1 UTI/yr 
2.1234 > 2 Vaginitis/yr 
2.1235 > 1 Active Skin Infection/yr 
2.124 Abnormal physical finding 
2.14 Disqualification Criteria for Pre-test Evaluation 
2.141 Significant new symptoms of infection 
2.142 Testing likely to occur during menses (phase 
dependent ) 
2.143 4ny topical use (phase dependent) 
2.144 Abnormal physical finding 
2.145 Positive urine culture ( >10,00O/ml of each organism) 
2.146 Positive wet prep/GM stain 
2.147 Positive or indeterminate serum pregnancy test 
2.148 Positive urine drug screen 
APPENDIX G 
Presentation Material 
I 
I 
I 
Presentation made on April 4,1988 
I 
I 
I 
I 
1 
i 
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1 
I 
1 
1 
I 
1 
I 
I 
1 
1 
8 
I 
I 
I 
I 
I 
8 
I 
I 
I 
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2.15 Post-Test Evaluation 
2.151 Review shptom diary 
2.152 Review menstrual history 
2.153 Brief physical exam 
2.154 Repeat health profile (DUHP) 
2.155 Laboratory 
2.1551 U/A and culture 
2.1552 Wet prep/GM stain (if indicated) 
2.1553 Serum pregnancy test 
2.1554 Stool culture 
2.1555 Special studies 
2.16 Detection of Sick Subjects 
2.161 Continue symptom diary 
2.162 Monitor v i s i t s  to personal physician (by 
permission) 
2.163 Subject notifies 
5 

1. The use of human subjects in research committee (UHSRC) 
shall be composed of at least five (5) members, vith diverse 
backgrounds possessing the professional competence to promote complete 
and adequate reviev of research activities and ascertain acceptability 
in terms of institutional commitments and regulations, applicable law 
and standards of professional conduct and practice. 
2. Representation on the UHSRC shall include: 
a. M e n  and women. 
b. Representation of lore than one profession. 
c. At least one member vhose primary concerns are 
non-scientific, i.e., lawyer, ethicist, clergy 
mmber. 
d. At least one member vho is not affiliated vith 
tha institution, either personally or by immediate 
faail ia1 relationrhip. 
3. Bo persoah shall serve as a member of the UHSRC where 
such service would constitute a conflict of interest involving 
the proposed researcln project under review. 
4. The will invite individuals with specific 
competencies to assist in its review of complex issues. 
the scope of their invitation, that- invited individuals will 
serve as f u l l  members of the U H S K ,  except that they shall not 
have a vote. 
Within 
W. J. Crump,  M . D .  
3/28/88 
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AJPPENDIX 6 
CONSENT FORM 
FOR APPROVED NASA HUMAN RESEARCH 
1. I ,  the undersigned, do vo lun tar i l y  g ive my informed consent fo r  my par t i c -  
i pa t i on  as a tes t  subject I n  the fol lowing test ,  experiment, or  other 
evaluat ive procedure: 
NAME OF EXPERIMENT 
FLIGHT TO WHICH ASSIGNED 
NAME OF MSIGNATEO PRINCIPAL INVESTIGATOR 
NAME OF RESPONSIBLE NASA PROJECT SCIENTIST 
I understand that: 
This procedure i s  part of n experiment approved by NASA. 
I M performing these duties n a part ef my estplojmeftt, with . 
This procedure has bccm reviewed UICI approved by the JSC Human 
Research Policy a d  Procedures Coconittee (HRPPC) and determined that  
the yaccdwe involves reasw&le r i s k  t o  the subject. 
"Reasonable ria" mats t h a t  the risks of ham anttcipated i n  the 
proposed research are g c i t t r  than  t h  o r d i m w i l y  encountered i n  
d a i l y  l i f e  QT d w i q  the pevformmca of rout ine tests, but considered 
t o  be proper when weighing the ant ic ipated b e n e f i t s  and the impor- 
tance of the knowledge to be gained from the research. 
The procedure h s  been explained t o  me p r i o r  t o  the execution o f  this  
form. I was afforded an opportunity t o  ask questions, and a l l  ques- 
t i ons  asked were answered. 
I dm *medically qua l i f i ed  to  par t i c ipa te  i n  the procedure. 
I may withdraw from the procedure at any t ime unless, as recomnended 
by the Pr inc ipa l  Investigator, or hisfher &signee, the withdrawal i s  
dangerous or impossible. 
22 
T. I ,  the undersigned, the Principal Invest igator  o f  the experiment desig- 
nated above, c e r t f f y  that: - 
(a )  I have accurately described the procedure t o  the t e s t  subject. 
(b)  The tes t  set-up Involves reasonable r i s k  t o  the t e s t  subject. A l l  
equipment used has been inspected and c e r t i f i e d  for safe and proper 
operation. 
( c )  The t e s t  subject i s  medical ly qua l i f fed  to  par t i c ipa te .  
(d )  The t e s t  protocol has not been changed frm that approved by the JSC 
H u m a n  Research Pol i c y  and Procedures C o m i  t t e e  (HRPPC) . 
APPROVED: 
Test Subject Oat e 
P r inc ipa l  Invest igator Oate 
Pro jec t  Sc i ent i s t  Oate 
Thfs'conserrt form Is v a l i d  f o r  a $0-day perfd from the date of signature by 
the subject and th.e Princlprl Inves t iga tor  (which dates *Id k fden t fca l ) .  
A sf+, drttd cow of the fom should' k fomrrdtd to the J X  Flamaro k e w c h  
Pollcy and Procedures Cormittee, Mall Code SA, Lyndon 8 .  3o)#rsor, Space Center, 
Houston, Texas 77058. 
2.11 Initial Evaluation - 
2.111 Name of personal physician 
2.112 Recent illnesses 
2.113 Past medical history 
2.1131 Chronic illnesses (Hypertension, 
Diabetes, etc.) 
2.1132 Regular medicines, including OCP’s 
and OTC 
2.1133 Menstrual history 
2.1134 Regular cream, ointment, oil use 
2.1135 Other drugs, alcohol, tobacco 
2.1136 Active skin or hair disorder 
2.1137 Frequency of minor infectious 
diseases 
2.114 Physical Exam 
2.115 Health Profile (WHP) 
2.116 Laboratory 
2.1161 CBC 
2.1162 U/A and culture 
2.1163 Wet prep/GM Stain (if indicated) 
2.1164 Serum pregnancy test 
2.1165 Stool culture 
2.1166 Special studies 
2.117 Skin test anergy pack and PPD (Reading 
required in 48 hours) 
2.118 Begin spptom diary 
1 
4/88 
2.12 Disqualification Criteria for Initial Evaluation - 
2.121 No personal physician 
2.122 Any chronic illness or regular medicine 
intake 
2.123 Frequent minor illnesses 
2.1231 > 4 colds/yr 
2.1232 > 2 GE/yr 
2.1233 > 1 UTI/yr 
2.1234 > 2 Vaginitis/yr 
2.1235 > 1 Active Skin Infection/yr 
2.124 Abnormal physical finding 
2.125 Poor DUHP score 
2.126 Abnormal lab 
2 
4/88 
2.13 Pre-Test Evaluation 
2.131 
2.132 
2.133 
2.134 
2.135 
- 
Review symptom diary 
Review recent menstrual history 
Review recent topical use 
Brief physical exam 
Laboratory 
2.1351 U/A and culture 
2.1352 Wet prep/GH stain (if indicated) 
2.1353 Serum pregnancy test 
2.1354 Urine drug screen (legal ramifications) 
2.1355 Special Studies 
3 
I 
1 
I 
I 
1 
1 
I 
I 
I 
I 
I 
b 
I 
I 
I 
I 
I 
I 
~I 
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2.14 Disqualification Criteria for Pre-test Evaluation - 
2.141 Significant new symptoms of infection 
2.142 Testing likely t o  occur during menses (policy 
decision) 
2.143 Any topical use on prohibited list 
2.144 Abnormal physical finding 
2.145 Positive urine culture ( >10,00O/ml of each 
organism) 
2.146 Positive vet prep/GH stain 
2.147 
2.148 Positive urine drug screen (legal) 
Positive or indeterminate serum pregnancy test 
4 
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P R O P E R T Y  P O T A D L E  
L I M I T  
C H Y S I C A L  
color 
98S, d f 8 8 o l v . d  0 
- c o n d u c t l v t t y  T D D  
#88, fro0 0 
p 8 r t i e u l a t . 8  6 0  
rolldr, t o t a l  e 1 0 0  
PH 6 . 0 - 8 . 0  
8OlidS, d l 8 8 .  
S U r f 8 C t a R t 8  
t 8 S t O .  o d o r  . 3  
t u r b i d i t y  
A L S T N L T I C S  
C a t  en8 
A n i o n s  
CQ2 
I Y O R C A N l C  
&ET A L  L f C S  
- A  Luni n w  
-Ant  i moay 
A r s e n i c  
B a r  i urn 
- 8 e r y l l  f u m  
a 6 o r o n  
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Ca 1 c i urn 
Ch r o n i  urn 
Cobr I t 
C o p p e r  
I r o n  
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N a g n e s  i urn 
M a n g a n e s e  
M e r c u r y  
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N i c k e l  
~ P o t a s s i u r  
Se 1 e n  i urn 
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T D D  
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1 . o o  
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T D D  
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T B O  
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0 . 0 s  
0 . 0 s  
0 . 0 5  
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T BO 
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0 . 0 5  
T B D  
T B D  
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L I M I T  
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0 
0 
4 0  
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1 .00  
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0 . 0 1  
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ORIGINAL PAGE !3 
OF POOR Q U A M Y  
DONOR SAFEGUARDS 
Exposure and Risk - 
I 
1 Sources 
Hygiene Wastes 
Urine 
Humidity Condensate 
Routes 
Skin Contact including mucous membranes 
Transdermal 
Inhala tion 
Ingestion 
Exposure 4 & T&-”’+-;.. .- 
Intermittent rn Q 
I 
I 
Isc RiS 
1 
Chemical 
Biological 
0 
TABLE 3-4 
RECOMMENDATIONS FOR MONITORING 
- PHYSICAL 
CONDUCTIVITY 
C O W R  
TURBIDITY 
PH 
. INORGANIC 
Non-Metals 
Ammonia 
Chloride 
Bromide 
Iodide 
Nitrate 
Phosphate 
Sulfate 
Metals 
Arsenic 
Barium 
Cadmium 
Calcium 
Ch rom i urn 
Copper 
Iron 
Lead 
Magnesium 
Manganese 
Mercury 
Nickel 
Potassium 
Selenium 
Silver 
Zinc 
ORGANICS 
Cyanide 
TOC 
Total Toxic Organics (TTO) 
WICROBIOLOGICAL 
Total Bacteria 
Total coliforms 
Heterotrophs 
Non-Saprophytic 
Legionellae 
TABLE 3-5 I 
I 
II 
@ 
I 
I 
METHODS AND INSTRUMENTATION FOR WATER QUALITY VERIFICATION 
PARAMETER - METHOD INSTRUMENTATION 
PHYSICAL 
CONDUCTIVITY 
COLOR 
TURBIDITY 
PH 
INORGANIC 
Non-Metals 
Ammonia 
Chloride 
Bromide 
Iodide 
Nitrate 
Nitrogen, 
Phosphate 
Sulfate 
Metals 
Arsenic 
Barium 
Cadmium 
Chromium 
Coppar 
Iron 
Lard 
Ilanganere 
Mercury 
loickal 
Fetassiur 
Selenium 
Silver 
Z i n c  
-8iUB 
ORGANICS 
EPA 120.1  
EPA 110.3 
EPA 150 
EPA 180 
EPA 
EPA 
EPA 
EPA 
EPA 
Total EPA 
EPA 
CPA 
350.2 
300.0 
300.0 
300.0 
300.0 
351.3 
300.0 
300.0 
EPA 206.3 
EPA 200.7 
t P A  213.2 
EPA 200.7 
EPA 200.7 
BPA 200.7 
EPA 239.2 
tPA 200.7 
EPA 200.7 
EPA 245.1 
EPA 258.1 
EPA 270.3 
EPA 272.2 
EPA 200.7 
EPA 249.2 
Cyanide EPA 335.2 
Halogenated Hydrocarbon EPA 612 
Organic *ids 
Organic Alcohols 
Pesticides EPA 608 
Phenols EPA 604 
Toc EPA 415.2 
Total Toxic Organics EPA 624, 625 
Cond. Meter 
w-VIS 
pH Meter 
Nephelometer 
w-VIS 
Ion Chromatograph 
Ion Chromatograph 
Ion Chromatograph 
Ion Chromatograph 
w-VIS 
Ion chromatograph 
Ion Chromatograph 
AAII 
ICP 
MG 
I C P  
ICP 
ICP 
MG 
ICP 
ICP 
llg Analyzer 
rn 
MF 
MH 
AAG 
ICP 
w-VIS 
GC/ECD 
mLc 
"IC 
GC/ECD 
GC/FID 
TOC Analyzer 
=/lq;g: 
S E C O N D A R Y  R E Q U I R E W E W T S  (COUl.) 
CODpOund sourco ADt . T o x i c i  ty 
polmitic acid 
POntrnO, 2,S-dlrOthyl- 
pontrno, 2,2,4-triDethyl- 
6-Dothyl-2-prntrnonr 
2 - ~ o t h y l - 2 , 4 - p o n t r n o d i o l  
prntrno, 4 , 4 - d i ~ r t h y l - l -  
phorphrto, diothyl prntyl- 
phorphrto, triothyl- 
phorphrto, t o r t r ~ o t h y l p y r o -  
phorphrto, t o t r r ~ o t h y l p y r o -  
1 -propono 
propionic reid 
propylono g l y c o l  
Pyrrolidino 
pyrrolidino, W-methyl- 
pyrrolidono 
r tyrrno 
rrlicylic acid 
thiophon., 
t h i our or 
thiouror, trtrraothyl 
trtrrhydro-1,l-dioxidr 
uror  
Undtcrnoic Acid 
n - u n d r c r n o  
vrni 1 l r n  
Xy 1 r n o  1 
xylonor, total 
7 
1 -  
1 100 
1 so 
1 1 1 0  
1 100 
1 67 
1 12 
1 2 
2 100 
1 100 
1 6.000-17,222 or1 r a t  L O s O  1 5 1 0 ~ ~  
1 300 
1 
1 100 
1 so i h n  LDn T C L o  376ppm 
6 350000 or1 rat C B s 0  89las 
1 15 
1 5 0 0 - 5 0 8  
1 5 5  
1 * 1 6 , 0 0 0  
4 200 
i v n  mur L O S O  1 4 0 m g  
6 200 or1 rat L B s 0  158Omg 
o r l  DUS 107Omg 
s o  
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z 
I 
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S E C O N D A R Y  R E O U I R E M E M T S  (COMT.) 
Coapound S o u r c r  A D t .  l o x  i c i t y  
c r p r y l l c  r c l d  1 
c y r n u r r t o ,  t r l r l l y l i r o -  1 -  
c r r b o x y l i c  r c l d r  4 
c a r b o x y l i c  a c i d s  2 
c r r b o x y l l c  r c l d r  3 
c r r b o x y l l c  a c i d s  (5) 7 
c r r b o x y l i c  a c i d  c r p d r  ( 4 )  6 
c r r b o x y l i c  a c i d s  ( 2 )  1 
unknoun  e r r b o x y l i c  a c i d s  1 
e r p r o l r c t r .  1 
c a r b o n  d i r u l f f d 8  1 
C a p r o i c  A c i d  
273ppb I v n  BUS L O s o  600.1 
12PPb 
40,800ppb 
92 ‘21  Oppb 
81,SOOppb 
3, 5OOppb 
52, OOOppb 
43, OOOppb 
2,633ppb 
1 5, OOOppb 
1 4  - ? 2 2 p p b  
or1 r a t  L D L o  3 0 0 0 a a  
b 8 C r n r l  o r l  r a t  L O s o  3730.1 
B o d e c y l  r l c o h o l  i p r  r r t  L O s o  800mg 
d r c r n  cmpdr ( 2 )  4 28Dppb 
d o d r c r n o l  3 lDDppb 
d i b r n z o f u r r n  1 20 
d i m r t h y l - b r n r r n r  m e t h a n o l  1 1 6Ppb 
diex8lrnr c a p d r  3 6OOppL 
8 t h 8 r ,  . thy1 p r o p y l  1 S ~ P P ~  
r t h r r ,  
8thyl.n. # l y C O l  m o n o b u t y l -  1 1 @Oppb 
8 t h 8 r ,  
p - c h l o r o p h r n y l  r r t h o x y i r o b u t y l  4 COOppb 
8 t h 8 r S ,  m l y c o t  ( 2 )  1 5SQppb 
3 9OOppb 
f u r f u r y l  r l c o h o l  5 21. o r 1  r a t  L D s o  2 7 5 m g  
H c p t a n o i c  A c i d  
4 - h e p t r n o n r  
h e p t r n o n r  e r p d r  ( 2 )  
H c x a n o l  
h r x r n o l ,  2 - . t hy ! -1 -  
h b x 8 n o l ,  S - r n 8 t h Y t - l -  
2 - h r x r n o n e  
c y c l o h e x a n o n e  
o r 1  mus L O S O  16Ong 
6 l e d p p b  
4 6(3ppb 
o r 1  r a t  L D S O  7201119 
6 lOOppb 
1 1SOppb 
1 5OPPb 
1 35PPb 
i s o p h o r o n e  1 JPPb 
l a c t o n e  cmpdr 3 130ppb 
m o r p h o l l n e ,  4 - e t h y l  1 470ppb 
m o r p h o l i n c ,  n - e t h y l  1 400ppb 
n o n r n e d i o r t r ,  
b i r ( 2 - 8 t h y l  h 8 x y l ) -  1 1, lOOppb 
n o n r n e d i e i e  acid 1 6PPb 
o c t r n o r t o ,  D 8 t h y l -  3 2OOppb 
S L E O W O A R V  R E Q U I R E M E N T S  
Co8pound S o u r c e  A r t .  T o x i c t t y  
A c o t l c  A c f d  s -  300 O r l  h 8 n  TOLO 1470 U #  6 1 1  
t h l  hmn T O L O  816ppm/Smin 
o c o t l c  r c l d ,  p h e n y l  4 400 
acetat., e t h a n o l  e t h o x y  1 1 a 0  
a c e t a t o ,  v l n y l  1 s o  
d l a c e t o n o  a l c o h o l  1 19PPb 
a c e t o n e  3 3300 o r 1  hmn T C L o  5 O O p p m  E y e  
a c e t o n e  tmpdr ( 2 )  4 2SOppb 
r z o p I n - 2 - o n 0 ,  h e x a h v d r o  1 $11 73ppb 
an1  I In. 1 ~ O P P ~  
2 - n l t r o a n l l t n o  1 200ppb 
3 - n t t r o a n l l t n e  1 2OOppb 
4 - n t t r o r n f l i n r  1 2OOppb 
a c r y l a t e ,  3 - m e t h o X y - b u t y l  3 130pp8  
1 sL3 4.3pp8 
A d l p i c  A c l d  o r 1  r a t  L D L B  3600mg 
r d l p r t o ,  t e t r a m e t b y l o n e  1 &P?b 
amide, b u t y l  b r n x e n e r u l f o n  1 4PPb 
a 8 t d 0 ,  M , n - d l - n - b u t y l f O r 8 -  1 4@P# 
amfde, M - 8 e t h y l - U - e t h y t  f o r m - 1  1 , 103ppb 
4-chlorornlllne 1 1 Obppb 
a a i d e ,  N a n - d i m e t h y l  f o r m -  1 5 L l p p b  
r a i d e r  (4) 1 3 19Oppb 
amides  ( 2 )  2 4bOppb 
amine,  d i m e t b y l  o r 1  r a t  L D s 0  6 9 8 r g  
a m i n e ,  N , n - d t m e t h y l  b e n z y l -  1 8Oppb 
rain., d i - n - b u t y l  t 7 4 ~ ~ )  
8 8 i R O S  ( 2 )  1 2OOppb 
alc0h.1 C D p d S  ( 2 1  3 SOOOppb 
atkeno ( C z , l s 8 )  3 1 OPpb 
B u t y r i c  A c i d  
b u t y r a t e s ,  3 - h y d r o x y  
- t r i m e t h y l p o n t y l i r o  1 
1 - b u t a n m i n e ,  n - b u t y l -  1 
b u t r n o r t e , 2  8 e t h o x y n e t h y l - 2 -  1 
2 - b u t r n o n e  1 
b u t a n o n e ,  3 - m e t h y l - 2 -  1 
b e n z o i c  a c i d  1 
3 
b e n z o i c  a c i d  crapds ( 2 )  4 
6 
b e n z a l d e h y d e  3 
b e n z a l d e h y d e  cnpds ( 3 )  c 
b e n z y l  r l c o h o l  1 
b e n r i s o x a z o l e  1 
o f 1  r a t  L D S O  2 9 4 0 m g  
300ppb 
180ppb 
S ~ P P ~  
9OOppb 
60PPb 
500ppb o r 1  r a t  L D S O  3 0 4 0 m g  
848ppb 
3000ppb 
lSOppb 
1000ppb o r 1  r a t  L D s O  1300mg 
1 SOppb 
47OOppb o r 1  r a t  L D S O  1330mg 
1 OOppb 
C o r p o u n d  
r C r n r p h t h 8 n r  
r c r n r p h t h y l o n r  
a n t h r a c e n e  
brnx t d i  nr 
? R f W A R I  R E P U I R E l E Y 1 S  ( C O Y T . )  
s o u r e r  A r t  b e t .  
1 .  100 
1 
b r n r o - a - r n t h r r c r n r  
b r n r o - a - p y r r n r  
b r n r o - b - f l u o r r n t h r n r  
3 , 4 - b r n x o f l u o r r n t h r n r  
b e n r o ( g , h , l ) p r r y l r n r  
b c n r o ( k ) f l u o r r n t h r n r  
b i r ( 2 - c h l o r o  8 t h o x y ) r r t h r n e  
b i 8 ( 2 - ~ h l o r o r t h y l ) r t h r r  
bir(2-:hloroiropropyl)rthrr 
b i r ( 2 - 8 t h y l h 8 x y l ) p h t h . L l t r  
4 - b r o r o p h r n y l  p h r n y l  r t h r r  
b u t y l b r n r y l  p h t h r l r t .  
2 - c h l o r o  n r p h t h r l r n r  
4 - c h l o r o p h r n y l  p h r n y l  r t h r r  
d i b r n r o ( 8 , h ) r n t h r r c e n r  
1 , 2 - d i c h l o r o b r n r r n r  
1 , 3 - d i c h l o r o b e n r r n r  
l , i - d l c h l o r o b r n z r n r  
3 , 3 ' - d i c h l o r o b r n x i d i n e  
d i e t h y l  p h t h r l r t r  
d i n r t h y l  p h t h r l r t r  
d i - n - b u t y l  p h t h a l a t e  
2 , b - d i n i t r o  t o t u r n 8  
2 , 6 - d i n i t r o  t o l u r n r  
d i - n - o c t y l  p h t h r l r t r  
1 , 2 - d i p h r n y l h y d r r x i n r  ( a 8  .ZObenZ8n8) 
f l o u r r n t h r n r  
f l u o r r n o  
h e x r c h  I o r o b 8 n z 8 n 8  
h r x r c h l o r o b u t r d i r n r  
hexrchlorocycloprntrdfrne 
hcx8chlorocth8ne 
i n d e n o ( l , 2 , 3 - o d ) p y r r n c  
f r o p h o r o n r  
2 - r r t h y l  n r p h t h r l r n c  
n r p h t h r l r n r  
n i t r o b r n x r n r  
Y - n i t r o 8 o d i 8 r t h y l r ~ i n r  
C h r y t r n r  
1 
8 
1 
1 
1 
100  
40 
103 
1 0 0  
40 
100 
I-nitrorodi-n-propylrrinr 
a - n f t r o r o d i p h r n y l r ~ i n r  
p h r n r n t h r r n e  
p h t h a l r t r  8 S t 8 r 8  ( 2 )  6 350 
p h t h r l r t r  8 8 t 8 r 8  1 140-15,000 
p h t h a l r t 8 ,  b i r ( 2 - 8 t h y l  h 8 x y l ) -  6 103 
p y r r n r  
1 , 2 , ) - t f f C h l O f O b 8 n 2 8 n 8  
2 , 3 , 7 , 6 - t r t r r c h l o r o d f b . n t o - p - d i o x i n  
p h t h r l r t r ,  d i r t h y l  p r n t y l -  1 49 
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Corpound 
P R I M A R Y  R E Q U I R E M E W 1 8  (Cowl.) 
tourco ABt 
ACID COMPOUWDt 
p-chloro-m-crorol 
4,6-dinitrocrorol 
phono 1 
2 -  ch I orophono 1 
Z04-dichlorophenol 
2,4,6-trichlorophenol 1 
pontrchlorophonol 
4-chloro-3-rothylphonol 
2,4-di~rthylphonol 
2-nitrophonol 
4-nitrophonol 
2,4-dinitrophonol 
2 - ~ o t h y l d i n i t r o p h e n o l  1 
2 - ~ o t h y l  phonol 1 
)-..thy1 phonol 1 
phonol, 2,6-di 
phonol, 
- t - b ~ t y l - 4 - ~ 0 t h y l -  1 
4 - ( l 0 l - d i ~ ~ t h y l ~ t h y I ) l  
phonol cBpdr ( 8 )  6 
phon01 cmpdr 4 
phonol cmpdr (6) 2 
phonol,2,6-di 
- t - b u t y l - i - m e t h y l -  8 
dotoc t od 
ZOO 
4 0  
6 5 0  
10 
16 
13 
2 , 2 0 0  
600 
2 7s 
150 
Compound 
V O L A T l  LEI 
SPECIFIC TOXICAUTS 
P R I N A R Y  R E O U I R E W E W T S  
- 
Source ABt 
det re  t ed 
1 Acetyl benzene 
Acrolefn 
Acrylonltrlte 
Benzene 
Bromochloromethane 1 
B r O D O C h l O r O p r O p r n ~  1 
@ r omof orm 
Bromomethrne 1 
I r o m o d l c h l o r o m ~ t h r n e  
Carbontrtrrchlorlde 
Chlorobenrrnr 
Chlorodibromomethrne 
Chloroethrne 
2-thloroethyl vlnyl ether 
Chloroform 
Chtororethrne 1 
Dibromochloromethrne 
blchlorobutrne 1 
1.1-dichloroethrne 
1.2-dichloroethrne 
1,l-dlchlororthylene 
trans 1.2-dichloroethylenc 
Dichlorofluoromethrne 1 
1.2-dichloropropane 
1,3-dlchleropropene 1 
1.2-dlchloropropylene 
Dimrthytbenzene- 
methrnrmlne 1 
e t h y l  benzene 
methyl bromide 
m e t h y l  rhlorlde 
methylene chloride 
1,1,2,2-tetrrchlororthrne 
tetrrchloroethylene 
toluene 
1,2-tranr-dichloroethylene 
l,l,l-trichloroetlrne 
trichlororthylrne 
trichloroflueromethrne 1 
vinyl c h l e r f d e  
16 
so0 
sao 
100 
100 
s o 0  
s o  
t o o  
230 
S O  
SPECIFIC TOXICANTS 
Definition: 
Primary 
EPA Priority Pollutants and related compounds 
Volatiles 
Acid Extractables 
Base/Neu tral Extract ables 
Metabolites 
Oxidation Products 
Pharmaceuticals 
Illicit Drugs 
Secondary 
All Other 
0 
P R O P E R T Y  
I Y O R G A W  1 C 
NOYMETALLICS 
Aaaon i a 
B romf  d o  
Ch 1 o r  { d o  
C h l o r f n o  
F l u o r  i d o  
l o d i d o  
r i t r r t o  
M i  t r i  t o  
? O T A B L E  
11111 T 
(PP.1 
0 . 5 0  
110 
250  
T D D  
1.00 
15 
10 
T D D  
M i t r o # o n ,  t o t a l  I D 0  
? h o r p h o r o u r  T B O  
Sul  f a t o  250  
tulf i d o  0.05 
Sulfito T D D  
C y a n i d o  
I a l @ # t n a t o d  
O i l  & E r o a s o  
O r g a n i c  h k c .  
O r g a n i c  a c i d s  
P h e n o l s  
Spec i f  i c  
T O C  
T T O C  
l o x  
H y d r o c a r b o n s  
T o x i c a n t s  
M I C R O B I A L  
B a c t e r  i a  
T o t a l  
A n a e r  o b t r  
A e r o b e s  
Cram p o s i t i v e  
Gram n e g a t i v e  
E .  c o l i  
E n t e r i c  
V i r u s e s  ( P F U )  
Y e a s t ,  m o l d s  
B A C T E R I C I O E  ( m g / L )  
R e s i d u a l  h a l o .  
m i n i m u m  0.50 
m a x i  m u m  4 . 0 0  
R A D I O L O G I C A L  ( p C i / L )  
a l p h a  90 S r  10 
r l p h a  2 2 6  Ra 3 
b e t a  3 U  1 # 008  
Y Y G I E Y E  YIOSH L ? A  P O T A D L L  
L I M I T  L I M I T  . 
0 . 5 0  
1 BD 
1 I D  
T D D  
1 . o o  
T B O  
1 D O  
T D D  
T B D  
110 
T B O  
0 .05  
T D O  
T B O  
T B O  
T B D  
1 DO 
T B D  
1 
TDD 
T B O ~ 1 0 , 0 0 8  
T B D * l ,  0 8 0  
T DD 
1 DD 
1 DD 
T 80 
T 8 D  
1 eo 
T O O  
T O O  
1 8 0  
T B D  
0 . 5 0  
6 . 0 0  
T BO 
T DD 
f BO 
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TABLE 3-9 
SAMPLING FREQUENCY REQUIRED FOR WATER QUALITY VERIFICATION 
PARAMETERS REAL-TIME NEAR REAL DELAYED 
TIME (24 H R S )  
PHYSICAL 
Conductivity 
Color 
PH 
Turbidity 
x X 
X 
X 
X 
X 
X 
X 
X 
X 
X I INORGANIC 
Non-Metals 
Ammonia 
Chloride 
Bromide 
Iodide 
Nitrate 
Phosphate 
Sulfate 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
c. 
L- 
Y 
% 
I 
I 
I 
Metals 
Arsenic 
Barium 
Cadmium 
Chromium 
Copper 
Iron 
Lead 
Manganese 
Mercury 
Selenium 
Silver 
Zinc 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
I 
d 
r 
ORGANICS . e  
-%- Cyanide 
Total Toxic Organics (TTO) 
X TOC 
X 
X 
X 
X 
X 
X 
BACTERIA 
Total Bacteria 
Total Coliforms 
Heterotrophs 
Non-Saprophytic 
Legionellae 
X X 
X 
X 
X 
FUNGI AND YEAST 
I 
I 
I 
I 
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ECLSS WATER RECOVERY TEST REVIEW 
- May 19, 1988 
Building 4610,  Room 2081 
Agenda 
o INTRODUCTION DR. HUMPHRIES 9 :  30-9: 45 
o ECLSS TEST OVERVIEW MR. SCHUNK 9: 45-10: 15 
o WATER RECOVERY TEST DR. HUMPHRIES 1C:15-10:45 
OVERVIEW 
o BREAK 10:45-11:00 
o WATER RECOVERY TEST MR. BAGDIGIAN 11:oo-12:oo 
DESCRIPTION MS. MORTAZAVI 
MS. MCGRIFF 
0 
0 
0 
0 
0 
0 
LUNCH 
MAN SYSTEMS SIMULATOR 
PROTOCOLS 
MAN SYSTEMS SIMULATOR 
EQIJ I PMENT 
CHEMICAL SAMPLING AND . 
ANALYS IS 
MICROBIAL SAMPLING AND 
ANALYSIS 
BREAK 
TEST SUBJECT 
SAFEGUARDS 
SUMMARY/ACTIONS 
12:oo-1:oo 
MR. WHITMAN 1: 00-1: 4 5  
MS. TRAWEEK 1 : 4 5 - 2 :  30 
MS. SERR 2 : 3 0 - 2 : 4 5  
MS. RICHARD 2:45-3:00 
3:OO-3:15 
MR. KILGORE 3:15-4:OO 
DR. HUMPHRIES 4:OO-4:12 
ECLSS WATER RECOVERY TEST REVIEW 
- 
May 20, 1988 
Building 4610, Room 5#025 
Agenda 
o INTRODUCTION DR. HUMPHRIES 8 : 30-8  : 40 
o MEDTCAL/LEGAL ASPECTS DR. CRUMP 8: 40-9: 45 
o BREAK 9:45-10:00 
o MSFC/JSC INTERFACE 
DISCUSSION 
1O:OO-10:30 DR. HUMPHRIES 
o TECHNOLOGY DEMONSTRATION MR. RAY 
PROGRAM PLANS 
o FAST (PHASE XI) TEST 
RESULTS 
MR. WHITLEY 10:45-11:15 
o SUMMARY/ACTIONS DR. HUMPHRIES W 1 5 - 1 1 :  30 
o TEST FACILITY TOUR MR. SCHUNK 11:30-12:30 
b 
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METHODS AND INSTRUMENTATION POR WATER QUALITY VERIPICATION 
WETHOD INSTRUMENTATION 
PHYSICtZuI 
CONDUCTIVITY 
CQofxIR 
TURBIDITY ' 
FIE 
INORGANIC 
Nan-Hetal8 
ammonia 
Chloride 
Bsomide 
Iodide 
Nitrate 
Nitrogen, 
Phosphate 
Sulfate 
Arsenic 
Barium 
Cadmium 
chromium 
COPP- 
Iron 
Lead 
Magnesium 
Manganese 
Mercury 
Nick01 
Potassium 
Selenium 
Silver 
Zinc 
ORGANICS 
Total 
EPA 120.1 
EPA 110.3 
EPA 150 
EPA 180 
EPA 350.2 
EPA 300.0 
EPA 300.0 
EPA 300.0 
EPA 351.3 
EPA 300.0 
EPA 300.0 
EPA 300.0 
EPA 206.3 
EPA 213.2 
EPA 200.7 
EPA 200.7 
EPA 239.2 
EPA 200.7 
EPA 200.7 
EPA 245.1 
EPA 249.2 
EPA 258.1 
EPA 270.3 
EPA 272.2 
EPA 200.7 
EPA 200.1 
EPA 200.7 
Cyanide EPA 335.2 
Halogenated Hydrocarbon EPA 612 
Organic Acids 
Organic Alcohols 
Pm8ticid.8 BPA 608 
Phenols EPA 604 
Toc EPA 415.2 
Total Toxic Organicr EPA 624, 625 
Cond. Meter 
w-VIS 
pH Metor 
Nepheloutar 
w-VIS 
Ion Chromatograph 
Ion Chromatograph 
Ion Chroratograph 
Ion Chroratagraph 
w - V I S  
Ion Chromatograph 
Ion Chromatograph 
MH 
ICP 
M G  
ICP 
ICP 
ICP 
M G  
ICP 
ICP 
Hg Analyzer 
M G  
AAF 
MH 
M G  
ICP 
w-VIS 
GC/BCD 
HPIL 
H P U  
GC/ICD 
GC/FID 
TOC Analyzer 
=/ns 
I 
I 
I 
I 
I 
3 
8 
1 
m 
1 
1 
I 
M 
U 
1 
1 
1 
u 
I 
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METHODS AWD 1"RUMENTATION FOR WATER QUALITY VERIFICATION 
PA.RkMET El? 
P H X S I W  
CONDUCFIVITY 
C- w 
TURBIDITY 
INORGANIC 
Non-Metals 
Ammonia 
Chloride 
Bromide 
Iodide 
Nitrate 
WETPK)D 
EPA 120.1 
EPA 110.3 
EPA 150 
EPA 180 
EPA 350.2 
EPA 300.0 
EPA 300.0 
EPA 3 0 0 . 0  
EPA 300.0 
Nitrogen, Total EPA 351.3 
Phosphate EPA 3 0 0 . 0  
Sulfate EPA 308.0 
Metals 
Arsenic 
Ikrium 
Cadmium 
chsmitun 
GoglPcr 
1- 
u m d  
m i -  -== 
Ikrcury 
nickel 
Potassium 
Selenium 
Silver 
Zinc 
ORGANICS 
EPA 2M. 3 
tpA m . 7  
ERa 213.2  
EPA 2w.t 
EPA 2BQ.7 
EPA 200.7 
E m  239.2 
t P A  200.7 
ZPA 200.7 
t P A  24S.1 
BPA 249.2 
EPA 258.1 
SPA 270.3 
gPA 272.2 
EPA 200.7 
Cyanide EPA 335.2 
Halogenated Hydrocarbon EPA 612 
Organic Acids 
Organic Alcohols 
Pesticides EPA 608 
Phenols EPA 604 
Total Toxic Organics 'EPA 624, 625 
TOC EPA 415.2 
INSTReRlENTATION 
Cod. Meter 
w - V I S  
pH Meter 
Mephelometer 
w - V I S  
Ion Chromatograph 
Ion Chromatograph 
Ion Chroaratograph 
Ion Chromatograph 
w-VIS 
Ion Chromatograph 
Ion Chromatograph 
M x  
ICP 
M C  
ICP 
ICP 
ICP 
AAG 
ICP 
ICP 
H g  Analyzer 
AAG 
AAF 
AAH 
AAG 
ICP 
w-VIS 
GC/ECD 
HPLC 
HPLC 
GC/ECD 
GC/FID 
TOC Analyzer 
GC/MS 
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Number k e y  f o r  t h e  s o u r c e s :  
H C H S  
* HCHlE B E N D S  
T I l h E S  SH4 
T l M S  UIRIW+ R A Y  D I S T I L L A T E  
U R I N E  R A Y  B I S T I L L A T E  (88.. 8 8  T I M E S  U r i n e ? )  
V C D  UaINd RAU D I S T I L L A T E  
P O S T  T R E A T E D  S H R  R A Y  D I S T I L L A T E  
P O S T  T R E A T E D  V C D / T I I E S  R A Y  D I S T I L L A T E  
Key t o  8 . b b r e v f r t i o n r :  
O r 1  = oral 
i v n  = i n t r a v e n o u s  
I p r  = i n t r a p e r i t o n e a l  
Hrnn = human 
Mus = mouse 
K e y  t o  t o x i c i t y  i n f o r m a t i o n :  
LDLo * Lowest  p u b t i s h e d  l e t h a l  d o s e  ( m # / K # )  
T C L o  = Lowest  p u b l i s h e d  t o x i c  c o n c e n t r a t i o n  ( m g / K g )  
TDLo = Lowest  p u b l i s h e d  t o x i c  d o s e  ( m # / K # )  
ORIGINAL PAGE IS 
OE POOR QUALITY 
('L c*-q-- 
S E C O N D A R Y  R E Q U I R E M E N T S  ( C O N T . )  
I 
I 
I 
I 
I 
I 
Compound S o u r c e  A m t .  
o c t r n o l  4 1 PPb 
o c t r n o r t e ,  m e t h y l -  5 2OOppb 
orrlfc a c f d  3 S7Oppb o r 1  hmn LDLo 700mg 
o c t r n o f c  a c i d  5 2OOOOppb 
o c t e t e t r r e n e ,  f o r m y l c y t l o  3 SOPPb 
p 8 l m i t f C  8 C i d  7 10 I v n  B U S  LD50 s ? m O  
3 ' 30ppb 
8 1 OPPb 
p e n t e n e ,  2 , s - d i m e t h y l -  1 so 
p e n t a n e ,  2 , 2 , 4 - t r f B e t h y l -  1 100 
4 - m e t h y l - 2 - p e n t r n o n e  1 s o  
2-methyl-2,4-pentanediol 1 410 
p e n t e n e ,  4 , 4 - d i m e t h y l - l -  1 100 
p h o s p h r t e ,  d i e t h y l  p e n t y l -  1 6 7  
p h o s p h a t e ,  t r i e t h y l -  1 12 
p h o s p h e t e ,  t e r t r B e t h y l p y r o -  1 2 
p h o s p h r t e ,  t e t r a m e t h y l p y r o -  2 100  
1 - p r o p e n e  1 100 
p r o p f o n f c  r c f d  1 6,000-55,400 o r l  r e t  L D s o  1510mg 
8 1 so0 
S 840 
p r o p y t e n o  mty'col 1 sa0 
pyrrrlfdfne, I - m e t h y l -  1 t i  
?yrrrlfdfne o r 1  r a t  L D s 0  800ag  
p y r r o l f d o n e  1 100 
8 t ytone  1 5 0  o r 1  mu8 LDso 316.9 
O a l f C Y t f C  8 C f d  4 550000 o r 1  r a t  LDso 891.0 
sulfone, m e t h y l -  4 20 
t h f o p h e n e ,  
t e t r a h y d r o - 1 . 1 - d i o x i d e  1 1s 
t h f o u r e r  1 500-SO0 
t h f o u r e r ,  t e t r e m e t h y l  1 3s 
t o l u o n i t r f l e  4 4OOppb 
t h i o u r e r  cmpd (D.U. 174) 1 500 Cast  O B t )  
u n d e c r n o f c  e c i d  
n - u n d e c r n e  
u r e a  
vrn f  11 e n  
X y l e n o l  
x y l e n e s ,  t o t a l  
r y l  ene 
5 SO f v n  mu8  L D S O  140.9 
4 200 
1 *16,000 
4 200 o r 1  r a t  LDs0 1580ng 
4 so 
o r 1  .US LOsO lO7Ong 
1 so 
4 D - 
E -0 u.nB 
ethyl a l c o h o l  
Source 
4 
1 
3 
furfuryl a l c o h o l  5 
4 
furan, 2,s-di-methyltetrahydro 4 
formic acfd 
hrptanoic acid 
2-heptanonr 
4-heptanont 
heptanonr cmpdr ( 2 )  
heptyl a l c o h o l  
hexanol, 2-ethyl-l- 
hexanol, 5-mothyl-1- 
2-hexanone 
hoxanone, cycle= 
hexrnoic a c f d  
hoxanofc a c f d ,  2-othyl 
bvdrosarbon, unraturated 
2,S-hoxrnedlone 
S-beXOn8-2,S-dfone 
Hcxenol 
Hexanal 
fraphorone 
lactic a c l d  
lactono cmp4s 
l o c t o n o ,  delta 
lrctono, oommr 
lrctrne, @ammahepta 
(evulfnote, m o t h y 1  
morphalfne 
morpholfne, )-ethyl 
morphotfne, n - e t h y l  
myrfrtlc a c f d  
nonanedfoate, 
nonrnedfoic acfd 
nonanofc acfd 
bi8(2-@thyl hexyl)- 
4 
3 
4 
6 
4 
4 
4 
6 
1 
1 
1 
3 
1 
4 
S 
S 
1 
S 
S 
S 
S 
S 
f 
4 
1 
4 
1 
1 
8 
1 
1 
3 
Amt. 
lOOppb o r 1  man L D L o  SO m a  
86000ppb 
S000ppb 
2OOppb o r 1  mu8 L D s o  16Omg 
1OOppb 
5PPb 
Z ~ P P ~  
6OPPb 
1 PPb 
1 OOppb 
1 SOppb 
o r 1  r a t  L O s o  t20ma 
o r 1  rat L O s o  4 1 9 0 n a  
5OPPb 
35PPb 
2OOOppb 
7SOppb 
3.PPb 
5 bppb 
100ppb 
PPb 
14000ppb o r 1  hmn L D L o  1 4 0  m a  
4000 
SPPb 
47Oppb 
4OOppb 
lOppb fvn BU8 L D s O  t3.8 
1 , 1 OOppb 
6PPb 
2OOOppb o r 1  rat L O s o  3200ao 
k A Z 0 i C  a c i d  
benzoic a c i d ,  2 - b y 4 r o x y  
bentole a c i d  cmpdr (2) 
bent a 1 dek yde 
bentold.hyde, 4-methyl 
benzaldehyde cmpdr (3) 
benryl olcohol 
bentiroxozole 
butyldihydroxybentene 
3 
4 
S 
4 
- 6  
3 
4 
4 
. 4  
1 
1 
4 
caprylic a c i d  1 
cyanurate, triallyliro- 1 
corboxylic ocidr 4 
carboxylic o c i d r  2 
carboxylic a c i d 8  3 
carboxv\le a c i d 8  ( 5 )  7 
carboryllc a c i d  CBpd 3 
carboxytic acid CBpd8 (4) 6 
carboxyltc a-cid; ( S i .  - 1  
rntnorcr corboxylic rcidr 1 
caprolacta. 
- -  Ca raic A c l d  - 
1 - .  .. 
carbon df;ulf i r e  1 
B c - a n a l  
n- docano 4 
&*can cmpda ( 2 )  4 
C.taaotc a c i d  J 
0 odeey t 1 coho 1 S 
h 4 o c a a o l  3 
4 M o t r n o i c  ocid 3 
d e c o n o l ,  o t h o x y - d o - 1  S 
decanot, h o x a -  3 
d i ben I f Y r an 
d f ~ o t h y l - b o n s o n o  mothanot t 
dlOXOlan0 t.pd8 S 
4loxalan0, 2 , 4 - d l ~ a t h y l - 1 , 3 -  S 
1 
dioxalano, 2 - o t h y l ~ 4 - ~ 0 t h y l - l , 3 -  3 
othor, othyl propyl 1 
othor, 
othylano a l y c o l  BOnObUtyl- 1 
3 
othor, 
p-chlorophonyl mothoxyirobutyl 4 
e t h o r ~ ,  g l y c o l  ( 2 )  1 
S 
.othorr, a l y c o l  ( 2 )  3 -  
8 4 0 p p b  
1000ppb 
8 4 8 p p b  
JOOOppb 
1SOppb 
1000ppb o r 1  r a t  L O s o  13OOnp 
2OPPb 
1OOppb 
lf0ppb 
lOOppb 
1 OPPb 
4700ppb o r 1  r a t  L O s o  1330ng 
273-4lOppb frn B U S  L B s o  6 0 0 m g  
12PPb 
4 0  , 6OOppb 
92,210ppb 
81, SOOppb 
3 , SOOppb 
SOOppb 
f 2  , OOOppb 
43, OQOppb 
2 , 6 S f p p b  
15, OOOppb 
14 - 722ppb 
o r 1  rat L D L o  3000ng 
o r 1  rat L O f o  3 7 S O r s  
1fOppb 
28Oppb 
SOOOppb 
l@Oppb fpr r a t  L O f o  600.1 
10Oppb 
SOOOppb 
SOPPb 
2@PPb 
20 
I ~ P P ~  
6OOppb 
10Oppb 
SOOppb 
lOOppb 
2OOppb 
4OOppb 
SSOppb 
6 O P P b  
OOOppb 
Compound 
Ace t a 1 d t h y d e  
c c e t a l d ~ h y d e ,  t r i c h l o r o -  
a c e t i c  a c i d  
a c e t i c  a c i d ,  p h e n y l  
a c e t a t e ,  e t h a n o l  e t h o x y  
a c e t a t e ,  v i n y l  
a c e t o n e  
h y d r o x y e c e t o n e  
d i a c e t o n e  a l c o h o l  
a c e t o n e  c a p d s  ( 2 )  
S E C O N D A R Y  R E Q U l R E M E Y T S  
S o u r c e  Aat.  
\<' \\-- c \  
T o x i c i t y  
4. 
5 
3 
7 
4 
1 
1 
3 
4 
1 
4 
a c r y t a t e ,  3 - a e t h o x y - b u t y l  3 
1 
r z e p i n - 2 - o n e ,  b e x a h y d r o  1 S L l  
1 SLJ 
a n i  1 i n e  1 
2 - n + t r o r n i l i m e  1 
3 - n i t r o e n i l i a .  1 
4 - n l t r o a n i l i n e  1 
o d i p r t e ,  t e t r a r e t h y l e n e  1 
nib, b a t y l  b e n r e n e r u l f o n  1 
n t d e ,  # , a - d I - a - b u t y l f o r m -  1 
Hi&, a - m e t h y l - a - e t h r l  f o r m - 1  
4 - c h l o r o o n i l l n e  1 
meld., a , n - d i m e t h y l  f o r m -  1 
. r i d e r  (1) 1 
mf4.r ( 2 )  2 
omfa*, I , n - d f m e t h y l  b e n z y l -  1 
w i n e ,  d t - n - b u t y l  1 
n l r e r  0) 1 
r l c o h o l  cmpdr ( 2 )  3 
d f c h l o r o r l t y l  4 
A d i p i c  A c i d  
m i n i ,  d i m e t h y l  
r l k r ~ b e  CC2,ns,) f 
D u t y r i c  A c i d  8 
- t r i m e t h y l p e n t y l i r o  1 
1 - b u t r n a a f n e ,  n - b u t y l -  1 
b u t a n o a t e , 2  m e t h o x y m r t h y l - 2 -  1 
2 - b u t r n o n e  1 
bu tanone ,  S - m e t h y l - 2 -  1 
b e n z o t c  a c i d  1 
4 
b u t y r r t r r ,  3 - h y d r o x y  
D u t y r r l d e h y d r  
o r 1  r a t  L O S O  l 9 S O m g  
28 
300-31200  o r 1  h n n  T D L o  1 4 7 0  ug G I 1  
35900 
488 
180 
5 0  
150 
19PPb 
2SOppb 
1 SOppr 
2OOppb e s t  @at 
94 e 
1808-3300  o r 1  r b t  L D S O  5 3 O O m g  
73PPb 
4. Jppr 
2OPPb 
2OOppb. 
2OOppb 
2OOppb 
o r 1  r a t  L D L o  3 6 0 0 m g  
4PPb 
bppb 
4OPPb 
11 Ofppb 
1OOppb 
54 1 ppb 
3 19Oppb 
4OOppb 
o r 1  r a t  LOJO 69bna 
8OPPb 
74 PPb 
2OOppb 
SOOOppb 
1 OOppb 
1 .PPb 
SOppb o r l  r a t  2940n#  
JOOppb 
16Oppb 
55PPb 
o r 1  r a t  L O s o  2 4 9 O n p  
9OOppb 
6OPPb 
2OOOppb 
SOOppb o r 1  r a t  3 0 4 D l l ~  
ORIGINAL PAGE IS 
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P R I M A R Y  R E O U I R E W E N T S  ( C O Y T . )  
C oapound Source 
B A S E / I E U T R A L S  ( C O N T . )  
* p h t h r l o t c ,  d i e t h y l  p e n t y l -  1 
p h t h o l o t c  e s t e r s  ( 2 )  6 
* p h t h o l o t e  e s t e r s  1 
p h t h a l o t c  ester c r p d s  (4) 3 
p h t h o l r t c  e s t e r  c a p d r  (3) 8 
p h t h o l r t c ,  b i s ( 2 - e t h y l  h e x y l ) -  8 
* p h t h r l o t c ,  b i r ( 2 - e t h y l  h e x y l ) -  1 
p y r  cnc 
1 , 2 , C - t r i c h l o r o b a n t c n c  
2 , 3 , 7 , b - t c t r r c h l o r o d i b e n z o - ~ - d i o x i n  
P E S T I C I D E  C O M P O U N D S  
A l d r i n  
l p h r -  BWC 
b e t  - B M C  
@onma - B W C 
de 1 t a -  BIC 
c h 1 o r o& ne 
4 , 4 * - D M  
4 . 4 .  -3DE 
4 , 4' - 8 D f  
d f e l d r l n  
o n d o r u t f a n  I 
e n d o r a l f a n  I 1  
e n * r u l f a n  r r l f a t e  
w d r  I n 
enclrfn a l h h y d e  
Imp t aeC L o r 
h e p z a e h l o r e p d x l d e  
toxaphene 
? C # - l O l 6  
P C I -  1221 
? C B  - 1232 
C C I  - 1242 
PED-1248 
? C I -  t 2 5 4  
? C I -  1260 
Aat D o t .  
49 
3 5 8  
1 4 @ - 1 5 * @ @ @  
75 
2 8  
* 103 
4 6 0 0  
ORIGINAL PAGE IS 
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Compound 
B A S E / N E U T R A L S  
P R I M A R Y  R E Q U I R E M E N T S  (CONT.) 
Source A m t  Dit. 
rcenrphthenc 
rcenrphthylenc 
rnthrrcenc 
bent Idi ne 
bcnzo-8-enthrrccnc 
bcnto-8-pyrcnc 
bcnto-b-fluorrnthcnc 
3,4-benrofluorrnthcnc 
bcnto(g,h,l)perylenc 
bcnzo(k)fluorrnthenc 1 
bic(2-chloro ethoxy)acthrnc 
bis(2-chlorocthyl)sthcr 
b i s ~ 2 - c h l o r o i r o p r o p y l ~ e t h c r  
4-bronophanyl phenyl ether 
butytbentyl phthrirtt 
2-ch10r0 nrphth8lene 
4-chloraphenyl phenyl ether 
~ h r  sene i 
diD-nro(e,h)onthr.ccnc 
1,2-dlchlorobenrone 
1 ,: dichlorobeniohe 
1 , 4  diehlorobentone 
3,3--dfehlorobantldlne 
d i e *. h y 1 ph t h 1 e t 
d i  - *-butyl phth81,rte 
2 A-dfnltro toluene 
2,6-dinitro toluono 
d i  -n-oct'yl phthwlote 
1 , 2 - d i q h ' ~ l h y d ~ r t i n o  (as  rzobensen*) 
flourmnthene 
f 1 uor  en. 
hex och 1 0 r oben 2 en8 
hex reh  1 or obut 04 l o m  
h c x + c h l o r o c y c l r ~ e ~ t r ~ f ~ n e  
hex &e h 1 r o e  t Lone 
ind~n~<l,2,S-.~))yrone 
i r ~ o r r ~ w  
2-rethyl nophtholene 
noph thrlene 
nitrobenteno 
I-nitt.8o~i.etLylo.lne 
r - n t t r e r o ~ i - n = p r o p y l o ~ l n e  
r-nitrored~phenylr.ine 
pbenrnthrene 
d i e- thy1 ph thr 18tC 
1 
1 
1 
1 
100 
* 100 
i 
I 
f 
i 
f 
0 0  
100 
2 QO 
240  
9 
4 0  
100 
' 
ORIGINAL PAGE IS 
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I 
t o ~ p o u n d  
A t  IO COMPOUNDS 
K *-[\ - - L  
P R I M A R Y  REQUIREMENTS (CONT.) 
Source ADt 
det ec ted 
0-  c r e s o l  a 
phenol a 
p-chloro-.-cresol 
4,6-dlnltrocresol 
3 
dtchlorophenol 4 
2-chlorophenol 
2.4-dtchlorophenol 
2,4,~-trlehlorophrnol 1 
4 
pentachlorephenol 
chloromethylphcnol 4 
4-chloro-3-methylphenol 
2,4-dl~ethylphenol 
2-nltrophenol 4 
4-nltrophenol 
2,4-dlnftrophenol 
2-~ethyld(nttropheno1 1 
methylphenol 4 
2-Dotkyl phon01 1 
4-.ethyl phenol 1 
phenol, 2 , 6 - d l  
phenol, 
4-(1,l-dlmethylethyl)l 
phenol cmpdr 4 
phenol tmpdr ( 8 )  6 
phenol cmpdr (6) 2 
phenol,2,6-d! 
-1-butyL-4-methyl- 8 
phenol (trrbollc actdl 4 
phenol, c h l e r o -  adduct 4 
phenol, dlchloromethyl 4 
-t-butyl-4-..thyl- 1 
phenol, t-butyt 4 
160 
ORIGINAL PAGE IS 
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150  
3 
5 5  
200 
25 
30 
265 
40 
1000 
& S O  
10 
16 (20ppb est omt) 
1s 
2,200 
600 
275 
150 
460 
100 
100 
1so 
S P E C f ~ l C  TOXfCAWTt 
PRIMARY RtOUIREMEYlS 
Compound source 
0 Acetyl benzene 1 
S 
A e r o  1 e t  n 
Acrylonttrtle 
Altylbenzene 4 
Benzene 
Bromochloromethrne 1 
Bromof o r m  
Broaomethrne 1 
dtbromomethrnr S 
Bromodtchloromethrne 
Cerbontetrrchlortde 
Chlorobenzene S 
Chlorodtbromomethene 
Chloroethrne 
2-ChlOrO8thyl vtnyl ether 
Chloroform 4 
S 
. Chloromethrne 1 
Dtbromochloroaethrnr 
Ptehlorobutrne 1 
1,l-dlchtoroethrne 
l,l-dithloroethylene 
trrnr 1,2-dlcbloroothylene 
b D~thlorotluoromethene 1 
1,2-d~chloropreprne 
l,S-dlchlore)ropene 1 
l,2-dtchloropropylene 
0 
Bromochloropropene 1 
l82-dlChlOf0Othrn8 
a 0lmethylbenrene- 
methrnrmfno 1 
othyl benxone . 
methyl bromjde 
methyl chlortde 
methylene chlortde 8 
propr-dt-one thlerlde b 
1,1,2,2-tetroch10reeth~ne 
tetrrchtoreethylrnr 
to 1 uene 
1,2-trrnr-dtchlereethy~ene 
10l,l-trlehloroethene 
trichloroethylene 
tr~chlorofluoromethrne 1 
v i n y l  thlorfdo 
Amt 
detect ed 
16 t2Oppb est r m t )  
so 
s o  
so0 
so0 
100 
10 
S 
10 
b 
100 
SO0 
so 
100 
250 
200 
so 
s o  
Proposed Water Qua l i t y  Requirements (cont 'd) 
P R O P E R T Y  ? O T A B L E  
IIORCAIl C 
IOIIETALLICL (.@/L) 
A 8 8 o n  18 0.50 
* B r o ~ i d e  TBD 
Chlor Id. 2 5 0  
*Ch 1 o r  I n e  TBD 
f luorlde t . 0 0  
lrdide 15 
I I  trrte 10 
*Mltrito TBD 
*litcogen, tot81 TBD 
*?hosphorous 1 I D  
S u l  f ot e 2 5 0  
t u l f  ide 0.05 
*Sulf i t e 1 BD 
Lllll 
Cyrnide 200 
I r l o ~ e n r t e d  
lydrotrrbons TBDel0 
* O f 1  & Crease TBD 
O r ~ r n l c  Ale. lBD*SOO 
Or@rnfc r c i d 8  TBD*SOO 
P l e n e  1 1 
t ) . C l f  I C  
t O X l C r n t 8  TBD 
t o e  , T B 0 * 5  00 
l T O C  TBD * 100 
* T t ~ h 8 l 0 8 O t h l n e S  T B D  
BAClERlC1DE ( D O / L )  
Rerldurl h810. 
D f  nf 8 U 8  0.50 
8 8 X  f DUD 4.00 
R A O I O L O C I C A L  (pCi/L) 
alpha 90 tr 10 
o l p h r  226 I o  3 
bet8 )I 1,000 
I Y 6 1 E I E  
Lllll 
( D B / L )  
0.50 
TBO 
TBD 
TBD 
1 .oo 
110 
TBD 
TBD 
TBD 
TBD 
TBD 
0.05 
T B D  
T B D  
1 BD 
TBD 
TBD 
TBD 
1 
1 B D  
TBO*lO,OOO 
lB0*1,000 
TBD 
(tfU/dL ) 
TBO 
TBD 
T B D  
TBO 
1 BO 
TBD 
T B D  
TBD 
T B D  
0.50 
6.00 
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I: 
1 
8 
I 
8 
t 
1 
1 
I 
6 
I 
* P R O P E R T Y  P O T A O L E  
111111 
rurfoctrntr 
torte, odor 
turbtdt t y  
A l S T W E T f C t  
Cattonr 
Anton8 
< . I *  
I l O R C A l  I C 
R E T A L L I C S  
* A  1 uml num 
*#nt Irnony 
I-ronlc 
B r r l u m  
* B e r y l l i u m  
r d d r o n  
Cedrn f Y 8  
ea 1 c f urn 
C h r 0.1 urn 
* C o b r l  t 
*Coppar 
Iron 
l o r d  
Ilranoa I urn 
Ionarnoae 
~ o r c u r y  
* lo l~bdonurn 
I { c k r l  
Cotorrlu. 
Se I on t urn 
S f  lver 
* l h r l l  fum 
* l l n  
* T I  trnlum 
2lnc 
I V 6 l E l E  
k i n 1 1  
100  
100 
0 
@ 
4 0  
s . 0 -0 .0  
1 0 0  
1 OD 
.S 
1 O D  
.so0 , 
( m a / L )  
M A  
MA 
8 A  
(rna/l)  
1 0 )  
1 0 0  
a.01 
1 .oo 
100 
@.e l  
TOD 
O.@S 
l a 0  
I .OD 
@.SO 
@ . O S  
@.OS 
@.as 
a. a02 
1 0 0  
@.OS 
1 OB 
@.el  
@.@S 
T O @  
TOB 
100  
S . @ O  
1 0 0  
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NASA INSTITUTIONAL REVIEW BOARD - COMPOSITION 
At least: 
1. One NASA-employed Physician. 
2. One NASA member of Chief Counsel's Office. 
3. One NASA memhr of local Safety office. 
4. One member with non-scientific expertise. 
5. One member not affiliated with NASA. 
6. Non-voting invited experts. 
Senior level NASA employee appointed as Chairperson. 
- NMI 7100.8A 
11./86 
c 
I 
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IMPORTANCE OF "MJbJ IN LOOP" TESTING 
e Hard to separate input/output 
e Biological Variability 
e Maintains high standard of research at all times 
0 Never before accomplished 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
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I 
I 
1 
I 
I 
I 
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- 
ADDITIONAL REQUIREMENTS FOR "MAN IN LOOP" TESTING 
0 Test Subject Safeguards 
e Expanded Medical Support Program 
0 Increased Sampling and Analysis 
o New Research Areas 
L t 
!&J 
t 
~ 
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TIME REQUIREMENTS FOR MONITORING WATER QUALITY PARAMETERS 
PARAMETERS REAL-TIME NEAR REAL DELAYED 
(On Line) TIME (24 HRS)  
PHYSICAL 
Conductivity 
Color 
PH 
Turbidity 
INORGANIC 
Non-Metals 
Ammonia 
Chloride 
Bromide 
Iodide 
Nitrate 
Phosphate 
Sulfate 
Metals 
Arsenic 
Barium 
Cadmium 
Chromium 
Copper 
Iron 
Laad 
Manganese 
Mercury 
Selenium 
Silver 
Zinc * 
ORGANICS 
Cyanide 
Phenols 
Toc 
TOX 
Total Toxic Organics (TTO) 
MICROBIOLOGICAL 
Total Bacteria 
Total Coliforms 
Heterotrophs 
Non-Saprophytic 
Leg ionel lae 
Fungi (Yeast L Molds) 
Viruses (TBD) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 

n 
a 
a 
v) 
I 
I 
n 
3 
w 
Z 
d c. s 
0 
I.I 
0 
0 
0 
b 
0 
pe e 
c 
0 
W 
7 
s 
v) 
) I .  
v) 
W' c 
- 
m 
1 
II 
t 
b 
c 
0 0  
0 0 0 
1. The use of human subjects in research committee (UHSRC) 
shall be composed of at least five (5) members, with diverse 
backgrounds possessing the professional competence to promote 
complete and adequate review of research activities and ascertain 
acceptability in terms of institutional commitments and 
regulations, applicable law and standards or professional conduct 
and practice. 
2. Representation on the UHSRC shall include: 
a. Men and women. 
b. Representation of more than one profession. 
c. At lease one menber whose primary concerns are 
non-scientific, i.e., lawyer, ethicist, clergy 
nember . 
d. At least one member who is not affiliated with 
the institution, either personally or by immediate 
.familial relationship. - 
3. No person shall serve as a member of the UHSRC where 
such service would constitute a conflict of interest involving 
the proposed research project under review. 
4. The UHSRC will invite individuals with =pecific 
competencies to assist in its reviev of complex issues; Within 
the scope of their invitation, these invited individuals will 
serve as full members of the UHSRC, except that they shall n8t 
have a vote. 
.- - 
Model Federal Policy 
Office of Science 
and Technology Policy (OSTP) 
6 / 8 6  
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Presentation made on June 30,1988 and July 5,1988 
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Specific Toxicants 
Definition 
Demonstrated toxicity 
Demonstrated Occurenct in water (air) 
Known industrial product or degradation product 
Primary 
EPA Priority Pollutants and related compounds (60) 
Secondary (170) 
Exposure and Risk 
sour#s 
Hygiene Wastes 
Shower 
Clothes Washing 
Dish Washing 
Urine 
Humidity Condensate 
Routes 
Skin Contact including mucous membranes 
Transdermal 
Inhahtiob 
Intestion 
m== 
Intermittent (for ground testing) 
LiabaEty Exposure 
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Presentation made on September 7,1988 
INITIAL SCREENING (R.N.) 
1) Informed consent 
2) Health questionnaire (HQ) 
3) Health profile (DUHP) 
4 )  Begin symptom dairy 
5) Appointsent with examining physician (EP) 
INITIAL EXAX ( M . D . )  
1) History and physical 
2) Lab drawn 
3) Skin tests placed 
4) EP indicates opinion to environmental health physician (EHP)- 
48 hour delay 
SUBJECT LAB 
Complete Blood Count 
Urinalysis 
Wet Preparation 
Serum Pregnancy 
Stool 
Urine Drug Screening 
(Qual itat ive) 
HIV 
HEP Profile 
APPENDIX E 
2.12 Disqualification Criteria for Initial Evaluation 
2.121 No personal physicran 
2.122 Any chronic illness or regular medicine intake 
2.123 Frequent minor illnesses 
2.1231 > 4 colds/yr 
2.1232 > 2 GE/Yr 
2.1233 > 1 UTI/yr 
2.1234 > 2 Vaginitis/yr 
2.1235 > 1 Active Skin Infection/yr 
2.124 Abnormal physical finding 
2.14 Disqualification Criteria for Pre-test Evaluation 
2.141 Significant new symptoms of infection 
2.142 Testing likely to occur during menses (phase 
dependent) 
2.143 Any topical use (phase dependent) 
2.144 Abnormal physical finding 
2.145 
2.146 Positive wet prep/GM stain 
Positive urine culture ( >lO,OOO/ml of each organism) 
2.147 
2.148 Positive u r i n e  drug screen 
P o s i t i v e  or indeterminate  serum pregnancy test 
PRE-TEST EXAM (M. D. ) 
(ONE-WEEK PRIOR TO IWOLVEXENT) 
1) B r i e f  history and physical 
2 )  Lab drawn 
3 )  EP i n d i c a t e s  opinion to  EHP- 48  hour delay 
SUBJECT HEALTH SURVEILLANCE 
8 
1) Symptoa diary continued 
2 )  Brief history and physical a t  1 week, 
first participation. 
6 and 12 months after 
3 )  Monthly review of any MD visits for 24 months by EHP. 1 
I 
R 
3 
HEART 
ABD 
GU 
NEURO/MS 
HEALTH PROFILE 
LABORATORY 
ROUTINE 
S P E C I A L  
S K I N  TEST 
P P D  
ANERGY 
I N  .1 T I  A L EVALUATION (CONTINUED) 
AWLCOMMENTS 
- -  SYMPTOM DIARY 
I have examined the above named subject and be l ieve  he/she 
(is) (is n o t )  qual i f ied  to  be involved in the water recovery test 
a t  MSFC. 
n. D. 21- 
DATE 
APPENDIX D 
MEDICAL EVALUATION, SUBJECTS 
FOR WATER RECOVERY TEST, MSFC 
FIRST MIDDLE 
NAME: 
LAST - 
ADDRESS 
AGE DATE OF BIRTH 
WORK AREA WORK PHONE 
HOME PHONE MAIL CODE 
-- IN CASE OF EMERGENCY, CONTACT: 
PHONE 
PERSONAL PHYSICIAN 
ADDRESS PHONE 
INITIAL EVALUATION 
PMH 
CHRONIC ILLNESSES 
MEDS 
MENSTRUAL HISTORY 
RECENT I L L N E S S E S  
TOPICAL U S E  
HABITS ( D ,  T ,  A )  
SKIN/HAIR DISORDER 
MINOR ILLNESS FREQUENCY 
PHYSICAL EXAM 
S K I N  
HEENT 
LUNGS 
APPENDIX D 
MEDICAL EVALUATION, SUBJECTS 
FOR WATER RECOVERY TEST,  MSFC 
NAME: 
LAST F I R S T  MIDDLE 
ADDRESS 
AGE DATE OF BIRTH 
WORK AREA WORK PHONE 
HOME PHONE MAIL CODE 
I N  CASE OF EMERGENCY, CONTACT: 
PHONE 
PERSONAL PHYSICIAN 
ADDRESS PHONE 
PRE-TEST EVALUATION 
& &.&& COMMENTS 
SYMPTOM DIARY 
MENSTRUAL HISTORY 
TOPICAL USE 
PHYSICAL EXAH 
LABORATORY 
ROUTINE 
- -  S P E C I A L  
I have examined t h e  prev ious  named subject and b e l i e v e  
he/she (is) ( i s  not) qual i f i ed  to be involved i n  the  water 
recovery test a t  MSFC. 
1. 
2 .  
3 .  
4 .  
5 .  
6. 
7 .  
a .  
Detailed Test Activities 
Insert Microbiological sampling section, including 
methodologic information similar to Appendix C and D of 
Garcia Shower Proposal. 
Insert chemical sampling section, including information 
similar to Appendix C and D of Garcia Shover Proposal. 
Insert pharmaceutical sampling section, including information 
similar to Appendix C and D of Garcia Shower Proposal. 
Insert overview of sampling schedule, including frequency and 
volumes necessary with mass balance estimate. 
Insert section of Human Subject pool selection/evaluation 
process (Crump‘s Outline). 
Insert incremental plan for adding creams, drugs, menstrual 
blood. 
Insert Boeing’s plan for orientation, pre-involvement 
education. 
Insert water certification process similar to NASA-JSC SAE 
Shower Publication, updated for more frequent sampling 
schedule. 
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APPENDIX H 
Budget Summary 
I 
FINANCIAL REPORT SUMMARY 
I 
I 
I 
CONTRACT : FNAS Environmental Control Medical Support Team 
ACCOUNT NUMBER: 5-31806 
REPORT PERIOD: 12/7/87 - 9/30/88 
Budget Expended Encumbered Balance 
I. Salary &I Wages 47,889.00 46,651.43 300.00 937.57 
11. Fringe 10,057.00 9,656.89 0.00 400.11 
111. Operating Expenses 1 , 625.00 5,663.25 0.00 <4,038.25> 
0.00 IV. Laboratory Supplies 0.00 0.00 0.00 
V. Travel 4,754.00 594.23 1,431.00 2,728.77 
0.00 0.00 VI. Facility Useage 0.00 0.00 
I 
I 
I 
I 
VII. Indirect 30,876.00 29,892.26 686.88 296.86 
TOTAL: 95,201.00 92,458.06 2 , 417.88 325.06 
Date: 10/31/88 
Prepared by: M.V. Kilgore, Jr. 
